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ABSTRACT
Alteration of mitotic gene furiction has recently been discovered to play a key role in
tumor formation and cancer progression through the induction of chromosomal
aberrations and genomic instability. Polo-like-kinase-1 is a critical mitotic regulator,
overexpressed in human tumors, that functions in mitotic entry after cellular stress,
centrosome maturation, mitotic spindle control, and cytokinesis, which are all
disregulated in cancer cells. To study the role of Polo-like kinases we took advantage of
the recent discovery that the polo-box domain of Polo-like kinases is a phosphorylation-
dependent binding module that regulates targeting of Polo-like kinases to their substrates.
To identify the interactors of Polo-box domains we developed and performed a mitotic-
specific yeast two hybrid and a pulldown mass spectrometry screen. This yielded a large
number of specific interactors known to be involved in a vast variety of mitotic processes
including those previously described to be involved in tumor progression. We
demonstrate that Polo-like kinase regulation of cytokinesis-specific guanine-nucleotide
exchange factors for the small G-protein Rho is necessary for proper actomyosin ring
contraction and cytokinesis. Additionally we demonstrate that Polo-like-kinase-1 directly
regulates the activity of the Rho-effector-kinase ROCK2, and thus Polo-like kinases
modulate Rho signaling both upstream and downstream of Rho during cytokinesis. In
addition to Polo-box domains we also worked on two other phosphorylation-dependent
binding domains involved in cell cycle checkpoints that become disregulated in cancer
cells, tandem BRCT domains and WW domains. We examined the molecular basis for
phosphorylation-dependent recognition by the tandem BRCT domains of BRCA1
through oriented-peptide-library screening and determination of an X-ray crystal
structure of the domain bound to a phosphopeptide. This allowed us to rationalize why
inherited mutations within the tandem BRCT domains of BRCA1 promote breast and
ovarian cancer in humans. Secondly, we assayed WW domains that were generated from
in silico determined sequences for natural-like function to more fully understand the
folding and binding requirements of this domain class. All three domains (tandem BRCT
domains, Polo-box domains, and WW domains) are attractive targets for cancer
therapeutics as they participate in control of processes necessary for genomic stability
that become disregulated in cancer.
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Chapter One
Polo-like Kinases Control Mitotic Progression
Portions Adapted and Expanded From:
Drew M. Lowery, Dan Lim, and Michael B. Yaffe.
Structure and Function of Polo-like Kinases. Oncogene 24, 2005.
Contributions:
Dan originally wrote the sections on Polo-box structure that are expanded here and made
Figure 1.4, and Mike contributed significant input to many sections. I expanded and re-
wrote all previously written sections, wrote the new sections, and made the remaining
figures.
The primary function of the eukaryotic cell cycle is the complete and accurate
transmission of the full genetic material to the two daughter cells. In order to coordinate
the multitude of cellular events required, there has to be an over-arching regulatory
strategy to provide spatial and temporal control of each step. Part of this order is
established through separation of distinct cell cycle phases (G1, S, G2, M) by checkpoints
that ensure that the previous series of events has completed before the next series of
events begins. Particularly difficult to coordinate is M phase, or mitosis, as an
interconnected series of events, including centrosome separation, spindle assembly and
disassembly, chromosome segregation, and cytokinesis, need to play out in rapid
succession with no room for error. Errors in these processes lead to gene tic instability
and chromosomal aberrations, which are a hallmark of tumor formation and cancer, that
have recently been implicated as being a potential initiating event in some cancers [1-4].
Thus, a full understanding of the mitotic control machinery will enable great insight into
the processes of tumor initiation and progression, and hopefully lead to the ability to
prevent tumors from forming [5, 6]. This thesis further describes the roles of Polo-like
kinase regulation of mitotic processes, particularly cytokinesis, in an attempt to
understand the consequences of disregulation of Polo-like kinases that are seen in human
cancers.
General Roles and Evolution of Polo-like kinases
Polo-like kinases (Plk) play key roles during multiple stages of mitosis, including
prophase, metaphase, anaphase, and cytokinesis, in addition to less well-understood roles
during G1/S and in response to DNA damage [7]. Originally named after the phenotype
in flies, polo was found to encode a protein kinase whose mutation resulted in abnormal
spindle poles [8, 9]. Flies, budding yeast, and fission yeast contain a single Plk family
member (Polo, Cdc5, and Plol respectively), while humans, mice, frogs, and worms have
3 Plk family members, denoted Plkl/Plxl/Plcl, Plk2/Plx2/Plc2 (originally known as Snk)
and Plk3/Plx3/Plc3 (originally known as Fnk or Prk).
Plks are defined by two conserved features - an N-terminal Ser/Thr kinase
domain and a C-terminal duplicated Polo-box region (Figure 1.1). The kinase domains
are very highly conserved among all Plks, and most closely resemble those in Aurora
kinases and calcium/calmodulin-dependent kinases. The region that encompasses the
two C-terminal Polo-boxes is much less conserved, with only -70 amino acids
considered to form the "core", which constitutes less than half the full length of the C-
terminal domain. This entire region has recently been re-named the Polo-box domain
(PBD) due to the fact that it functions as a single unit, as described in detail below.
In humans, Plkl is expressed primarily during late G2 and M phases, where it
appears to regulate much of the machinery involved in mitosis [7, 10]. Plk2 is expressed
primarily in early G1, where it may control entry into S phase [11-13]. Plk3 appears to
be expressed at constant levels throughout the cell cycle, and plays a role in several stress
response pathways, including those activated by DNA damage and spindle disruption
[14-17]. Plk2 and Plk3 may also have overlapping roles with Plkl in several mitotic
functions, most notably Golgi fragmentation and cytokinesis [18-22]. In addition, Plk2
and Plk3 have roles in remodeling post-mitotic neurons [23, 24]. Yeast and flies
probably accomplish the same set of functions using only their single Plk family
members, though the mitotic functions of these kinases have been more extensively
studied. Similarly, there has been only limited study of worm Plks, and the data so far
suggests that these genes have only limited overlapping functions with other Plkl
orthologs and paralogs [7].
Each of the three Plks in humans, mice, and frogs appear to be orthologous
between species and paralogous within a species, since phylogenetic analysis of their
sequences reveals that each group clusters separately (Figure 1.2A). Thus, the expansion
from one to three Plks must have been an early evolutionary event. However, this
expansion appears to have occurred at least twice because the three worm Plk paralogs
cluster together separately from the Plks of other organisms. This is consistent with the
individual worm Plks having less functional overlap with the other Plk family members.
Plk genes from organisms with single family members are slightly more evolutionarily
conserved with the Plkl class than any other, belying their conserved mitotic function
(Figure 1.2B).
There are no identified proteins with homology to Plks in bacteria, archae, or
plants. This is somewhat surprising for plants because they have cyclin dependent
kinases and much of the same cell cycle machinery as yeast and animals. However,
plants also show many novel features of cell cycle control [25]. With several plant
genome sequencing projects complete or nearly complete, it seems increasingly unlikely
that plant Plks are still awaiting discovery.
A fourth family member has also been characterized in humans and mice, and
sequenced in frogs and flies, called Sak or Plk4. Plk4 has a C-terminus that is highly
divergent from the other Plk family members, though its kinase domain closely resembles
all other Plks. At the extreme C-terminus, Plk4 contains a single "Polo-box" instead of
the tandem "Polo-box" repeats seen in all other Plks. This single "Polo-box" is the most
divergent in sequence and has been shown to mediate Plk4 dimerization in vitro and
when overexpressed in vivo [26]. Like all other Plks, Plk4 has been implicated in
orchestrating cytokinesis [26-28], but its function remains largely unknown. The large
(>500 amino acids) region between the kinase and the single Polo-box in Plk4 is a
complete mystery as it has no obvious strong homology to any known proteins, and no
function has been assigned to it.
Function of the Polo-Box Domain
Plk activity is controlled by intracellular localization, in addition to being
regulated at the level of protein abundance. During prophase and metaphase, Plkl and
related family members localize to centrosomes and spindle pole bodies [29-34], where
they are required for spindle assembly and centrosome maturation, presumably by
phosphorylating largely unknown centrosome-associated targets [35, 36]. Plkl family
members then re-localize to the spindle midzone during late anaphase [10, 30, 33, 37, 38],
perhaps facilitating microtubule sliding or some aspect of kinetochore dynamics [39], and
eventually come to flank the central portion of the cytokinetic bridge (i.e. the midbody)
during telophase and cytokinesis [10, 31, 33, 39, 40]. At least for Cdc5, a portion of the
protein is localized at the future site of cytokinesis (the bud neck in budding yeast) from
late G2 onward [41] indicating that Plks may be involved in organizing the structures that
will eventually result in cytokinesis.
The PBD is critical for both Plk localization and function, since mutations in the
conserved residues of human Plk1 result in loss of Plkl localization to spindle poles and
the bud neck and an inability to support mitosis at the restrictive temperature in cdc5-ts
complementation experiments [29]. Overexpression of the isolated PBD causes a failure
to complete cytokinesis in budding yeast [42], and pre-anaphase arrest in mammalian
cells [43]. The molecular basis of PBD function was clarified by the recent finding that
the entire PBD, including both Polo-boxes, the region between them, and a portion of the
linker between the end of the kinase domain and the first Polo-box, function as a single
phosphoserine/threonine-binding module that bind proteins after they have been
phosphorylated by CDKs [44]. Intriguingly, the optimal sequence motif recognized by
the PBD is Ser-[pSer/pThr]-[Pro/X], suggesting that Cdks, MAP kinases, and other
mitotic kinases might generate "priming" phosphorylations on substrates or docking
proteins to localize Plks in the vicinity of their substrates. An optimal PBD-binding
phosphopeptide displaces the PBD from binding to centrosomes in experiments using
permeabilized cells [44], and mutations in the PBD that prevent phospho-peptide binding
(Fig lA) also prevent centrosomal localization [45]. The optimal binding motif for all
Plks tested (including Plk2, Plk3, Plxl, and Cdc5) was the same as for Plkl, with very
strong selection seen for Ser in the position before the phosphorylated residue and very
little selection elsewhere [45]. Binding of the Plkl PBD to a filter array of peptides,
based on the optimal binding peptide with one residue mutated in each spot, indicates that
the Ser in the -1 position is an absolute requirement for binding phosphopeptides in vitro
[45]. Other positions showed varying degrees of specificity, with the inability of certain
residues at certain positions to bind the PBD, the most obvious feature [45]. Thus, the
phosphopeptide-binding function of the PBD is conserved across species and among
family members, and is intricately linked to how Plks control cell cycle progression
through mitosis.
There are two alternative, though not mutually exclusive, models for how the
PBD might function to direct Plk kinase activity (Figure 1.3). In one model, which we
refer to as the "processive phosphorylation" model, the PBD first binds to a site on a
protein that has been previously phosphorylated by a mitotic priming kinase. This
positions the kinase domain of Plk to phosphorylate the same protein at another site. This
type of processive phosphorylation is seen for the Tyr kinase Src, which contains a pTyr-
binding SH2 domain [46-48], and for the Ser/Thr kinase GSK-3, whose kinase domain
contains a separate pSer/pThr-binding pocket in the substrate binding cleft [49].
Plk1 substrates should contain both PBD-binding sites and kinase
phosphorylation motifs if the processive model is correct. Therefore, the model can be
examined by looking at known Plk substrates, of which a subset will be discussed here
cursorily and many more will be discussed in great detail in the following section (see
below and Table 1.1). Verified in vivo Plkl substrates include Cdc25C [50], Brca2 [51],
Mytl [52], cyclin B [53-55], NudC [56], N1p [57], TCTP [58], MKlpl [39, 59], MKlp2
[60], Grasp65 [61, 62], and Weel [41, 63]. All of these contain potential PBD-binding
sites, but only half nutch the phosphorylation motif of the only known priming kinases
for PBD-binding, CDK/MAPK. Also, Cdc25C, MKlpl, MKlp2, TCTP, Grasp65, and
NudC have been definitively shown to interact with the Plkl-PBD [44, 45, 56, 58-62].
(Interactions with the other substrate proteins have either not been examined or have only
been assessed with full-length Plkl.) In addition, Cdc25C, Brca2, MKlp2, Grasp65,
Weel, and Mytl are known to be phosphorylated by Cdkl, and NudC, cyclin B and
TCTP are similarly phosphorylated by mitotic kinases other than Plkl, although the
identity of these kinases and the sites and timing of phosphorylation are not known.
Taken together, these data suggest that the processive phosphorylation model may apply
to at least some of these substrates.
In vitro, however, Plkl can phosphorylate bacterially-produced (and therefore
unprimed) Cdc25C [64], TCTP [58], Mytl [52], cyclin B [53],[53] and NudC [56],
suggesting that priming phosphorylation is not absolutely required under conditions of
high substrate and enzyme concentration. The kinetics and efficiency of phosphorylation,
before and after a priming phosphorylation, were not investigated for most of these
substrates. Phosphorylation of Cyclin B by Erk, however, was found to dramatically
enhance its subsequent phosphorylation by Plk1 [55], suggesting a potential role of PBD-
binding in Cyclin B phosphorylation by Plkl. Another protein, Emil, was recently
identified as a Plkl substrate in vitro [65]. Emil could be phosphorylated by non-
physiological concentrations of Plkl that were -20-fold higher than those found in
mitotic extracts. However, if Emil was first phosphorylated by Cdkl, then the amount of
Plk1 that was required was reduced to physiological levels. Quantification of this effect
revealed that incubation of Emil with Cdkl, prior to incubation with Plkl, increased the
phosphorylation of Emil by Plkl by three-fold [65]. Unfortunately. the sites of Cdkl
phosphorylation on Emil, or the ability of Emi 1 to associate with the PBD of Plkl, were
not examined. Nevertheless, this data clearly agrees with a processive phosphorylation
model. Another recent study demonstrated that Weel phosphorylation by Plkl was
stimulated by phosphorylation of Weel by Cdkl [63]. The site of phosphorylation by
Cdkl perfectly matched a consensus site for PBD binding, again indicating a role for the
processive model, though this interaction was not directly addressed in the study. A
separate study demonstrated that these same events likely occur for the budding yeast
homolog of Weel, Swel, though the priming kinase was suggested to be Cla4 instead of
Cdkl [41].
A novel substrate of Plxl, claspin, was recently described [66]. Claspin binds to
the PBD of Plxl through a phospho-dependent interaction and is subsequently
phosphorylated on a nearby site [67]. The timing of these two events was clearly
delineated, and the necessity of PBD binding for the subsequent phosphorylation event
was demonstrated. Thus, claspin is the first Plk substrate to definitively use the
processive phosphorylation model, though cyclin B, Emil, and Weel are very strong
candidates for additional Plk substrates that use this process.
A second alternative model is the "distributed phosphorylation" model, in which
the ligand, to which the Polo-box domain binds, is distinct from the substrates, which the
Plk kinase domain phosphorylates (Figure 1.3). In this case, Polo-box domain-binding to
a phosphorylated scaffold or docking protein localizes the kinase domain to specific sub-
cellular structures, proximal to substrates of the kinase domain which could even be
bound to the same scaffold molecule. The movement of Plkl, from centrosomes to
kinetochores and the spindle midzone, and then to the septin ring as cells progress from
G2 through mitosis, is consistent with this model. Most of the putative scaffold
molecules have yet to be defined, but there are at least two potential examples of such
Plkl scaffolds. One of the roles of Plkl -related family members is the activation of the
Anaphase Promoting Complex (APC), and Cdc23/Cut23 is responsible for localizing
Plk/Plol to the APC, where additional Plkl/Plol substrates are found [68, 69]. The
kinesin-like proteins Mklpl/2, which seem to carry Plk1 to the central spindle during
anaphase and telophase [59, 60], may be the scaffolds for Plkl's role in cytokinesis,
which presumably requires multiple substrates. Both of the Plkl scaffolds, Cut23 and
Mklpl/2, are themselves substrates of Plkl, suggesting that they function as more than
simple docking sites.
Both models will surely turn out to be correct for specific Plk substrates, though
which model will predominate is an open question. In either case, the PBD appears to
function as an "AND" gate in the lingo of systems biology, by "integrating" the activity
of other mitotic kinases with that of Plks. By functioning as a pSer/pThr-binding module,
the PBD ensures that Plk-mediated progression through M-phase and sequential
activation of discrete mitotic events occurs if, and only if, a prior CDK/MAPK or other
mitotic kinase phosphorylation has occurred. In the processive phosphorylation model,
the PBD functions as an "integrator" in time - the priming phosphorylation event has to
occur at the same time that Plk kinase is present and active, or else the PBD binding site
will be lost through the rapid action of phosphatases. In the distributive phosphorylation
model, the PBD functions as an "integrator" in space - substrates must be localized in
close proximity to the phosphorylated scaffold molecule to which the PBD has bound.
Cancer Connection of Polo-like Kinases
Elevated Plkl levels have been found in a wide variety of human tumors
including non-small-cell-lung cancer [70], esophageal carcinomas [71], breast cancer
[72], ovarian cancer [73, 74], pancreatic cancer [75, 76], head/neck squanrus cell
carcinomas [77], melanomas [78], colorectal cancer [79, 80], prostate carcinomas [81],
hepatoblastoma [82], and papillary carcinomas [83]. Even more importantly, Plk1
expression levels have prognostic value in determining the course of some of the cancers
listed above, including melanoma, colorectal cancer, and hepatoblastoma [78, 82, 84]. A
subset of these studies have also demonstrated that high Plkl expression is tightly
correlated with future metastasis [82, 85]. Thus, Plkl clearly has a role in oncogenesis,
though there is no evidence that Plkl is an initiating factor in of any of these tumors, and
mutations or epigenetic changes in Plkl have not been observed in these human tumor
samples. In transformed cell lines, Plkl expression is also consistently elevated, and
several mutations have been found in the C-terminal region of Plkl that disrupt its
interaction with HSP90 [86].
Data from cell culture systerm further supports a role for Plkl in oncogenic
transformation. Overexpression of Plkl in NIH 3T3 cells produces the classic
transformed phenotype of foci formation in soft agar and tumor formation in nude mice
[87]. The opposite experiment of inhibiting Plkl activity in transformed cells, such as
U20S cells, completely eliminates the ability of these cells to form foci [88]. Inhibition
of Plkl in HeLa cells by antibody injection also blocked proliferation [35]. Antisense
oligonucleotides that down-regulate Plkl cause decreased cell proliferation in MDA-MB-
435 breast cancer cells and A549 non-small cell lung cancer cells in vitro, and tumor
regression when these cells were xenografted onto nude mice [89, 90]. Interestingly, the
viability of non-transformed cells such as amniocytes, mesangial cells and skin
fibroblasts was unaffected by these types of Plkl down-regulation [89]. Depletion of
Plkl levels through siRNA, in transformed cell lines derived from tumors, causes
apoptosis along with mitotic catastrophe [88, 90, 91]. Strikingly, in primary non-
transformed cell lines, depletion of Plkl causes only minor cell cycle delays [90, 92].
Co-depletion of p53, however, mimics the cell death phenotypes seen in tumor-derived
cell lines [92]. In a mouse bladder cancer model, Plkl knockdown by siRNA was able to
shrink tumor size [93].
The recent development of small molecule inhibitors of Plkl have shed further
light on this subject. The first ATP-competitive inhibitors of Plkl to be described were
scytonemin [94, 95] and the previously known PI3K inhibitor, wortmannin [96].
However, both these compounds have significant off-target effects that cause cell cycle
phenotypes irrespective of their ability to inhibit Plkl [94, 96], making them useful solely
as starting points for generating Plkl-specific inhibitors. A high-throughput screening
program at Boehringer-Ingelheim led to the identification of BI 2356, which inhibits Plkl
activity with an IC50 of 0.8nm, and is at least 10,000 fold selective for Plkl compared to
the range of kinases studied [97]. In cell culture, this inhibitor prevents the proliferation
of a large number of human tumor cell lines by inducing pro-metaphase arrest and
subsequent apoptose [97]. These effects extended to mouse xenograft models where
treatment with BI 2356 inhibited tumor growth and in some cases caused tumor
regression [97]. This drug is now in clinical trials. Another ATP-competitive inhibitor of
Plkl, LFM-A13, blocked mitosis in breast cancer and glioblastoma cells and delayed
toxicity in the MMTV/neu transgenic mouse [98]. A third inhibitor potently inhibits the
proliferation of a wide variety of tumor cell lines [99]. Overall, the reports on inhibition
of Plkl through every achievable means point to a critical role for Plkl in tumor cell
maintenance, if not initiation, and demonstrate that Plkl is an excellent target for anti-
cancer therapeutics. Thus, we set out to determine more Plk substrates through
identification of PBD binding proteins in order to gain a greater understanding of Plk
function in mitosis and its cancer-promoting properties.
Generation of Polo-box Domain Binding Sites
One way to discover the pathways that Plks and the PBD contribute to is to
identify the kinases that can generate PBD binding sites. So, what kinases might these
be? Any kinase active during a time in the cell cycle when Plk is active, or is active
before Plk but has its phosphorylation sites preserved until Plk is active, and which can
phosphorylate a Ser or Thr with a Ser in the preceding residue, has the potential to
generate PBD binding sites. The initially described PBD binding site-generating kinase
is Cdkl/cyclin B [44, 45], as described for many proteins in the previous section. One
recent interesting example is that Weel phosphorylation by Plkl was stimulated by
phosphorylation of Weel by Cdkl [63, 100]. The site of phosphorylation by Cdkl
perfectly matched a consensus site for PBD binding (Table 1.1). A separate study
demonstrated that these same events likely occur for the budding yeast homolog of Weel,
Swel, though the priming kinase for PBD binding was suggested to be Cla4 instead of
Cdkl [41]. Thus, though the Plk-dependent regulation of Weel is conserved between
budding yeast and humans, the upstream kinase is different, suggesting that the PBD
binding is the critical event, not the mechanism of generation of the phosphorylation site.
There are other CDKs that act at various stages of mitosis. Cdkl/cyclinA is
active during G2 and early mitosis and alnost certainly generates some PBD binding
sites, as many of the known PBD binding sites that are assigned to Cdkl/cyclinB from in
vitro evidence could just as easily be generated by Cdkl/cyclinA in vivo. As part of the
translational shutdown during mitosis, cap-independent translation is increased, and this
generates another CDK, known as p58, which is translated from an internal ribosome
entry site in Cdkl 1. Intriguingly, lack of p58 due to siRNA causes centrosome, spindle,
and cytokinesis defects, in part because Plkl is no longer properly recruited to mitotic
structures [101-103]. This suggests that during late mitosis, p58 may be generating the
PBD binding sites on proteins involved in cytokinesis, when Cdkl/cyclinB activity is no
longer present. MAP (mitogen activated protein) kinase cascades have also been
implicated in mitosis at least in early development [104-107]. As MAPKs generate a
similar pSP motif to CDKs and allow for Ser in the -1 position, they could also be
responsible for generating PBD binding sites, though no current evidence for this exists.
Interestingly, Plkl has been shown to generate its own PBD binding sites on the
cytokinesis kinesin MKLP2 [60], the cytokinesis protein PRC1 [108], and the
kinetochore scaffold PBIP1 [109] (Table 1.1). There is no strong selection for any
residue in the -1 position in the optimal phosphorylation motif of Plks [52] (Jes
Alexander - personal communication), so at random, 1 out of 20 Plk phosphorylation
sites would make a good PBD binding site. MKLP2 and PRC1 both participate in control
of cytokinesis. Thus, during late mitosis, when Cdkl activity is eliminated through
degradation of cyclin B by the APC/C [110], it appears that Plkl takes over the job of
generating PBD binding sites. Why PBIP1 would use a Plkl -generated PBD binding site
for its function at kinetochores is unclear, but perhaps the interaction needs to be stable
through the metaphase-to-anaphase transition. How Plkl is recruited to these molecules
in order to generate a PBD binding site is a mystery, though the story for PRC1 may be
explained by a second kinase and PBD binding site. Two PBD binding sites were
identified in PRC1, though the Plkl-generated binding site was found to have a stronger
phenotype when mutated in vivo [108]. However, the other binding site was close by,
and mutation of it also resulted in cytokinesis defects and improper recruitment of Plkl to
the central spindle [108]. Thus, this site, when phosphorylated by an unknown kinase
(though perhaps also Plkl), either regulates the accessibility of the Plkl-generated PBD
binding site or, more likely, serves as a signal for initial PBD recruitment to PRC 1 where,
subsequently, Plkl can generate its own stronger PBD binding site. PRC1 is also
phosphorylated by Cdkl [108, 111], but this phosphorylation actually prevented
recruitment of Plkl to PRC 1.
The PBD binding ability of Emil suggests that Cdkl and Plk1 can also
collaborate to create proteins with strong PBD binding sites. Emil is an APC/C inhibitor
that is degraded by the SCF ubiquitin ligase, causing Emil destruction and allowing
progression beyond prometaphase. B-TrCP is the targeting subunit of the SCF for Emil
and binds Emil through the classical phospho-degron motif DpSGXXpS in a Plkl
dependent process [112]. The first phosphorylated Ser in the motif is contained within a
standard Plk phosphorylation motif, but both are phosphorylated by Plkl in vitro (Table
1.1) and respond to Plkl overexpression in vivo [112]. Emil is also a Cdkl target [65,
112] and interacts with the PBD [112]. Emil could be phosphorylated by non-
physiological concentrations of Plkl that were about 20-fold higher than those found in
mitotic extracts. When Cdkl was added to the reaction, it also phosphorylated Emil and
lowered the amount of Plk1 required for maximum phosphorylation to physiological
levels [65]. This clearly suggests that Cdkl generates a PBD binding site on Emil, but
Emi contains no sites that look likely to be phosphorylated by Cdkl and bind the PBD.
Instead, perhaps multiple low affinity PBD sites are generated by the Cdkl
phosphorylation of Emil, targeting Plkl to Emil and enhancing Plkl's activity towards
Emil. Confusingly, mutation of all of the presumed Cdkl phosphorylation sites in Emil
did not eliminate PBD binding, as a Ser-pS motif within the phospho-degron sequence
also contributed to PBD binding [112]. Thus, it seems Emil is targeted by Plkl after
PBD binding to Emil at multiple suboptimal Cdkl sites and at an optimal site that may
be generated by Plkl itself, after being weakly targeted to Emil by Cdkl. This
mechanism may be a general one, as it seems quite useful in setting a threshold of Cdkl
activity for PBD binding, but then allowing strong PBD binding after Cdkl activity has
risen high enough for Emi 1 to be fully phosphorylated.
Other mitotic kinases might also generate PBD binding sites. Both Aurora A
[113] and Aurora B [114] are known to crosstalk with Plkl, though currently the only
known information flow is from Plkl to the Aurora kinases. The phosphorylation motifs
for both Aurora kinases consist of an Arg in the -2 position relative to the phosphorylated
residue, with no particular selection for the residue in the -1 position [115, 116]. Thus, it
is possible that for certain processes, there might be information flow from Aurora
kinases to Plks. Aurora A is localized to the centrosome during G2 and early M [117] at
the same time that Plkl is also localized there [7]. Both kinases are required for proper
centrosome maturation and separation [7, 117]. While Aurora A and Plkl may have
distinct substrates at the centrosome, it is possible and logical that they share substrates,
though none are currently known. Requiring multiple upstream inputs to create an
activity is a common motif in cell cycle processes that can only go in one direction.
Aurora B and Plkl have multiple points of location and functional overlap during mitosis
[7, 117] which are conserved all the way back to budding yeast [118]. The kinases co-
localize at kinetochores where both are required for proper spindle orientation, and after
satisfaction of the spindle attachment checkpoint, Plk1 modifies Aurora B behavior by
phosphorylating the Aurora B regulator INCENP [114]. Both kinases then become
"chromosome passenger proteins" and stay at the spindle midzone through anaphase and
telophase, where they have several shared substrates including vimentin [119, 120] and
MKLP1 [39, 59, 121]. Aurora B might generate a PBD binding site on MKLP1, as
discussed below. Vimentin is a peculiar case. It has been demonstrated that Cdkl
generates a PBD binding site on vimentin [120], but the Aurora B phosphorylation site in
vimentin [119] could also be a PBD binding site (Table 1.1). The Ser immediately
preceding the Ser which is phosphorylated by Aurora B, however, is a phosphorylation
target for a member of the family of Rho-activated kinases [119], which would render the
site unable to bind the PBD. Whether there is some interplay between all these
phosphorylation sites in vimentin is unexplored. In summary, further connections
between Plkl and Aurora kinases are likely.
Beyond Aurora kinases, there are yet more mitotic kinases that might generate
PBD binding sites. Nek2 is present at the centrosome and required for centrosome
maturation [122] like Plkl and Aurora A. One of the targets of Nek2 is Nlp (ninein-like
protein), which is a mother centriole-specific protein that is displaced from the
centrosome at the G2/M transition [57, 123]. Nlp appears to be a priming kinase for Plkl
for several reasons: the displacement of Nlp from the centrosome is dependent on both
Nek2 and Plkl phosphorylation of Nlp, phosphorylation of Nlp by Plkl is disrupted by
overexpression of kinase-dead Nek2, and Nlp phosphorylation by Plkl in vitro is
enhanced by preincubation of Nlp with Nek2 [123]. Plkl does interact with Nip, but this
has only been shown for full-length kinase-dead Plkl and not the isolated PBD [57].
Identification of the Nek2-dependent phosphorylation sites on Nlp, and verification that
the PBD binds Nlp, will most likely demonstrate that Nek2 can generate PBD binding
sites. If this is the case, there will likely be other centrosome targets of Nek2 that are
bound by the PBD and phosphorylated by Plkl to facilitate centrosome separation and
maturation. Other Nek family kinases are still being explored. Nek9, like Nek2,
localizes to centrosomes and is required for spindle assembly by binding to Ran GTPase
[124, 125] and also activates the Nek family kinases Nek6 and Nek7 [126]. Thus, many
other Nek family kinases might turn out to be involved in mitotic processes and be PBD
binding site-generating kinases.
A less well-known mitotic kinase is LATS2 which, when deleted in mice, results
in centrosome fragmentation and cytokinesis defects [127], and when knocked-down by
siRNA in human cells, results in impaired centrosomal localization of gamma-tubulin and
failure of mitotic spindle formation [128]. LATS2 is a target of Aurora A [129] at the
centrosome, where it localizes during early mitosis [128, 129] and contributes to the
Mdm2-p53 signaling axis during mitosis [130]. LATS1 also has mitotic roles, as
knockdown causes the accumulation of multinucleate cells [131]; it interacts with and
modulates Cdkl activity [132, 133]; and it localizes to mitotic apparatus, including
centrosomes, spindle, and the midbody [133]. Thus, both LATS1 and LATS2 could
contribute to Plkl signaling networks. Some other Ser/Thr kinases active in mitosis
include LIMK1 [131, 134], GSK3-P [135-137], Haspin [138, 139], PBK [140, 141],
casein kinase II [142, 143], MEK1 [144-146], PAK [147-149], Kin4 in budding yeast
[150, 151]; Bubl, BubR1, and TAO1 in the spindle attachment checkpoint [152, 153];
Cdcl5 and Dbf2 in the mitotic exit network in budding yeast [154]; Kicl and Cbkl in the
regulation of Ace2 and morphogenesis network in budding yeast [155]; Rockl, Rock2,
and citron kinase in actomyosin ring contraction [156]. Some of these kinases have
highly specialized functions and perhaps only a few substrates, so it is less likely that
they generate PBD binding sites than the more generic mitotic kinases, though Plk1 and
Cdc5 are required for many of the functions that they perform [7, 154, 157, 158]. Mpsl
is another kinase involved in centrosome function and spindle attachment [159, 160]
which generates a PBD binding site on the Bloom Syndrome helicase, Blm [161].
Plks contribute to many of the same processes in meiosis as in mitosis, but some
differences exist, and other kinases might generate PBD binding sites in meiosis that do
not play a role in mitosis. In vertebrate meiosis, unfertilized eggs are arrested in
metaphase II, and fertilization triggers a transient increase in cytosolic free Ca 2+. This
activates Ca2+/calmodulin-dependent protein kinase II (CaMKII) among other proteins
and kinases. One of the targets of CaMKII is Emi2 [162], which is an APC/C inhibitor
that contributes to the metaphase arrest in these oocytes and is degraded upon metaphase
arrest release [163]. Upon Ca2+ influx, CaMKII phosphorylates Emi2 at two sites in
(R/K)XS(S/T) motifs which make, both, good targets of CaMKII and good binding sites
for the PBD after phosphorylation [162] (Table 1.1). At least in vitro, CaMKII
phosphorylation of these motifs did induce PBD binding, and in vivo, these motifs were
required for proper release of metaphase arrest [162]. Also, Plxl phosphorylates Emi2 in
vitro at a site that targets Emi2 for degradation upon metaphase arrest release [163], and
prior phosphorylation of Emi2 by CaMKII makes it a better substrate for Plxl [164].
Since Plxl with an intact PBD was also required for proper metaphase arrest release [162,
164], this strongly argues that Plxl phosphorylates Emi2 in a CaMKII and PBD-
dependent manner in vivo. CaMKII does not currently have a known mitotic role,
making CaMKII a meiosis-specific PBD binding site-generating kinase. Other meiotic-
specific kinases might also generate PBD binding sites
In what may seem to be a completely different process from mitosis and meiosis,
Plkl has found a role in response to DNA damage. However, ultimately, Plkl is
functioning in this process to promote the resolution of the DNA damage response and a
return to cell cycle progression by entering mitosis. Thus, this can be seen as the same
role which Plkl is known to play in mitotic entry [7]. In fact, many of the proteins
involved are the same, as the DNA damage response inhibits Cdkl, Cdc25B/C, and Plkl
itself, while activating the Cdkl inhibitory kinase Weel [165]. Outside of these
pathways already understood from the study of mitosis control by Plkl, Plkl also plays a
role in turning off the pathways that signal the DNA damage response in the first place.
This was first discovered in budding yeast, where, after a double strand DNA break, yeast
will arrest in the G2 phase of the cell cycle. When an unrepairable break is engineered,
the yeast cell will eventually enter mitosis with the break (so called adaptation), but yeast
cells lacking Cdc5 are never able to turn off DNA damage signaling and continue through
the cell cycle [166]. A similar phenomenon was seen in Xenopus eggs, as the presence of
DNA damage did not prevent cell cycle continuation forever [67]. Instead, cell cycle re-
entry in the presence of DNA damage was dependent on Plkl phosphorylation of claspin,
and Plkl was targeted to claspin through PBD binding to an SpTQ motif generated by the
DNA damage-responsive protein kinase ATR [67] (Table 1.1). Plkl control of claspin
turned off DNA damage signaling, as claspin is required to continually produce the cell
cycle arrest signal [67, 167]. This adaptation response to DNA damage only makes sense,
from an evolutionary standpoint, in single-cell organisms and in embryos where the
parent does not spend a great deal of time nuturing its progeny. In human cells, an
apoptotic response has been commonly observed, but continuation through the cell cycle
after DNA damage can occur at prolonged timepoints [168], perhaps to allow cells to die
by mitotic catastrophe if the cells fail to apoptose. Plkl is required for mitotic entry after
DNA damage [169], and Plkl does control claspin [170-172], though the upstream kinase
directing PBD binding is probably Cdkl rather than ATR [171] (Table 1.1). There is
another point of contact between DNA damage signaling and Plkl in human cells, as
Plkl binds Chk2, a DNA damage checkpoint kinase, in a PBD-dependent manner on an
SpTQ site generated by ATM [173-175] (Table 1.1). Thus, ATM and ATR can also
generate in vivo relevant PBD binding sites. Whether other kinases in these pathways
such as Chkl, Chk2, and MAPKAPK2 [175, 176] can also generate PBD binding sites is
presently unknown.
There are many PBD interacting proteins with no identified or putative PBD
binding sites. One of these proteins is TCTP, translationally controlled tumor protein,
which is a Plkl substrate and PBD binder but for which no clear PBD binding site exists
[58]. Two Plkl -dependent phosphorylation sites were identified in TCTP, one of which
is Ser 64 which is surrounded by a Glu and a Thr. Perhaps, this site was misidentified. and
Plkl actually phosphorylates the Thr, which would generate a PBD binding site [44, 45]
(Table 1.1) as well as position the acidic residue two positions upstream of the
phosphorylated residue in an optimal Plkl phosphorylation site [52]. Thus, TCTP could
have a Plkl -generated PBD binding site like the other proteins described earlier. More
likely, since the region of TCTP required for PBD binding does not contain this site [58],
TCTP interacts with the PBD in a phospho-independent manner or indirectly.
NudC, nuclear distribution protein C, is also a Plkl target and PBD binder with no
clear PBD binding site [56]. The two mapped Plkl-dependent phosphorylation sites on
NudC do not generate PBD binding sites [56]. However, NudC does localize to the
spindle midzone and midbody during cytokinesis [177], where Plkl is present. Since no
other kinase has been shown to phosphorylate NudC in mitosis, this suggests that NudC
may be a Plki target without direct binding to the PBD as described by the distributive
phosphorylation model (Figure 1.3). The evidence against this theory is that NudC is
required for Plkl localization to the kinetochores [178] and spindle midzone [177], but
this may be due to indirect effects of improper complex formation or mitotic progression
without NudC. Oddly, NudC mutated in its Plkl phosphorylation sites no longer recruits
Plkl to kinetochores despite still being capable of binding PlkI in vitro [178], suggesting
that Plkl phosphorylation of NudC is required for proper kinetochore formation. NudC
might also bind the PBD in a phospho-independent way, as it was identified as a PBD
binder in a phage display approach where it was unlikely to be phosphorylated [56] .
MKLP1 has been a known Plkl substrate for a long time [39], and it was more
recently demonstrated to be a direct PBD binder [59]. Since MKLP1 is involved in
cytokinesis and localized to the central spindle [39] like MKLP2, PRC1, and Cyk-4, it
seems likely that MKLP1 is also targeted by the PBD through a Plkl-dependent
phosphorylation site. This seems plausible since Plkl can generate a Ser-phosphoserine
motif on MKLP1 [59] (Table 1.1). However, this site by sequence analysis appears to be
an Aurora-dependent site and not a Plkl -dependent site, and this was subsequently
proved [121]. However, this site is well outside the region of MKLP1 required for PBD
binding [59]. This suggests that there is a third kinase that generates the initial PBD
binding site, after which perhaps Aurora B further contributes to PBD binding to MKLP1.
Cyclin B1 also has a complicated set of phosphorylations. Four phosphorylation
sites within cyclin B have been known for a long time, and this phosphorylation was
thought to direct localization of cyclin B to the nucleus [179]. Two of these sites (S 133
and S 147) were found to be phosphorylated by Plkl, promoting translocation of cyclin
B1 to the nucleus [54] (Table 1.1). Other studies refuted that the S147 site was
phosphorylated by Plkl [53, 55] and suggested that Plkl phosphorylation is not the
critical step that allows cyclin B 1 translocation [53]. The other two mapped
phosphorylation sites (S126 and S128) were in consensus Cdkl-phosphorylation motifs,
and could be phosphorylated in vitro by both Cdkl and the MAPK Erk2 [55]. When
cyclin B 1 was pre-phosphorylated by Erk2, this increased Plkl activity towards cyclin B 1
by three to four-fold [55], suggesting that the Erk2 phosphorylation sites created a PBD
binding site. Oddly though, Plkl could phosphorylate unknown sites, in addition to S133
(but not S147), in cyclin B1 after pre-phosphorylation with Erk2 [55], so the additional
activity seen could simply be the result of these additional accessible sites. Overall, the
issue of how Plkl targets cyclin B1 is very much unresolved, as perhaps Cdkl or Erk2
generate PBD binding sites, but it is more likely that cyclin B 1 does not directly bind the
PBD.
In summary, as more PBD binding sites are identified, the mechanisms of PBD
recruitment are further delineated. Single strong PBD binding sites can be generated by
Cdkl as seen with Bubl [180], Cdc25C [44], Ect2 [181], INCENP [114], Mytl [52],
PICH [182], and TTDN1 [183] (Table 1.1). Multiple weak PBD binding sites can be
generated by Cdkl that collaborate to recruit Plkl as seen in Emil [65, 112] and Nir2
[184] (Table 1.1). Other kinases can generate PBD binding sites such as Nek2 on Nlp
[57, 123], CaMKII on Emi2 [162-164], MPS1 on Blm [161], ATM on Chk2 [173],
possibly Erk2, and possibly Aurora B (Table 1.1). During late mitosis, Plkl can generate
its own PBD binding sites on PRC1 [108], MKPL2 [60], and maybe PBIP1 [109] (Table
1.1). Also, many Plkl substrates do not seem likely to directly bind the PBD, or at least
not in a phospho-dependent manner such as cohesin [185], NudC [56], and TCTP [58]
(Table 1.1). In summation, a large variety of mechanisms exist to generate PBD binding
sites and target Plks to their substrates, though most function through direct recruitment
of the PBD to a single phosphorylated residue in a target protein.
Activation and Phosphorylation of Plks
The cell cycle dynanics of Plks has been examined primarily for Cdc5 and Plkl.
The levels of these Plks rise dramatically in the G2 phase of the cell cycle, starting from
undetectable levels during GI and beginning their rise in mid S-phase [10, 186, 187].
With this rise in protein levels, there is a concordant increase in kinase activity, but the
activity rises much more dramatically than the levels, implicating an activation event [38,
186, 188]. Both the protein levels and the activity peak at the metaphase-anaphase
transition, before returning to the interphase baseline at the beginning of the next GI
phase, due to degradation of these Plks by the APC/C [34, 186, 188-190].
Studies of Plkl, Plxl, Polo and Cdc5 have established that activation of these
kinases requires their direct phosphorylation [32, 186, 188, 191-193]. Plkl and Plxl
activation have been the most extensively examined in mechanistic and structural detail,
although activation of other family members is believed to occur through the same
mechanisms. Several conserved Ser and Thr residues are present within the kinase
domains of Plks. Mutation of two of these, T210 and S137 in Plkl (or the corresponding
residues T201 and S128 in Plxl and T197 and S124 in Plol), to Asp, as a mimic of
phosphorylation, results in the formation of activated Plkl, Plxl, and Plol [33, 194-196].
Mutation of these residues results in multiple mitotic phenotypes as discussed below.
T210/201 lies within the T-loop of the Plk kinase domain and has been confirmed
to be an in vivo phosphorylation site, through phosphopeptide mapping of Plkl,
immunoprecipitated from nocodazole-arrested lysates, and Plxi, immunoprecipitated
from mitotic Xenopus egg extracts [195, 197]. Phosphorylation in T-loops is a common
mechanism of activation for many protein kinases, including Aurora A/B, PKA, Cdkl/2,
Erkl/2, Rskl/2, Akt/PKB, and Meki [198]. Recent work using multiple phosphospecific
antibodies to T210 have demonstrated that this epitope is phosphorylated throughout
mitosis, in particular in nocodazole-arrested cells [199, 200]. It is generally believed that
phosphorylation at T210 is a requirement for Plk activation, because the phosphomimic
mutations mentioned earlier activate the kinase, T210V mutations prevent activation [33,
194, 195], and recognition of Plkl by the phosphoT210 antibody correlates with Plkl
kinase activity [199, 200]. The corresponding phosphomimic mutation in human Plk2
also activates the kinase [12], suggesting that this is a conserved mechanism of Plk
activation.
Production of a T201D mutant form of Plxl, in a Xenopus egg extract system,
resulted in acceleration of Cdc25C activation during mitotic entry and delayed Cdc25C
deactivation during mitotic exit, although T201D expression was not sufficient to induce
the first mitotic cell cycle. Additionally, there was a delay in cyclin B2 degradation
during anaphase and a corresponding delay in the loss of Cdc2 kinase activity [33]. On
the other hand, overexpression of a T210D mutant form of Plkl in HeLa cells caused an
increased G2/M population [195], probably due to accelerated mitotic entry and
subsequent mitotic delay [191, 200]. After a prolonged mitotic phase, from nuclear
envelope breakdown to anaphase onset, Plkl-T210D expressing cells underwent
successful cytokinesis, although it was often accompanied by excessive blebbing of the
cell membrane coincident with cleavage furrow ingression [200].
There have been at least two proposals for the upstream kinase that
phosphorylates T210/201 - Xenopus Plkkl (equivalent to human SLK or Stkl0) and
PKA. xPlkkl was purified as the Plxl T201-phosphorylating factor in Xenopus oocyte
extracts [201]. A more recent study demonstrated that xPlkkl may actually be
downstream of Plxl, and the two kinases could function in a positive feedback loop to
phosphorylate and activate each other [202]. Immunodepletion of xPlkkl did not prevent
activation of Plxl or alter the kinetics of mitotic entry in Xenopus egg extracts, as
monitored by H1 kinase activity, implying that this loop is not required. Activation of
Plx by phosphorylation was still required, implying that there must be another kinase
that can phosphorylate Plxl T201 in the xPlkkl depleted extracts. Both human SLK and
Stkl0 have been shown to phosphorylate human Plkl at T210 in vitro and are able to
stimulate Plkl activation in vivo [203, 204]. It was previously believed that Stkl0 could
not be the Plkl-activating kinase because the mouse homolog, LOK, was only expressed
in lymphatic tissues. However, more complete expression profiling has shown that StklO
is expressed in most tissues, so both SLK and StklO remain viable candidates or partners
for Plkl T210 phosphorylation. PKA has also been shown to be able to phosphorylate
T201 and activate Plxl activity in vitro [197]. In this same study, xPlkkl was not able to
phosphorylate Plxl T201, creating a currently unresolved discrepancy in the field.
In contrast to T210/201, there is no mass spectrometry evidence for the in vivo
phosphorylation of S137/128. At least two studies searched directly for S137/128
phosphorylation, using tryptic phosphopeptide analysis combined with mass-
spectrometry in mitotic Xenopus extracts [197], and phosphopeptide mapping and
phosphoamino acid analysis in mammalian cells [195], but both failed to identify
phosphorylated S137. Although these and other studies did identify a number of other
phosphoserine residues [188, 197, 201, 205], none of these sites have been shown to have
functional significance. A single phosphospecific antibody made to this site has
suggested that S137 is phosphorylated during late nitosis, as it recognized Plki after a
nocodazole release but not in a nocodazole block [199, 200]. Oddly, the antibody only
works for immunoprecipitation, so the data really only shows that Plkl is
immunoprecipitated with this antibody, and not that the S137 site is phosphorylated
within PlkI [199, 200]. Furthermore, the S137A mutation failed to prevent activation of
Plkl/Plxi and did not produce any noticeable phenotypes when overexpressed,
suggesting that phosphorylation of this site is not critical in vivo [33, 195]. Still, the
phenotypes seen with an S137D mutant form of Plkl are striking. When overexpressed
in HeLa cells, the S137D mutant Plkl caused the cells to arrest as a G1/S population
rather than the G2/M population seen with T210D or wild type, and the double mutant
S137D/T210D also shows the G1/S block [195]. Accelerated mitotic entry is seen in the
S137D and S137/T210D-expressing cells, despite their very slow S phase progression
[200]. The cells that entered mitosis died at high rates of around 50%, and those that did
not die failed in cytokinesis and gave rise to a single multinucleate daughter cell [200].
Mechanistically, it appears that these mutant Plkl proteins activate the APC in an
unregulated manner, leading to the lack of a spindle checkpoint, as shown by the inability
of cells expressing these Plkl mutants to arrest using microtubule poisons [200]. The
equivalent S128D/T201D double mutant in Plxl caused cleavage arrest, resulting in large
cells, when injected into a Xenopus two cell embryo, and was able to induce the first
mitotic cycle in a Xenopus egg extract system, unlike wild type or single mutants of Plxl
[33]. Together, this data suggests that if S137/128 is phosphorylated in vivo, it is
probably only a transient event during late mitosis, with implications for APC activation
during anaphase.
The systems that have been used to map phosphorylation sites in Plks have
focused primarily on metaphase-arrested or asynchronous cells, and were therefore suited
to identify stable phosphorylation sites, perhaps explaining the failure to date to observe
Ser-137/128 phosphorylation Since Plks show striking changes in subcellular
localization during late mitosis, and participate in different processes at these times than
during earlier stages of mitosis [7], the possibility for additional post-translational
modifications of Plks, such as Ser-137 phosphorylation, during the post-metaphase stages
remains promising. Demonstration that Ser-137/128 is phosphorylated in vivo, and
identifying the kinase responsible for this event, would be an advance in the field.
The data for the activation of Cdc5 and Plol is somewhat different. Activation of
Cdc5, as well as Plkl, is dependent on mitotic CDK activity. This makes sense as Plks
are mitotic kinases, and without mitotic CDK activity, there is no mitosis. However,
there is no direct evidence that CDKs directly activate Plks through phosphorylation
except for one study [193]. Four resides downstream of the Plki T210 site is another Thr
that is contained within a minimal CDK consensus phosphorylation site. This site is
conserved throughout Plks, and was found to be phosphorylated in vivo in Cdc5 [193],
though the T210 equivalent residue in Cdc5 (T238) was also found phosphorylated [193].
Mutation of the CDK site in Cdc5 to an Ala eliminated kinase activity of Cdc5 in vitro
[193], however, this only demonstrates that the site cannot be an Ala for proper kinase
function. The one piece of data that really suggests that Cdc28 can activate Cdc5 is that
Cdc5 treated with a phosphatase in vitro has no activity, but after the addition of Cdc28.
the activity of Cdc5 is restored [193]. Plol may be activated by the same activation loop
phosphorylation as the other Plks [196], but it is also activated by a completely different
mechanism through phosphorylation of residue S402 by SRP [206], a stress response
protein kinase. Phosphorylation of Plo 1 on this site promotes its interaction with the
spindle pole body [206], probably by eliminating the negative regulation between the
kinase domain of Plol and its PBD. Future work will clarify which sites are
phosphorylated in the various Plks at what times of the cell cycle. These phosphorylation
site potentially allow some (as yet unknown) combinatorial control of Plk activity.
Biological Functions of Polo-like Kinases
Plk1 and Homologues
Polo-like-kinase-1, and its characterized homologs (Cdc5 in budding yeast, Plol
in fission yeast, Polo in Drosophila, and Plxl in Xenopus), play key roles during multiple
stages of mitosis, including prophase, metaphase, anaphase, and cytokinesis [7, 158].
Plki and Plxl are required for the timely activation of the Cdc25C phosphatase, that
initiates mitotic onset through dephosphorylation of cyclin-B/Cdk complexes [32, 33, 64,
207-210]. During prophase and metaphase, Plkl and related family members localize to
centrosomes and spindle pole bodies [29-34], where they are required for proper
centrosome maturation and spindle assembly [32, 35, 36], presumably by
phosphorylating a critical set of as-yet-unknown molecular targets. Plk1 family members
then relocalize to the spindle midzone during anaphase [10, 33, 37, 38], perhaps
facilitating microtubule sliding or some aspect of kinetochore dynamics [39], and later
flank the central portion of the cytokinetic bridge (i.e. the midbody) during telophase and
cytokinesis [10, 31, 33, 39]. In Xenopus oocytes, Plxl kinase activity facilitates the bulk
of cohesion release from chromosomes during prophase [185], while Cdc5 has been
shown to directly phosphorylate the Scc 1 cohesin subunit, making it a better substrate for
the protease separase that triggers sister chromatid separation in anaphase [211]. Plol is
required for formation of the actin ring and septum during cytokinesis [212], and loss of
Cdc5 results in cytokinetic arrest, while overexpression of the isolated Cdc5 C-terminus
causes incomplete cleavage septa and aberrant septin ring structures [42]. Data showing
a similar role for Polo-like kinases in cytokinesis in animal cells is beginning to
accumulate [39, 43, 177, 194, 213, 214]. Additionally, Plks are both regulators and
substrates of the APC, phosphorylating several APC subunits, together with Cyclin
B/Cdkl, to activate APC ubiquitin ligase activity towards cyclins, as well as towards Plks
themselves [34, 68, 69, 189, 215, 216]. This Plk-regulated destruction process is required
for mitotic exit [215], and its own auto-catalytically-trigged ubiquitin-mediated
destruction likely explains the observed variation of Plk protein levels during the cell
cycle, with maximal levels during late G2 and early M, and nearly non-existent levels
during late G1 and throughout S [10, 39].
Activation of Cdc25C, the phosphatase that activates CDK1/CyclinB to drive
mitotic entry, results from a series of Cdc25C phosphorylation events mediated by both
CDK1/CyclinB and Plks, but the connection between these kinase phosphorylation
events has remained mysterious [33, 64, 209, 217-220]. The Plk PBD binding motif
rationalizes the synergy between these two kinase pathways, with CDK1/CyclinB
providing priming phosphorylations on PBD motifs in Cdc25C, that target Cdc25C to
Plks in a timely and efficient manner. Plk1 has also been reported to directly
phosphorylate cyclin B [53, 54], inactivating a nuclear export sequence and targeting
cyclin-B to the nucleus [54], but this is controversial, as described earlier. A new model
for this activation loop has recently been coalescing from the observation that Cdc25B
and Plkl are required for mitotic entry after a DNA damage-mediated G2 cell cycle arrest
[169]. Initial activation of Cdc25B by the action of Plkl and some cyclin-Cdk complex,
perhaps CDK2/CyclinA, could start the mitotic entry process. Cdc25B, in turn, would
lead to an initial activation of CDK1/CyclinB at the centrosome and translocation of
active CDK1/CyclinB into the nucleus, where it provides priming phosphorylating of
nuclear Cdc25C. Since Plkl is both nuclear and cytoplasmic [10], nuclear Plkl could
then provide the final activating phosphorylation events required for Cdc25C activation
in this compartment, with subsequent activation of additional CDK1/CyclinB and further
priming of additional Cdc25C. This sequence of events generates a positive feedback
loop, in which Plk acts as the "trigger kinase" [10, 33, 64] and Cdc25B acts as the "starter
motor"[221, 222]. This fits with the observation that elimination of a single Plk PBD
binding site results in incomplete activation of Cdc25C in vivo [44]. Additional targets
of Plkl involved in mitotic entry are the CDK1 inhibitory kinases, Weel and Mytl,
which are both targeted for inactivation by Plkl [41, 52, 63, 100, 221, 222]. Thus, Plks
play a crucial role in nearly all known aspects of generating mitotic kinase activity.
In parallel with and subsequent to mitotic entry, centrosomes have to mature and
the mitotic spindle must form. The very first observation of Polo mutants noted a high
number of monopolar spindles or bipolar spindles with one of the poles displaying
abnormal morphology [9]. Work in other organisms including human confirms that
interference with the activity of Plks leads to severe spindle defects [8, 35, 88, 90]. These
defects are thought to result from a failure of centrosome separation and maturation, as
Plks regulate both positive and negative regulators of this process. Nip and OP 18 are
negative regulators of microtubule nucleation, that are inhibited by Plkl and Polo,
respectively [57, 123, 223]. Plkl also directly binds gamma-tubulin [224] and recruits it
to centrosomes [35], where it can perform its function as the site of spindle nucleation.
The microtubule stabilizing proteins, Asp and TCTP, are also regulated by Polo and Plkl,
respectively [36, 58]. This might be the central biological role for Plks as spindle defects
have been the primary phentoype identified using several recently reported Plk inhibitors
[225-227].
Perhaps the critical point in mitosis is the metaphase-to-anaphase transition,
where the cell switches from getting chromosomes and other cellular rmchinery ready, in
a state of high CDK activity, to the stage where segregation of chromosomes and other
material occurs, in a state of low CDK activity. This transition is delayed, until
everything is fully prepared, by the spindle assembly checkpoint, which monitors bipolar
orientation of each chromosome through the sensing of tension [153]. The 3F3/2 epitope
at kinetochores is correlated with a lack of tension, and was recently shown to be
generated by the activity of Plks [228]. Plk activity is also required for the localization of
some proteins to the kinetochore [228], though the spindle assembly checkpoint is still
active when Plk activity is absent [185, 228, 229]. However, the ultimate target of the
spindle assembly checkpoint is the APC/C (anaphase promoting complex or cyclosome),
which is under the direct regulation of Plks both through phosphorylation of APC/C
subunits [230] and phosphorylation of APC/C inhibitors [65, 112]. Functionally, the
APC/C is poised to degrade both securin and cyclin B, which allows activation of
separase and cleavage of cohesin, resulting in sister chromosome separation [153]. Plks
also play a role in this part of the metaphase-to-anaphase transition, by regulation of
separase cleavage of cohesin [185, 211, 231] and regulation of the cohesion protecting
protein shugoshin [232].
The role of Plks in anaphase events has been most well-studied in budding yeast,
where the FEAR (cdc 14 early anaphase release network) and MEN (mitotic exit network)
networks have been worked out in great detail [154, 233, 234]. Though the requirement
for Cdc5 in these networks is definitive, the exact mechanisms behind Cdc5 control of
these processes is not clear. The purpose of these networks is to activate Cdcl4, the
phosphatase that dephosphorylates many of the CDK sites generated in early mitosis
[233]. Fission yeast have an analogous pathway to MEN, termed SIN, that is also
controlled by Plo 1, but it has a slightly different biological role [154]. In animal cells,
very little is known about these pathways, other than that the role of Cdcl4 is highly
conserved and required for turning off mitotic CDK signaling. Very recently, a
connection between Plkl and Cdcl4 was shown [235], suggesting that the role of Plks in
this process is conserved. So, as in mitotic entry, Plks mediate many events (FEAR,
MEN, and APC activation) that ultimately impinge on the control of CDK1/CyclinB
activity.
At the end of mitosis, Plks still have yet another job to do, which is control of
cytokinesis. Cytokinesis failure has been seen in weaker alleles of Polo that get past
spindle failure [214], in overexpression studies with Plkl [191], and in Plkl inhibition
studies, if the spindle defect is circumvented [43, 88]. As mentioned earlier, all Plks
studied localize to the spindle midzone, cleavage furrow, and midbody [10, 30, 31, 33,
37-41], where they have multiple substrates [39, 51, 59, 60, 108, 120, 181]. Disruption
of Plk signaling through Nir2 [184], NudC [56], Npml [236], MKLP1 [59],MKLP2 [60],
Cep55 [237], and PRC1 [108], causes cytokinesis defects and, many times, failures. Why
there needs to be so many targets of Plks to regulate cytokinesis is unclear, as is the
actual function of most of these proteins in cytokinesis. Regulation of MKLP1 by Plkl
has been suggested to modify the microtubule bundling ability of MKLP1 [39, 59], and
regulation of Ect2 by Plkl has been suggested to modify the RhoGEF activity of Ect2
[181]. However, for the most part, the data regarding Plk regulation of cytokinesis
proteins has been solely limited to localization control, which, while critically important,
does not give any insight into the molecular underpinnings of the physical process of
cytokinesis.
Plks also have roles outside mitosis, in meiosis and in the DNA damage response.
The general role of Plks in meiosis seems to be similar to their roles in mitosis,
particularly, in regulating cohesion during the different meiotic stages, exact details of
which continue to be elaborated [238, 239]. Plkl is itself a target of the DNA damage
checkpoint pathway, undergoing phosphorylation and inactivation by Chk2, in response
to DNA damage [240]. Furthermore, Plkl is found in association with Chk2 at
centrosomes, even in the absence of DNA damage, although the interaction appears to be
dependent upon ATM activity [174]. This makes sense, as many cell cycle regulators are
turned off by the DNA damage pathway. However, in the case of Plks, they are also
required to exit the DNA damage response, as detailed earlier for the Plk substrate
claspin, and described in detail for Cdc5 in a series of papers [166, 241-243]. How small
amounts of Plk activity are generated during a cell cycle arrest, to allow cell cycle re-
entry, is currently unclear.
Plk2
Plk2 was first identified as a serum-inducible immediate-early response gene in
NIH 3T3 cells [13]. Its mRNA levels and protein levels track together across the cell
cycle, with a spike in G1/S and with minimal amounts at other times [12, 13]. In addition,
Plk2 is a stress-responsive gene, that is downstream of p53 transcriptional activation after
X-ray irradiation, UV, and other DNA damaging agents [18, 244]. However, Plk2 is a
nonessential gene that can be fully knocked out in mice [245], and whose knockdown
shows no ill effects in common human cell lines [18]. Plk2-knockout MEFs do show a
slightly reduced growth rate, and the embryos are slightly growth retarded [245],
suggesting that Plk2 does have a general cell cycle role. This cell cycle role is probably
related to centriole duplication, as overexpression and depletion of Plk2 lead to an
increase and decrease, respectively, of centrosome numbers in cell culture models, in a
functional kinase-dependent manner [246]. Oddly, silencing of Plk2 by siRNA in the
presence of mitotic inhibitors, such as nocodazole, resulted in apoptosis during mitosis
[18], suggesting a requirement for p53 induction of Plk2 in maintaining cell viability
during a spindle checkpoint arrest, though this could be a downstream effect of the
centriole duplication problem seen in a different study [246]. In adult tissues, Plk2 is
found in some non-cycling organs such as the heart, lung, and specific regions of the
brain [11, 13], where the Plk2 gene is responsive to stimuli that promote synaptic
plasticity [24]. In the brain, the Plk2 PBD has a specific interaction with SPAR (spine-
associated RapGAP) [23]. Cell culture models show that Plk2 phosphorylates SPAR,
leading to its degradation [23], which has been correlated with the depletion of mature
dendritic spines and corresponding increase in the exploratory precursors of spines [23].
The only other known neuronal interactor of Plk2 is CIB (calcium and integrin binding
protein) [24], which was shown to inhibit Plk2 activity in a cell culture system [12].
Overall, there is still very little understood about Plk2 function, and in particular there is
nothing known about the role of the Plk2 PBD, other than that it targets Plk2 to bind
SPAR [23] and that it selects the same phosphopeptides in vitro as Plkl [45].
Plk3
Some of the reported Plk3 data is similar to that for Plk2, as Plk3 was also first
identified as an immediate-early response gene to FGF signaling in NIH 3T3 cells [15].
All the neuronal information for Plk2 is equally true for Plk3, as Plk3 has been shown to
bind CIB [24] and SPAR [23] in neuronal cells, where its expression is also responsive to
stimuli that promote synaptic plasticity [24]. The need for two Plks to do the same thing
is unclear as well as logically baffling. Despite these similarities, Plk3 cell cycle roles
have very little functional overlap with Plk2. Instead of the protein amount tracking the
mRNA amount, Plk3 protein is nearly completely stable throughout the cell cycle [14,
247] despite the mRNA only being expressed during the G1 phase [15, 248, 249].
Explaining this continual protein level, it appears that Plk3 normally exists in an inactive
state [14] in the cytoplasm [250]. since Plk3 protein is rapidly degraded in the nucleus via
a ubiquitin-associated pathway [251]. So, what stimuli promote Plk3 activity?
Plk3 kinase activity is activated upon oxidative stress and DNA damage through
an ATM-dependent pathway, likely through direct phosphorylation of Plk3 by ATM [16,
252]. This is the exact opposite of the effect of DNA damage and other stressors on Plkl
function, as discussed earlier. The role of Plk3 during the damage response is thought to
be two-fold, as Plk3 interacts with, phosphorylates, and enhances the activity of Chk2 [14,
17] along with phosphorylating Ser-20 on p53 [252]. This site on p53 has long been
known to be important for p53-mediated cell cycle arrest, and thought to be
phosphorylated by Chkl and Chk2 [253-255]. However, the sequence surrounding the
site closely matches the known Plk consensus motif [52], with an acidic residue two
positions upstream of the phosphorylated serine. The sequence does not match the
known Chk consensus motif [256], which requires a basic residue three positions
upstream of the phosphorylated serine. Another Plk3 substrate during stress responses
has been reported to be Cdc25C [257, 258], with a phosphorylation site of Ser-216,
which is also thought to be a Chkl and Chk2 site [259, 260]. In this case, the site
conforms to the Chk consensus motif and not the Plk consensus motif, and the belief in
the field is that this site is not actually phosphorylated by Plk3. If Plk3 did target Cdc25C
directly it should hit the same sites as Plkl, since they have similar kinase domains (see
below) and similar PBD binding motifs [45]. Overall, the cases of p53 Ser-20 and
Cdc25C Ser-216 suggest that Plk3 has overlapping and intertwining roles with the Chk
kinases during the DNA damage response.
Following along with Plk3's opposite function during the DNA damage response
as Plkl, Plk3 also has shown to be oppositely correlated with cancers, as compared to
Plkl. Many studies have shown a decrease in Plk3 mRNA expression in tumor samples
compared to non-tumorigenic tissue [249, 261-263]. Also, ectopic expression of Plk3
slows cell cycle time [262] and results in cell cycle arrest along with apoptosis [19, 22],
all in a kinase activity-dependent manner. So, clearly, Plk3 has a tumor suppressor
function, as opposed to the oncogenic function of Plkl.
Further confusing the mystery of the relationship of Plkl and Plk3 is that both
these kinases can rescue the cdc5-1 temperature sensitive allele at the restrictive
temperature in budding yeast [194], suggesting overlapping function. At the least, Plkl
and Plk3 must have some overlapping PBD binding specificities [45], and overlapping
kinase motifs (personal communication - Jes Alexander). In fact, overexpression of the
Plk3 PBD results in the same localization pattern as that seen with Plkl. with clear
localization to the centrosome, spindle poles, central spindle, and midbody [264].
Furthermore, overexpression of GFP-tagged full-length Plk3 causes cytokinesis failures,
with subsequent rounding up and cell death [19]. In cycling cells, both proteins are
present during mitosis, so the separation of Plkl and Plk3 function must be due to
upstream regulation or components in the linker region between the kinase and PBD that
do not affect the function in budding yeast. More recently, reports have suggested that
endogenous Plk3 localizes to the nucleolus, and plays a role in the G1/S transition [265],
so the real cell cycle function of Plk3 remains controversial.
Plk4
Plk4, as described earlier, is by far the most divergent member of the Plk family.
It contains only a single polo-box region, and is highly unlikely to bind phosphopeptides
(see below). Plk4 expression levels rise in S phase and stays fairly high through mitosis
before falling again as cells re-enter G1 [266]. The regulation of the activity of Plk4 and
its protein level changes across the cell cycle are not yet known, but it is solely expressed
in cycling tissues in adults [267]. Like Plkl, Plk4 is an essential gene, as the mouse
knockout is inviable, dying at E7.5 [28]. These embryos display large numbers of mitotic
cells with high cyclin B levels, suggesting that Plk4 is absolutely essential for passing
through some stage of mitosis [28]. Cells grown from these embryos display a large
number of cells arresting as a dumbell shape, indicative of telophase failure [28]. Thus,
Plk4 deficient cells probably are defective in mitotic exit during anaphase, but continue
cycling into telophase until the CDK activity arrests the cells. Knockdown of Plk4 in cell
culture systems gives similar results, as cells arrest [267] and apoptose [268].
Fascinatingly, cells from Plk4 mouse heterozygotes display slow growth, centrosomal
amplification, multipolar spindles, and aneuploidy [269]. This points to a
haploinsufficiency of Plk4 activity, and strikingly, these mice develop multifocal liver
tumors of high grade with prominent mitotic irregularities [269]. Overall, this suggests
that Plk4 could have tumor suppressor functions, though there have not been
comprehensive studies correlating Plk4 levels or function with tumor samples. The
actual function of Plk4 during mitosis is elusive. Plk4 localizes to the centrosomes and
midbody, much like Plkl, dependent on both its polo-box and the linker between the
polo-box and the kinase domain [28]. What Plk4 does at the midbody is unclear, but at
the centrosome, it probably functions in centriole duplication [270, 271], like Plk2.
Polo-like Kinase Structures
Structure of the Plk4 Polo Box
Structural analysis of the Polo-box first emerged from the crystal structure of the
single Polo-box of murine Plk4 (residues 845-919) [26]. The structure revealed that the
Polo-box had crystallized as an intermolecular dimer with a clam-like shape, consisting,
in total, of two a-helices and two six-stranded antiparallel 3-sheets. Each 1-sheet
contained four contiguous strands from one Polo-box (1-strands 6, 1, 2 and 3), with the
remaining two strands coming from the other Polo-box. The association of 1-strand 3
from both Polo-boxes formed a hinge region, opposite to which was an interfacial cleft
and pocket (-17 x 8 x 12 A). The presence of 9 of 19 conserved hydrophobic residues
lining the interior of the pocket hinted at a possible ligand binding function, although
actual ligands of the Plk4 Polo-box dimer remain to be identified.
The dimeric structure of the Plk4 Polo-box seen in the crystals was also shown to
occur within cells using coimmunoprecipitation assays of differentially tagged Plk4 Polo-
box constructs [26]. Interestingly, a C-terminal construct of Plk4 containing residues 596
to 836 (Plk4 241) but lacking the Polo-box region was also observed to dimerize, indicating
the presence of one or more dimerization domains in addition to the Polo-box within Plk4.
The subcellular localization of enhanced green fluorescence protein (EGFP) fusion
constructs of the Polo-box region alone, and of full-length Plk4 in NIH 3T3 cells,
suggested that the Polo-box may play a role in targeting Plk4 to centrosomes and the
cleavage furrow. However, in contrast to loss of localization observed for Polo-box
truncations in other members of the Plk family, subcellular localization of Plk4 was not
disrupted by deletion of the Polo-box. Significant loss of proper subcellular localization
of Plk4 was only observed if both the C-terminal region following the kinase domain, but
preceding the Polo-box (residues 596-836), and the Polo-box itself were deleted. Given
the ability of the Polo-box and Plk4241 constructs to dimerize, it is unclear if the observed
subcellular localizations of these domains result from their interaction with components
of centrosomes and the cleavage furrow or from association with endogenous Plk4.
Structure of the Plk1 Polo-box domain
Crystal structures of the Polo-box domain (PBD) of human Plkl [45, 272]
revealed some similarities and a number of key differences fromthe structure of the Plk4
Polo-box dimer. Each of the individual Polo-box repeats (PB1 and PB2) in Plkl consisted
of a self-contained six-stranded 1-sheet and a-helix (Figure 1.4A). This was similar to
the structure of the single a-helix/p-sheets seen in the Plk4 Polo-box dimer, however in
the Plk4 structure, each of the 3-sheets contains contributions from two Polo-boxes. In
contrast, no strand swapping was observed in the Plkl PBD 3-sandwich. Furthermore,
the association between the Polo-box repeats in Plki differed completely from that of the
Plk4 Polo-box dimer. The 3-sheets in the Plkl PBD pack together with the two a-helices
on either side of the j-sandwich, such that residues located at the interface in the Plk4
Polo-box homodimer correspond to residues on the exterior faces of the 3-sandwich in
the PlkI PBD. The PBD also contained a Polo cap (Pc) region consisting of an a-helix
connected via a linker (L1) to the first O-strand of PB1 and a second linker (L2)
connecting the two Polo-box repeats, helping to hold both Polo-boxes in the correct
orientation.
Peptide library screening to determine the optimal phosphopeptide motifs
recognized by the PBDs of human Plkl, Plk2 and Plk3, Xenopus Plx1 and
Saccharomyces cerevisiae Cdc5 revealed a strong selection for Ser in the pThr/pSer-1
position and a modest preference for Pro in the pThr/pSer+1 position [44, 45]. Crystal
structures of the human Plkl PBD in complex with its optimal phosphopeptide revealed
the structural basis of the phospho-dependent binding and motif recognition. The
phosphopeptide binding site is located at one end of a shallow cleft between the two 0-
sheets within the only highly conserved region on the PBD surface. The phosphate group
is bound via eight hydrogen-bonding interactions, involving indirect contacts through a
lattice of ordered water molecules and direct contacts arising from the pincer-like
arrangement of the His-538 and Lys-540 side chains. The importance of His-538 and
Lys-540 in phosphospecific binding was confirmed by mutation of these residues to Ala,
which eliminated binding [45]. The strong selection for Ser at the pThr-1 position can be
accounted for by three hydrogen bond interactions of the Ser- 1 side chain hydroxyl to the
main chain atoms of Trp-414 and with the backbone carbonyl of Leu 491 via a water
molecule. Van der Waals contacts between the Ser-1 CO atom and the C81 of a strictly
conserved Trp-414 side chain reveal that larger hydroxyl-containing side chains such as
Thr or Tyr at the pThr/pSer-1 position would result in a steric clash. The importance of
Trp-414 is shown by the fact that a W414F mutation results in loss of centrosomal Plki
localization and failure of this mutant to rescue the cdc5-1 allele in S. cerevisiae [194].
The pThr/pSer+1l Pro residue makes a smaller contribution to the binding surface and
likely increases binding affinity by introducing a kink via its trans peptide bond
conformation, to direct the residues C-terminal to it back towards the binding surface,
thereby reducing the entropic penalty of binding. Structure-based sequence alignments of
the Plkl PBD with other PBDs suggest that all coordinate phosphate in a similar manner
as the His-538, Lys-540, and Trp-414 residues and surrounding regions are completely
conserved (Figure 1.4B). Similarly, the inverted structure of the dimeric PLK4 polo-box
region suggests that it cannot possibly bind phosphopeptides in the same manner as the
other Plk family members [26], and almost definitely does not bind phosphopeptides at
all (Andy Elia - personal communication).
Another set of Plkl-PBD structures, complexed with phosphorylated and non-
phosphorylated versions of the Plkl-PBD Cdc25C target peptide, were recently published
[273]. The structures were nearly identical to each other and the previously published
structures, with the only notable exception that the loop connecting to the two polo-boxes
(residues 488-507) was unstructured when bound to the non-phosphorylated Cdc25C
peptide [273]. This region was also unstructured in the previously described apo
structure [272], but is well-structured in the presence of a phosphorylated peptide [45,
272, 273]. These residues flank the bound peptide, and contribute some minor
interactions between the backbone of the Plkl-PBD and the peptide, as well as with the
ordered water molecules [45]. Whether this loop is floppy until phosphopeptide binding
has not been studied, but this crystal structure observation certainly suggests that the
stabilization of this loop could be a major contributor to the selectivity of the Plkl -PBD
towards phosphopeptides compared to non-phosphopeptides.
A mutually inhibitory interaction between the Plkl kinase domain and Polo-box
domain results in both a -3-fold reduction in kinase activity and a -10-fold reduction in
phosphopeptide binding by the PBD, with significantly reduced phosphospecificity [45,
191, 194, 274]. Conversely, binding of the optimal phosphopeptide to full-length Plkl
stimulated kinase activity by -2.6 fold, and suggests that binding of the PBD to substrates
with primed phosphorylation sites simultaneously targets Plkl to its substrates and
activates the kinase domain. The structural basis for regulatory interaction between the
kinase and Polo-box domains remains unclear. In the Src family of protein tyrosine
kinases, intramolecular binding of the SH2 domain to a C-terminal phosphotyrosine motif
positions the N-terminal SH3 domain for binding to a linker connecting the SH2 and
kinase domains [275, 276]. The SH3 domain and the linker interact with the kinase
domain to stabilize it in an inactive conformation. This mechanism of intramolecular
regulation does not appear to be applicable to Plkl, due to the absence of an internal
optimal PBD motif. Additionally, mutations of the His-538/Lys-540 pincer residues, that
disrupt phosphospecific binding by the PBD, do not abrogate binding of the PBD to the
isolated kinase domain in trans. These observations indicate that the sites of interaction
on the PBD with phosphopeptide ligands and with the kinase domain are distinct. Partial
overlap of these sites, such that binding at one site sterically occludes binding to the other
site, however, would provide one possible mechanism of the mutually inhibitory
interaction.
An alternative mechanism to regulate catalytic activity via an intramolecular
phosphopeptide binding domain is illustrated by the SHP family of phosphatases, in
which binding of the N-terminal SH2 domain to the phosphatase domain partially
occludes the catalytic cleft and distorts the conformation of the SH2 domain, reducing its
phospholigand affinity [277]. Conversely, phospholigand binding to the SH2 domain
results in activation by stabilizing an alternate conformation of the SH2 domain, with
reduced affinity for the phosphatase domain. A similar "molecular switch" mechanism
may be applicable to the Polo-box domain and would be consistent with its reduced
phospho-dependent binding in full-length Plkl and the increased activity of full-length
Plkl, upon addition of optimal phosphopeptide. Crystal structures of the PBD in the apo
state and in complex with its optimal phosphopeptide reveal that phosphopeptide binding
does not induce significant conformational changes in the PBD [272], except for the
previously described observation that the linking region between the two polo-boxes is
ordered, when bound to a phosphopeptide, and unstructured, when not [273]. Thus, the
linking loop could be the location of influence by the kinase domain to control
phosphobinding affinity. Additionally it is not known if the kinase active site is simply
occluded as in the SHP phosphatases, or if the kinase domain adopts a distinct inactive
conformation when bound to the PBD. A crystal structure of full-length Plkl or a
complex of the isolated kinase domain with the PBD will be needed to observe the kinase
domain and the PBD in their mutually inhibited states.
Structure of the Plk1 kinase domain
Very recently, a structure of the isolated Plkl kinase domain was published [278],
but no other structures of Plk family member kinase domains have been solved. The
structure was determined with a T210V mutation, in order to lock in an inactive
conformation, and with ATP analogs, to help order the substrate binding cleft.
Unsurprisingly, the Plkl kinase domain adopts a typical kinase fold. with the ATP
binding cleft between an N-terminal f3-sheet containing lobe and a C-terminal a-helical
containing lobe [278]. Oddly, the activation loop assumed an extended conformation
typical of active kinase structures [278], despite the attempt to generate an inactive form
by prevention of activation loop phosphorylation by mutation of the phosphorylated
residue. However, this extended activation loop conformation is stabilized by a zinc ion
not previously seen in kinase structures that is coordinated by residues from several
different molecules of kinase domain. Furthermore, the absolutely conserved interaction
between the activation loop and the catalytic lysine seen in structures of active Ser/Thr
kinases is not present [198] due to zinc ion coordination. Thus, the activation loop's
conformation is controlled by crystal contacts, and not by its intrinsic structure, making
interpretation of this region and its impact on Plkl activation unwarranted and prone to
artifact.
Ser-137 of Plkl shares a similar surrounding sequence context as Thr-210 and has
been proposed to be a second site of phosphorylation [195], although this remains
controversial as discussed above. In the Plkl kinase structure, Ser-137 is solvent-
exposed and located within the presumed peptide binding cleft, near the predicted
substrate Ser/Thr-3 position. However, gross conformational changes and/or movements
of the two lobes of the kinase domain would be required to make Ser-137 accessible to a
kinase, suggesting that it is never phosphorylated in vivo [278]. Phosphorylation of Ser-
137 would be expected to introduce a strong negative charge and increase selectivity for a
positively charged residue, such as Arg or Lys in the substrate at the -3 position.
Interestingly, the crystal structure of Akt/PKB in complex with GSK3-peptide shows a
negatively charged residue at this position (Glu 236) forming a bi-dentate salt bridge to
the -3 Arg of GSK3-peptide [279]. A similar interaction is also observed in the structure
of a PKA-peptide complex [280]. Thus, phosphorylation of Ser-137, if it occurs, might
be expected to alter Plk substrate specificity, leading to phosphorylation of alternative
targets than those selected when Ser-137 is not phosphorylated. Intriguingly, Ser-137 of
Plkl is conserved in Plk2 (Ser 166) and Plk3 (Ser 107) but is replaced with glutamate in
Plk4 (Glu 96).
Prospects for structure-based drug design
As discussed earlier, Plkl is likely to be a highly effective target for anti-cancer
drug design. The Plkl kinase domain is an obvious target for drug development, and
high-throughput screening and structure-based approaches used in the discovery and
optimization of inhibitors of other protein kinases can be applied [281-283]. The deep
cavity of the ATP binding pocket of kinases provides an excellent binding site for small
molecules, and consequently the majority of available kinase inhibitors are ATP analogs.
The lack of specificity of many such inhibitors is a significant problem, however, owing
to the highly conserved nature of the ATP-binding pocket. In some cases, selectivity can
be achieved by exploiting unique structural features. For example, deschloro-flavopiridol
utilizes an additional less-conserved pocket within the ATP-binding site of CDK2 [284].
The diaryl urea, and quinazolinone and pyridol-pyrimidine classes of p38 MAP kinase
inhibitors, also exploit novel binding sites within the ATP-binding pocket, some of which
are created by inducing subtle conformational changes [285, 286]. High specificity is
also achieved by targeting a distinct inactive conformation of a kinase, as shown by the
inhibition of Abelson tyrosine kinase by STI571/Gleevec [287]. Crystal structures of the
Plkl kinase domain in the true active and inactive conformations will be extremely
valuable for the optimization of lead compounds.
The recent Plkl kinase domain structure [278] allows identification of areas of the
Plkl active site that can be exploited to generate specific inhibitors. The striking
differences of the Plkl ATP binding pocket, compared to other kinases, are the presence
of a Cys at the roof of the pocket and a Phe at the bottom of the pocket which are much
more commonly Val and Leu. This creates a larger-than-average space at the roof and a
smaller-than-average space at the bottom of Plkl's ATP binding pocket. There is also a
cluster of three arginines in a solvent-exposed region of the Plkl ATP binding pocket that
contains no positively charged residues and a highly conserved glycine in most kinases.
All these residues are well conserved in Plk2 and Plk3, but not Plk4. One potential
method of creating specificity towards Plkl, and at the expense of Plk2, is to target
binding in the site created by Leu132 in Plkl, which is a tyrosine in Plk2 and in most
other kinases. The Plkl inhibitor BI 2536 was recently demonstrated to be highly
selective towards Plkl, though it also inhibits other Plk family members [97]. Docking
of this inhibitor into the Plk kinase domain structure suggests that it utilizes the
anomalous Cys67 and Leu132 to form its specific binding pocket [278]. Structural
models of the other recent inhibitors with the Plkl kinase domain structure have not been
reported. Now that several Plkl inhibitors and the kinase domain structure are known,
structures of the inhibitors bound to the kinase domain will be necessary to understand
exactly how specificity is generated by these compounds. These structures can then be
readily utilized for structure-based drug design, by modification of the current inhibitors
at appropriate places.
The Polo-box domain presents an additional unique target for the development of
novel and specific Plk inhibitors, since it is essential for normal Plk function. To date,
disruption of protein-protein interactions have been looked upon unfavourably as targets
for drug design, primarily because such interactions often involve burial of large amounts
of hydrophobic surface. However, the identification of a relatively polar, small optimal
phosphopeptide ligand for the PBD, capable of disrupting Plk-substrate interactions [44],
suggests that small molecules should be sufficient to accomplish this task. Furthermore,
the availability of Plk PBD optimal phosphopeptides should facilitate development of
high throughput assays for small molecule inhibitors that will disrupt PBD function,
while the availability of crystal structures of the PBD-phosphopeptide complex will
facilitate structure-based optimization of any lead compounds identified in these screens.
And, as there are no other proteins with structure known to be similar to the polo-box
domain, off target affects should be minimal. Specificity among the different Plk family
members would be very difficult to achieve, as they all appear to have the sanm
phosphopeptide selectivity [45]. There is one potential PBD inhibitor currently in the
literature, HMN-214, which has broad spectrum antitumor activity in mouse xenograft
models [288]. This drug has passed through phase I clinical trials [289], and supposedly
inhibits Plkl subcellular localization but not kinase activity [289]. This makes it appear
that HMN-214 is a PBD inhibitor, but as this data is all unpublished, it is hard to know.
Summary and Preview of Thesis
A role for Plkl as an oncogene in a variety of human tumors is becoming
increasingly clear. Identifying the biological mechanisms of Plkl function and substrates
of Plks will be critical to understanding and subsequently modulating Plk function. The
large amount of conservation between the roles of Plks in different organisms allows a
variety of systems to be used for addressing Plk function. What is known is that Plks
play critical roles during multiple stages of cell cycle, and in particular mitotic,
progression. All Plks contain an N-terminal Ser/Thr kinase catalytic domain and a C-
terminal region that contains one or two Polo-boxes. For Plks 1, 2, and 3, and their
homologs, the entire C-terminal region, including both Polo-boxes, functions as a single
modular phosphoserine/threonine-binding domain known as the Polo-box domain. In the
absence of a bound substrate, the PBD inhibits the basal activity of the kinase domain.
Phosphorylation-dependent binding of the PBD to its ligands releases the kinase domain
while simultaneously localizing Plks to specific subcellular structures. These
observations suggest that the PBD integrates signals arising from other mitotic kinases to
target the activated kinase towards distinct substrates. Thus, identification of PBD targets
is one mechanism to identify Plk substrates and to gain a greater understanding of the
roles of Plks in the regulation of mitotic processes.
In this thesis, we set out to identify the PBD interactors of Plkl through a pull-
down mass spectrometry approach (Chapter Two) and the PBD interactors of Cdc5
through a novel mitotic-specific yeast two hybrid screen (Chapter Three). The recent X-
ray crystal structures of the PBD provided insights into the structural basis for PBD
function, and allow us to create and use optimal negative controls to identify the
phosphorylation-specific interactors of the PBD. The results from both these screens led
us to explore the role of Plkl and Cdc5 in cytokinesis, where we demonstrate that both
Plks modulate members of the Rho signalling network during cytokinesis, including
proteins downstream of RhoA (Chapter Two) and upstream of Rhol/A (Chapter Four).
Our extensive data sets lead us to a number of hypotheses on the mitotic roles of Plks,
and on various specific proteins that might be regulated by Plks, which are explored in
Chapter Five. In addition to the work on Plks, we describe the identification of tandem
BRCT domains as phosphorylation-dependent binding domains involved in DNA
damage-dependent signalling (Appendix One), and the functional characterization of
designed WW domains (Appendix Two), which are another class of phosphorylation-
dependent binding domains involved in cell cycle control and cancer susceptibility.
Figure 1.1: Domain structure and key residues of Polo-like kinases.
Polo-like kinases contain an amino-terminal kinase domain and a carboxy-terminal Polo-
box domain connected by a short linker. Plks are activated by phosphorylation of a
conserved Thr residue within the T-loop (Thr-210), and bind phosphopeptides through a
pocket in the Polo-box domain containing the key residues Trp-414, His-538, and Lys-
540. Numbering is for human Plkl.
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Figure 1.2: Phylogenetic analysis of Polo-like kinase family members.
(A) Full length sequences of known Plk family members were aligned using ClustalW
[290]. A rooted tree was constructed using PHYLIP [291] showing one model of
evolutionary descent.
(B) An unrooted tree shows the distance relationship between Polo-like kinases from
organisms containing only a single Plk family member (Polo, Plol, Cdc5) from other
members of the Plk family.
B.
Figure 13: Two proposed models for Polo-box Domain-mediated substrate
targeting.
In the distributive model (upper), Plks are targeted to specific subcellular locales through
binding of the PBD to a single protein. Additional substrates of the kinase domain are
then encountered in these locations. In this model, Plks function as spatial integrators of
mitotic signalling. In the processive model (lower), PBD binding to a protein targets that
protein for subsequent phosphorylation by Piks. In this model, Plks function as temporal
integrators of mitotic phosphorylation events.
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Figure 1.4: Structures of the Pikl Polo-box domain
(A) The structure of the Plkl Polo-box domain (PDB accession code: IUMW) is shown.
The optimal phosphopeptide (Pro-Met-Gln-Ser-[phospho-Thr]-Pro-Leu) is shown in stick
representation with yellow carbons and with the phosphate group highlighted with
transparent spheres. The two Polo boxes (PBI and PB2) are colored red and blue, while
the Polo cap (Pc) is colored green. Figure created with Molscript [292] and Raster3D
[2931.
(B) Structure based alignment of PBDs from indicated Plks with critical residues for
phosphopeptide recognition marked with a star (Trp-414, His-538, and Lys-540 in Plkl).
Figure is adapted from Elia et al. Figure 3A [45].
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Table 1.1: Polo-like Kinase Substrate and Polo-box Domain Binders
Protein Mapped Plkl Potential Polobox Interacts With Presumed Kinase Reference
Phosphorylation Domain Binding Plkl Polobox that Generates
Site(s) Site' Domain PBD binding site
Aspl ND many (S/T)P sites ND CDK1 [36]
Bfal ETS"F, NTT•L SS4P ND CDKI [294-296]
Blm ND SSI44, SSusTP + MPS1 [161]
Brca2 DMS' 3W, ST"P, SS'siP, ND CDK1 [51]
DES239L ST231 P, ST3 193P,
SS32 19p, ST 324 2p
Bubi ND SW0P + CDK1 [180]
BubR1 ELT V, EAT'u"V STY2uP + CDK1 [180, 297]
Cdc25C EFS'9iL STIuP + CDK1 [44, 50]
Cdc27 QDT I91, NDS42 /L, many (S/T)P sites Not tested CDKI [230]
DSS435I
Cenexin Not tested SS7/9 P + CDK1 [298]
Cep 170 ND P, SS31 P, ND CDKI [299]
ST765p, SS139 8P
Cep55 NES L AS2P, KS4' P + CDK1, Erk2 [237]
Chk2 ND STOQ + ATM [173, 174]
Claspin' SDS'uGQGS34Y SFTP ND CDK1 [171]
one or both
Cohesin ND ESS 40V, VST' T, Not tested Plk ? Indirect [185]
SCC16  QST199S b in der ?
Cyclin B ETSi'-G, AFS 47 D ASiz PS UP, ND CDKI? ERK2? [53-55]
1 ST1'4LP Indirect binder?
Ect2 ND ST43P + CDK1 [181]
Emil EDS 4 G, YSS'49 F ASzP, YT P, + CDK1 and Plkl [65, 112]
GS98P, VS102 P,
92' 149
EDS GYSS F
Emi2 QDS GYSDS L RSST', RLST) + CaMKII [162-164]
one or both
Grasp65 ND SSzzP + CDK1 [61, 62]
INCENP Not tested SToP + CDKI [114]
Kizuna DLT' 91 SS4P, SS- 1  + CDK1 [300]
Mcm2 Not tested SS' 3 P, SS2"P, SS41P + CDK1 [301]
MKLP1F RRS9 "S, RSS 912T RSS91§T + Aurora? [39, 59, 121]
MKLP2 EHSR SL EHS5'2 L + Plk1 [60]
Mytl" DSS42"L, DDS4 L ST45P ND CDK1 [52, 302]
DLS469D, EDT4 9 5L
Nddl ESS"L SS3 P ND CDK1 [303]
Netl ESSQ, DAS4 L, STP Not tested CDK1 [304-307]
NVS60F, ERS24 2F,
Sand many more
Table 1.1: Continued
ND = not determined but does interact with full length Plk and is a substrate of Plk.
Not tested = not tested as a Plk1 substrate
None = no clear potential PBD binding sites
Table 1.1: Notes
1Proteins are labeled as interacting with the PBD if an interaction with full length Plk
was demonstrated to be phosphorylation dependent in addition to if an interaction is
observed with the isolated PBD. The Polo-box domain binding sites for Blm, Bub 1,
Cdc25C, Chk2, Cyk4, Ect2, Emi2, INCENP, Mytl, Nir2, PICH, PRC1, TTDN1,
vimentin, and Weel have been identified in the indicated references.
2 Asp has only been shown to be a Plk substrate and binder in drosophila.
3All data on Bfal are from budding yeast.
4 Only the subset of the in vitro mapped phosphorylation sites that were also seen in vivo
are listed [230]. The APC subunits APC1, APC4, and AP7 were also were shown to be
phosphorylated by Plkl in vitro though none of the mapped sites were seen in vivo.
Xenopus claspin contains an ST 906Q motif instead of an STP motif at the potential PBD
binding site. This site was proven to be the PBD binding site and is generated by the
DNA damage responsive protein kinase, ATR [67]. A different site was described to be
phosphorylated by Plxl in xenopus claspin, SSS 934F [67], then in human claspin.
6 Cohesin, SCC1, phosphorylation sites have been identified in budding yeast [211, 231],
but the human data suggests a slightly different mode of regulation though it is still Plkl
dependent [185].
7 The S147 site in cyclin B1 is probably not phosphorylated by Plkl [53, 55].
8 Emi2 data is from xenopus oocytes, but all relevant sites are completely conserved in
human Emi2.
9 The sites ascribed to Plkl in MKLP1 are probably generated by Aurora B, and this has
been proved for the latter site [121].
0o The PBD binding site in Mytl is confirmed in the xenopus system [302], but only
suggested in the mammalian system.
" All data on Nddl are from budding yeast.
12 All data on Netl are from budding yeast.
13 OP18 has only been demonstrated to be a Plk substrate and binder in Xenopus.
14 Shugoshin sites are from drosophila data though the sites are conserved in human
shugoshin and the data that has been published indicates the same regulation is occurring.
References
1. Kops, G.J., Weaver, B.A., and Cleveland, D.W. (2005). On the road to cancer:
aneuploidy and the mitotic checkpoint. Nat Rev Cancer 5, 773-785.
2. Jallepalli, P.V., and Lengauer, C. (2001). Chromosome segregation and cancer:
cutting through the mystery. Nat Rev Cancer 1, 109-117.
3. Li, J.J., and Li, S.A. (2006). Mitotic kinases: the key to duplication, segregation,
and cytokinesis errors, chromosomal instability, and oncogenesis. Pharmacol Ther
111, 974-984.
4. Perez de Castro, I., de Carcer, G., and Malumbres, M. (2007). A census of mitotic
cancer genes: new insights into tumor cell biology and cancer therapy.
Carcinogenesis 28, 899-912.
5. Jackson, J.R., Patrick, D.R., Dar, M.M., and Huang, P.S. (2007). Targeted anti-
mitotic therapies: can we improve on tubulin agents? Nat Rev Cancer 7, 107-117.
6. Miglarese, M.R., and Carlson, R.O. (2006). Development of new cancer
therapeutic agents targeting mitosis. Expert Opin Investig Drugs 15, 1411-1425.
7. Barr, F.A., Sillje, H.H., and Nigg, E.A. (2004). Polo-like kinases and the
orchestration of cell division. Nat Rev Mol Cell Biol 5, 429-440.
8. Llamazares, S., Moreira, A., Tavares, A., Girdham, C., Spruce, B.A., Gonzalez,
C., Karess, R.E., Glover, D.M., and Sunkel, C.E. (1991). polo encodes a protein
kinase homolog required for mitosis in Drosophila. Genes Dev 5, 2153-2165.
9. Sunkel, C.E., and Glover, D.M. (1988). polo, a mitotic mutant of Drosophila
displaying abnormal spindle poles. J Cell Sci 89 (Pt 1), 25-38.
10. Golsteyn, R.M., Schultz, S.J., Bartek, J., Ziemiecki, A., Ried, T., and Nigg, E.A.
(1994). Cell cycle analysis and chromosomal localization of human Plkl, a
putative homologue of the mitotic kinases Drosophila polo and Saccharomyces
cerevisiae Cdc5. J Cell Sci 107 (Pt 6), 1509-1517.
11. Liby, K., Wu, H., Ouyang, B., Wu, S., Chen, J., and Dai, W. (2001). Identification
of the human homologue of the early-growth response gene Snk, encoding a
serum-inducible kinase. DNA Seq 11, 527-533.
12. Ma, S., Liu, M.A., Yuan, Y.L., and Erikson, R.L. (2003). The Serum-Inducible
Protein Kinase Snk Is a G(1) Phase Polo-Like Kinase That Is Inhibited by the
Calcium- and Integrin-Binding Protein CIB. Mol Cancer Res 1, 376-3 84.
13. Simmons, D.L., Neel, B.G., Stevens, R., Evett, G., and Erikson, R.L. (1992).
Identification of an early-growth-response gene encoding a novel putative protein
kinase. Mol Cell Biol 12, 4164-4169.
14. Bahassi el, M., Conn, C.W., Myer, D.L., Hennigan, R.F., McGowan, C.H.,
Sanchez, Y., and Stambrook, P.J. (2002). Mammalian Polo-like kinase 3 (Plk3) is
a multifunctional protein involved in stress response pathways. Oncogene 21,
6633-6640.
15. Donohue, P.J., Alberts, G.F., Guo, Y., and Winkles, J.A. (1995). Identification by
targeted differential display of an immediate early gene encoding a putative
serine/threonine kinase. J Biol Chem 270, 10351-10357.
16. Xie, S., Wu, H., Wang, Q., Cogswell, J.P., Husain, I., Conn, C., Stambrook, P.,
Jhanwar-Uniyal, M., and Dai, W. (2001). Plk3 functionally links DNA damage to
cell cycle arrest and apoptosis at least in part via the p53 pathway. J Biol Chem
276, 43305-43312.
17. Xie, S., Wu, H., Wang, Q., Kunicki, J., Thomas, R.O., Hollingsworth, R.E.,
Cogswell, J., and Dai, W. (2002). Genotoxic stress-induced activation of Plk3 is
partly mediated by Chk2. Cell Cycle 1, 424-429.
18. Bums, T.F., Fei, P., Scata, K.A., Dicker, D.T., and El-Deiry, W.S. (2003).
Silencing of the novel p53 target gene Snk/Plk2 leads to mitotic catastrophe in
paclitaxel (taxol)-exposed cells. Mol Cell Biol 23, 5556-5571.
19. Conn, C.W., Hennigan, R.F., Dai, W., Sanchez, Y., and Stambrook, P.J. (2000).
Incomplete cytokinesis and induction of apoptosis by overexpression of the
mammalian polo-like kinase, Plk3. Cancer Res 60, 6826-6831.
20. Xie, S., Wang, Q., Ruan, Q., Liu, T., Jhanwar-Uniyal, M., Guan, K., and Dai, W.
(2004). MEKl-induced Golgi dynamics during cell cycle progression is partly
mediated by Polo-like kinase-3. Oncogene 23, 3822-3829.
21. Ruan, Q., Wang, Q., Xie, S., Fang, Y., Darzynkiewicz, Z., Guan, K., Jhanwar-
Uniyal, M., and Dai, W. (2004). Polo-like kinase 3 is Golgi localized and
involved in regulating Golgi fragmentation during the cell cycle. Exp Cell Res
294, 51-59.
22. Wang, Q., Xie, S., Chen, J., Fukasawa, K., Naik, U., Traganos, F., Darzynkiewicz,
Z., Jhanwar-Uniyal, M., and Dai, W. (2002). Cell cycle arrest and apoptosis
induced by human Polo-like kinase 3 is mediated through perturbation of
microtubule integrity. Mol Cell Biol 22, 3450-3459.
23. Pak, D.T., and Sheng, M. (2003). Targeted protein degradation and synapse
remodeling by an inducible protein kinase. Science 302, 1368-1373.
24. Kauselmann, G., Weiler, M., Wulff, P., Jessberger, S., Konietzko, U., Scafidi, J.,
Staubli, U., Bereiter-Hahn, J., Strebhardt, K., and Kuhl, D. (1999). The polo-like
protein kinases Fnk and Snk associate with a Ca(2+)- and integrin-binding protein
and are regulated dynamically with synaptic plasticity. Embo J 18, 5528-5539.
25. Dewitte, W., and Murray, J.A. (2003). The plant cell cycle. Annu Rev Plant Biol
54, 235-264.
26. Leung, G.C., Hudson, J.W., Kozarova, A., Davidson, A., Dennis, J.W., and
Sicheri, F. (2002). The Sak polo-box comprises a structural domain sufficient for
mitotic subcellular localization. Nat Struct Biol 9, 719-724.
27. Hudson, J.W., Chen, L., Fode, C., Binkert, C., and Dennis, J.W. (2000). Sak
kinase gene structure and transcriptional regulation. Gene 241, 65-73.
28. Hudson, J.W., Kozarova, A., Cheung, P., Macmillan, J.C., Swallow, C.J., Cross,
J.C., and Dennis, J.W. (2001). Late mitotic failure in mice lacking Sak, a polo-
like kinase. Curr Biol 11, 441-446.
29. Lee, K.S., Grenfell, T.Z., Yarm, F.R., and Erikson, R.L. (1998). Mutation of the
polo-box disrupts localization and mitotic functions of the mammalian polo
kinase Plk. Proc Natl Acad Sci U S A 95, 9301-9306.
30. Logarinho, E., and Sunkel, C.E. (1998). The Drosophila POLO kinase localises to
multiple compartments of the mitotic apparatus and is required for the
phosphorylation of MPM2 reactive epitopes. J Cell Sci 111 (Pt 19), 2897-2909.
31. Moutinho-Santos, T., Sampaio, P., Amorim, I., Costa, M., and Sunkel, C.E.
(1999). In vivo localisation of the mitotic POLO kinase shows a highly dynamic
association with the mitotic apparatus during early embryogenesis in Drosophila.
Biol Cell 91, 585-596.
32. Qian, Y.W., Erikson, E., Li, C., and Maller, J.L. (1998). Activated polo-like
kinase Plxl is required at multiple points during mitosis in Xenopus laevis. Mol
Cell Biol 18, 4262-4271.
33. Qian, Y.W., Erikson, E., and Maller, J.L. (1999). Mitotic effects of a
constitutively active mutant of the Xenopus polo-like kinase Plxl. Mol Cell Biol
19, 8625-8632.
34. Shirayama, M., Zachariae, W., Ciosk, R., and Nasmyth, K. (1998). The Polo-like
kinase Cdc5p and the WD-repeat protein Cdc20p/fizzy are regulators and
substrates of the anaphase promoting complex in Saccharomyces cerevisiae.
Embo J 17, 1336-1349.
35. Lane, H.A., and Nigg, E.A. (1996). Antibody microinjection reveals an essential
role for human polo-like kinase 1 (Plkl) in the functional maturation of mitotic
centrosomes. J Cell Biol 135, 1701-1713.
36. do Carmo Avides, M., Tavares, A., and Glover, D.M. (2001). Polo kinase and
Asp are needed to promote the mitotic organizing activity of centrosomes. Nat
Cell Biol 3, 421-424.
37. Glover, D.M., Hagan, I.M., and Tavares, A.A. (1998). Polo-like kinases: a team
that plays throughout mitosis. Genes Dev 12, 3777-3787.
38. Golsteyn, R.M., Mundt, K.E., Fry, A.M., and Nigg, E.A. (1995). Cell cycle
regulation of the activity and subcellular localization of Plkl, a human protein
kinase implicated in mitotic spindle function. J Cell Biol 129, 1617-1628.
39. Lee, K.S., Yuan, Y.L., Kuriyama, R., and Erikson, R.L. (1995). Plk is an M-
phase-specific protein kinase and interacts with a kinesin-like protein,
CHO1/MKLP-1. Mol Cell Biol 15, 7143-7151.
40. Song, S., Grenfell, T.Z., Garfield, S., Erikson, R.L., and Lee, K.S. (2000).
Essential function of the polo box of Cdc5 in subcellular localization and
induction of cytokinetic structures. Mol Cell Biol 20, 286-298.
41. Sakchaisri, K., Asano, S., Yu, L.R., Shulewitz, M.J., Park, C.J., Park, J.E., Cho,
Y.W., Veenstra, T.D., Thorner, J., and Lee, K.S. (2004). Coupling morphogenesis
to mitotic entry. Proc Natl Acad Sci U S A 101, 4124-4129.
42. Song, S., and Lee, K.S. (2001). A novel function of Saccharomyces cerevisiae
CDC5 in cytokinesis. J Cell Biol 152, 451-469.
43. Seong, Y.S., Kamijo, K., Lee, J.S., Fernandez, E., Kuriyama, R., Miki, T., and
Lee, K.S. (2002). A spindle checkpoint arrest and a cytokinesis failure by the
dominant-negative polo-box domain of Plkl in U-2 OS cells. J Biol Chem 277,
32282-32293.
44. Elia, A.E., Cantley, L.C., and Yaffe, M.B. (2003). Proteomic screen finds
pSer/pThr-binding domain localizing Plkl to mitotic substrates. Science 299,
1228-1231.
45. Elia, A.E., Rellos, P., Haire, L.F., Chao, J.W., Ivins, F.J., Hoepker, K.,
Mohammad, D., Cantley, L.C., Smerdon, S.J., and Yaffe, M.B. (2003). The
molecular basis for phosphodependent substrate targeting and regulation of Plks
by the Polo-box domain. Cell 115, 83-95.
46. Scott, M.P., and Miller, W.T. (2000). A peptide model system for processive
phosphorylation by Src family kinases. Biochemistry 39, 14531-14537.
47. Mayer, B.J., Hirai, H., and Sakai, R. (1995). Evidence that SH2 domains promote
processive phosphorylation by protein-tyrosine kinases. Curr Biol 5, 296-305.
48. Pellicena, P., and Miller, W.T. (2002). Coupling kinase activation to substrate
recognition in SRC-family tyrosine kinases. Front Biosci 7, d256-267.
49. Frame, S., and Cohen, P. (2001). GSK3 takes centre stage more than 20 years
after its discovery. Biochem J 359, 1-16.
50. Toyoshima-Morimoto, F., Taniguchi, E., and Nishida, E. (2002). Plkl promotes
nuclear translocation of human Cdc25C during prophase. EMBO Rep 3, 341-348.
51. Lin, H.R., Ting, N.S., Qin, J., and Lee, W.H. (2003). M phase-specific
phosphorylation of BRCA2 by Polo-like kinase 1 correlates with the dissociation
of the BRCA2-P/CAF complex. J Biol Chem 278, 35979-35987.
52. Nakajima, H., Toyoshima-Morimoto, F., Taniguchi, E., and Nishida, E. (2003).
Identification of a consensus motif for Plk (Polo-like kinase) phosphorylation
reveals Mytl as a Plkl substrate. J Biol Chem 278, 25277-25280.
53. Jackman, M., Lindon, C., Nigg, E.A., and Pines, J. (2003). Active cyclin B1-Cdkl
first appears on centrosomes in prophase. Nat Cell Biol 5, 143-148.
54. Toyoshima-Morimoto, F., Taniguchi, E., Shinya, N., Iwamatsu, A., and Nishida,
E. (2001). Polo-like kinase 1 phosphorylates cyclin Bi and targets it to the
nucleus during prophase. Nature 410, 215-220.
55. Yuan, J., Eckerdt, F., Bereiter-Hahn, J., Kurunci-Csacsko, E., Kaufmann, M., and
Strebhardt, K. (2002). Cooperative phosphorylation including the activity of polo-
like kinase 1 regulates the subcellular localization of cyclin B 1. Oncogene 21,
8282-8292.
56. Zhou, T., Aumais, J.P., Liu, X., Yu-Lee, L.Y., and Erikson, R.L. (2003). A role
for Plkl phosphorylation of NudC in cytokinesis. Dev Cell 5, 127-138.
57. Casenghi, M., Meraldi, P., Weinhart, U., Duncan, P.I., Korner, R., and Nigg, E.A.
(2003). Polo-like kinase 1 regulates Nlp, a centrosome protein involved in
microtubule nucleation. Dev Cell 5, 113-125.
58. Yarm, F.R. (2002). Plk phosphorylation regulates the microtubule-stabilizing
protein TCTP. Mol Cell Biol 22, 6209-6221.
59. Liu, X., Zhou, T., Kuriyama, R., and Erikson, R.L. (2004). Molecular interactions
of Polo-like-kinase 1 with the mitotic kinesin-like protein CHO1/MKLP-1. J Cell
Sci 117, 3233-3246.
60. Neef, R., Preisinger, C., Sutcliffe, J., Kopajtich, R., Nigg, E.A., Mayer, T.U., and
Barr, F.A. (2003). Phosphorylation of mitotic kinesin-like protein 2 by polo-like
kinase 1 is required for cytokinesis. J Cell Biol 162, 863-875.
61. Lin, C.Y., Madsen, M.L., Yarm, F.R., Jang, Y.J., Liu, X., and Erikson, R.L.
(2000). Peripheral Golgi protein GRASP65 is a target of mitotic polo-like kinase
(Plk) and Cdc2. Proc Natl Acad Sci U S A 97, 12589-12594.
62. Sutterlin, C., Lin, C.Y., Feng, Y., Ferris, D.K., Erikson, R.L., and Malhotra, V.
(2001). Polo-like kinase is required for the fragmentation of pericentriolar Golgi
stacks during mitosis. Proc Natl Acad Sci U S A 98, 9128-9132.
63. Watanabe, N., Arai, H., Nishihara, Y., Taniguchi, M., Hunter, T., and Osada, H.
(2004). M-phase kinases induce phospho-dependent ubiquitination of somatic
Weel by SCFbeta-TrCP. Proc Natl Acad Sci U S A 101, 4419-4424.
64. Kumagai, A., and Dunphy, W.G. (1996). Purification and molecular cloning of
Plxl, a Cdc25-regulatory kinase from Xenopus egg extracts. Science 273, 1377-
1380.
65. Moshe, Y., Boulaire, J., Pagano, M., and Hershko, A. (2004). Role of Polo-like
kinase in the degradation of early mitotic inhibitor 1, a regulator of the anaphase
promoting complex/cyclosome. Proc Natl Acad Sci U S A 101, 7937-7942.
66. Kumagai, A., and Dunphy, W.G. (2000). Claspin, a novel protein required for the
activation of Chkl during a DNA replication checkpoint response in Xenopus egg
extracts. Mol Cell 6, 839-849.
67. Yoo, H.Y., Kumagai, A., Shevchenko, A., and Dunphy, W.G. (2004). Adaptation
of a DNA replication checkpoint response depends upon inactivation of Claspin
by the Polo-like kinase. Cell 117, 575-588.
68. Golan, A., Yudkovsky, Y., and Hershko, A. (2002). The cyclin-ubiquitin ligase
activity of cyclosome/APC is jointly activated by protein kinases Cdkl -cyclin B
and Plk. J Biol Chem 277, 15552-15557.
69. May, K.M., Reynolds, N., Cullen, C.F., Yanagida, M., and Ohkura, H. (2002).
Polo boxes and Cut23 (Apc8) mediate an interaction between polo kinase and the
anaphase-promoting complex for fission yeast mitosis. J Cell Biol 156, 23-28.
70. Wolf, G., Elez, R., Doermer, A., Holtrich, U., Ackermann, H., Stutte, H.J.,
Altmannsberger, H.M., Rubsamen-Waigmann, H., and Strebhardt, K. (1997).
Prognostic significance of polo-like kinase (PLK) expression in non-small cell
lung cancer. Oncogene 14, 543-549.
71. Tokumitsu, Y., Mori, M., Tanaka, S., Akazawa, K., Nakano, S., and Niho, Y.
(1999). Prognostic significance of polo-like kinase expression in esophageal
carcinoma. Int J Oncol 15, 687-692.
72. Wolf, G., Hildenbrand, R., Schwar, C., Grobholz, R., Kaufmann, M., Stutte, H.J.,
Strebhardt, K., and Bleyl, U. (2000). Polo-like kinase: a novel marker of
proliferation: correlation with estrogen-receptor expression in human breast
cancer. Pathol Res Pract 196, 753-759.
73. Takai, N., Miyazaki, T., Fujisawa, K., Nasu, K., Hamanaka, R., and Miyakawa, I.
(2001). Expression of polo-like kinase in ovarian cancer is associated with
histological grade and clinical stage. Cancer Lett 164, 41-49.
74. Weichert, W., Denkert, C., Schmidt, M., Gekeler, V., Wolf, G., Kobel, M., Dietel,
M., and Hauptmann, S. (2004). Polo-like kinase isoform expression is a
prognostic factor in ovarian carcinoma. Br J Cancer 90, 815-821.
75. Weichert, W., Schmidt, M., Jacob, J., Gekeler, V., Langrehr, J., Neuhaus, P.,
Bahra, M., Denkert, C., Dietel, M., and Kristiansen, G. (2005). Overexpression of
Polo-like kinase 1 is a common and early event in pancreatic cancer.
Pancreatology 5, 259-265.
76. Gray, P.J., Jr., Bearss, D.J., Han, H., Nagle, R., Tsao, M.S., Dean, N., and Von
Hoff, D.D. (2004). Identification of human polo-like kinase 1 as a potential
therapeutic target in pancreatic cancer. Mol Cancer Ther 3, 641-646.
77. Knecht, R., Elez, R., Oechler, M., Solbach, C., von Ilberg, C., and Strebhardt, K.
(1999). Prognostic significance of polo-like kinase (PLK) expression in squamous
cell carcinomas of the head and neck. Cancer Res 59, 2794-2797.
78. Strebhardt, K., Kneisel, L., Linhart, C., Bernd, A., and Kaufmann, R. (2000).
Prognostic value of pololike kinase expression in melanomas. Jama 283, 479-480.
79. Macmillan, J.C., Hudson, J.W., Bull, S., Dennis, J.W., and Swallow, C.J. (2001).
Comparative expression of the mitotic regulators SAK and PLK in colorectal
cancer. Ann Surg Oncol 8, 729-740.
80. Takahashi, T., Sano, B., Nagata, T., Kato, H., Sugiyama, Y., Kunieda, K., Kimura,
M., Okano, Y., and Saji, S. (2003). Polo-like kinase 1 (PLK1) is overexpressed in
primary colorectal cancers. Cancer Sci 94, 148-152.
81. Weichert, W., Schmidt, M., Gekeler, V., Denkert, C., Stephan, C., Jung, K.,
Loening, S., Dietel, M., and Kristiansen, G. (2004). Polo-like kinase 1 is
overexpressed in prostate cancer and linked to higher tumor grades. Prostate 60,
240-245.
82. Yamada, S., Ohira, M., Horie, H., Ando, K., Takayasu, H., Suzuki, Y., Sugano, S.,
Hirata, T., Goto, T., Matsunaga, T., Hiyama, E., Hayashi, Y., Ando, H., Suita, S.,
Kaneko, M., Sasaki, F., Hashizume, K., Ohnuma, N., and Nakagawara, A. (2004).
Expression profiling and differential screening between hepatoblastomas and the
corresponding normal livers: identification of high expression of the PLK1
oncogene as a poor-prognostic indicator of hepatoblastomas. Oncogene 23, 5901-
5911.
83. Ito, Y., Miyoshi, E., Sasaki, N., Kakudo, K., Yoshida, H., Tomoda, C., Uruno, T.,
Takamura, Y., Miya, A., Kobayashi, K., Matsuzuka, F., Matsuura, N., Kuma, K.,
and Miyauchi, A. (2004). Polo-like kinase 1 overexpression is an early event in
the progression of papillary carcinoma. Br J Cancer 90, 414-418.
84. Weichert, W., Kristiansen, G., Schmidt, M., Gekeler, V., Noske, A., Niesporek, S.,
Dietel, M., and Denkert, C. (2005). Polo-like kinase 1 expression is a prognostic
factor in human colon cancer. World J Gastroenterol 11, 5644-5650.
85. Kneisel, L., Strebhardt, K., Bernd, A., Wolter, M., Binder, A., and Kaufmann, R.
(2002). Expression of polo-like kinase (PLK1) in thin melanomas: a novel marker
of metastatic disease. J Cutan Pathol 29, 354-358.
86. Simizu, S., and Osada, H. (2000). Mutations in the Plk gene lead to instability of
Plk protein in human tumour cell lines. Nat Cell Biol 2, 852-854.
87. Smith, M.R., Wilson, M.L., Hamanaka, R., Chase, D., Kung, H., Longo, D.L.,
and Ferris, D.K. (1997). Malignant transformation of mammalian cells initiated
by constitutive expression of the polo-like kinase. Biochem Biophys Res
Commun 234, 397-405.
88. van Vugt, M.A., van de Weerdt, B.C., Vader, G., Janssen, H., Calafat, J.,
Klompmaker, R., Wolthuis, R.M., and Medema, R.H. (2004). Polo-like kinase-1
is required for bipolar spindle formation but is dispensable for anaphase
promoting complex/Cdc20 activation and initiation of cytokinesis. J Biol Chem
279, 36841-36854.
89. Elez, R., Piiper, A., Kronenberger, B., Kock, M., Brendel, M., Hermann, E.,
Pliquett, U., Neumann, E., and Zeuzem, S. (2003). Tumor regression by
combination antisense therapy against Plkl and Bcl-2. Oncogene 22, 69-80.
90. Spankuch-Schmitt, B., Wolf, G., Solbach, C., Loibl, S., Knecht, R., Stegmuller,
M., von Minckwitz, G., Kaufmann, M., and Strebhardt, K. (2002).
Downregulation of human polo-like kinase activity by antisense oligonucleotides
induces growth inhibition in cancer cells. Oncogene 21, 3162-3171.
91. Liu, X., and Erikson, R.L. (2003). Polo-like kinase (Plk)1 depletion induces
apoptosis in cancer cells. Proc Natl Acad Sci U S A 100, 5789-5794.
92. Liu, X., Lei, M., and Erikson, R.L. (2006). Normal cells, but not cancer cells,
survive severe Plkl depletion. Mol Cell Biol 26, 2093-2108.
93. Nogawa, M., Yuasa, T., Kimura, S., Tanaka, M., Kuroda, J., Sato, K., Yokota, A.,
Segawa, H., Toda, Y., Kageyama, S., Yoshiki, T., Okada, Y., and Maekawa, T.
(2005). Intravesical administration of small interfering RNA targeting PLK-1
successfully prevents the growth of bladder cancer. J Clin Invest 115, 978-985.
94. Stevenson, C.S., Capper, E.A., Roshak, A.K., Marquez, B., Eichman, C., Jackson,
J.R., Mattern, M., Gerwick, W.H., Jacobs, R.S., and Marshall, L.A. (2002). The
identification and characterization of the marine natural product scytonemin as a
novel antiproliferative pharmacophore. J Pharmacol Exp Ther 303, 858-866.
95. Stevenson, C.S., Capper, E.A., Roshak, A.K., Marquez, B., Grace, K., Gerwick,
W.H., Jacobs, R.S., and Marshall, L.A. (2002). Scytonemin--a marine natural
product inhibitor of kinases key in hyperproliferative inflammatory diseases.
Inflamm Res 51, 112-114.
96. Liu, Y., Shreder, K.R., Gai, W., Corral, S., Ferris, D.K., and Rosenblum, J.S.
(2005). Wortmannin, a widely used phosphoinositide 3-kinase inhibitor, also
potently inhibits mammalian polo-like kinase. Chem Biol 12, 99-107.
97. Steegmaier, M., Hoffmann, M., Baum, A., Lenart, P., Petronczki, M., Krssak, M.,
Gurtler, U., Garin-Chesa, P., Lieb, S., Quant, J., Grauert, M., Adolf, G.R., Kraut,
N., Peters, J.M., and Rettig, W.J. (2007). BI 2536, a potent and selective inhibitor
of polo-like kinase 1, inhibits tumor growth in vivo. Curr Biol 17, 316-322.
98. Uckun, F.M., Dibirdik, I., Qazi, S., Vassilev, A., Ma, H., Mao, C., Benyumov, A.,
and Emami, K.H. (2007). Anti-breast cancer activity of LFM-A13, a potent
inhibitor of Polo-like kinase (PLK). Bioorg Med Chem 15, 800-814.
99. Lansing, T.J., McConnell, R.T., Duckett, D.R., Spehar, G.M., Knick, V.B.,
Hassler, D.F., Noro, N., Furuta, M., Emmitte, K.A., Gilmer, T.M., Mook, R.A.,
Jr., and Cheung, M. (2007). In vitro biological activity of a novel small-molecule
inhibitor of polo-like kinase 1. Mol Cancer Ther 6, 450-459.
100. Watanabe, N., Arai, H., Iwasaki, J., Shiina, M., Ogata, K., Hunter, T., and Osada,
H. (2005). Cyclin-dependent kinase (CDK) phosphorylation destabilizes somatic
Weel via multiple pathways. Proc Natl Acad Sci U S A 102, 11663-11668.
101. Petretti, C., Savoian, M., Montembault, E., Glover, D.M., Prigent, C., and Giet, R.
(2006). The PITSLRE/CDK1 lp58 protein kinase promotes centrosome
maturation and bipolar spindle formation. EMBO Rep 7, 418-424.
102. Wilker, E.W., van Vugt, M.A., Artim, S.A., Huang, P.H., Petersen, C.P.,
Reinhardt, H.C., Feng, Y., Sharp, P.A., Sonenberg, N., White, F.M., and Yaffe,
M.B. (2007). 14-3-3sigma controls mitotic translation to facilitate cytokinesis.
Nature 446, 329-332.
103. Hu, D., Valentine, M., Kidd, V.J., and Lahti, J.M. (2007). CDK1 lp58 is required
for the maintenance of sister chromatid cohesion. J Cell Sci 120, 2424-2434.
104. Borysov, S.I., Cheng, A.W., and Guadagno, T.M. (2006). B-Raf is critical for
MAPK activation during mitosis and is regulated in an M phase-dependent
manner in Xenopus egg extracts. J Biol Chem 281, 22586-22596.
105. Zhang, W.L., Huitorel, P., Glass, R., Fernandez-Serra, M., Arnone, M.I., Chiri, S.,
Picard, A., and Ciapa, B. (2005). A MAPK pathway is involved in the control of
mitosis after fertilization of the sea urchin egg. Dev Biol 282, 192-206.
106. Zhang, W.L., Huitorel, P., Geneviere, A.M., Chiri, S., and Ciapa, B. (2006).
Inactivation of MAPK in mature oocytes triggers progression into mitosis via a
Ca2+ -dependent pathway but without completion of S phase. J Cell Sci 119,
3491-3501.
107. MacCorkle, R.A., and Tan, T.H. (2004). Inhibition of JNK2 disrupts anaphase
and produces aneuploidy in mammalian cells. J Biol Chem 279, 40112-40121.
108. Neef, R., Gruneberg, U., Kopajtich, R., Li, X., Nigg, E.A., Sillje, H., and Barr,
F.A. (2007). Choice of Plkl docking partners during mitosis and cytokinesis is
controlled by the activation state of Cdkl. Nat Cell Biol 9, 436-444.
109. Kang, Y.H., Park, J.E., Yu, L.R., Soung, N.K., Yun, S.M., Bang, J.K., Seong,
Y.S., Yu, H., Garfield, S., Veenstra, T.D., and Lee, K.S. (2006). Self-regulated
Plkl recruitment to kinetochores by the Plkl-PBIP1 interaction is critical for
proper chromosome segregation. Mol Cell 24, 409-422.
110. Irniger, S. (2002). Cyclin destruction in mitosis: a crucial task of Cdc20. FEBS
Lett 532, 7-11.
111. Fu, C., Yan, F., Wu, F., Wu, Q., Whittaker, J., Hu, H., Hu, R., and Yao, X. (2007).
Mitotic phosphorylation of PRC1 at Thr470 is required for PRC1 oligomerization
and proper central spindle organization. Cell Res 17, 449-457.
112. Hansen, D.V., Loktev, A.V., Ban, K.H., and Jackson, P.K. (2004). Plkl regulates
activation of the anaphase promoting complex by phosphorylating and triggering
SCFbetaTrCP-dependent destruction of the APC Inhibitor Emil. Mol Biol Cell 15,
5623-5634.
113. De Luca, M., Lavia, P., and Guarguaglini, G. (2006). A functional interplay
between Aurora-A, Plk1 and TPX2 at spindle poles: Plkl controls centrosomal
localization of Aurora-A and TPX2 spindle association. Cell Cycle 5, 296-303.
114. Goto, H., Kiyono, T., Tomono, Y., Kawajiri, A., Urano, T., Furukawa, K., Nigg,
E.A., and Inagaki, M. (2006). Complex formation of Plkl and INCENP required
for metaphase-anaphase transition. Nat Cell Biol 8, 180-187.
115. Cheeseman, I.M., Anderson, S., Jwa, M., Green, E.M., Kang, J., Yates, J.R., 3rd,
Chan, C.S., Drubin, D.G., and Barnes, G. (2002). Phospho-regulation of
kinetochore-microtubule attachments by the Aurora kinase Ipllp. Cell 111, 163-
172.
116. Honda, R., Korner, R., and Nigg, E.A. (2003). Exploring the functional
interactions between Aurora B, INCENP, and survivin in mitosis. Mol Biol Cell
14, 3325-3341.
117. Fu, J., Bian, M., Jiang, Q., and Zhang, C. (2007). Roles of Aurora kinases in
mitosis and tumorigenesis. Mol Cancer Res 5, 1-10.
118. Rancati, G., Crispo, V., Lucchini, G., and Piatti, S. (2005). Mad3/BubR1
phosphorylation during spindle checkpoint activation depends on both Polo and
Aurora kinases in budding yeast. Cell Cycle 4, 972-980.
119. Goto, H., Yasui, Y., Kawajiri, A., Nigg, E.A., Terada, Y., Tatsuka, M., Nagata, K.,
and Inagaki, M. (2003). Aurora-B regulates the cleavage furrow-specific vimentin
phosphorylation in the cytokinetic process. J Biol Chem 278, 8526-8530.
120. Yamaguchi, T., Goto, H., Yokoyama, T., Sillje, H., Hanisch, A., Uldschmid, A.,
Takai, Y., Oguri, T., Nigg, E.A., and Inagaki, M. (2005). Phosphorylation by
Cdkl induces Plkl-mediated vimentin phosphorylation during mitosis. J Cell Biol
171, 431-436.
121. Guse, A., Mishima, M., and Glotzer, M. (2005). Phosphorylation of ZEN-
4/MKLP1 by aurora B regulates completion of cytokinesis. Curr Biol 15, 778-786.
122. O'Connell, M.J., Krien, M.J., and Hunter, T. (2003). Never say never. The NIMA-
related protein kinases in mitotic control. Trends Cell Biol 13, 221-228.
123. Rapley, J., Baxter, J.E., Blot, J., Wattam, S.L., Casenghi, M., Meraldi, P., Nigg,
E.A., and Fry, A.M. (2005). Coordinate regulation of the mother centriole
component nlp by nek2 and plkl protein kinases. Mol Cell Biol 25, 1309-1324.
124. Roig, J., Groen, A., Caldwell, J., and Avruch, J. (2005). Active Nerccl protein
kinase concentrates at centrosomes early in mitosis and is necessary for proper
spindle assembly. Mol Biol Cell 16, 4827-4840.
125. Roig, J., Mikhailov, A., Belham, C., and Avruch, J. (2002). Nerccl, a mammalian
NIMA-family kinase, binds the Ran GTPase and regulates mitotic progression.
Genes Dev 16, 1640-1658.
126. Belham, C., Roig, J., Caldwell, J.A., Aoyama, Y., Kemp, B.E., Comb, M., and
Avruch, J. (2003). A mitotic cascade of NIMA family kinases. Nerccl/Nek9
activates the Nek6 and Nek7 kinases. J Biol Chem 278, 34897-34909.
127. Yabuta, N., Okada, N., Ito, A., Hosomi, T., Nishihara, S., Sasayama, Y., Fujimori,
A., Okuzaki, D., Zhao, H., Ikawa, M., Okabe, M., and Nojima, H. (2007). Lats2 is
an essential mitotic regulator required for the coordination of cell division. J Biol
Chem.
128. Abe, Y., Ohsugi, M., Haraguchi, K., Fujimoto, J., and Yamamoto, T. (2006).
LATS2-Ajuba complex regulates gamma-tubulin recruitment to centrosomes and
spindle organization during mitosis. FEBS Lett 580, 782-788.
129. Toji, S., Yabuta, N., Hosomi, T., Nishihara, S., Kobayashi, T., Suzuki, S., Tamai,
K., and Nojima, H. (2004). The centrosomal protein Lats2 is a phosphorylation
target of Aurora-A kinase. Genes Cells 9, 383-397.
130. Aylon, Y., Michael, D., Shmueli, A., Yabuta, N., Nojima, H., and Oren, M.
(2006). A positive feedback loop between the p53 and Lats2 tumor suppressors
prevents tetraploidization. Genes Dev 20, 2687-2700.
131. Yang, X., Yu, K., Hao, Y., Li, D.M., Stewart, R., Insogna, K.L., and Xu, T.
(2004). LATS 1 tumour suppressor affects cytokinesis by inhibiting LIMK1. Nat
Cell Biol 6, 609-617.
132. Morisaki, T., Hirota, T., lida, S., Marumoto, T., Hara, T., Nishiyama, Y.,
Kawasuzi, M., Hiraoka, T., Mimori, T., Araki, N., Izawa, I., Inagaki, M., and
Saya, H. (2002). WARTS tumor suppressor is phosphorylated by Cdc2/cyclin B
at spindle poles during mitosis. FEBS Lett 529, 319-324.
133. Nishiyama, Y., Hirota, T., Morisaki, T., Hara, T., Marumoto, T., Iida, S., Makino,
K., Yamamoto, H., Hiraoka, T., Kitamura, N., and Saya, H. (1999). A human
homolog of Drosophila warts tumor suppressor, h-warts, localized to mitotic
apparatus and specifically phosphorylated during mitosis. FEBS Lett 459, 159-
165.
134. Sumi, T., Matsumoto, K., and Nakamura, T. (2002). Mitosis-dependent
phosphorylation and activation of LIM-kinase 1. Biochem Biophys Res Commun
290, 1315-1320.
135. Wakefield, J.G., Stephens, D.J., and Tavare, J.M. (2003). A role for glycogen
synthase kinase-3 in mitotic spindle dynamics and chromosome alignment. J Cell
Sci 116, 637-646.
136. Acevedo, N., Wang, X., Dunn, R.L., and Smith, G.D. (2007). Glycogen synthase
kinase-3 regulation of chromatin segregation and cytokinesis in mouse
preimplantation embryos. Mol Reprod Dev 74, 178-188.
137. Yeh, T.Y., Sbodio, J.I., and Chi, N.W. (2006). Mitotic phosphorylation of
tankyrase, a PARP that promotes spindle assembly, by GSK3. Biochem Biophys
Res Commun 350, 574-579.
138. Dai, J., Sultan, S., Taylor, S.S., and Higgins, J.M. (2005). The kinase haspin is
required for mitotic histone H3 Thr 3 phosphorylation and normal metaphase
chromosome alignment. Genes Dev 19, 472-488.
139. Dai, J., Sullivan, B.A., and Higgins, J.M. (2006). Regulation of mitotic
chromosome cohesion by Haspin and Aurora B. Dev Cell 11, 741-750.
140. Nandi, A.K., Ford, T., Fleksher, D., Neuman, B., and Rapoport, A.P. (2007).
Attenuation of DNA damage checkpoint by PBK, a novel mitotic kinase, involves
protein-protein interaction with tumor suppressor p53. Biochem Biophys Res
Commun 358, 181-188.
141. Abe, Y., Takeuchi, T., Kagawa-Miki, L., Ueda, N., Shigemoto, K., Yasukawa, M.,
and Kito, K. (2007). A Mitotic Kinase TOPK Enhances Cdkl/cyclin B1-
dependent Phosphorylation of PRC1 and Promotes Cytokinesis. J Mol Biol 370,
231-245.
142. Cardenas, M.E., Dang, Q., Glover, C.V., and Gasser, S.M. (1992). Casein kinase
II phosphorylates the eukaryote-specific C-terminal domain of topoisomerase II in
vivo. Embo J 11, 1785-1796.
143. Escargueil, A.E., Plisov, S.Y., Filhol, O., Cochet, C., and Larsen, A.K. (2000).
Mitotic phosphorylation of DNA topoisomerase II alpha by protein kinase CK2
creates the MPM-2 phosphoepitope on Ser-1469. J Biol Chem 275, 34710-34718.
144. Chung, E., and Chen, R.H. (2003). Phosphorylation of Cdc20 is required for its
inhibition by the spindle checkpoint. Nat Cell Biol 5, 748-753.
145. Home, M.M., and Guadagno, T.M. (2003). A requirement for MAP kinase in the
assembly and maintenance of the mitotic spindle. J Cell Biol 161, 1021-1028.
146. Roberts, E.C., Shapiro, P.S., Nahreini, T.S., Pages, G., Pouyssegur, J., and Ahn,
N.G. (2002). Distinct cell cycle timing requirements for extracellular signal-
regulated kinase and phosphoinositide 3-kinase signaling pathways in somatic cell
mitosis. Mol Cell Biol 22, 7226-7241.
147. Zhao, Z.S., Lim, J.P., Ng, Y.W., Lim, L., and Manser, E. (2005). The GIT-
associated kinase PAK targets to the centrosome and regulates Aurora-A. Mol
Cell 20, 237-249.
148. Thiel, D.A., Reeder, M.K., Pfaff, A., Coleman, T.R., Sells, M.A., and Chernoff, J.
(2002). Cell cycle-regulated phosphorylation of p21-activated kinase 1. Curr Biol
12, 1227-1232.
149. Banerjee, M., Worth, D., Prowse, D.M., and Nikolic, M. (2002). Paki
phosphorylation on t212 affects microtubules in cells undergoing mitosis. Curr
Biol 12, 1233-1239.
150. D'Aquino, K.E., Monje-Casas, F., Paulson, J., Reiser, V., Charles, G.M., Lai, L.,
Shokat, K.M., and Amon, A. (2005). The protein kinase Kin4 inhibits exit from
mitosis in response to spindle position defects. Mol Cell 19, 223-234.
151. Pereira, G., and Schiebel, E. (2005). Kin4 kinase delays mitotic exit in response to
spindle alignment defects. Mol Cell 19, 209-221.
152. Draviam, V.M., Stegmeier, F., Nalepa, G., Sowa, M.E., Chen, J., Liang, A.,
Hannon, G.J., Sorger, P.K., Harper, J.W., and Elledge, S.J. (2007). A functional
genomic screen identifies a role for TAO 1 kinase in spindle-checkpoint signalling.
Nat Cell Biol 9, 556-564.
153. Musacchio, A., and Salmon, E.D. (2007). The spindle-assembly checkpoint in
space and time. Nat Rev Mol Cell Biol 8, 379-393.
154. Bardin, A.J., and Amon, A. (2001). Men and sin: what's the difference? Nat Rev
Mol Cell Biol 2, 815-826.
155. Nelson, B., Kurischko, C., Horecka, J., Mody, M., Nair, P., Pratt, L., Zougman,
A., McBroom, L.D., Hughes, T.R., Boone, C., and Luca, F.C. (2003). RAM: a
conserved signaling network that regulates Ace2p transcriptional activity and
polarized morphogenesis. Mol Biol Cell 14, 3782-3803.
156. Matsumura, F. (2005). Regulation of myosin II during cytokinesis in higher
eukaryotes. Trends Cell Biol 15, 371-377.
157. Lee, K.S., Park, J.E., Asano, S., and Park, C.J. (2005). Yeast polo-like kinases:
functionally conserved multitask mitotic regulators. Oncogene 24, 217-229.
158. van de Weerdt, B.C., and Medema, R.H. (2006). Polo-like kinases: a team in
control of the division. Cell Cycle 5, 853-864.
159. Fisk, H.A., Mattison, C.P., and Winey, M. (2003). Human Mpsl protein kinase is
required for centrosome duplication and normal mitotic progression. Proc Natl
Acad Sci U S A 100, 14875-14880.
160. Stucke, V.M., Sillje, H.H., Arnaud, L., and Nigg, E.A. (2002). Human Mpsl
kinase is required for the spindle assembly checkpoint but not for centrosome
duplication. Embo J 21, 1723-1732.
161. Leng, M., Chan, D.W., Luo, H., Zhu, C., Qin, J., and Wang, Y. (2006). MPS1-
dependent mitotic BLM phosphorylation is important for chromosome stability.
Proc Natl Acad Sci U S A 103, 11485-11490.
162. Hansen, D.V., Tung, J.J., and Jackson, P.K. (2006). CaMKII and polo-like kinase
1 sequentially phosphorylate the cytostatic factor Emi2/XErpl to trigger its
destruction and meiotic exit. Proc Natl Acad Sci U S A 103, 608-613.
163. Schmidt, A., Duncan, P.I., Rauh, N.R., Sauer, G., Fry, A.M., Nigg, E.A., and
Mayer, T.U. (2005). Xenopus polo-like kinase Plxl regulates XErpl, a novel
inhibitor of APC/C activity. Genes Dev 19, 502-513.
164. Liu, J., and Maller, J.L. (2005). Calcium elevation at fertilization coordinates
phosphorylation of XErpl/Emi2 by Plxl and CaMK II to release metaphase arrest
by cytostatic factor. Curr Biol 15, 1458-1468.
165. Bartek, J., and Lukas, J. (2007). DNA damage checkpoints: from initiation to
recovery or adaptation. Curr Opin Cell Biol 19, 238-245.
166. Toczyski, D.P., Galgoczy, D.J., and Hartwell, L.H. (1997). CDC5 and CKII
control adaptation to the yeast DNA damage checkpoint. Cell 90, 1097-1106.
167. Gewurz, B.E., and Harper, J.W. (2006). DNA-damage control: Claspin
destruction turns off the checkpoint. Curr Biol 16, R932-934.
168. Syljuasen, R.G., Jensen, S., Bartek, J., and Lukas, J. (2006). Adaptation to the
ionizing radiation-induced G2 checkpoint occurs in human cells and depends on
checkpoint kinase 1 and Polo-like kinase 1 kinases. Cancer Res 66, 10253-10257.
169. van Vugt, M.A., Bras, A., and Medema, R.H. (2004). Polo-like kinase-1 controls
recovery from a G2 DNA damage-induced arrest in mammalian cells. Mol Cell
15, 799-811.
170. Mailand, N., Bekker-Jensen, S., Bartek, J., and Lukas, J. (2006). Destruction of
Claspin by SCFbetaTrCP restrains Chkl activation and facilitates recovery from
genotoxic stress. Mol Cell 23, 307-318.
171. Peschiaroli, A., Dorrello, N.V., Guardavaccaro, D., Venere, M., Halazonetis, T.,
Sherman, N.E., and Pagano, M. (2006). SCFbetaTrCP-mediated degradation of
Claspin regulates recovery from the DNA replication checkpoint response. Mol
Cell 23, 319-329.
172. Mamely, I., van Vugt, M.A., Smits, V.A., Semple, J.I., Lemmens, B., Perrakis, A.,
Medema, R.H., and Freire, R. (2006). Polo-like kinase-1 controls proteasome-
dependent degradation of Claspin during checkpoint recovery. Curr Biol 16,
1950-1955.
173. Tsvetkov, L.M., Tsekova, R.T., Xu, X., and Stem, D.F. (2005). The Plkl Polo
box domain mediates a cell cycle and DNA damage regulated interaction with
Chk2. Cell Cycle 4, 609-617.
174. Tsvetkov, L., Xu, X., Li, J., and Stem, D.F. (2003). Polo-like kinase 1 and Chk2
interact and co-localize to centrosomes and the midbody. J Biol Chem 278, 8468-
8475.
175. Zhou, B.B., and Elledge, S.J. (2000). The DNA damage response: putting
checkpoints in perspective. Nature 408, 433-439.
176. Reinhardt, H.C., Aslanian, A.S., Lees, J.A., and Yaffe, M.B. (2007). p53-deficient
cells rely on ATM- and ATR-mediated checkpoint signaling through the
p38MAPK/MK2 pathway for survival after DNA damage. Cancer Cell 11, 175-
189.
177. Aumais, J.P., Williams, S.N., Luo, W., Nishino, M., Caldwell, K.A., Caldwell,
G.A., Lin, S.H., and Yu-Lee, L.Y. (2003). Role for NudC, a dynein-associated
nuclear movement protein, in mitosis and cytokinesis. J Cell Sci 116, 1991-2003.
178. Nishino, M., Kurasawa, Y., Evans, R., Lin, S.H., Brinkley, B.R., and Yu-Lee, L.Y.
(2006). NudC is required for Plkl targeting to the kinetochore and chromosome
congression. Curr Biol 16, 1414-1421.
179. Li, J., Meyer, A.N., and Donoghue, D.J. (1995). Requirement for phosphorylation
of cyclin B 1 for Xenopus oocyte maturation. Mol Biol Cell 6, 1111-1124.
180. Qi, W., Tang, Z., and Yu, H. (2006). Phosphorylation- and polo-box-dependent
binding of Plkl to Bub1 is required for the kinetochore localization of Plkl. Mol
Biol Cell 17, 3705-3716.
181. Niiya, F., Tatsumoto, T., Lee, K.S., and Miki, T. (2006). Phosphorylation of the
cytokinesis regulator ECT2 at G2/M phase stimulates association of the mitotic
kinase Plki and accumulation of GTP-bound RhoA. Oncogene 25, 827-837.
182. Baumann, C., Korner, R., Hofmann, K., and Nigg, E.A. (2007). PICH, a
centromere-associated SNF2 family ATPase, is regulated by Plkl and required for
the spindle checkpoint. Cell 128, 101-114.
183. Zhang, Y., Tian, Y., Chen, Q., Chen, D., Zhai, Z., and Shu, H.B. (2007). TTDN1
is a Plkl -interacting protein involved in maintenance of cell cycle integrity. Cell
Mol Life Sci 64, 632-640.
184. Litvak, V., Argov, R., Dahan, N., Ramachandran, S., Amarilio, R., Shainskaya, A.,
and Lev, S. (2004). Mitotic phosphorylation of the peripheral Golgi protein Nir2
by Cdkl provides a docking mechanism for Plkl and affects cytokinesis
completion. Mol Cell 14, 319-330.
185. Sumara, I., Vorlaufer, E., Stukenberg, P.T., Kelm, O., Redemann, N., Nigg, E.A.,
and Peters, J.M. (2002). The dissociation of cohesin from chromosomes in
prophase is regulated by Polo-like kinase. Mol Cell 9, 515-525.
186. Cheng, L., Hunke, L., and Hardy, C.F. (1998). Cell cycle regulation of the
Saccharomyces cerevisiae polo-like kinase cdc5p. Mol Cell Biol 18, 7360-7370.
187. Hardy, C.F., and Pautz, A. (1996). A novel role for Cdc5p in DNA replication.
Mol Cell Biol 16, 6775-6782.
188. Hamanaka, R., Smith, M.R., O'Connor, P.M., Maloid, S., Mihalic, K., Spivak,
J.L., Longo, D.L., and Ferris, D.K. (1995). Polo-like kinase is a cell cycle-
regulated kinase activated during mitosis. J Biol Chem 270, 21086-21091.
189. Charles, J.F., Jaspersen, S.L., Tinker-Kulberg, RL., Hwang, L., Szidon, A., and
Morgan, D.O. (1998). The Polo-related kinase Cdc5 activates and is destroyed by
the mitotic cyclin destruction machinery in S. cerevisiae. Curr Biol 8, 497-507.
190. Lindon, C., and Pines, J. (2004). Ordered proteolysis in anaphase inactivates Plkl
to contribute to proper mitotic exit in human cells. J Cell Biol 164, 233-241.
191. Mundt, K.E., Golsteyn, R.M., Lane, H.A., and Nigg, E.A. (1997). On the
regulation and function of human polo-like kinase 1 (PLK1): effects of
overexpression on cell cycle progression. Biochem Biophys Res Commun 239,
377-385.
192. Tavares, A.A., Glover, D.M., and Sunkel, C.E. (1996). The conserved mitotic
kinase polo is regulated by phosphorylation and has preferred microtubule-
associated substrates in Drosophila embryo extracts. Embo J 15, 4873-4883.
193. Mortensen, E.M., Haas, W., Gygi, M., Gygi, S.P., and Kellogg, D.R. (2005).
Cdc28-dependent regulation of the Cdc5/Polo kinase. Curr Biol 15, 2033-2037.
194. Lee, K.S., and Erikson, R.L. (1997). Plk is a functional homolog of
Saccharomyces cerevisiae Cdc5, and elevated Plk activity induces multiple
septation structures. Mol Cell Biol 17, 3408-3417.
195. Jang, Y.J., Ma, S., Terada, Y., and Erikson, R.L. (2002). Phosphorylation of
threonine 210 and the role of serine 137 in the regulation of mammalian polo-like
kinase. J Biol Chem 277, 44115-44120.
196. Maclver, F.H., Tanaka, K., Robertson, A.M., and Hagan, I.M. (2003). Physical
and functional interactions between polo kinase and the spindle pole component
Cutl2 regulate mitotic commitment in S. pombe. Genes Dev 17, 1507-1523.
197. Kelm, O., Wind, M., Lehmann, W.D., and Nigg, E.A. (2002). Cell cycle-
regulated phosphorylation of the Xenopus polo-like kinase Plxl. J Biol Chem 277,
25247-25256.
198. Johnson, L.N., Noble, M.E., and Owen, D.J. (1996). Active and inactive protein
kinases: structural basis for regulation. Cell 85, 149-158.
199. Tsvetkov, L., and Stem, D.F. (2005). Phosphorylation of Plkl at S137 and T210
is inhibited in response to DNA damage. Cell Cycle 4, 166-171.
200. van de Weerdt, B.C., van Vugt, M.A., Lindon, C., Kauw, J.J., Rozendaal, M.J.,
Klompmaker, R., Wolthuis, R.M., and Medema, R.H. (2005). Uncoupling
anaphase-promoting complex/cyclosome activity from spindle assembly
checkpoint control by deregulating polo-like kinase 1. Mol Cell Biol 25, 2031-
2044.
201. Qian, Y.W., Erikson, E., and Maller, J.L. (1998). Purification and cloning of a
protein kinase that phosphorylates and activates the polo-like kinase Plxl. Science
282, 1701-1704.
202. Erikson, E., Haystead, T.A., Qian, Y.W., and Maller, J.L. (2004). A feedback
loop in the polo-like kinase activation pathway. J Biol Chem.
203. Ellinger-Ziegelbauer, H., Karasuyama, H., Yamada, E., Tsujikawa, K., Todokoro,
K., and Nishida, E. (2000). Ste20-like kinase (SLK), a regulatory kinase for polo-
like kinase (Plk) during the G2/M transition in somatic cells. Genes Cells 5, 491-
498.
204. Walter, S.A., Cutler, R.E., Jr., Martinez, R., Gishizky, M., and Hill, R.J. (2003).
StklO0, a new me mber of the polo-like kinase kinase family highly expressed in
hematopoietic tissue. J Biol Chem 278, 18221-18228.
205. Wind, M., Kelm, O., Nigg, E.A., and Lehmann, W.D. (2002). Identification of
phosphorylation sites in the polo-like kinases Plxl and Plk1 by a novel strategy
based on element and electrospray high resolution mass spectrometry. Proteomics
2, 1516-1523.
206. Petersen, J., and Hagan, I.M. (2005). Polo kinase links the stress pathway to cell
cycle control and tip growth in fission yeast. Nature 435, 507-512.
207. Karaiskou, A., Cayla, X., Haccard, O., Jessus, C., and Ozon, R. (1998). MPF
amplification in Xenopus oocyte extracts depends on a two-step activation of
cdc25 phosphatase. Exp Cell Res 244, 491-500.
208. Karaiskou, A., Jessus, C., Brassac, T., and Ozon, R. (1999). Phosphatase 2A and
polo kinase, two antagonistic regulators of cdc25 activation and MPF auto-
amplification. J Cell Sci 112 (Pt 21), 3747-3756.
209. Qian, Y.W., Erikson, E., Taieb, F.E., and Maller, J.L. (2001). The polo-like
kinase Plxl is required for activation of the phosphatase Cdc25C and cyclin B-
Cdc2 in Xenopus oocytes. Mol Biol Cell 12, 1791-1799.
210. Abrieu, A., Brassac, T., Galas, S., Fisher, D., Labbe, J.C., and Doree, M. (1998).
The Polo-like kinase Plxl is a component of the MPF amplification loop at the
G2/M-phase transition of the cell cycle in Xenopus eggs. J Cell Sci 111 (Pt 12),
1751-1757.
211. Alexandru, G., Uhlmann, F., Mechtler, K., Poupart, M.A., and Nasmyth, K.
(2001). Phosphorylation of the cohesin subunit Sccl by Polo/Cdc5 kinase
regulates sister chromatid separation in yeast. Cell 105, 459-472.
212. Ohkura, H., Hagan, I.M., and Glover, D.M. (1995). The conserved
Schizosaccharomyces pombe kinase plo , required to form a bipolar spindle, the
actin ring, and septum, can drive septum formation in G and G2 cells. Genes
Dev 9, 1059-1073.
213. Adams, R.R., Tavares, A.A., Salzberg, A., Bellen, H.J., and Glover, D.M. (1998).
pavarotti encodes a kinesin-like protein required to organize the central spindle
and contractile ring for cytokinesis. Genes Dev 12, 1483-1494.
214. Carmena, M., Riparbelli, M.G., Minestrini, G., Tavares, A.M., Adams, R.,
Callaini, G., and Glover, D.M. (1998). Drosophila polo kinase is required for
cytokinesis. J Cell Biol 143, 659-671.
215. Descombes, P., and Nigg, E.A. (1998). The polo-like kinase Plxl is required for
M phase exit and destruction of mitotic regulators in Xenopus egg extracts. Embo
J 17, 1328-1335.
216. Kotani, S., Tugendreich, S., Fujii, M., Jorgensen, P.M., Watanabe, N., Hoog, C.,
Hieter, P., and Todokoro, K. (1998). PKA and MPF-activated polo-like kinase
regulate anaphase-promoting complex activity and mitosis progression. Mol Cell
1, 371-380.
217. Kurnagai, A., and Dunphy, W.G. (1992). Regulation of the cdc25 protein during
the cell cycle in Xenopus extracts. Cell 70, 139-151.
218. Hoffmann, I., Clarke, P.R., Marcote, M.J., Karsenti, E., and Draetta, G. (1993).
Phosphorylation and activation of human cdc25-C by cdc2--cyclin B and its
involvement in the self-amplification of MPF at mitosis. Embo J 12, 53-63.
219. Izumi, T., and Maller, J.L. (1995). Phosphorylation and activation of the Xenopus
Cdc25 phosphatase in the absence of Cdc2 and Cdk2 kinase activity. Mol Biol
Cell 6, 215-226.
220. Izumi, T., and Maller, J.L. (1993). Elimination of cdc2 phosphorylation sites in
the cdc25 phosphatase blocks initiation of M-phase. Mol Biol Cell 4, 1337-1350.
221. Gabrielli, B.G., De Souza, C.P., Tonks, I.D., Clark, J.M., Hayward, N.K., and
Ellem, K.A. (1996). Cytoplasmic accumulation of cdc25B phosphatase in mitosis
triggers centrosomal microtubule nucleation in HeLa cells. J Cell Sci 109 (Pt 5),
1081-1093.
222. Lanmmer, C., Wagerer, S., Saffrich, R., Mertens, D., Ansorge, W., and Hoffmann,
I. (1998). The cdc25B phosphatase is essential for the G2/M phase transition in
human cells. J Cell Sci 111 (Pt 16), 2445-2453.
223. Budde, P.P., Kumagai, A., Dunphy, W.G., and Heald, R. (2001). Regulation of
Op18 during spindle assembly in Xenopus egg extracts. J Cell Biol 153, 149-158.
224. Feng, Y., Hodge, D.R., Palmieri, G., Chase, D.L., Longo, D.L., and Ferris, D.K.
(1999). Association of polo-like kinase with alpha-, beta- and gamma-tubulins in
a stable complex. Biochem J 339 (Pt 2), 435-442.
225. Lenart, P., Petronczki, M., Steegmaier, M., Di Fiore, B., Lipp, J.J., Hoffmann, M.,
Rettig, W.J., Kraut, N., and Peters, J.M. (2007). The small-molecule inhibitor BI
2536 reveals novel insights into mitotic roles of polo-like kinase 1. Curr Biol 17,
304.-315.
226. McInnes, C., Mazumdar, A., Mezna, M., Meades, C., Midgley, C., Scaerou, F.,
Carpenter, L., Mackenzie, M., Taylor, P., Walkinshaw, M., Fischer, P.M., and
Glover, D. (2006). Inhibitors of Polo-like kinase reveal roles in spindle-pole
maintenance. Nat Chem Biol 2, 608-617.
227. Peters, U., Cherian, J., Kim, J.H., Kwok, B.H., and Kapoor, T.M. (2006). Probing
cell-division phenotype space and Polo-like kinase function using small
molecules. Nat Chem Biol 2, 618-626.
228. Ahonen, L.J., Kallio, M.J., Daum, J.R., Bolton, M., Manke, I.A., Yaffe, M.B.,
Stukenberg, P.T., and Gorbsky, G.J. (2005). Polo-like kinase 1 creates the
tension-sensing 3F3/2 phosphoepitope and modulates the association of spindle-
checkpoint proteins at kinetochores. Curr Biol 15, 1078-1089.
229. van Vugt, M.A., Smits, V.A., Klompmaker, R., and Medema, R.H. (2001).
Inhibition of Polo-like kinase-1 by DNA damage occurs in an ATM- or ATR-
dependent fashion. J Biol Chem 276, 41656-41660.
230. Kraft, C., Herzog, F., Gieffers, C., Mechtler, K., Hagting, A., Pines, J., and Peters,
J.M. (2003). Mitotic regulation of the human anaphase-promoting complex by
phosphorylation. Embo J 22, 6598-6609.
231. Hornig, N.C., and Uhlmann, F. (2004). Preferential cleavage of chromatin-bound
cohesin after targeted phosphorylation by Polo-like kinase. Embo J 23, 3144-3153.
232. Clarke, A.S., Tang, T.T., Ooi, D.L., and Orr-Weaver, T.L. (2005). POLO kinase
regulates the Drosophila centromere cohesion protein MEI-S332. Dev Cell 8, 53-
64.
233. Stegmeier, F., and Amon, A. (2004). Closing mitosis: the functions of the Cdcl4
phosphatase and its regulation. Annu Rev Genet 38, 203-232.
234. Stegmeier, F., Visintin, R., and Amon, A. (2002). Separase, polo kinase, the
kinetochore protein Slkl9, and Spol2 function in a network that controls Cdcl4
localization during early anaphase. Cell 108, 207-220.
235. Yuan, K., Hu, H., Guo, Z., Fu, G., Shaw, A.P., Hu, R., and Yao, X. (2007).
Phospho-regulation of HSCDC 14A by polo-like kinase 1 is essential for mitotic
progression. J Biol Chem.
236. Zhang, H., Shi, X., Paddon, H., Hampong, M., Dai, W., and Pelech, S. (2004).
B23/nucleophosmin serine 4 phosphorylation mediates mitotic functions of polo-
like kinase 1. J Biol Chem 279, 35726-35734.
237. Fabbro, M., Zhou, B.B., Takahashi, M., Sarcevic, B., Lal, P., Graham, M.E.,
Gabrielli, B.G., Robinson, P.J., Nigg, E.A., Ono, Y., and Khanna, K.K. (2005).
Cdkl/Erk2- and Plkl -dependent phosphorylation of a centrosome protein, Cep55,
is required for its recruitment to midbody and cytokinesis. Dev Cell 9, 477-488.
238. Lee., B.H., and Amon, A. (2003). Role of Polo-like kinase CDC5 in programming
meiosis I chromosome segregation. Science 300, 482-486.
239. Brar, G.A., Kiburz, B.M., Zhang, Y., Kim, J.E., White, F., and Amon, A. (2006).
Rec8 phosphorylation and recombination promote the step-wise loss of cohesins
in meiosis. Nature 441, 532-536.
240. Smits, V.A., Klompmaker, R., Arnaud, L., Rijksen, G., Nigg, E.A., and Medema,
R.H. (2000). Polo-like kinase-1 is a target of the DNA damage checkpoint. Nat
Cell Biol 2, 672-676.
241. Lee, S.E., Moore, J.K., Holmes, A., Umezu, K., Kolodner, R.D., and Haber, J.E.
(1998). Saccharomyces Ku70, mrel 1/rad50 and RPA proteins regulate adaptation
to G2/M arrest after DNA damage. Cell 94, 399-409.
242. Pellicioli, A., Lee, S.E., Lucca, C., Foiani, M., and Haber, J.E. (2001). Regulation
of Saccharomyces Rad53 checkpoint kinase during adaptation from DNA
damage-induced G2/M arrest. Mol Cell 7, 293-300.
243. Lee, S.E., Pellicioli, A., Malkova, A., Foiani, M., and Haber, J.E. (2001). The
Saccharomyces recombination protein Tidlp is required for adaptation from
G2/M arrest induced by a double-strand break. Curr Biol 11, 1053-1057.
244. Shimizu-Yoshida, Y., Sugiyama, K., Rogounovitch, T., Ohtsuru, A., Namba, H.,
Saenko, V., and Yamashita, S. (2001). Radiation-inducible hSNK gene is
transcriptionally regulated by p53 binding homology element in human thyroid
cells. Biochem Biophys Res Commun 289, 491-498.
245. Ma, S., Charron, J., and Erikson, R.L. (2003). Role of Plk2 (Snk) in mouse
development and cell proliferation. Mol Cell Biol 23, 6936-6943.
246. Warnke, S., Kemmler, S., Hames, R.S., Tsai, H.L., Hoffmann-Rohrer, U., Fry,
A.M., and Hoffmann, I. (2004). Polo-like kinase-2 is required for centriole
duplication in mammalian cells. Curr Biol 14, 1200-1207.
247. Chase, D., Feng, Y., Hanshew, B., Winkles, J.A., Longo, D.L., and Ferris, D.K.
(1998). Expression and phosphorylation of fibroblast-growth-factor-inducible
kinase (Fnk) during cell-cycle progression. Biochem J 333 (Pt 3), 655-660.
248. Anger, M., Kues, W.A., Klima, J., Mielenz, M., Kubelka, M., Motlik, J., Esner,
M., Dvorak, P., Carnwath, J.W., and Niemann, H. (2003). Cell cycle dependent
expression of Plkl in synchronized porcine fetal fibroblasts. Mol Reprod Dev 65,
245-253.
249. Li, B., Ouyang, B., Pan, H., Reissmann, P.T., Slamon, D.J., Arceci, R., Lu, L.,
and Dai, W. (1996). Prk, a cytokine-inducible human protein serine/threonine
kinase whose expression appears to be down-regulated in lung carcinomas. J Biol
Chem 271, 19402-19408.
250. Winkles, J.A., and Alberts, G.F. (2005). Differential regulation of polo-like kinase
1, 2, 3, and 4 gene expression in mammalian cells and tissues. Oncogene 24, 260-
266.
251. Alberts, G.F., and Winkles, J.A. (2004). Murine FGF-inducible kinase is rapidly
degraded via the nuclear ubiquitin-proteosome system when overexpressed in
NIH 3T3 cells. Cell Cycle 3, 678-684.
252. Xie, S., Wang, Q., Wu, H., Cogswell, J., Lu, L., Jhanwar-Uniyal, M., and Dai, W.
(2001). Reactive oxygen species-induced phosphorylation of p53 on serine 20 is
mediated in part by polo-like kinase-3. J Biol Chem 276, 36194-36199.
253. Hirao, A., Kong, Y.Y., Matsuoka, S., Wakeham, A., Ruland, J., Yoshida, H., Liu,
D., Elledge, S.J., and Mak, T.W. (2000). DNA damage-induced activation of p53
by the checkpoint kinase Chk2. Science 287, 1824-1827.
254. Shieh, S.Y., Ahn, J., Tamai, K., Taya, Y., and Prives, C. (2000). The human
homologs of checkpoint kinases Chkl and Cdsl (Chk2) phosphorylate p53 at
multiple DNA damage-inducible sites. Genes Dev 14, 289-300.
255. Chehab, N.H., Malikzay, A., Appel, M., and Halazonetis, T.D. (2000).
Chk2/hCdsl functions as a DNA damage checkpoint in G(1) by stabilizing p53.
Genes Dev 14, 278-288.
256. O'Neill, T., Giarratani, L., Chen, P., Iyer, L., Lee, C.H., Bobiak, M., Kanai, F.,
Zhou, B.B., Chung, J.H., and Rathbun, G.A. (2002). Determination of substrate
motifs for human Chkl and hCdsl/Chk2 by the oriented peptide library approach.
J Biol Chem 277, 16102-16115.
257. Bahassi el, M., Hennigan, R.F., Myer, D.L., and Stambrook, P.J. (2004). Cdc25C
phosphorylation on serine 191 by Plk3 promotes its nuclear translocation.
Oncogene 23, 2658-2663.
258. Ouyang, B., Li, W., Pan, H., Meadows, J., Hoffmann, I., and Dai, W. (1999). The
physical association and phosphorylation of Cdc25C protein phosphatase by Prk.
Oncogene 18, 6029-6036.
259. Matsuoka, S., Huang, M., and Elledge, S.J. (1998). Linkage of ATM to cell cycle
regulation by the Chk2 protein kinase. Science 282, 1893-1897.
260. Sanchez, Y., Wong, C., Thoma, R.S., Richman, R., Wu, Z., Piwnica-Worms, H.,
and Elledge, S.J. (1997). Conservation of the Chkl checkpoint pathway in
mammals: linkage of DNA damage to Cdk regulation through Cdc25. Science
277, 1497-1501.
261. Holtrich, U., Wolf, G., Yuan, J., Bereiter-Hahn, J., Karn, T., Weiler, M.,
Kauselmann, G., Rehli, M., Andreesen, R., Kaufmann, M., Kuhl, D., and
Strebhardt, K. (2000). Adhesion induced expression of the serine/threonine kinase
Fnk in human macrophages. Oncogene 19, 4832-4839.
262. Dai, W., Li, Y., Ouyang, B., Pan, H., Reissmann, P., Li, J., Wiest, J., Stambrook,
P., Gluckman, J.L., Noffsinger, A., and Bejarano, P. (2000). PRK, a cell cycle
gene localized to 8p21, is downregulated in head and neck cancer. Genes
Chromosomes Cancer 27, 332-336.
263. Ando, K., Ozaki, T., Yamamoto, H., Furuya, K., Hosoda, M., Hayashi, S.,
Fukuzawa, M., and Nakagawara, A. (2004). Polo-like kinase 1 (Plkl) inhibits p53
function by physical interaction and phosphorylation. J Biol Chem 279, 25549-
25561.
264. Jiang, N., Wang, X., Jhanwar-Uniyal, M., Darzynkiewicz, Z., and Dai, W. (2006).
Polo box domain of Plk3 functions as a centrosome localization signal,
overexpression of which causes mitotic arrest, cytokinesis defects, and apoptosis.
J Biol Chem 281, 10577-10582.
265. Zimmerman, W.C., and Erikson, R.L. (2007). Polo-like kinase 3 is required for
entry into S phase. Proc Natl Acad Sci U S A 104, 1847-1852.
266. Fode, C., Binkert, C., and Dennis, J.W. (1996). Constitutive expression of murine
Sak-a suppresses cell growth and induces multinucleation. Mol Cell Biol 16,
4665-4672.
267. Fode, C., Motro, B., Yousefi, S., Heffernan, M., and Dennis, J.W. (1994). Sak, a
murine protein-serine/threonine kinase that is related to the Drosophila polo
kinase and involved in cell proliferation. Proc Natl Acad Sci U S A 91, 6388-6392.
268. Li, J., Tan, M., Li, L., Pamarthy, D., Lawrence, T.S., and Sun, Y. (2005). SAK, a
new polo-like kinase, is transcriptionally repressed by p53 and induces apoptosis
upon RNAi silencing. Neoplasia 7, 312-323.
269. Ko, M.A., Rosario, C.O., Hudson, J.W., Kulkarni, S., Pollett, A., Dennis, J.W.,
and Swallow, C.J. (2005). Plk4 haploinsufficiency causes mitotic infidelity and
carcinogenesis. Nat Genet 37, 883-888.
270. Bettencourt-Dias, M., Rodrigues-Martins, A., Carpenter, L., Riparbelli, M.,
Lehmann, L., Gatt, M.K., Carmo, N., Balloux, F., Callaini, G., and Glover, D.M.
(2005). SAK/PLK4 is required for centriole duplication and flagella development.
Curr Biol 15, 2199-2207.
271. Habedanck, R., Stierhof, Y.D., Wilkinson, C.J., and Nigg, E.A. (2005). The Polo
kinase Plk4 functions in centriole duplication. Nat Cell Biol 7, 1140-1146.
272. Cheng, K.Y., Lowe, E.D., Sinclair, J., Nigg, E.A., and Johnson, L.N. (2003). The
crystal structure of the human polo-like kinase- 1 polo box domain and its
phospho-peptide complex. Embo J 22, 5757-5768.
273. Garcia-Alvarez, B., de Carcer, G., Ibanez, S., Bragado-Nilsson, E., and Montoya,
G. (2007). Molecular and structural basis of polo-like kinase 1 substrate
recognition: Implications in centrosomal localization. Proc Natl Acad Sci U S A
104, 3107-3112.
274. Jang, Y.J., Lin, C.Y., Ma, S., and Erikson, R.L. (2002). Functional studies on the
role of the C-terminal domain of mammalian polo-like kinase. Proc Natl Acad Sci
U S A 99, 1984-1989.
275. Sicheri, F., Moarefi, I., and Kuriyan, J. (1997). Crystal structure of the Src family
tyrosine kinase Hck. Nature 385, 602-609.
276. Xu, W., Doshi, A., Lei, M., Eck, M.J., and Harrison, S.C. (1999). Crystal
structures of c-Src reveal features of its autoinhibitory mechanism. Mol Cell 3,
629-638.
277. Hof, P., Pluskey, S., Dhe-Paganon, S., Eck, M.J., and Shoelson, S.E. (1998).
Crystal structure of the tyrosine phosphatase SHP-2. Cell 92, 441-450.
278. Kothe, M., Kohls, D., Low, S., Coli, R., Cheng, A.C., Jacques, S.L., Johnson, T.L.,
Lewis, C., Loh, C., Nonomiya, J., Sheils, A.L., Verdries, K.A., Wynn, T.A., Kuhn,
C., and Ding, Y.H. (2007). Structure of the catalytic domain of human polo-like
kinase 1. Biochemistry 46, 5960-5971.
279. Yang, J., Cron, P., Good, V.M., Thompson, V., Hemmings, B.A., and Barford, D.
(2002). Crystal structure of an activated Akt/protein kinase B ternary complex
with GSK3-peptide and AMP-PNP. Nat Struct Biol 9, 940-944.
280. Bossemeyer, D., Engh, R.A., Kinzel, V., Ponstingl, H., and Huber, R. (1993).
Phosphotransferase and substrate binding mechanism of the cAMP-dependent
protein kinase catalytic subunit from porcine heart as deduced from the 2.0 A
structure of the complex with Mn2+ adenylyl imidodiphosphate and inhibitor
peptide PKI(5-24). Embo J 12, 849-859.
281. Fabbro, D., Ruetz, S., Buchdunger, E., Cowan-Jacob, S.W., Fendrich, G.,
Liebetanz, J., Mestan, J., O'Reilly, T., Traxler, P., Chaudhuri, B., Fretz, H.,
Zimmermann, J., Meyer, T., Caravatti, G., Furet, P., and Manley, P.W. (2002).
Protein kinases as targets for anticancer agents: from inhibitors to useful drugs.
Pharmacol Ther 93, 79-98.
282. Noble, M.E., Endicott, J.A., and Johnson, L.N. (2004). Protein kinase inhibitors:
insights into drug design from structure. Science 303, 1800-1805.
283. Stout, T.J., Foster, P.G., and Matthews, D.J. (2004). High-throughput structural
biology in drug discovery: protein kinases. Curr Pharm Des 10, 1069-1082.
284. De Azevedo, W.F., Jr., Mueller-Dieckmann, H.J., Schulze-Gahmen, U., Worland,
P.J., Sausville, E., and Kim, S.H. (1996). Structural basis for specificity and
potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. Proc Natl
Acad Sci U S A 93, 2735-2740.
285. Pargellis, C., Tong, L., Churchill, L., Cirillo, P.F., Gilmore, T., Graham, A.G.,
Grob, P.M., Hickey, E.R., Moss, N., Pav, S., and Regan, J. (2002). Inhibition of
p38 MAP kinase by utilizing a novel allosteric binding site. Nat Struct Biol 9,
268-272.
286. Tong, L., Pav, S., White, D.M., Rogers, S., Crane, K.M., Cywin, C.L., Brown,
M.L., and Pargellis, C.A. (1997). A highly specific inhibitor of human p38 MAP
kinase binds in the ATP pocket. Nat Struct Biol 4, 311-316.
287. Schindler, T., Bornmann, W., Pellicena, P., Miller, W.T., Clarkson, B., and
Kuriyan, J. (2000). Structural mechanism for STI-571 inhibition of abelson
tyrosine kinase. Science 289, 1938-1942.
288. Takagi, M., Honmura, T., Watanabe, S., Yamaguchi, R., Nogawa, M., Nishimura,
I., Katoh, F., Matsuda, M., and Hidaka, H. (2003). In vivo antitumor activity of a
novel sulfonamide, HMN-214, against human tumor xenografts in mice and the
spectrum of cytotoxicity of its active metabolite, HMN-176. Invest New Drugs 21,
387-399.
289. Garland, L.L., Taylor, C., Pilkington, D.L., Cohen, J.L., and Von Hoff, D.D.
(2006). A phase I pharmacokinetic study of HMN-214, a novel oral stilbene
derivative with polo-like kinase-1 -interacting properties, in patients with
advanced solid tumors. Clin Cancer Res 12, 5182-5189.
290. Thompson, J.D., Higgins, D.G., and Gibson, T.J. (1994). CLUSTAL W:
improving the sensitivity of progressive multiple sequence alignment through
sequence weighting, position-specific gap penalties and weight matrix choice.
Nucleic Acids Res 22, 4673-4680.
291. Felsenstein, J. (1997). An alternating least squares approach to inferring
phylogenies from pairwise distances. Syst Biol 46, 101-111.
292. Esnouf, R.M. (1997). An extensively modified version of MolScript that includes
greatly enhanced coloring capabilities. J Mol Graph Model 15, 132-134, 112-133.
293. Merritt, E.A., and Murphy, M.E. (1994). Raster3D Version 2.0. A program for
photorealistic molecular graphics. Acta Crystallogr D Biol Crystallogr 50, 869-
873.
294. Hu, F., Wang, Y., Liu, D., Li, Y., Qin, J., and Elledge, S.J. (2001). Regulation of
the Bub2/Bfal GAP complex by Cdc5 and cell cycle checkpoints. Cell 107, 655-
665.
295. Geymonat, M., Spanos, A., Walker, P.A., Johnston, L.H., and Sedgwick, S.G.
(2003). In vitro regulation of budding yeast Bfal/Bub2 GAP activity by Cdc5. J
Biol Chem 278, 14591-14594.
296. Lee, S.E., Jensen, S., Frenz, L.M., Johnson, A.L., Fesquet, D., and Johnston, L.H.
(2001). The Bub2-dependent mitotic pathway in yeast acts every cell cycle and
regulates cytokinesis. J Cell Sci 114, 2345-2354.
297. Matsumura, S., Toyoshima, F., and Nishida, E. (2007). Polo-like kinase 1
facilitates chromosome alignment during prometaphase through BubR1. J Biol
Chem 282, 15217-15227.
298. Soung, N.K., Kang, Y.H., Kim, K., Kamijo, K., Yoon, H., Seong, Y.S., Kuo, Y.L.,
Miki, T., Kim, S.R., Kuriyama, R., Giam, C.Z., Ahn, C.H., and Lee, K.S. (2006).
Requirement of hCenexin for proper mitotic functions of polo-like kinase 1 at the
centrosomes. Mol Cell Biol 26, 8316-8335.
299. Guarguaglini, G., Duncan, P.I., Stierhof, Y.D., Holmstrom, T., Duensing, S., and
Nigg, E.A. (2005). The forkhead-associated domain protein Cep 170 interacts with
Polo-like kinase 1 and serves as a marker for mature centrioles. Mol Biol Cell 16,
1095-1107.
300. Oshimori, N., Ohsugi, M., and Yamamoto, T. (2006). The Plkl target Kizuna
stabilizes mitotic centrosomes to ensure spindle bipolarity. Nat Cell Biol 8, 1095-
1101.
301. Stuermer, A., Hoehn, K., Faul, T., Auth, T., Brand, N., Kneissl, M., Putter, V.,
and Grummt, F. (2007). Mouse pre-replicative complex proteins colocalise and
interact with the centrosome. Eur J Cell Biol 86, 37-50.
302. Inoue, D., and Sagata, N. (2005). The Polo-like kinase Plxl interacts with and
inhibits Mytl after fertilization of Xenopus eggs. Embo J 24, 1057-1067.
303. Darieva, Z., Bulmer, R., Pic-Taylor, A., Doris, K.S., Geymonat, M., Sedgwick,
S.G., Morgan, B.A., and Sharrocks, A.D. (2006). Polo kinase controls cell-cycle-
dependent transcription by targeting a coactivator protein. Nature 444, 494-498.
304. Azzam, R., Chen, S.L., Shou, W., Mah, A.S., Alexandru, G., Nasmyth, K., Annan,
R.S., Carr, S.A., and Deshaies, R.J. (2004). Phosphorylation by cyclin B-Cdk
underlies release of mitotic exit activator Cdcl4 from the nucleolus. Science 305,
516-519.
305. Visintin, R., Stegmeier, F., and Amon, A. (2003). The role of the polo kinase
Cdc5 in controlling Cdcl4 localization. Mol Biol Cell 14, 4486-4498.
306. Shou, W., Azzam, R., Chen, S.L., Huddleston, M.J., Baskerville, C., Charbonneau,
H., Annan, R.S., Carr, S.A., and Deshaies, R.J. (2002). Cdc5 influences
phosphorylation of Netl and disassembly of the RENT complex. BMC Mol Biol
3,3.
307. Loughrey Chen, S., Huddleston, M.J., Shou, W., Deshaies, R.J., Annan, R.S., and
Carr, S.A. (2002). Mass spectrometry-based methods for phosphorylation site
mapping of hyperphosphorylated proteins applied to Netl, a regulator of exit from
mitosis in yeast. Mol Cell Proteomics 1, 186-196.
308. Eckerdt, F., Yuan, J., Saxena, K., Martin, B., Kappel, S., Lindenau, C., Kramer,
A., Naumann, S., Daum, S., Fischer, G., Dikic, I., Kaufmann, M., and Strebhardt,
K. (2005). Polo-like kinase 1-mediated phosphorylation stabilizes Pinl by
inhibiting its ubiquitination in human cells. J Biol Chem 280, 36575-36583.
309. Feng, Y., Yuan, J.H., Maloid, S.C., Fisher, R., Copeland, T.D., Longo, D.L.,
Conrads, T.P., Veenstra, T.D., Ferris, A., Hughes, S., Dimitrov, D.S., and Ferris,
D.K. (2006). Polo-like kinase 1-mediated phosphorylation of the GTP-binding
protein Ran is important for bipolar spindle formation. Biochem Biophys Res
Commun 349, 144-152.
310. Saigusa, K., Imoto, I., Tanikawa, C., Aoyagi, M., Ohno, K., Nakamura, Y., and
Inazawa, J. (2007). RGC32, a novel p53-inducible gene, is located on
centrosomes during mitosis and results in G2/M arrest. Oncogene 26, 1110-1121.
311. Badea, T., Niculescu, F., Soane, L., Fosbrink, M., Sorana, H., Rus, V., Shin, M.L.,
and Rus, H. (2002). RGC-32 increases p34CDC2 kinase activity and entry of
aortic smooth muscle cells into S-phase. J Biol Chem 277, 502-508.
Chapter Two
Proteomic Screen Defines the Polo-box Domain
Interactome and Identifies Rock2 as a Plk1 Substrate
Published: Drew M. Lowery, Karl Clauser, Majbrit Hjerrild, Dan Lim, Jes Alexander,
Kazu Kishi, Steen Gammeltoft, Steven A. Carr, and Michael B. Yaffe.
Proteomic Screen Defines Mitotic Polo-box Domain Interactome and Identifies Rho
Kinase as a Plk1 Substrate in Cytokinesis. EMBO 26, 2007.
Contributions:
Karl Clauser performed all mass spectrometry analysis and generated Tables 2.1 and 2.2
and figure 2.10 along with writing the appropriate methods sections. Majbrit Hjerrild and
I performed the experiments in figures 2.1C-E, 2.2, 2.3, 2.8F, and 2.9 and wrote the
initial draft of the manuscript. Dan Lim contributed to the initial experimental design as
outlined in figure 2.1B and assisted in protein purification. Jes Alexander assisted with
bioinformatic analysis and generated the random protein datasets that allowed the
construction of figure 2.5. Kazu Kishi performed the localization experiment shown in
figure 2.8E. Steven Carr provided intellectual support, helped design experiments, and
provided mass spectrometry facilities. Mike helped design and analyze most of the
experiments, re-wrote the manuscript with me, and provided intellectual support. All
other work was performed by myself.
Abstract
Polo-like kinase-1 (Plkl) phosphorylates a number of mitotic substrates, but the
diversity of Plkl -dependent processes suggests the existence of additional targets. Plkl
contains a specialized phosphoserine-threonine binding domain, the Polo-box domain
(PBD), postulated to target the kinase to its substrates. Using the specialized
phosphoserine-threonine binding domain, the Polo-box domain (PBD), of Polo-like
kinase-1 (Plkl) as an affinity capture agent, we performed a screen to define the mitotic
Plkl-PBD interactome by mass spectrometry. We identified 622 proteins that showed
phosphorylation-dependent mitosis-specific interactions, including proteins involved in
well-established Plkl-regulated processes, and in processes not previously linked to Plkl
such as translational control, RNA processing, and vesicle transport. Many proteins
identified in our screen play important roles in cytokinesis, where, in mammalian cells,
the detailed mechanistic role of Plkl remains poorly defined. We go on to characterize
the mitosis-specific interaction of the Plkl-PBD with the cytokinesis effector kinase Rho-
associated coiled-coiled domain-containing protein kinase 2 (Rock2), denonstrate that
Rock2 is a Plkl substrate, and show that Rock2 co-localizes with Plkl during cytokinesis.
Finally, we show that Plkl and RhoA function together to maximally enhance Rock2
kinase activity in vitro and within cells, and implicate Plkl as a central regulator of
multiple pathways that synergistically converge to regulate acto-myosin ring contraction
during cleavage furrow ingression.
Introduction
In eukaryotic cells, Polo-like kinase-1 (Plkl) and related orthologues perform a
wide variety of essential functions during mitosis [1-3]. Levels of Plkl peak in late G2
and early M, accompanied by dramatic changes in subcellular localization as cells transit
through various mitotic stages [4]. During interphase and early prophase Plkl resides
primarily at the centrosome, where it facilitates centrosome maturation, separation, and
microtubule nucleation during late prophase and prometaphase [5-7]. By metaphase, a
fraction of Plkl has relocalized to the kinetochores, where it seems to be involved in
regulating aspects of spindle checkpoint function and the metaphase-anaphase transition
[8, 9]. During anaphase, Plkl is concentrated in the spindle midzone, where it probably
facilitates microtubule sliding, while following chromosome segregation, Plkl remains in
the central spindle and midbody, where it participates in ingression of the cleavage
furrow [10, 11]. Particularly prominent cytokinetic phenotypes are observed in budding
and fission yeast where mutations in the respective Plkl orthologues, Cdc5 and Plo 1,
result in incomplete assembly of actomyosin and septin ring structures along with
delayed and improper deposition of septal material [12, 13].
Although these and related mutational studies have provided many insights into
Cdc5/Plol function in simple model organisms, the diversity of Plkl functions in higher
eukaryotes makes it difficult to comprehensively identify Plkl -regulated pathways or
define the bulk of the Plkl interactome using standard molecular genetics techniques.
Separation of function alleles are hard to identify due to the presence of a single common
binding pocket and substrate phosphorylation cleft shared by most, if not all substrates
[14, 15]. Full genetic disruption of the drosophila Plkl orthologue, polo, causes
embryonic lethality [16], while full depletion of the Xenopus Plkl orthologue, Plxl,
prevents mitotic entry [17].
More recently, RNA interference has been used to examine the effect of Plk1
depletion in human cell lines, revealing a marked dependence of phenotype on the
particular genetic background of the cell. In tumor derived cell lines depletion of Plk1
causes apoptosis along with mitotic catastrophe, making the delineation of specific Plkl
functions difficult [18, 19]. In other immortalized cell lines, depletion of Plkl causes a
delay in mitotic entry with subsequent arrest at prometaphase, preventing analysis of later
phenotypes without sensitization strategies to avoid activation of various mitotic
checkpoints. If both the DNA damage and spindle checkpoints are bypassed, Plkl -
depleted cells can complete an apparently normal mitosis, however chromosome
segregation fails [20, 21]. In non-transformed cell lines, depletion of Plkl causes only
very minor cell cycle defects, although co-depletion of p53 mimics the cell death
phenotypes seen in tumor derived cell lines [18]. The various Plkl -depletion phenotypes
are complicated by varying degrees of Plkl knockdown, since a 90% knockdown of Plkl
in HeLa cells can allow normal mitotic processes whereas a -100% depletion completely
blocks cell cycle progression [18, 22].
In an effort to more comprehensively elucidate the substrates and interacting
proteins of Plkl, we pursued a biochemical/proteomic approach. All Polo-like kinases
have a similar protein architecture including a N-terminal Ser/Thr kinase domain and a
conserved C-terminal Polo-box domain (PBD) (Figure 2. 1A). The PBD of Plks was
previously identified in our lab as a pSer/pThr-binding module that specifically
recognizes Ser-[pSer/pThr]-Pro/X motifs on peptides with low micromolar affinity (Elia
et al., 2003a). Phospho-dependent ligand recognition by the PBD is necessary for
targeting of Plkl to specific substrates (i.e. processive phosphorylation) as well as for the
dynamic re-localization of Plkl to specific subcellular structures during mitosis where
other Plkl targets reside (i.e. distributive phosphorylation) [23]. We therefore performed
affinity purification and mass spectrometry studies to identify Plkl PBD-interacting
proteins from U20S cells at different stages of the cell cycle.
Our strategy was to define all putative interacting partners, and then select one
particular sub-network to investigate in more detail at the molecular level. We identified
approximately six hundred proteins that were members of phosphorylation-dependent
Plk1 PBD interacting complexes. These proteins are known to be involved in a wide
variety of mitotic processes, including processes not previously thought to be regulated
by Plkl. We chose to focus on the roles of Plkl in regulating cytokinesis. The
requirement for Plkl and its orthologues for proper initiation and completion of
cytokinesis has been well established in unicellular organisms [24, 25] and drosophila
[26], and several previously described PBD-associated proteins are known to play roles
in this process in mammalian cells [10, 11, 27], although exactly how Plkl fits into the
complete cytokinesis network in unclear. One of the major upstream regulators of
cytokinesis is RhoA, which, together with its downstream targets, controls the formation
and constriction of the actomyosin ring at the cleavage furrow [28]. The functions of Plkl
and Rho GTPases may be linked, since cytokinesis-specific GEFs for Rho were recently
identified as Plk targets both in mammalian cells [29] and by our recent work in budding
yeast [13].
We now report that Plk1 functions in multiple parallel overlapping pathways with
RhoA, and directly interacts with a subset of critical effectors of RhoA. We demonstrate
that Plkl and RhoA synergize to maximally activate the cytokinetic protein kinase Rock2
in vitro and within cells, and that Plkl and Rock2 interact directly in vivo in a
phosphorylation-dependent mitosis-specific manner, with maximal co-localization at the
midbody during cytokinesis.
Results and Discussion
The Plk1 Polo-box domain shows mitosis-specific interactions with many proteins
involved in diverse aspects of cell division.
To identify potential targets of Plkl, we examined the ability of the isolated PBD
to bind to proteins in a cell cycle-dependent manner. Recombinant Plkl PBD was
expressed in bacteria and purified to homogeneity (Figure 2.1C). We also purified a His-
538 Ala/Lys-540 Met double mutant form of the PBD which does not bind to
phosphorylated ligands [15] and therefore serves as an optimal negative control to reveal
sticky non-specific interactions or phospho-independent protein-PBD interactions that
might arise from high abundance. The wild type and mutant PBD proteins were cross-
linked to sepharose CN-4B beads and used as an affinity matrix. Human osteosarcoma
U20S cells were arrested at the G1/S transition by a double thymidine block or arrested
in mitosis by treatment with nocodazole. Cell cycle synchronization was verified by
FACS (Figure 2.1D). Lysates from these two cell populations were prepared and equal
amounts of total protein were applied to columns containing either the wild type or
mutant PBD column. After extensive washing with a near neutral pH medium-salt buffer
that is not expected to disrupt complexes, PBD-interacting proteins were eluted off the
columns by competition with an optimal PBD binding phospho-peptide (YMQS-pT-PK)
[30]. The recovered proteins were then separated by SDS-PAGE and visualized by
SYPRO Ruby staining (Figure 2.1B top).
Both the wild type and mutant PBD bound very weakly, and with similar affinity,
to a variety of proteins in the Gl/S cell lysate. In marked contrast, the wild type PBD, but
not the mutant PBD, showed very strong binding to a large number of proteins in the
mitotic cell lysates (Figure 2.1E). The darkest band at 25kd is the PBD itself indicating
that there is some leeching of the PBD from the column. These observations suggest that
the Plkl PBD can specifically interact with many mitotic proteins in a phospho-
dependent manner. Furthermore, because Plkl has been reported to interact with
microtubules [31], we used nocodazole treatment to obtain the mitotically arrested cells,
as this drug depolymerizes microtubules and should therefore minimize potential indirect
interactions of the PBD with other microtubule-interacting proteins. The affinity-based
purification assay shown in Figure 2. 1E could either isolate mitotic proteins that bound
directly to the PBD, or proteins that were not themselves direct PBD-interactors but
instead were components of larger PBD-associated complexes. The specificity of PBD
binding was therefore investigated by Far-Western blotting. Many of the mitotic proteins
captured with the wild type PBD were capable of direct interaction. In contrast, none of
the proteins that were retained by the mutant PBD showed a strong detectable interaction
with the wild type PBD in this assay (Figure 2.2A).
To examine the extent to which the binding of mitotic ligands to the PBD is
dependent upon phosphorylation, nocodazole-arrested cell lysates were dephosphorylated
with X-phosphatase prior to the PBD pull down. As shown in Figure 2.2B, both the
number of recovered ligands and intensity of ligand binding was greatly reduced after
phosphatase treatment of the mitotic cell lysates. Next, to investigate if any of the Plkl
PBD-interacting proteins were also potential Plkl substrates; the affinity purified proteins
were incubated with a constitutively active mutant of full-length Plkl, Plkl-T2 10D, in
the presence of 32P-y-ATP. As shown in Figure 2.2C, incubation with Plkl -T210D
resulted in the direct phosphorylation of many of these PBD-interacting proteins. Taken
together, the data in Figures 2.1 and 2.2 strongly support a model where the PBD
facilitates the interaction of Plkl with a wide range of mitotic targets that have undergone
prior priming phosphorylation during mitosis, and indicates that a subset of the
interacting proteins are themselves Plk1 substrates.
Liquid chromatography tandem mass spectrometry (LC/MS/MS) was used to
identify the mitotic PBD-interacting proteins. Each lane of the gel from the nocodazole
arrested cell lysates in Figure 2.1E was excised, cut into 12 pieces as indicated (Figure
2.1E), and subjected to in-gel digestion with trypsin. The extracted peptide mixtures were
then separated using reverse phase HPLC, which was coupled to an LTQ-FT hybrid ion
trap Fourier transform mass spectrometer for peptide identification (Figure 2.1B bottom),
and the corresponding proteins identified by database searching. For each protein, the
relative ratio of wild-type/mutant PBD-bound abundances was determined using the sum
of the extracted ion current measured for each sequenced peptide precursor ion in the
intervening MS scans of the LC/MS/MS chromatogram. Proteins were then categorized
as being wild-type specific (peptide ions only present in the wild-type PBD eluents),
wild-type enriched (peptide ions present at >20-fold intensity in the wild-type PBD
eluents compared to the mutant PBD eluents), and non-specific (peptide ions present at
<20-fold intensity in the wild-type versus mutant PBD eluents). In total, we identified
622 distinct proteins that were at least 20-fold more abundant in the wild type PBD pull
down compared to the mutant H538A/K540M PBD pull down and were considered to be
potential PBD interaction partners (Table 2.1). All proteins were characterized according
to GO categories defining their molecular function [32] (Figure 2.4A).
We selected a small random subset of proteins identified in the mass
spectrometry-based screen for further validation based on the availability of antibodies:
Lamin A, Cofilin, MCMs, the protein kinase CK2 alpha, myosin phosphatase targeting
subunit 1 (MYPT) and Rock2. Pull downs from mitotic lysates followed by
immunoblotting confirmed that all these proteins preferentially interacted with wild type
PBD compared to the mutant PBD (Figure 2.3A). The cell cycle-dependent interaction of
the selected proteins with the PBD was investigated by performing in vitro pulldown
assays with lysates from double thymidine blocked (Gl) and nocodazole-treated (M)
cells. As shown in Figure 2.3B, interactions between the PBD and all of these proteins
were mitotic specific. To investigate the requirement for phosphorylation, mitotic lysates
were treated with X-protein phosphatase prior to PBD pull-downs and immunoblotting
for. In each case, interaction of these proteins with the PBD was either eliminated or
substantially reduced following phosphatase treatment (Figure 2.3C). Thus, all six of the
interactions tested were mitotic phosphorylation-dependent interactions.
The complete set of proteins identified in our PBD interactome included proteins
previously demonstrated to associate with Plkl such as MCMs [33], septins [25], anillin,
(shown to be a Plkl substrate in vitro; [34]), and members of the 20S proteasome complex
[35]. Some other known endogenous Plkl interacting proteins, such as Cdc25C, were not
identified in this screen, likely as a result of our nocodazole treatment/spindle checkpoint
arrest strategy, which appeared to enrich for late mitotic targets. Plkl targets such as
Cdc25C and Weel are thought to play a role in entry into mitosis, and thus might not
bind to Plk1 once mitosis is underway. Additional Plkl interactors such as Bub3 are only
expected to be engaged after the spindle checkpoint is extinguished.
Most of the PBD interacting proteins identified in this study have not been
previously reported. Many of those proteins participate in a broad range of cellular
functions that show distinct changes during mitosis; transcription, translation, splicing
and metabolism (Figure 2.4A). Intriguingly, although protein synthesis is necessary for
mitotic entry and progression, the overall rate of protein synthesis in mitotic cells has
been reported to be markedly decreased to 25-30% of the rate seen in interphase cells
[36]. At the same time the synthesis of a number of proteins including c-myc is enhanced
during mitosis [37]. Transcription and mRNA splicing has also been shown to be
inhibited during mitosis [38]. The metabolic state of mitotic cells also undergoes
significant alterations in order to accommodate disruption and distribution of membrane
compartments and components [39]. Recently a transcriptional co-activator protein, Nddl,
has been discovered to be a direct substrate of Cdc5, the yeast Plkl orthologue. Cdc5
was recruited to specific promoters where it phosphorylated Nddl to activate
transcription of cell cycle regulated genes involved in mitotic progression [40]. Plkl has
also been shown to regulate the nuclear translocation of the transcription factor HSF 1
[41]. Thus we can anticipate further roles for Plk1 in these processes.
Bioinformatic analysis reveals that Plk1 Polo-box domain ligands are enriched in
Ser-[Ser/Thr]-Pro motifs and are potential Plkl substrates.
In order to help distinguish between indirect and direct interactors, each of the
PBD-interacting proteins identified by mass spectrometry was evaluated for the presence
of an optimal PBD recognition motif. Isolated phosphopeptides bind to the Plkl PBD
through the optimal consensus motif S-[pS/pT]-[P/X], where the Ser residue preceding
the pSer/pThr makes 3 hydrogen bonding interactions with the PBD (one through a
bound water molecule) and contributes significantly to ligand affinity [15]. As seen in
Figure 2.4B, PBD recognition motifs were identified in 47.3% of the wild-type-specific
PBD-interacting proteins and 41.3% of the wild-type-enriched interactions. In contrast,
only 16.2% of the non-specific PBD-interacting proteins contained this motif. To
determine whether these values were statistically significant, we generated 2000 'mock'
protein datasets by randomly selecting either 622 (the total number of combined wild-
type PBD-specific or -enriched interactions: Fig 2.4B, column 1, red boxes) or 277
proteins (the total number of non-specific interactions: Fig 2.4B, column 1, gray box)
from the current human NCBI RefSeq collection, and examined these datasets of
randomly selected proteins for the percentage of proteins containing S-[S/T]-P motifs. As
shown in Figure 2.5A and B, the distribution of the number of protein in each of the
random datasets containing S-[S/T]-P motifs was roughly normally distributed, with the
same average value of 31.4%. The percentage of PBD-specific or -enriched interacting
proteins containing S-[S/T]-P motifs that we identified in our mass spectrometry-based
screen (average value 45.3%) was over 7 standard deviations above the mean from that
expected for a similar sized collection of random proteins (Figure 2.5B). Likewise, the
percentage of PBD non-specific interacting proteins containing S-[S/T]-P motifs was
over 5 standard deviations below that expected (Figure 2.5A). Thus, our non-biased
method for identifying PBD interactors greatly enriched for proteins that contained the
optimal motifs necessary for PBD binding suggesting that the optimal PBD binding motif
for isolated phosphopeptides likely functions in an analogous way for many full-length
phosphoprotein ligands.
The wild-type PBD -specific or -enriched interacting proteins were also evaluated
for the presence of potential Plkl phosphorylation sites [E/D]-X-[S/T]-[F/L/I/Y/W/V/M]
[42]. Among the 282 proteins that contain a PBD recognition motif, this motif was found
in 88% of the proteins. In contrast, among the 340 proteins that do not contain a PBD
recognition motif this phosphorylation motif was present in 75% of the proteins (Figure
2.4B). We performed a similar statistical analysis for putative Plkl phosphorylation sites
in random proteins datasets containing either 282 proteins (the number of wild-type PBD
-specific or -enriched interactions containing S-[S/T]-P motifs: Figure 2.4B, blue boxes,
column 2) or 340 proteins (the number of wild-type PBD -specific or -enriched
interactions not containing S-[S/T]-P motifs: Figure 2.4B, white boxes, column 2). This
revealed a similar mean value of 74.4% (Figure 2.5C, D). The co-occurrence of a Plkl
phosphorylation motif in the S-[S/T]-P motif-containing PBD-specific or -enriched
proteins found in our mass spectrometry-based screen was nearly 5 standard deviations
greater than that expected by chance alone in a randomly selected set of proteins (Figure
2.5D). In contrast, for the PBD-specific or -enriched proteins found in our mass
spectrometry-based screen that lacked S-[S/T]-P motifs, the occurrence of a Plkl
phosphorylation motif was the same as that expected by random chance (Figure 2.5C).
We interpret these findings as evidence that Plk1 interactors capable of binding directly
to the PBD are likely to also be Plkl substrates, while proteins in complexes with direct
PBD interactors may be less likely to be Plkl substrates than the PBD interactors
themselves.
The mass spectrometry analysis of the PBD interacting proteins also resulted in
the mapping of 247 phosphorylation sites (Figure 2.4C, Table 2.2), although this was not
the primary intent of our study. The majority of mapped phosphorylation sites were
derived from the gel band tryptic digests of our PBD pulldowns with a few from a TiO2
IMAC using a tryptic digest of an aliquot of the PBD pulldowns. Within the tryptic
peptides, many of the phosphorylation motifs are present in a sequence context that is not
readily amenable to binding and elution from a reversed-phase column and
ionization/fragmentation by MS/MS (i.e. too short, long, hydrophobic, hydrophilic, or
contain too many nearby basic residues). Therefore, we expect to observe only a portion
of phosphopeptides actually present. In 282 proteins that were identified as wild-type
PBD -specific or -enriched interacting proteins (Fig 2.4B, column 2, blue boxes), we
were able to map 49 phosphorylation sites in 43 proteins that exactly matched the Ser-
(pSer/pThr)-Pro PBD recognition motif (Table 2.2). An additional 4 mapped sites
contained the motif Ser-pSer, which would also be expected to bind strongly to the PBD
[15]. Amongst the entire 899 proteins identified in our study we were able to map an
additional 168 phosphorylation sites matching the minimal consensus [pS/pT]P motif for
CDKs. Thus 90% of our mapped sites match the minimal CDK motif
A large network of proteins involved in cytokinesis is connected by Plk1 Polo-box
domain ligands.
In order to examine one part of the PBD interactome in more detail, we chose to
focus on a mitotic process in which Plkl was thought to be involved, but where many of
the details of Plkl -dependent regulation were unclear. At the end of mitosis, the parent
cell is cleaved into two daughter cells by a mechanical process known as cytokinesis.
During early cytokinesis the cell elongates and a cleavage furrow is created under the
plasma membrane by an actomyosin-based structure known as the contractile ring. The
spatial orientation of this ring is controlled by both the central spindle and septins. Later
in cytokinesis the two daughter cells remain connected by a cytoplasmic bridge called the
midbody, until abscission, when the two cells separate [28]. Cells lacking or
inappropriately overexpressing certain components for many of these processes fail to
complete cytokinesis, resulting in either cells arrested at the midbody stage, or as
binucleated cells. In budding and fission yeast, cytokinesis seems to be highly dependent
on the fungal homologue of Plkl [12]. In mammalian cells, there is data implicating Plkl
in the cytokinetic process, but exactly how Plkl is connected to the network of core
cytokinesis components is unknown. In addition to the incompletely understood role of
Plkl, regulation of cytokinesis is under the direct control of several other protein kinases
including CDK1, AuroraB, and the Rho-regulated protein kinases; Rockl, Rock2, and
Citron kinase.
To evaluate additional roles of Plkl in regulating cytokinesis, we examined
protein-protein interactions known to be involved in this process. First, we constructed
models of cytokinesis sub-networks for core protein-protein interactions controlling
central spindle organization, myosin activation, and actin dynamics based on recent
summaries and reviews [28, 43] with interaction data taken from the Human Protein
Reference Database [44] (Figure 2.6B-D). We then constructed a similar model of the
subset of Plkl -interacting proteins relevant to cytokinesis by searching for proteins with
described cytokinesis phenotypes that were also known to interact with Plkl from
published literature (Figure 2.6A) [10, 11, 27, 45-49]. As seen in Figure 2.6E, published
data allows only one direct link to be constructed between Plkl and the core cytokinesis
processes of actin dynamics and myosin activation, through the Rho-GEF Ect2. Plkl can
bind to and phosphorylate Ect2, and Ect2 depletion results in cytokinesis defects [29], but
the likely direct connection between Plkl and cytokinesis through Ect2 has not yet been
definitively shown. In budding yeast, however, we recently showed that the yeast Plkl
orthologue Cdc5 directs the localization of the RhoGEFs, Tusl and Rom2, to the bud
neck (the budding yeast equivalent of the mammalian furrow/midbody) and that Cdc5
phosphorylation of Tus 1 is necessary for cells to complete cytokinesis [13]. The only
other published link connecting Plkl to core components of the cytokinesis network is
through the intermediate filament protein vimentin, which appears to be a critical
substrate of both Rock and Plkl [48, 50] necessary for completion of cytokinesis.
We next examined which of the core cytokinesis proteins in panels B-D showed
mitosis-dependent interactions with the Plkl PBD in our screen (Figure 2.6F, yellow
circles). This revealed a total of 11 new putative Plkl -modulated core cytokinesis
interactions, including potential roles for Plkl in the direct regulation of several Rho-
dependent kinases (Figure 2.6F, circled red). To identify additional links between Plkl
and these core cytokinetic sub-networks, we expanded the network to include Plkl PBD-
interacting proteins identified in our screen that had previously been experimentally
validated to make direct protein-protein interactions with components of these core sub-
networks (Figure 2.6G, green circles). This resulted in creation of a more extended Plkl
PBD-annotated cytokinesis network that contained 27 new PBD-binding proteins that
touch the core cytokinesis components to form another 33 potential Plkl-regulated links
(Figure 2.6G, thick black lines, and Figure 2.7).
Plk1 co-localizes with Rock2 during cytokinesis and works synergistically with
RhoA to stimulate Rock2 kinase activity.
The large set of potential Plkl-regulated cytokinesis proteins revealed by this
mass spectrometry/proteomics approach exceeded our capacity to directly investigate in
an experimentally tractable manner. We therefore focused our attention on the subset of
Rho-regulated protein kinases and phosphatases in the core cytokinesis network that
control myosin activation (Figure 2.6F, circled red). We confirmed that each of these
proteins - Rockl, Rock2, Citron kinase, and MYPTI - bound to the Plkl PBD in a
phospho-dependent manner (Figure 2.6H), and proceeded to investigate Rock2 in detail.
Rock2 contains an N-terminal kinase domain and a C-terminal Rho-binding
domain and PH domain (Figure 2.8A), and phosphorylates myosin regulatory light chain
and myosin phosphatase targeting subunit in manner that is enhanced upon RhoA binding
[51]. To demonstrate an interaction between full-length Rock2 and Plkl within cells,
myc-tagged Rock2 and Flag-tagged Plkl containing either a wild-type or mutant PBD,
were co-expressed in U20S cells. Lysates were collected from asynchronous and
mitotically arrested cells. Immunoprecipitation of the lysates using anti-Flag M2 beads
revealed a strong mitosis-dependent interaction of full-length Plk1 containing a wild-type
PBD, but not a mutant PBD, with Rock2 (Figure 2.8B, C). Furthermore, this Plkl -Rock2
interaction was lost when the lysates were treated with X-phosphatase, confirming that
the interaction between the full length proteins was phospho-dependent (Figure 2.8D).
We also observed significant co-localization of the endogenous proteins during
cytokinesis, most prominently at the midbody (Figure 2.8E), consistent with previously
published localization data for each of these proteins individually [11, 52].
To investigate whether Rock2 could serve as a substrate for Plkl, full length
bovine Rock2 (Rock2-FL) as well as N-terminal kinase domain- (Rock2-CAT) and C-
terminal RBD and PH domain-containing fragments (Rock2-RBD/PH) of Rock2 were
phosphorylated by the Plkl kinase domain in vitro in the presence of [32 P]-y-ATP (Figure
2.9). Radioactivity was incorporated into all three fragments of Rock2. When in vitro
phosphorylated full-length Rock2 was analyzed by mass spectrometry, phosphorylated
peptides from only the C-terminal part of the molecule were detected, corresponding to
residues Thr-967 (DApTI), Ser-1099 (EEpSQ), a mono-phosphorylated species
phosphorylated on one of three consecutive serines from Ser-1132 to Ser-1134 (Figs.
2.8A, 2.9 and 2.10), and Ser-1374 (NQpSI). Three of these mapped sites conform to the
general Plkl kinase consensus motif [E/D]X[S/T] assuming that the third site is actually
Ser-1133 (DSpSSI), while the fourth site at Ser-1374 contains an N in the -2 position.
This pSer-2 Asn has been recently been reported in several mapped phosphorylation sites
targeted by Cdc5 [53], and fits with our unpublished data on the in vitro Plkl
phosphorylation consensus motif (J. Alexander and M.B. Yaffe unpublished). In addition,
Ser-1374 phosphorylation was reported in a high-throughput phospho-proteomics screen
[54] indicating that it is phosphorylated in vivo. All four of these motifs are conserved in
bovine, mouse, rat, and human Rock2. The most likely candidate Plkl N-terminal site in
Rock2 based on consensus motif matching is Thr-489, which is contained in a very acidic
stretch of sequence, and peptides containing that site were not recovered in either a
phosphorylated or non-phosphorylated form.
To assess the functional significance of Rock2 phosphorylation by Plkl, myc-
tagged bovine Rock2 was immunoprecipitated from 293T cells and its kinase activity
assayed using a substrate peptide from its physiological substrate, myosin regulatory light
chain (Figure 2.8F). Following phosphorylation, the myosin regulatory light chain
peptide substrate was recovered from solution by spotting onto P81 paper and the
incorporated radioactivity measured by scintillation counting. The addition of GTP-
loaded RhoA increased the basal activity of Rock2 by -3-fold, similar to the 2-fold
increase reported previously [55]. Intriguingly, phosphorylation of Rock2 by Plkl
resulted in a similar 2-fold elevation of Rock2 kinase activity even in the absence of
RhoA-GTP, while Plkl phosphorylation in combination with RhoA resulted in an even
more dramatic 6-fold enhancement. Control reactions containing RhoA-GTP, Plkl, and
myosin regulatory light chain substrate peptide did not result in detectable peptide
phosphorylation in the absence of Rock2, nor did additional control reactions containing
RhoA-GTP, Plkl and Rock2 but no peptide substrate. Therefore, the data in panels 5B-F,
taken together, suggests that both Plkl phosphorylation of Rock2 and RhoA-GTP binding
may act synergistically to maximize the kinase activity of Rock2.
To further verify that Plkl phosphorylation directly activated Rock2, we
constructed a mutant version of Rock2 lacking all four Plkl phosphorylation sites
(Rock2-4A). Both wild-type Rock2 and Rock2-4A had similar basal RhoA-activated
kinase activity in vitro towards myosin regulatory light chain in the absence of Plkl
(Figure 2.12A, lanes 1 and 2). Following pre-incubation of the wild-type and 4A mutant
of Rock2 with Plkl, only the wild-type Rock2, but not the Rock2-4A mutant, showed
enhanced protein kinase activity (Figure 2.12A, lanes 3 and 4).
In order to investigate the potential relevance of Plkl phosphorylation of Rock2
within cells, it was necessary to devise an assay in which Rock2 activity resulted in a
specific cellular phenotype. Because the pathways controlling acto-myosin ring
contraction during cytokinesis are highly redundant, with at least three kinases other than
Rock2 able to phosphorylate myosin regulatory light chain [51], simple knock-downs or
knock-outs of several of these kinases results in very mild or absent phenotypes. For
example, elimination of Rock2 alone, or even both Rock2 and Rockl by siRNA causes
only a slight increase in the population of multinucleated cells [56] (and data not shown).
We therefore took advantage of the fact that completion of cytokinesis requires that the
activity of RhoA and Rock2 be shut off in order to allow disassembly of the acto-myosin
ring [57]. Overexpression of Rock2 prevented this disassembly and resulted in delay or
failure of cells at the midbody stage to complete cytokinesis (Figure 2.12B).
We used siRNA to deplete endogenous Rock2 while simultaneously
overexpressing either the wild-type or 4A mutant forms of Rock2, and examined an
asynchronous population of Rock2-overexpressing cells for failure of cytokinesis exit. As
seen in Figure 2.12C, by 24 hrs after transfection over one-third of the cells that over-
expressed wild-type Rock2 and were in mitosis appeared to be in cytokinesis, compared
to -15% of the control cells. In contrast, overexpression of the Rock2-4A mutant that
cannot undergo Plk activation reduced the percentage of mitotic cells that were in
cytokinesis by about 50% compared to the wild-type Rock2. By 72 hrs following
transfection, overexpression of wild-type Rock2 resulted in a marked increase in the
population of cells with = 4N DNA content (Figure 2.12D, E), consistent with the
emergence of binucleated cells capable of undergoing additional rounds of DNA
replication, similar to what is seen in cells with persistently active RhoA [58]. This
phenotype was significantly diminished in the cells overexpressing the Rock2-4A mutant
in which Plkl cannot enhance Rock2 kinase activity. Together, this data suggests that
Plkl can phosphorylate Rock2 in vivo to regulate its activity.
In summary, our study has identified over 600 new mitotic phosphorylation-
dependent PBD ligands, and suggests an additional function for Plkl in regulating the
kinase activity of the RhoA effector kinases, Rock2, at specific subcellular mitotic
structures, in a manner that synergizes with RhoA-GTP binding as part of a novel
mechanism for Rock2 activation (Figure 2.12F). These findings suggest that Plkl may
participate in two distinct but synergistic processes to maximally activate Rock2, first by
facilitating the localized exchange of RhoA-GTP for RhoA-GDP via Ect2 or other GTP-
exchange factors, and second, by directly activating the RhoA-GTP effector kinase itself.
The experimental analysis of the Plkl PBD interactome places Plkl at the center of a
large network of mitotic protein-protein interactions, and suggests that Plkl may play a
much larger role than previously appreciated in regulating diverse aspects of mitosis.
Experimental Procedures
Cloning, Expression and Protein Purification
Nucleotides encoding the C-terminal Polo-box domain of human Plkl (residues
371-603) were cloned into the expression vector pET28a (Novagen). The fusion protein
contains an N-terminal His6-tag followed by MBP and a recognition site of Tev protease
between MBP and the PBD. Point mutations of His-538 and Lys-540 to Ala and Met,
respectively were introduced using the QuickChange mutagenesis kit (Stratagene) and
verified by sequencing. Proteins were expressed in E. coli BL21(DE3) cells and purified
by Ni-NTA affinity chromatography. The PBD was further purified by affinity
chromatography on amylose beads, cleaved with Tev protease, re-passaged through Ni-
NTA to remove the cleaved His6-MBP tag, and finally purified by gel filtration on a
Superose 12 column. GST-tagged Plkl and RhoA were expressed in bacteria and purified
by glutathione-affinity chromatography. Plasmids encoding Myc-tagged full length or the
C- and N-terminal fragment of Rock2 were kindly provided by K. Kaibuchi [59] and
point mutations were introduced as described above. The plasmids encoding Flag-tagged
Plkl were subcloned from previously described vectors [30, 60]. A hairpin shRNA
construct based on a previously described siRNA oligonucleotide that efficiently
knocked-down Rock2 [56] was cloned into a PollI driven miR-30 based expression
vector [61]. Constructs were transfected into U20S cells using Fugene (Roche) according
to manufacture's instructions with minor modifications. Myc-tagged protein was
immunoprecipitated as previously described [62], and Flag-tagged protein was
immunoprecipitated with M2 agarose (Sigma) according to manufacture's instructions.
Isolation of PBD-interacting proteins.
Wild-type and mutant PBD protein was coupled to CNBr activated sepharose 4B
beads (Amersham Biosciences) according to manufacturer's instructions. The beads were
transferred to a column and excess PBD washed away with Wash Buffer I (0.1 M Tris pH
8, 0.5 M NaCl and 1 mM DTT). The column was equilibrated with Wash Buffer II (50
mM Tris pH 8, 0.2 M NaCl, 2 mM DTT and 10 mM NaF), and the beads then incubated
with U20S cell lysate overnight. Unbound proteins were washed away with ten column
volumes Wash Buffer II. PBD interacting proteins were eluted by incubating the beads
with 2 mL of 1 mM phosphopeptide (YMQS-pT-PK) in Wash Buffer II for 1 hour at 40C.
The beads were washed with additional 2 mL of the phosphopeptide containing buffer.
Preparation of G1/S and Mitotic Cell lysates
Human osteosarcoma U20S cells were maintained in Dulbecco's modified
Eagle's medium supplemented with 10% fetal calf serum, 100 U/mL penicillin and 100
tg/mL streptomycin at 370C in a humidified atmosphere containing 5% CO 2. Cells were
grown to 50% confluence, arrested in G2/M by treatment with 50 ng/mL nocodazole for
14 hours, and collected by a "mitotic shake-off'. U20S cells were synchronized at the
GI/S transition by a double thymidine block. Cells were treated with 2.5 mM thymidine
for 16 hours and released from the thymidine block by washing twice with PBS followed
by incubation in fresh medium. Ten hours after release, thymidine was added for another
16 hours. Ten 15 cm plates were used for each pull down experiment. Cells were lysed in
lysis buffer (50 mM Tris-HC1, pH 7.5, 150 mM NaC1, 1% (v/v) NP-40, 5 mM EDTA, 2
mM DTT, 1 mM AEBSF, 1 glg/mL aprotinin, 1 gig/mL leupeptin, 10 jtM E64, 1 jtg/mL
pepstatin A, 1.6 jtg/mL benzamidine, 2 mM Na3VO4, 10 mM NaF, 20 nM microcystin
LR, 5 nM okadaic acid, 2 giM canthardin, 0.00073% p-bromotetramisole, 0.4 nM
cypermethrin, 100 giM dephostatin, 100 nM bestatin, 100 ng/mL TPCK) at 40C for 15
minutes. The lysates were cleared by centrifugation at 40C at 10,000xg for 15 minutes.
Alternatively, the lysis buffer contained 50 mM Tris-HC1, pH 7.5, 150 mM NaC1, 1%
(v/v) NP-40, 1 mM EDTA, 2 mM DTT, 2 mM AEBSF, 2 itg/mL aprotinin, 2 jtg/mL
leupeptin, 20 tM E64, 2 gg/mL pepstantin A, 3.2 pg/mL benzamidine, 3 mM MnCl 2 and
6000 U X-protein phosphatase (New England Biolabs) and dephosphorylation was
obtained by incubation at 300C for two hours.
Flow cytometry
FACS analysis was performed on U20S cells fixed in ice-cold ethanol and
incubated at 370 C for 30 minutes in PBS containing 1% BSA, 2 mg/mL RNase
(previously boiled for 5 minutes) and 125 gg/mL propidium iodide. For live cell FACS
experiments used in Figure 2.12, U20S cells were incubated with the cell permeable
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DNA dye DRAQ5 (Biostatus Limited) according to manufacture's instructions and
examined within two hours. Fluorescent signals were quantified on a FAC Star Plus
(Becton Dickinson) cell-sorting machine using Cell Quest software. Further analysis of
cell cycle distribution was performed using FlowJo software.
Far-Western analysis.
For Far-Western analysis, proteins eluted from wild type or mutant PBD columns
were separated by SDS-PAGE, and transferred onto a PVDF membrane. The membrane
was blocked in 5% skim milk in TBS-T and subsequently incubated with 6 tg/ml of PBD
at 40C for 6 hours. After washing with TBS-T, the PBD was detected with a-Plk cocktail
(Zymed Laboratories) as above.
Phosphorylation of substrates by Plk1
Proteins that were affinity purified with the wild type PBD were eluted and
phosphorylated in vitro by full-length Plkl-T210D. Samples were first incubated in
kinase buffer containing 50 mM Tris-HCI pH 8, 200 mM NaCI, 2 mM DTT, 5 mM NaF,
200 p.M ATP, 500 pM MgCl2 at 300C in the absence of radioactive ATP or Plkl for 2 hr
to allow saturation of Plkl -independent phosphorylation sites by any kinases that were
present in the reactions. 20 .tCi of [32 P]-y-ATP and 7 ng/ml Plk1 was then added, and the
reaction incubated for an additional 20 min at 300C, and products analyzed by SDS-
PAGE and autoradiography. To exanine Plkl phosphorylation of Rock2, Myc-tagged
full-length or the C- or N-terminal part of Rock2 was expressed in 293T cells by
transfection using calcium phosphate. Anti-Myc immunoprecipitates were
phosphorylated in vitro using Plkl and analyzed as above.
Mass spectrometry
Concentrated eluates from the wild-type and mutant PBD columns were boiled in
reducing sample buffer containing P-mercaptoethanol, separated by SDS-PAGE, and
visualized by SYPRO Ruby staining (Bio-Rad). Lanes from the gel were excised, cut into
12 fields as shown in Fig 2.1E and digested overnight at 370 C with an excess of
sequencing grade trypsin. Peptides were extracted from the gel with 50% acetonitrile/
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0.1% formic acid and concentrated in a Speed-Vac. Tryptic digests were analyzed with
an automated nano LC/MS/MS system, using an 1100 series autosampler and nano pump
(Agilent Technologies, Wilnington, DE) coupled to an LTQ-FT hybrid ion trap Fourier
transform mass spectrometer (Thermo Electron, San Jose, CA) equipped with a nanoflow
ionization source (James A. Hill Instrument Services, Arlington, MA). Peptides were
eluted from a (75 gtm x 10 cm) PicoFrit (New Objective, Woburn, MA) column packed
with (5 gtm x 200 A) Magic C-18AQ reversed-phase beads (Michrom Bioresources, Inc.,
Auburn, CA) using a 70 min acetonitrile/0.1% formic acid gradient at a flow rate of 250
nl/min to yield -25 sec peak widths. Data-dependent LC/MS/MS spectra were acquired
in -3 sec cycles; each cycle was of the form: 1 full FT MS scan followed by 8 MS/MS
scans in the ion trap on the most abundant precursor ions excluding charges 1 and
unknown charge, subject to accurate-mass, dynamic exclusion for a period of 45 sec.
Some of the phosphorylation sites were established with additional LC/MS/MS
experiments performed on aliquots of the gel band digests with the instrument operated in
a targeted mode where MS/MS of 5-17 precursor m/z's were repetitively taken in 3-9 sec
cycles throughout the acetonitrile gradient. These precursor masses were selected because
they correspond to the phosphorylated form of expected tryptic peptides containing
S[ST]P motifs derived from proteins confidently identified in aliquots of sample used for
the data-dependent experiments. For Rock2 phosphopeptide mapping both trypsin and
chymotrypsin were used to maximize coverage.
TiO2 Immobilized Metal Affinity Capture (IMAC) of phosphopeptides
An aliquot of the protein mixture eluted from the wild-type PBD column was put
through a Microcon 10kD filter to remove the eluting phosphopeptide, reduced with DTT,
alkylated with iodoacetamide, and digested with trypsin. Phosphopeptides were enriched
by TiO2 IMAC essentially as described previously [63]. Briefly, 2 AiL of Titansphere
material (GL Science, Japan) was placed above a plug of Empore C8 packed into a 200
piL StageTip [64]. The TiO2 column was washed with 30 jPL of 1% NH40H in 10%
acetonitrile/water, equilibrated with 30 jL 0.1% TFA. The peptide sample was loaded to
the TiO2 StageTip and first washed with 30 pL of 10% acetonitrile/0. 1% TFA followed
by 2 x 30 pL 80% acetonitrile/0.1% TFA. Phosphopeptides were eluted directly into
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autosampler vials, first with 30 •L of 1% NH40H in 10% acetonitrile/water ( -pH 10.5)
and followed by 30 pL of 1% NH40H in 80% acetonitrile/water (~pH 10.5). The eluates
were dried in a vacuum centrifuge and analyzed by data-dependent LC/MS/MS as
described above.
Protein identification, quantitation, and phosphosite determination.
MS/MS spectra passing the quality filter by having a sequence tag length > 0 (i.e.,
minimum of two masses separated by the in-chain mass of an amino acid) were
interpreted to determine protein identities and relative abundances using the
SpectrumMill v3.03b software package (Agilent Technologies Inc.; Santa Clara, CA).
Peptide sequences were interpreted from the MS/MS spectra by searching the human
subset of the NCBI non-redundant protein database supplemented with expected
contaminant proteins (October 2005, -125,000 entries). Initial search parameters
included f3-mercaptoethanol modification of cysteines, 30% minimum matched peak
intensity, +/- 0.05 Da and +/- 0.75 Da tolerance on precursor and product ion masses
respectively, 2 missed tryptic cleavages, ESI linear ion trap scoring parameters, and
allowed variable modifications included oxidized Met, deamidation of Asn and Gln, and
pyro-glutamic acid modification at N-terminal glutamines with a precursor MH+ shift
range of -18 to 65 Da. Identities interpreted for individual spectra were automatically
designated as valid by applying the following scoring threshold criteria to all spectra
derived from both lanes on the gel: protein details mode: protein score >25, peptide
(score, Scored Percent Intensity, delta rankl - rank2 ) peptide charge +2: (>8, >65%, > 2)
peptide charge +3: (>9, >65%, > 2) peptide charge +4: (>9, >70%, > 2) peptide charge
+2: (>6, >90%, > 1). These threshold parameters result in 899 proteins being considered
identified only when 2 or more non-phosphorylated unique peptides are identified in
16,293 spectra of moderate quality or better. The false positive rate for automated
interpretation of the MS/MS spectra using the above criteria was estimated by searching
all spectra passing the quality filter against the same database with all of the protein
sequences reversed. After applying the above criteria to the search results from the
reversed database 22 spectra passed the thresholds yielding 7 proteins (all large, 80kDa-
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3.8MDa, with 2 or 3 unique peptides, protein scores 25-36). Thus the estimated overall
false-positive identification rates are spectra: 0.1% (22/16,293) and protein: 0.8% (7/899).
In calculating scores at the protein level and reporting the identified proteins,
redundancy is addressed in the following manner: the protein score is the sum of the
scores of unique peptides. A unique peptide is the single highest scoring instance of a
peptide detected through an MS/MS spectrum. MS/MS spectra for a particular peptide
may have been recorded multiple times, (i.e. as different precursor charge states, isolated
from adjacent gel bands, modified by deamidation at Asn or oxidation of Met) but are
still counted as a single unique peptide. When a peptide sequence >8 residues long is
contained in multiple protein entries in the sequence database, the proteins are grouped
together and the highest scoring one and its accession number are reported. In some cases
when the protein sequences are grouped in this manner there are distinct peptides which
uniquely represent a lower scoring member of the group (isoforms and family members).
In these instances more than one member of the group is reported and counted towards
the total number of proteins and in Table 2.1 they are given related protein subgroup
numbers (i.e. 7 members of the 14-3-3 proteins were identified: YWHAB, YWHAE,
YWHAG, YWHAH, YWHAQ, YWHAZ, SFN and are listed as subgroup numbers 550.1
- 550.7). Overall 899 distinct proteins were identified in the samples from 784 protein
groups. In a few instances 2 distinct proteins have been found yet they currently share the
same NCBI official symbol (i.e. both shared and distinct peptides were found for the
related proteins 14286186, 34365273 which are currently both designated as ZNF 185).
MS/MS spectra of phosphopeptides obtained during LC/MS/MS of the TiO2
IMAC elutions, as well as the data-dependent and targeted analysis of the gel bands, were
interpreted in a second round of searches against only the subset of proteins confidently
identified from the unphosphorylated peptides observed during the data-dependent
LC/MS/MS of the gel band tryptic digests of the PBD pulldowns. The allowed variable
modifications were expanded to include phosphoserine and phosphothreonine, with a
precursor MH+ shift range of -18 to 177 Da. The spectrum of each phosphopeptide was
manually inspected by an expert. For -10% of phosphosites observed the MS/MS spectra
lack sufficient information to assign the site ofphosphorylation to a particular Ser or Thr
residue. In those cases that ambiguity is noted in Table 2.2 and the motif chosen to list in
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Table 2.1 and count in Figure 2.4B is preferentially chosen in the following order (the
optimal PBD-binding motif S-[pS/pTl-P, the minimal Cyclin-dependent kinase
phosphorylation motif ([pS/pT]-P), or none of the above ([pS/pT])..
Relative abundance of proteins in the wild-type and mutant PBD bound protein
pull-downs were determined using the ion current measured for each peptide precursor
ion in the intervening 100K resolution FT-MS scans of the data-dependent LC/MS/MS
analyses of the gel band tryptic digests from the PBD pulldowns. The chromatographic
peak area of each precursor ion was calculated in the region +/- 30 sees with +/- 0.04 m/z
windows around each individual member of the isotope cluster. An individual protein's
abundance was calculated as the total ion current measured for all peptide precursor ions
with MS/MS spectra confidently assigned to that protein. The determined protein ratios
are semi-quantitative, and are generally reliable to within a factor of 2-3-fold of the actual
ratio. Numerous experimental factors contribute to the variability in the determined
abundance for a protein, including incomplete digestion of the protein; widely varying
response of individual peptides due to inherent variability in ionization efficiency as well
as interference/suppression by other components eluting at the same time as the peptide
of interest (the matrix effect); differences in instrument sensitivity over the mass range
analyzed, and inadequate sampling of the chromatographic peak between MS/MS scans.
Immunoblotting
Proteins were separated by SDS-PAGE, transferred to a PVDF membrane and
immunoblotting was performed according to standard techniques. Proteins were detected
with 0.25 pg/mL a-Cofilin (Cytoskeleton), 1 pg/mL a-Lamin A/C (Upstate), a-MCM2-7
clone AS 1.1 (diluted 1:200; generous gift from Stephen Bell, Howard Hughes Medical
Institute, M.I.T.), 0.25 plg/mL a-Rock2 (BD transduction laboratories), 0.5 jtg/mL a-
MYPT1 (BD transduction laboratories), 4 pLg/mL a-Actinin cl (Upstate), 10 tg/mL a-
CKIIc (Calbiochem), 2 gtg/mL a-Anillin (Abcam), 0.5 gtg/mL a-Citron (BD transduction
laboratories), 1 gtg/mL a-Rockl (BD transduction laboratories), 0.8 jtg/mL a-Plkl
cocktail (Zymed Laboratories), 0.5 jg/mL a-Myc-Tag (Cell Signaling), 5jtg/mL M2 a-
Flag (Sigma), or a 1:5000 dilution of a-actin (Sigma). Following incubation with
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appropriate secondary antibodies, immuno-reactive proteins were visualized by enhanced
chemiluminescence (Amersham).
Rock2 kinase assays
Myc-tagged Rock2 was pre-incubated in kinase buffer (50 mM Tris pH 8, 200
mM NaCI, 2 mM DTT, 5 mM NaF, 200 pM ATP and 500 pM MgC12) containing 1 mM
GTP with or without 5 gg RhoA and/or 7 ng/pL Plkl kinase domain for 30 minutes at
300C. Reactions were then supplemented with 20 pCi [32P]-y-ATP and 50 gM substrate
peptide (Myosin Light Chain Kinase Substrate; AKRPQRATSNVFS; Sigma-Aldrich),
and aliquots of the reaction spotted onto squares of Whatman P81 paper after an
additional 0, 5, 10 or 20 minutes. The P81 paper was washed with 0.5% phosphoric acid
five times, and incorporation of 32P into the substrate peptide was assessed by
scintillation counting. For comparison of wild-type and 4A mutant ROCK2, full length
myosin light chain (Sigma) was used as a substrate, and the radiolabeled phosphate
incorporation was assessed by autoradiography following SDS-PAGE.
Immunofluorescence microscopy
Rock2 and Plkl co-localization was examined in sub-confluent U20S cells
transfected with the indicated plasmids and treated with 100 ng/ml nocodazole for 19
hours. Mitotic cells were collected and resuspended into Dulbecco's modified Eagle
medium supplemented with 10 % fetal calf serum and penicillin-streptomycin. The cells
were then re-seeded onto 18 mm2 glass coverslips and incubated for 75min at 370C. The
cells were washed with cold phosphate-buffered saline (PBS) and fixed with 3%
paraformaldehyde/2% sucrose in PBS for 15 min at room temperature. The fixed cells
were washed with PBS and permeablized with 0.5% Triton X-100 in buffer (30 mM Tris
buffer (pH 7.8), 75 mM NaCl, 0.3 M sucrose, 3 mM MgC12) for 15 min at room
temperature. Coverslips were blocked with 1% bovine serum albumin/l% sucrose in PBS
for 1 hour, and stained with mouse monoclonal anti-Rock2 antibody (Clontech
Laboratories) at 40C overnight. After washing, coverslips were stained with Alexa Fluor
488-labeled anti-mouse IgG antibody (Invitrogen, Carlsbad, CA) secondary antibody for
1 hour at room temperature. The coverslips were washed and then incubated with
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Rhodamine-labeled mouse monoclonal anti-Plkl antibody for 3 hours at room
temperature. Rhodamine-labeled mouse monoclonal anti-Plkl antibody was made using
mouse monoclonal anti-Plkl antibody (Zymed Laboratories) and EZ-Label Rhodamine
Protein Labeling Kit (PIERCE) according to the manufacturer's protocol. The coverslips
were then mounted onto slides with Fluoromount-G (Southern Biotechnologies)
containing 4',6'-diamidino-2-phenylindole (DAPI) for DNA staining. Images were
collected on a Deltavision (Carl Zeiss) and the Rock2:Plkl co-localization images were
digitally deconvolved using Softworx graphic processing software (SGI).
Mitotic phenotypes of Rock2-overexpressing cells were examined in sub-
confluent U20S cells seeded on coverslips and transfected with the indicated plasmids.
After 24-72hrs cells were fixed, washed, permeabilized blocked and stained with mouse
monoclonal anti-3-tubulin antibody (Sigma) for 1hr at room temperature, washed with
PBS, and stained with secondary antibody as above.. Transfected cells were scored by
eye for mitotic hallmarks (condensed DAPI and rounded shape) and for presence of a
tubulin bridge connecting two cell bodies each with a distinct DAPI signal. We are
grateful to the MIT CCR Microscopy and Imaging Core Facility for help with all
microscopy work.
Random Protein Dataset Generation and Analysis
The NCBI RefSeq protein collection (version 18 - released July 17, 2006) was filtered to
include only human proteins. Strictly computationally predicted proteins were then
removed from the collection. The resulting sequences (24314 proteins) were used to
generate 2000 random protein datasets of either 622, 277, 282, or 340 proteins using a
pseudo-random number generator. The proteins in these sets were then searched for the
presence of either a S-[S/T]-P motif for the sets with 622 and 277 proteins or a [E/D]-X-
[S/T]-[F/L/I/Y/W/M] motif for the sets with 282 and 340 proteins. The percent of
proteins containing the searched for motif was recorded, and a histogram generated
indicating the results for all 2000 sets.
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Figure 2.1: The Polo-box domain of Plk1 preferentially binds ligands in mitosis.
(A) Dormin structure of Plkl. Residues His-538 and Lys-540 are required for
phosphopeptide binding by the Polo-box domain (PBD).
(B) Experimental strategy for identifying cell cycle-dependent PBD ligands.
(C) Purity and equivalence of recombinant wild-type and mutant PBDs used for
interaction screening. Samples were analyzed by SDS-PAGE and stained with Coomassie
blue.
(D) U20S cells were synchronized at the G1/S transition by a double thymidine block or
in M-phase by nocodazole treatment, and DNA content analyzed by flow cytometry.
(E) Wild type (WT) and mutant (MUT) PBD was used to pull down interaction partners
from double thymidine blocked or the nocodazole-arrested U20S cell lysates. Bound
proteins were separated by SDS-PAGE and visualized by SYPRO Ruby staining. Lines
on right of gel indicate where gel was cut prior to subsequent mass spectrometry analysis
with each labeled section correlated with Table 2.1.
A C D
P oloW UT- oma•,i DoU13
K-WT IUT TIymWlM NMocodazole
i 3l 377 -1 37-
158K~ll!
B 2 35-
Scells 20-
• .J N.
ILL~ii
TfT block Nocodazole 2 4N 2N 4N
E PBD Pulldown
250
150s
ýAGE 100
37:
150.
50-ism
protein identimfation phosphopeptide mapping
108
pmI
Figure 2.2: Mitotic proteins bind to the Polo-box domain in a phospho-dependent
manner and are substrates of Plk1.
(A) Direct binding of PBD-interacting proteins. Proteins interacting with the WT and
MUT PBD from nocodazole arrested U20S cell lysates (Figure 2.1B) were transferred to
PVDF membrane and analyzed for direct binding by Far-Western analysis using the wild-
type PBD as a probe.
(B) Phosphorylation-dependent PBD interactions. Nocodazole arrested U20S cell lysates
were incubated with (+) or without (-) X-protein phosphatase prior to WT-PBD pull down.
The bound proteins were separated by SDS-PAGE and visualized by SYPRO Ruby
staining.
(C) Plki phosphorylation of PBD-interacting proteins. Wild type PBD was used to pull-
down interacting proteins from nocodazole arrested U20S cell lysates. The proteins were
incubated with or without active PlkI and 32P-y-ATP, separated by SDS-PAGE, and
visualized by autoradiography.
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Figure 2.3: Verification of mitosis-specific, phosphorylation-dependent, Polo-box
domain interacting proteins identified by mass spectrometry.
(A) WT and MUT PBD was used to affinity purify interaction partners from nocodazole
arrested U2OS cell lysate. Proteins were separated by SDS-PAGE and analyzed by
immunoblotting with the indicated antibodies.
(B) U20S cells were arrested at GI/S by a double thymidine block (T/T) or in M-phase
by nocodazole arrest (Noco.). Lysates were incubated with WT PBD and bound proteins
separated by SDS-PAGE and analyzed by immunoblotting with the indicated antibodies.
(C) Lysates from nocodazole-arrested U20S cells were incubated with (+) or without (-)
X-protein phosphatase at 300C for 2 hours prior to WT-PBD pull down. Bound proteins
were separated by SDS-PAGE and analyzed by immunoblotting with the indicated
antibodies.
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Figure 2.4: The Polo-Box Domain Interactome.
(A) Only WT PBD -specific or -enriched interacting proteins that contain at least one
match to the optimal PBD binding motif (S-[S/T]-P) are shown (Figure 2.4B, blue boxes,
column 2). Proteins were categorized according to their known biological function by GO
terms. Blue text indicates those proteins in which we were able to map at least one S-
[pS/p T-P site; dark blue indicates those that also contain an optimal Plkl phosphorylation
site, while light blue indicates those that do not. For the remaining proteins, those shown
in purple contain an optimal Plkl (E/D)X(S/T)qý phosphorylation site while those shown
in black do not. Previously known Plkl interactors are indicated with an asterisk.
(B) Summary statistics of proteins identified by mass spectrometry from Plkl PBD-
pulldown assays in nocodazole -arrested U2OS cells. Proteins were divided into three
categories based on specificity for the wild type versus mutant PBD. Dark red denotes
proteins that only bound to the wild-type PBD; light red, proteins with > 20-fold
enhanced binding to WT PBD; dark grey, proteins with <20-fold enhanced binding to
WT PBD. The presence of optimal PBD-binding S-[S/T]-P motifs are shown by dark and
light blue and grey filled bars in the 2nd column. White boxes in the second column
correspond to identified interacting proteins that do not contain the optimal PBD-binding
motif. Potential Plkl (E/D)X(S/T)(p phosphorylation sites are indicated by purple and
gray wedges in pie charts.
(C) A subset of phosphorylation sites in the WT specific/enriched versus non-specific
PBD-interacting proteins were mapped by mass spectrometry. Mapped sites were
categorized into those that matched the optimal PBD-binding motif (S-[pS/pT]-P, the
minimal peptide PBD-binding motif (S-[pS/p T), the minimal Cyclin-dependent kinase
phosphorylation motif ([pS/pT]-P), or none of the above ([pS/pT]).
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Figure 2.4 Continued
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Figure 2.5: Bioinformatic Analysis of the Polo-Box Domain Interactome.
(A, B) Distribution of (S-[S/T]-P) motif occurrence in 2000 random protein datasets. In
panel B each dataset contained 622 proteins while in panel A each dataset contained 277
proteins. The means and standard deviations of the distributions are shown. Thick vertical
arrows indicate the percentage of WT PBD-specific/enriched proteins (B) and WT PBD
non-specific proteins (A) that were observed to contain the S-[S/T]-P motif.
(C, D) Distribution of potential Plk1 phosphorylation motifs (E/D)-X-(S/T)-0 in 2000
random protein datasets. In panel D each dataset contained 282 proteins while in panel C
each dataset contained 340 proteins. Thick vertical arrow in (D) indicates the percentage
of WT PBD-specific/enriched interacting proteins containing both S-[S/T]-P motifs and
potential Plkl phosphorylation motifs. The arrow in (C) indicates the percentage of WT
PBD-specific/enriched interacting proteins that lack S-[S/T]-P motifs but contain
potential Plkl phosphorylation motifs.
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Figure 2.6: A data-driven Plkl-related cytokinesis network.
Circle color coding: orange, Plkl; red, myosin activation network; blue, actin dynamics
network; light purple, proteins bridging the actin and myosin networks; dark purple,
central spindle organization network; green, proteins not known to function as part of any
core cytokinesis network. Proteins are labeled using HUGO gene nomenclature except
for actin, tubulin, myosin, and myosin light chains. Myosin phosphatase is shown
generically as a node labeled MYPT (official gene symbol for the protein we identified is
PPP1R12A). Lines indicate direct protein-protein interactions, arrows indicate a kinase-
substrate relationship, and the filled circle between MYPT and myosin RLC indicates a
phosphatase-substrate relationship.
(A) The known Plkl network of proteins that participate in cytokinesis.
(B) The core cytokinesis network of central spindle organization.
(C) The core cytokinesis network of myosin activation.
(D) The core cytokinesis network of actin dynamics.
(E) Core cytokinesis network. The networks from panels A-D are shown connected by all
of the direct, experimentally verified, protein-protein interactions. The thick line between
Ect2 and RhoA represents the only mechanistic connection between previously known
Plkl-interacting proteins and the actomyosin cytokinesis subnetworks.
(F) Plkl-centric core cytokinesis network. The network in panel E redrawn with
additional interactions between Plkl and core network components as revealed by the
Plkl PBD interactome screen. Core cytokinesis network components detected in the Plkl
PBD interaction screen are shaded yellow. Red circle indicates the section of the network
selected for further study.
(G) A Plkl -PBD annotated cytokinesis network. A view of the core cytokinesis network
expanded to include additional Plkl PBD-interacting proteins that were detected in our
screen and are known to participate in protein-protein interactions with one or more of
the core cytokinesis components. Yellow shading indicates PBD-interacting proteins in
the core network; green shading indicates PBD-interacting proteins that also interact with
proteins in the core network; thick black lines denote interactions between core network
proteins and the additional Plk1 PBD-interacting proteins in the expanded network.
(H) Proteins within the red circled region from panel F were investigated as in Figure 2.3.
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Figure 2.6 Continued
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Figure 2.7: Plkl-centric Plkl-PBD annotated cytokinesis network
An alternative view of the data shown in Figure 2.6G with Plkl placed at the center.
Yellow shading indicates PBD-interacting proteins in the core network; green shading
indicates PBD-interacting proteins that also interact with proteins in the core network.
Lines indicate direct protein-protein interactions, arrows indicate a kinase-substrate
relationship, and the filled circle between MYPT and myosin RLC indicates a
phosphatase-substrate relationship.
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Figure 2.8: PlkI and RhoA synergistically activate Rock2.
(A) Domain structure of Rock2, with amino acid sequence indicated below. Plkl -
dependent phosphorylation sites were mapped by mass spectrometry and are indicated by
filled red circles.
(B) Plkl and Rock2 interact in cells during mitosis. Full length myc-tagged Rock2 and
Flag-tagged Plkl (containing WT or MUT PBD) were expressed in U20S cells. Lysates
from asynchronous cells or following mitotic arrest with nocodazole were
immunoprecipitated using M2 a-Flag beads, and immunoblotted for myc as shown. Note
that expression of the mutant Plkl was much higher than the wild type Plkl as expected
since overexpression of wild type Plkl is somewhat toxic to cells [65, 66].
(C) The amount of Rock2 co-precipitating with Plkl in panel B was quantified by
normalization relative to the level of Rock2 expression.
(D) Rock2-binding to Plkl in mitosis is phosphorylation-dependent. Myc-tagged Rock2
and Flag-tagged Plkl were co-expressed in U20S cells. Mitotic lysates were prepared
from nocodazole-arrested cells, treated for 2h with X protein-phosphatase or mock treated,
then immunoprecipitated using M2 a-Flag beads and immunoblotted for myc.
(E) Rock2 and Plkl co-localize at the midbody during cytokinesis. U20S cells were
released from a nocodazole block, and fixed and 1 hr later stained for endogenous Plkl
and Rock2. DNA was stained with DAPI. Deconvolution images are shown. Scale bars =
5Lnm.
(F) Plkl and RhoA synergize to amplify Rock2 kinase activity. Myc-Rock2 was
immunoprecipitated from asynchronous cells and kinase activity against a myosin light
chain peptide assayed in the presence or absence of RhoA and/or in response to Rock2
phosphorylation by PlkI. Error bars represent the standard deviation of 3 independent
experiments.
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Figure 2.8 Continued
MaDped SitesI Kinase RBD PH 1388 T967
92 34 94 1O781133
IS1374
B
Myc-ROCK2 Nocodazole Asynchronous
Flag-PLKI: WT MUT WT MUT
IP: (t-Flag *w -* Blot: n-fye
So ~ i Blot: a-mycLysate
Blot: ct-Flag
.1
Nocodlzoie
+ a-phosphatase
IP: "-Flag Blot: a-myc
Blot: anmyc 10
Blot: (1-Flag x
0
0
ROCK2 Kinase Activity
2.5-
20-
0.5-
S I I
0 5 10 15 20
+ROCK2
+ Plki + RhoA
+ROCK2 + RhoA
+ROCK2 + PlkI
+ROCK2 alone
-ROCK2
+ PtkI + RhoA
Minutes
a-ROCK2 a-PIk1
A
Lysate
DAPI
118
U
g0* m
Figure 2.9: Plk1 phosphorylates ROCK2 in vitro
(A) Domain structure of Rock2 constructs, with amino acid sequence boundaries shown.
Plk -dependent phosphorylation sites were mapped by mass spectrometry as indicated.
(B) The indicated Rock2 constructs were immunoprecipitated from 293T cells. The
proteins were then incubated with or without active Plk and 32P-[}ATP, separated by
SDS-PAGE, and visualized by autoradiography.
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Figure 2.10: Mass spectrometry spectra identifying PIk1 phosphorylation sites in
ROCK2
(A-D) MS/MS spectra of peptides containing the indicated sites are shown with b-ions in
blue and y-ions in red. Ions indicating neutral loss of phosphate from the precursor are
shown in green. The phosphorylation site in C could be any of the three consecutive
serines centered on SI 133.
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Figure 2.11: Expression of exogenous myc-tagged ROCK2.
Western blots with indicated antibodies are shown.
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Figure 2.12: Plk1 activates Rock2 in cells.
(A) Myc-Rock2 or myc-Rock2-4A was immunoprecipitated from asynchronous cells.
Each I.P. was split in half, and one-half pre-incubated with Plki for 60 min in the
presence of cold ATP. Following additional washing, Rock2 kinase activity against
myosin regulatory light chain was assayed in the presence of RhoA and 32P-y-ATP, and
analyzed by SDS-PAGE/autoradiography. A strong Rock2 autophosphorylation band is
also present. Lanes 1 and 2 in the left panel and lanes 3 and 4 in the right panel are each
from the same gel and autoradiograph allowing direct comparison.
(B) Overexpression of Rock2 causes accumulation of cells in terminal cytokinesis.
Asynchronous U20S cells were transfected with pEF-BOS (control) or pEF-BOS
expressing wild-type Rock2. Mitotic cells from the control transfections displayed a
normal rounded-up morphology, while many of the mitotic cells overexpressing Rock2
appeared to be in the terminal midbody stage of cytokinesis. Scale bars = 10rnm.
(C) Percentage of mitotic cells in cytokinesis 24 hrs after transfection with myc-Rock2,
myc-Rock2-4A, or control vectors. Mean values and S.D. from n=3 experiments.
(D) FACS profiles of cells 72 hrs after transfection with myc-Rock2 or myc-Rock2-4A.
(E) Percentage of cells containing greater than 4N DNA content from FACS profiles
above. These results are representative of n=3 independent experiments.
(F) A model of Plkl control of regulatory myosin light chain (RMLC) phosphorylation
during cytokinesis. Arrows indicate activation events and bars indicate inhibition events.
Kinases are indicated as squares, phosphatases as circles, GEFs as diamonds, and small
G-proteins as rounded squares.
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Figure 2.12 Continued
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Abstract
Protein phosphorylation is a ubiquitous regulatory mechanism for cellular signal
propagation, and the complexity of signaling networks presents a challenge to protein
kinase substrate identification. Substrates of Polo-like kinases are largely unknown,
despite the significant role of these kinases in coordinating mitotic cell cycle progression.
Here, we combine a novel application of the yeast two hybrid system to identify mitotic-
specific interactors of the polo-box domain of the budding yeast polo-like kinase with
chemical genetic, bioinformatic, and yeast proteomic tools for Polo-like kinase substrate
identification. The results from the yeast two hybrid screen were validated through a
polo-box domain pulldown screen from the TAP-tagged collection of yeast strains. In
total, 27 proteins were validated to be phosphorylation-dependent polo-box domain
interactors, out of 112 proteins attempted. Systematically-chosen candidate Cdc5
substrates were examined for loss of phosphorylation upon cellular Cdc5 inhibition using
a mono-specific pharmacological inhibitor, revealing five novel Cdc5 substrates. We
undertook further studies on Cyk3 (identified by yeast two hybrid), Cnm67 (identified by
bioinformatics), and Spc72 (identified as a Cdc5 substrate by chemical genetics). All
three proteins are in vitro substrates of Polo-like kinases, and contain polo-box domain
binding consensus motifs that, when mutated, eliminate Cdc-PBD binding. Interaction-
defective genetic studies with these mutants to determine whether PBD binding affects
their in vivo function are in process demonstrating a role for Cdc5 in regulating septum-
dependent cytokinesis through Cyk3, and mitotic nuclear positioning through Cnm67 and
Spc72.
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Introduction
Ensuring accurate chromosome segregation is fundamental to survival of a
species. Temporally and spatially regulated signaling events are required to monitor and
direct multiple cellular events during cell division. The Polo-like family of
serine/threonine protein kinases (Plks) have emerged as an important class of cell cycle
regulators that coordinate mitotic progression, with multiple roles from mitotic entry to
cytokinesis [1]. Humans have four Plks (Plkl-4), of which Plkl is the most thoroughly
characterized, motivated by its link to tumor development [1]. The budding yeast S.
cerevisiae has a single Plk, Cdc5, with 49% identity to Plkl in its kinase domain [2].
Cdc5 functions in adaptation to the DNA damage checkpoint, progression through G2/M,
cohesin cleavage at anaphase entry, and cytokinesis, with an essential role in promoting
mitotic exit as part of two signaling networks called FEAR and MEN [2].
The existence of a single Plk, the availability of several comprehensive strain
libraries of epitope-tagged genes [3], and the availability of chemical genetic tools for
dissection of kinases in budding yeast [4], makes it an attractive organism for the study of
Plk signaling pathways. Despite the multiple mitotic functions of Cdc5, only a few of its
substrates have been conclusively identified [5-8]. Cdc5 substrates are difficult to
identify for several reasons. First, both Cdc5 and its known substrates are low
abundance proteins present at less than 1500 copies per cell [3]. Additional Cdc5
substrates are also likely to be low abundance, as this is generally true for cell-cycle
regulatory proteins [3]. Furthermore, characterized phosphorylation sites in Plk
substrates have considerable sequence variation [9] and are of limited utility in
identifying likely candidate substrates.
This variation in phosphorylation site preference suggests alternative specificity
determinants, such as temporal and spatial regulation. Cdc5 levels are tightly cell cycle-
regulated with maximal activity in mitosis [2]. Cdc5's distinct localization pattern
includes the cytoplasmic face of the spindle pole body (SPB, the functional equivalent to
the mammalian centrosome), chromosomes, and the bud neck (the future site of
cytokinesis) [7, 10-12]. Accurate chromosome segregation requires coordination
between these structures. Cytoplasmic microtubules project from the SPB projects to
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move one set of duplicated chromosomes through the predetermined cleavage plane at
the bud neck [13]. Cytokinesis initiation follows a MEN signal at the SPB, which
monitors this anaphase spindle migration [13]. Mutations in a conserved C-terminal
region of Plks called the polo box domain (PBD).disrupt this Cdc5 sub-cellular
localization pattern [11]. The PBD is a phospho-serine/threonine binding module that
can directly target Plks to their substrates after prior "priming" phosphorylation of the
substrate by an upstream kinase [9, 14].
To identify further Cdc5 substrates, we used multiple independent methods. First,
we developed a novel modification of the yeast two hybrid system to identify mitotic-
specific interactors of the Cdc5-PBD, which are likely to also be Cdc5 substrates [9].
Secondly, we utilized a bioinformatic approach to rank-order all yeast proteins as
potential Cdc5 substrates. Thirdly, we directly identified Cdc5 substrates using a mono-
specific Cdc5 inhibitor, providing for interruption of the kinase substrate reaction at any
point in the cell cycle with preservation of the endogenous expression levels of all the
components. Hits from these screens were further verified as phosphospecific Cdc5
binders in a Cdc5-PBD pulldown assay. We are further analyzing the in vivo role of
Cyk3, identified by yeast two hybrid, Cnm67, identified by bioinformatics, and Spc72,
identified with the Cdc5 inhibitor assay. Spc72 and Cnm67 have known roles in
anchoring cytoplasmic microtubules at the spindle pole body and function in nuclear
positioning similar to the phenotype seen with Cdc5 inhibition. Cyk3 plays a role in the
cytokinesis septum pathway. We show that all three proteins are in vitro substrates of
Polo-like kinases, and experiments are in progress to analyze the regulation of these
proteins by Cdc5 through interaction-defective genetics experiments, utilizing mutants of
these proteins that no longer bind to the Cdc5-PBD.
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Results and Discussion
A Context Dependent Yeast Two Hybrid Screen for the Cdc5 Polo-box Domain
To identify Cdc5-PBD interactors, we designed a novel yeast two hybrid screen.
Standard yeast two hybrid screens have been successful in identifying some Plk
interactors including six with full length Cdc5 [15-19], and a report that contained the full
results of a PBD yeast two hybrid screen only identified eight interactors [20]. The total
number of PBD interactors in yeast is likely to be much higher. Given our identification
of over 600 specific Plkl-PBD interactors by a pulldown mass spectrometry approach
(Chapter Two) [22], and a gene ratio of approximately five for human to yeast, we expect
there to be 120 interactors of the Cdc5-PBD. Thus, there is a large discrepancy between
the number of yeast two hybrid-identified PBD interactions and the actual number that
exist. The reason that standard yeast two hybrids have not been more successful in
identifying PBD interactors is because, for the most part, these interactors are context-
dependent. Interactions between the PBD and its ligands take place only during mitosis
and are dependent on phosphorylation of those ligands by CDKs or other mitotic kinases
[14, 23]. Thus, the challenge was to design a novel yeast two hybrid approach that was
sensitive to context-dependent interactions, and was able to separate these specific
interactions that occur only at specific points during the cell cylce from the noise inherent
in a yeast two hybrid assay.
One new application of the yeast two hybrid system had been designed for exactly
this purpose. Guo and colleagues designed a yeast two hybrid strain that tethered a
particular kinase or acetyltransferase to a bait protein of interest, and then performed a
standard yeast two hybrid screen [24]. This strategy was able to identify either
phosphorylation- or acetylation-dependent interactions of the particular bait proteins
employed [24]. While this is certainly a viable strategy for many molecules, it requires
the exongenous enzyme to function in yeast cells and in a cis configuration to its target.
More critically, it only functions to identify the modification dependent interactions of
one protein, and is not able to efficiently identify all the proteins that interact with a
modification-dependent binding domain, such as the PBD. Also, overexpression or
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altered activation of some enzymes, such as cell cycle kinases, will prevent normal yeast
cell growth, which is a requirement for visualization of yeast two hybrid results, as the
positive signal is a yeast colony. Thus, this strategy would not work to identify PBD
interactors, though it may work to identify the PBD as an interactor of a particular bait
protein if the upstream kinase is chosen correctly.
To overcome some of these difficulties, we chose to identify the interactors of the
PBD of the budding yeast Plk, Cdc5, rather than the human homolog. Searching for
interactions between yeast proteins within yeast cells eliminates many of the contextual
challenges, as the appropriate kinases required for the phosphorylation-dependent
interactions are expressed normally, eliminating the need to express an exogenous kinase
or to rely on yeast kinases to phosphorylate human proteins. Also, since some of the
endogenous Cdc5 is nuclear interactions between the Cdc5-PBD and its ligands can take
place in the nucleus, which is required for interactions to drive gene expression in the
yeast two hybrid system. Thus, for example, identification of growth factor signaling-
dependent interactions in this system might be challenging since the kinases responsible
for generating the binding sites are only present in the cytoplasm.
As the first step in identifying Cdc5-PBD interactions we undertook a standard
yeast two hybrid screen as outlined in Figure 3.1A top. The Cdc5-PBD fused to the Gal4
DNA binding domain was used as the bait to screen for interaction with a library of yeast
genomic DNA fused to the Gal4 activation domain. The Cdc5-PBD and library
expressing strains were of separate mating type so interactions were detected by mating,
selection of diploids that contained both genes, and growth on plates lacking adenine.
The ade2 gene is under the control of Gal4 in this strain, so only in yeast with an
interaction between the Cdc5-PBD and the library fragment would this gene be expressed
and the yeast be able to survive without adenine supplemented in the media. As expected,
a vast number of colonies grew, indicating a large number of interactors. In order to
weed out the non-specific interactors and the general noise in the system, a harsh
selection criteria could have been employed, which likely would have resulted in similar
results to previous studies with a few high affinity interactions being identified. Instead,
as described earlier, a more comprehensive approach that strategically identified the
mitotic-specific interactions was desired.
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In order to achieve specificity for mitotic interactions, a measurement of
interaction strength under normal conditions versus mitotic conditions was required. The
budding yeast cell cycle is ninety minutes long with thirty minutes spent in mitosis, so the
mitotic-specific interactions should be present among the more weakly interacting clones
in the standard yeast two hybrid set-up. To enrich for cells in mitosis, we employed a
strategy of growing the yeast on plates containing benomyl, which is a microtubule
poison that disrupts the mitotic spindle and slows down or stops mitosis. Diploid yeast,
of the yeast two hybrid strain used here, were tested for their ability to grow on different
levels of benomyl (Figure 3.1B). The optimal concentration of benomyl for continued
slow growth without massive death was determined to be 25p.g/ml, and this was used in
all further studies. As a way to measure the interaction strength, a qualitative
colorimetric assay was employed (Figure 3.1A bottom). In addition to the commonly
known P-galactosidase, budding yeast also produce a-galactosidase under the control of
a galactose inducible promoter, which is expressed upon interaction in the yeast two
hybrid strain. This enzyme is secreted, and its activity can be monitored through the
addition of X-a-galactose to the media, which the enzyme cleaves into a blue substrate.
Thus, to measure the interaction strength of the hits from the first stage yeast two hybrid
under the mitotically-enriched condition of growth in the presence of benomyl, the yeast
clones were grown on plates containing X-ca-gal with or without benomyl (Figure 3.1A
bottom). A total of around 1500 colonies were picked as hits from the first stage yeast
two hybrid and tested in the second stage mitotic enrichment screen. As this second stage
is a qualitative assay the blue color was compared by eye and 264 colonies with
significantly darker blue color on the plates containing benomyl were selected as hits
(Figure 3.1C).
This second step has the added benefit of eliminating any self-activating
sequences, because they would not have an enhanced signal with the benomyl treatment.
Normally, with a genomic library, such as the one used here, a high percentage of hits in
a yeast two hybrid are actually sequences that can act to directly activate gene
transcription without an interaction with the bait protein. This requires another time-
consuming step to independently test all hits for self-activation in the absence of the bait
protein. None of the identified hits from the second stage of the yeast two hybrid were
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found to self-activate when tested, whereas seven out of seventy-five of a random sample
of hits that passed the first step of the yeast two hybrid were found to be self-activating.
Sequencing of the hits from the second stage identified 112 ORFs (Table 3.1) that
are involved in many expected and unexpected processes. Classification of the ORFs by
GO terms (Figure 3.2A) revealed that the second most populated category, after
uncharacterized, was the expected category of cell cycle. A more specfic breakdown of
the cell cycle proteins (Figure 3.2B) revealed that these proteins participated in the
known Cdc5-regulated processes of cytokinesis, spindle control, mitotic exit, general
mitosis, meiosis, and the unexpected category of nuclear pore dynamics. The nuclear
pore is known to dramatically alter its structure and function during mitosis and
throughout the cell cycle [25-28] as suggested by the fact that these two nuclear pore
proteins, Nupl70 and Nup188, are categorized by GO terms as having a cell cycle
regulatory role. Whether Cdc5 is involved in this process is presently unknown, although
the yeast two hybrid interactions between Cdc5-PBD and these nuclear pore proteins
suggest that this might be the case. The other major categories of interactors (Figure
3.2A) are similarly known to be regulated during the cell cycle, and in particular in
mitosis, but are not currently known to be regulated by Cdc5 or other Plks [2, 9, 29-32].
Despite the fact that yeast two hybrid interactions are assumed to be direct the
proteins identified as interacting with the Cdc5-PBD could be direct or could be part of
complexes that interact with the Cdc5-PBD. To partially address this, we checked for the
presence of optimal PBD binding motifs within all the identified ORFs (Table 3.1). The
optimal binding motif for the Cdc5-PBD, as determined by oriented peptide library
screening, is the same as for the Plkl-PBD, S(pS/pT)P with a minimal motif of S(pS/pT)
[23]. All but two of the 112 sequenced ORFs contains this minimal motif (much higher
than expected based on a random set of yeast proteins), suggesting that they may be
direct interactors of the Cdc5-PBD, if the proteins are phosphorylated during mitosis. In
addition 37 of the 112 (one third, significantly higher than the one quarter of a random set
of yeast proteins that contain this motif) contain an optimal binding motif (Table 3.1)
which could be generated by the budding yeast CDK Cdc28, and 11 of these 37 are
known to be Cdc28 substrates [21]. Thus, for these 37 proteins, we can hypothesize that
Cdc28 phosphorylates these proteins at their S(S/T)P motifs and generates a Cdc5-PBD
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binding site. Intriguingly, 61 of the 112 identified proteins have human homologs, based
on the identification of a human gene BLAST hit using the yeast gene with an E value
greater than 1x106, so many of the interactions could be conserved in human cells.
Bioinformatic Screen for Additional Cdc5 Polo-box Domain Interactors
The consensus phosphorylation motif of Cdc5 has not been determined, but there
are a few pieces of information that allow us to infer Cdc5's optimal phosphorylation
motif. Expression of both Plkl and Plk3 can rescue a yeast strain harboring a cdc5-1
allele at the restrictive temperature [33]. Thus, the phosphorylation motif of Cdc5 must
overlap significantly with Plkl and Plk3. The published phosphorylation motif of Plk1 is
(E/D)X(S/T)(aliphatic) [34], and more recently, several sites have been mapped with an
N in the -2 position consistent with our own in vitro results (Jes Alexander - personal
communication). Unfortunately, the motif of Plk3 has not been published, but it is
thought to be similar to Plkl (Jes Alexander - personal communication). Of the mapped
Cdc5 phosphorylation sites, they all fall within this general consensus [5-7, 35], and the
N in the -2 position seems to be favored by Cdc5 [1]. A sequence alignment of the
kinase domains of Plkl, Plk3, and Cdc5 reveals that all three kinases have similar degrees
of homology with each other, with Cdc5 being slightly more similar to Plkl (47%
identical) than Plk3 (41% identical) (Figure 3.3A,B). The only known critical residue for
regulation of Plks (T210 in Plkl) is conserved in all three kinases and the motif
surrounding it is highly conserved (Figure 3.3B). A structure of the kinase domain of
Plkl is now available [36], and what limited information can be inferred about the
prefered phosphorylation motif fits with the prior data. Similarly, models of the kinase
domain structures of Plk1 and Plk3 [9] suggest that both kinases have the same
phosphorylation motif. Thus, we conclude that the known phosphorylation motif for
Plkl is a good approximation of the phosphorylation motif for Cdc5.
Utilizing the approximate Cdc5 phosphorylation motif (E/D/N)X(S/T) and the
known Cdc5-PBD binding motif S(S/T)P [23] allows identification of potential Cdc5
substrates through bioinformatics (Figure 3.4A). Briefly, the roughly six thousand
predicted yeast proteins were searched with the Scansite profile scanning algorithm [37,
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38] for Cdc5 binding and phosphorylation sequence motifs, generating a "Cdc5 substrate
likelihood score" for each protein (more details are available in Methods). The
distribution of scores is represented in Figure 3.4B, with high scores representing likely
substrates. Notably, the group of best scoring-potential Cdc5 substrates was enriched in
low abundance proteins relative to the entire proteome, requiring a sensitive test of
candidate phophorylation (Figure 3.4C). Cdc5 substrate likelihood scores, combined
with functional criteria including previous demonstration of a cell cycle role and
localization that matched that of Cdc5, led us to choose 192 total candidate substrates.
Functional criteria are a useful filter for substrate sets [39], without which this approach
would not have been possible. Among the proteins identified by this approach were the
known Cdc5 substrates; Mcdl, Bfal, and Swel[5-7], with Swel, notably, the only of the
three previously shown to directly bind the PBD, ranked 12th highest overall.
Validation of Cdc5 Polo-box Domain Interactors by Pull-down
The Cdc5-PBD was known to be a phosphopeptide binding domain from previous
studies [23] which identified a phosphobinding motif. However, since the Cdc5-PBD
had not been crystalized, it was not entirely clear what mutant of the Cdc5-PBD should
be made to eliminate the phosphopeptide binding. A sequence alignment of the Plkl -
PBD and the Cdc5-PBD (Figure 3.5B) revealed that the critical residues for
phosphopeptide binding, based on the Plkl-PBD structure [23, 40], were conserved in the
Cdc5-PBD. Mutation of the analogous residues to the "pincer mutant" in Plkl-PBD [23]
were generated (H641A/K643M) and tested in a phosphopeptide binding experiment.
Cdc5-PBD wild-type or the mutant were in vitro transcribed and translated in the
presence of [35S]-methionine, and then bound to a degenerate peptide library that
matched the minimal consensus sequence of CDK phosphorylation or its non-
phosphorylated counterpart. The wild-type Cdc5-PBD bound specifically to the
phosphorylated peptide library as expected, and the mutant version bound weakly to both
libraries (Figure 3.5C left). As a positive control, the Plkl -PBD and its mutant were also
tested (Figure 3.5C right) and gave the same results as previously [23]. This confirms
that the Cdc5-PBD is functioning as a phosphobinding domain, in an analogous way to
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the Plkl-PBD, and identifies this mutant version of the Cdc5-PBD as an optimal negative
control for Cdc5-PBD binding experiments. A domain map of Cdc5 with critical
residues is shown in Figure 3.5A.
To further assess whether the proteins identified by the yeast two hybrid and the
bioinformatic method were actual ligands of the Cdc5-PBD, we designed a PBD pulldown
screen. The recently-generated TAP-tagged yeast strains were used as a source to generate
lysates with tagged yeast proteins [3]. These lysates were then incubated with beads coated
with either the wild-type Cdc5-PBD or the mutant Cdc5-PBD, identified earlier as not able to
bind phosphopeptides. After extensive washing, interaction was detected by a western blot
against the TAP tag using goat anti-rabbit IgG. Unfortunately, this detection procedure also
recognized the Cdc5-PBD (Figures 3.6 and 3.7), preventing the interrogation of any proteins
that run at the same size as the Cdc5-PBD. The criteria for choosing which proteins to
interrogate was as follows: a TAP-tagged strain for the gene existed; the predicted size of the
TAP-tagged protein did not overlap with the signal for the Cdc5-PBD; and a sufficient
number of molecules per cell [3] had to exist to allow visualization of the protein. After
applying these criteria all the remaining proteins identified by the yeast two hybrid method
were attempted, as well as the top hits of the bioinformatic screen, up to a total of 110 TAP-
tagged strains (Table 3.2). Of these 110 strains, 81 proteins could be seen in the lysate, 27
interacted specifically with the wild-type Cdc5-PBD (Figure 3.6), and 17 interacted non-
specifically with both the wild-type and mutant versions of the Cdc5-PBD (Figure 3.7). This
yields an approximately 75% success rate in visualizing a given TAP-tagged protein, and a
25% success rate in identifying specific Cdc5-PBD interactors. Of the proteins that bound
the Cdc5-PBD specifically, 23 were originally identified in the yeast two hybrid, out of 79
total interrogated, giving a success rate of 30% for confirming the yeast two hybrid
interaction. The success rate of the proteins originally identified by the bioinformatics screen
was only 13%, as only four proteins were identified as being specific interactors; cnm67,
cbf5, Itel, and mcm2. This suggests that the non-biased approach of the yeast two hybrid
was more useful for the identification of real Cdc5-PBD interactors.
As with the yeast two hybrid results, the hits from the pulldown validation assay
were categorized by GO terms and grouped by commonalities therein (Figures 3.6 and
3.7). Proteins involved in mitotic processes, in RNA regulation, and uncharacterized
proteins were identified among both the specific and non-specific interactors, while all
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three ribosome-associated proteins were non-specific interactors. Additionally, proteins
that play roles in known Cdc5-dependent mitotic processes, such as spindle regulation,
mitotic exit, and cytokinesis were also identified as specific Cdc5-PBD interactors. The
categories of metabolic control and protein modification, also, were represented, though
any connection between Cdc5 and these processes is currently unknown. Future work to
connect Cdc5 function with these various cellular processes should prove an interesting
and fruitful area of research. Only half of the specifically-interacting proteins contain an
optimal Cdc5-PBD binding site that could be generated by CDK, suggesting that either
other kinases also generate Cdc5-PBD binding sites, or these interactions are not direct,
but instead are identified through another member of a complex that does contain a Cdc5-
PBD binding site. Unfortunately, the minimal consensus phosphorylation site for Cdc5 is
too common, among yeast proteins to make any conclusions about its representation in the
identified interactions, but all do contain a potential Cdc5 phosphorylation site.
The most obvious question from this list of Cdc5-PBD interactors is why some of
the previously known Cdc5 interactors, such as Bfal, Netl, Sccl, and Swel [5-7, 12, 35,
41, 42] are missing. These proteins may be absent for many reasons. For Scc 1, it is
likely that the Cdc5-PBD does not directly bind this protein, since it does not contain an
optimal Cdc;5-PBD binding site. Thus, it may have been missed in the yeast two hybrid
and it would not have selected in the bioinformatics search. This highlights a limitation
of this approach, which is that proteins in complex with direct Cdc5-PBD interactors may
be critical Cdc5 substrates, but they will not necessarily be identified by any of the
approaches used here. Bfal is supposed to be inactivated by Cdc5 to allow mitotic exit to
proceed [5]. This does not take place under conditions of spindle checkpoint so this may
explain why the interaction was not seen in the benomyl enriched yeast two hybrid screen.
Similarly, Swe 1 is a ligand and substrate of Cdc5 that only interacts during the entry into
mitosis, but would not be expected to remain bound to Cdc5 during an extended mitotic
state. The non-identification of these two known Cdc5-PBD binders suggests that the
screens presented here are also limited to identifying proteins that interact with the Cdc5-
PBD during the core middle phase of mitosis, consisting of spindle and chromosome
dynamics, rather than those that transiently interact with the Cdc5-PBD at early or late
times during mitosis. By this line of reasoning, Netl should have been identified, but it
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was not. One possibility is that Netl was not present in the library despite the library
having a five-fold genomic coverage. Overall the Cdc5-PBD pulldown verifies several
interesting Cdc5-PBD interactions, suggesting many future studies.
Generation of an Inhibitable Cdc5
We sought to engineer budding yeast Cdc5 to be selectively inhibited by a small
molecule, for identification of Plks substrates in intact cells. Our primary method for
selective kinase inhibition is the introduction of a space-creating gatekeeper residue
mutation coupled with a space-filling bulky derivative of the pyrazolopyrimidine (PP 1)
kinase inhibitor scaffold [43]. We replaced CDC5 at its endogenous locus with the cdc5-
as1 allele (analog sensitive) encoding an L158G gatekeeper mutation. This change
confers a modest 6-fold decrease in kcat/Km and slight increase in doubling time,
indicating that Cdc5(L158G) is a functional kinase (data not shown). Surprisingly, we
were unable to obtain significant inhibition of cdc5-asl using a variety of PP1 analogues,
despite the fact that a diverse collection of other protein kinases have proven amenable to
this approach (Jen Paulson - personal communication). Thus, the ATP binding site of
Cdc5 differs enough from other kinases that a new inhibitor strategy is necessary.
Fortunately, the Cdc5 active site contains an uncommon cysteine, C96 (Figure
3.8A). A homologous cysteine in RSK and MSK was recently shown to be irreversibly
inactivated by a pyrrolopyrimidine-based inhibitor containing an electrophile at the C-2
position [44]. We, therefore, reasoned that this, or a similar electrophilic inhibitor, might
also bind and inactivate Cdc5(L158G) by virtue of the absence of a bulky gatekeeper
residue and the presence of a naturally occurring Cys at position 96 (Figure 3.8B). As
shown in Figure 3.8C, we observed that growth of the cdc5-asl strain, but not the wild-
type strain, was prevented by treatment with the pyrrolopyrimidine -based inhibitor CMK.
Together, the cdc5-asl strain and the CMK inhibitor provide a system for the potent and
selective inhibition of Cdc5 in vivo. More extensive study revealed that the growth arrest
upon Cdc5 inhibition is due to a spindle positioning defect such that the daughter
nucleus fails to migrate into the daughter cell (Jen Paulson - personal communication).
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Cdc5 Substrates Identified in Candidate Based Screen
In additon to the use of the bioinformatic analysis to choose proteins for inclusion
in the Cdc5-PBD pulldown validation assay, these proteins were also tested in a Cdc5
substrate assay. To test these candidate substrates for Cdc5-dependent phosphorylation
in vivo, we also used the TAP tagged yeast strain collection. This approach is predicted
not to alter the cellular concentration of the protein, while providing an ultra-sensitive
handle for immunological detection [3]. To avoid false-positive phosphorylation effects
caused by Cdc5 overexpression, cdc5-asl expressed from the endogenous Cdc5 locus as
the sole source of Cdc5 was systematically introduced into TAP-tagged strains (Figure
3.9A). Since there is no general antibody that can detect all of the different Cdc5
phosphorylation sites, the Cdc5-dependent phosphorylation status of the TAP-tagged
candidates was monitored by gel shift, a straightforward and well-established method for
determining in vivo phosphorylation state [21]. We focused on the candidates that
exhibited a gel shift in a nocodazole induced G2/M arrest, when Cdc5 is active, but not in
a G1 arrest, when Cdc5 is not expressed [45]. These were then treated during the G2/M
arrest for 20 minutes with 10 gpM CMK and compared with DMSO-treated controls.
Out of 74 proteins that shifted in G2/M, five proteins exhibited reproducible
Cdc5-dependent changes in their gel shift (Figure 3.9B). These are likely to be direct
Cdc5 substrates, since CMK was added for only 20 minutes. Significantly, of the three
known Cdc5 substrates included in our screen, two, Bfal and Mcdl [5, 6], showed a
pronounced downshift upon Cdc5 inhibition. Similarly, two novel potential Cdc5 targets,
Spc72 and Ulp2, also downshift upon Cdc5 inhibition. Spc72 is a previously described
phosphoprotein, but the upstream kinase had not been identified [46]. Ulp2 is a
desumoylase with roles in centromeric cohesion and recovery from checkpoint arrest [47,
48], processes in which Cdc5 functions [2]. Intriguingly, Cdc5 inhibition resulted in an
upshift of Mihl; however, the chemical nature of the modified form of Mihl is unclear,
since it is unusual for loss of phosphorylation to result in a slower migrating form.
However, Mih is the budding yeast homolog of the human protein, Cdc25, which is a
known Plkl target [14], though it is not clear that Mihl has the same function in budding
yeast cells that Cdc25 does in human cells. Notably, each identified protein reportedly
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exists at less than 1400 molecules/cell. Unfortunately, we were limited by the proportion
of phosphoproteins that demonstrate significant phosphorylation shifts. Further advances
in mass spectrometric approaches that quantitatively detect differences in low
stoichiometry phosphopeptides in a complex mixture are necessary to improve this
approach [49].
Regulation of Cyk3, Cnm67, and Spc72 by Cdc5
In order to further investigate the role of Cdc5 in controlling mitotic progression
we chose to study some of the validated interactions in more detail. We chose one
protein identified through the yeast two hybrid screen, Cyk3, one identified through
bioinformatics and validated by Cdc5-PBD pulldown, Cnm67, and one identified as a
Cdc5 substrate, Spc72. All three proteins are predicted to contain a single Cdc28-
generated PBD binding site, contain multiple optimal Cdc5 phosphorylation sites, and
have known functions in mitosis [50-57]. Cyk3 is the only known Cdc28 target among
them [21]. The single predicted Cdc5-PBD binding site allows easy generation of non-
binding mutants of Cyk3, Cnm67, and Spc72, which then can be used for interaction
defective genetic studies to determine the role of Cdc5-PBD binding in the regulation of
these proteins. Based on the full oriented peptide library screening data for the Cdc5-
PBD [23], we decided to mutate the serine in the single STP motif in each protein to a
valine, since this was the most disfavored residue for binding at this position. This
should completely eliminate binding as a similar mutation blocks interaction between the
Plkl-PBD and Cdc25C [14], and isothermal calorimetry data suggests that in vitro, a
peptide with a valine at the -1 position relative to the phosphorylated residue binds with
weaker than 150pM affinity to the Plkl-PBD [14].
First, we performed the Cdc5-PBD pulldown assay, as described previously, on
Spc72, and found that it does indeed bind specifically to the Cdc5-PBD (Figure 3.10A),
consistent with previous reports that suggested interaction between these proteins [17, 58].
The interaction is also regulated by cell cycle stage, since Spc72 binds the PBD less well
in a GI than in G2/M arrest (Figure 3.10B). Mutation of the predicted Cdc28-generated
Cdc5-PBD binding site on Spc72 (S232) greatly reduces binding (Figure 3.10C). Some
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residual binding was observed in this mutant and may reflect contributions from other
sites in Spc72 or Cdc5-PBD interactions with Spc72 binding partners. However, the
amount of mutant Spc72 that came down with the Cdc5-PBD is similar to the amount of
wild-type Spc72 that came down with the Cdc5-PBD from G1 arrested cells. This
suggests either a background level of Spc72 in this assay that cannot be eliminated, or
that Spc72 binds the Cdc5-PBD weakly in a phospho-independent manner, in addition to
its strong phospho-dependent interaction. The mutants of Cyk3 (S350V) and Cnm67
(S120V) have been generated, but tagged forms need to be made to allow detection in the
pull-down assay.
In addition, to demonstrate that Cyk3, Cnm67, and Spc72 could serve as
substrates for Plks in vitro, the wild-type TAP-tagged proteins were immunoprecipitated
from yeast lysates and incubated with Plkl kinase domain and radioactive ATP.
Radioactivity was incorporated into all three proteins (Figure 3.11A, B) demonstrating
that, in vitro, they can serve as substrates of Plks. This suggests that, in vivo, they are
also substrates, since they directly interact with the Cdc5-PBD, placing them in an
optimal position to be phosphorylated by Cdc5.
With the non-binding mutants in hand, interaction-defective genetics studies can
be carried out. The deletion strain of cyk3 is viable and exhibits a clumping phenotype
when grown at 300 C or higher, that is minimized when grown at room temperature [50].
This phenotype results from the inability of mother and daughter yeast cells to
completely separate after mitosis is complete. Mitotic exit is completed in these cells,
because the cells proceed through the next round of the cell cycle thus eventually forming
clumps of cells stuck together [50]. The defect in the Acyk3 strain appears to be
improper septum deposition, as the bud neck septum is thicker than normal in the these
cells. Cyk3 probably plays a direct role in this process, as cyk3 contains a
transglutaminase domain, localizes to the bud neck [50, 59], and has synthetic lethality
phenotypes consistent with it being a member of the septum pathway [50]. All of these
phenotypes are rescued in the deletion strain by expression of the wild-type proteins [50].
To test whether the cyk3 Cdc5-PBD non-binding mutant rescues these phenotypes it will
be expressed in the deletion strain. In preliminary experiments, it appears that the non-
Cdc5-PBD binding mutant is similar to the deletion strain in clumping, whereas
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expression of wild-type cyk3 fully rescues this phenotype (Figure 3.12A). This places
Cdc5 as an upstream activator of both the septum and the actomyosin ring contraction
pathways (Chapter Four) in budding yeast cytokinesis. In addition to demonstrate that
the mutant cyk3 is specifically defective in the septum pathway we will test its synthetic
lethality with myol.
Unfortunately, though the systematic deletion strains of cnm67 and spc72 are
viable, they are functionally crippled due to a severe defect in chromosome segregation
caused by the inability of the daughter nucleus to migrate into the daughter cell [51, 52,
54, 56]. Thus, to examine the properties of the cnm67 and spc72 non-Cdc5-PBD
interacting mutants they were placed into a hetrozygous diploid deletion strain. This
strain will be sporulated and selected for the presence of the plasmid encoding the wild-
type or mutant gene and the genomic deletion of the gene. These strains will always be
grown at room temperature until assay, to alleviate the nuclear migration defect and avoid
the introduction of mutations into the strain. For further ease of visualization, a GFP-
tagged beta tubulin gene was inserted into the heterozygous diploid deletion strains at the
genomic locus. Spindle orientation of the various strains will then be monitored by
fluorescence microscopy. We expect that the strains harboring the mutant versions of the
genes will have nuclear positioning defects, which will suggest that Cdc5 regulation of
Cnm67 and Spc72 is required for proper mitotic spindle orientation and nuclear migration
into the daughter cell. These Cdc5-PBD non-binding mutants might not be as severe as
full deletions, but considering that Cnm67 and Spc72 have similar localizations at the
spindle pole body and similar deletion phenotypes, a combination of the two non-binding
mutants might produce a more severe effect.
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Experimental Procedures
Molecular Biology Techniques
Residues 357-705 of Cdc5 (analogous to 345-603 of Plkl) were cloned between
the BamH1 and SalI sites in the pGBD vector. The same Cdc5 fragment was cloned
between the BamH1 and XhoI sites in the pGEX-4T1 vector and the pcDNA3.1+hisC
vector. Site-directed mutagenesis was carried out using the QuikChange Site-Directed
mutagenesis kit (Stratagene) to make a H641A/K643M version of the Cdc5-PBD. The
pGEX-Cdc5-PBD constructs were transformed into the Rosetta2 bacterial expression
strain, and GST-Cdc5PBD protein was produced by induction of OD600 = 0.7 cells with
0.4mM IPTG for 16hrs at room temperature. Bacterial pellets were spun down from the
overnight cultures, lysed by sonication in lysis buffer (50mM Tris pH7.5, 150mM NaC1,
5mM EDTA, ImM PMSF), and GST fusion proteins purified by incubation with GSH
beads overnight at 40C. Beads were washed extensively with TBST and TBS, and
resuspended in TBS with lmM PMSF. The purity of protein was analyzed by coomassie
blue staining of SDS-PAG and the amount of protein was determined by comparison to
standard amounts of BSA. Protein was used within one week of generation, and checked
for maintenance of full length protein at each time of use. Cyk3452-613 was subcloned into
pGEX-4T1 and a C522A mutation generated by the Quickchange method as above.
GST-tagged Cyk3 proteins were induced and purified as above from BL21 cells. Cell
cycle synchronization was obtained by GI arrest with alpha factor for 3 hours, followed
by washing to release (0 min time point). Alpha factor was re-added at 70-80 minutes
when arresting in the following GI. Alpha factor was used at 1 pg/ml for bar- cells and
20 ptg/ml for bar+ cells. G2/M arrests were obtained by nocodazole treatment at 15
gg/ml for 3 hours. For phosphorylation gel shifts, cell extracts were prepared in urea
lysis buffer as described [21], and 5 jtg of protein was loaded on 5%, 7.5%, or 10%
Criterion gels (Biorad) for western blotting.
Yeast Genetic Techniques
Media and genetic techniques were as previously described [60]. To generate
cnm67 constructs, the endogenous cnm67 gene from 500bp upstream to 500bp
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downstream of the genomic locus was cloned into pRS416 between the XhoI and BamHI
sites by standard subcloning procedures. An analogous process was used to generate
cyk3 and spc72 constructs in leu and ura marked plasmids, respectively. Spc72 plasmids
encoded an 1302N difference from published sequence, which was confirmed in a W303
strain. Site-directed mutagenesis was carried out using the QuikChange Site-Directed
mutagenesis kit (Stratagene) to generate cnm67S120V, cyk3S350V, spc72S231A, and
cyk3C522A. Mutagenesis was confirmed using restriction digests and full gene DNA
sequencing. The Acnm67 heterozygous diploid strain generated by the Yeast knockout
consortium was purchased from Open Biosystems. GFP-beta-tubulin on a leucine marker
was inserted into this strain, and correct integration was confirmed by colony PCR and by
subsequent DNA sequencing of the genomic locus. The various cnm67 constructs were
transformed into this strain and spores were selected on media lacking uracil, leucine, and
containing kanamycin to generate haploids with the GFP-beta-tubulin, the genomic
cnm67 deletion, and the covering cnm67 plasmid. These strains were used for
examination of cnm67 function. The Acyk3 haploid strain generated by the Yeast
knockout consortium was transformed with the various cyk3 constructs and these strains
were used for examination of cyk3 function The cyk3 constructs were also transformed
into a haploid Acyk3Amyol strain with a myol covering plasmid on a ura selectable
plasmid. These strains were grown on 5-FOA plates to eliminate the myol plasmid to
determine whether the cyk3 plasmids can rescue the double deletion of cyk3 and myol.
TAP-tagged yeast strains were purchased from Open Biosystems as described [3].
Plasmids containing a CDC5 (YMR001C) genomic fragment in pRS315 (p3 15-CDC5)
and pRS306 (p306-CDC5) were gifts of J. Charles. The cdc5-asl allele (encoding
Cdc5(L158G)) was introduced into p315-CDC5 and p306-CDC5 by QuikChange site-
directed mutagenesis (Stratagene), generating p315-cdc5-asl and p306-cdc5-as1. The
cdc5-asl allele was introduced at the CDC5 locus by standard two-step gene
replacement, except in the TAP-tagged library strains (Open Biosystems). The cdc5-asl
allele was systematically introduced into TAP-tagged strains as follows. A MA Te strain
derived from EY1274 carrying a canlA::MFAlp-LEU2 selectable marker (E.K. O'Shea,
Harvard University) was transformed with a marker fusion PCR product generated by
amplification, of cdc5-asl and k. lactis URA3 genes. The entire cdc5-asl gene was
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sequenced in the resultant integrated strain. This strain was then crossed to selected
MATa HIS3 marked TAP-tagged library strains [3] using a manual 96-pinning tool (V&P
Scientific). After sporulation, TAP-tagged MATa haploids were selected on synthetic
media lacking histidine, arginine, leucine, and uracil and containing 50 gpg/ml canavanine
(Sigma).
Yeast Two Hybrid
The Cdc5-PBD clone in pGBD was transformed into the PJ69-4a strain [61]. Self
activation was tested by growth on SC -ade plates, and minimal self activation was
observed. A yeast full genomic DNA library in pGAD in the PJ69-4a strain was
obtained as a gift from A. Amon at MIT. Strains were grown, mated, and titered as
described [61]. For the first yeast two hybrid selection, the 4x10 6 diploid yeast were
plated on each of ten plates of synthetic complete media without adenine and grew at
300C for ten days. About 1500 single colonies were picked and streaked onto SC -leu/-
trp plates to ensure diploid status and to re-generate single colonies. Single colonies were
picked and grown as patches on SC -ade plates with 52 patches per plate. Actively
growing patches were replica-plated onto plates containing 20pg/ml 5-bromo-4-chloro-3-
indolyl alpha-D-galactopyranoside (X-a-gal) (Clontech) and then onto plates containing
both 25jpg/ml benomyl and 20gg/ml X-a-gal in YPD. X-a-gal is cleaved by the secreted
enzyme ca-galactosidase, which is under the control of a gal responsive promoter, into a
blue precipitate. Plates were grown for two days at 300C before pictures were taken of
each plate on a light box with a digital camera. Nearly all of the patches turned blue on
the X-a-gal containing plates. 264 of the patches on the benomyl containing plates were
bright blue compared to the same strain on the plates without benomyl. These strains
were picked and grew well on SC -leu/-trp/-ura, which once again confirmed the diploid
status and interaction. The strains were grown in SC -leu media to enrich for the pGAD
plasmid at the expense of the pGBD plasmid, and plasmid DNA was prepared by
standard yeast miniprep procedure [60]. The insert in the pGAD plasmid was amplified
by PCR using primers specific to the GAL4-AD fragment on the 5' end and a primer
generic to both the pGAD and pGBD vectors on the 3' side. PCR products were run on
agarose gels to determine size, and the concentration of DNA was determined by
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spectrophotometer reading. 100ng of DNA per 1000bp of length of DNA was sent for
sequencing using the upstream PCR primer as a sequencing primer. The resulting DNA
sequences were blasted against the yeast genome to identify the region of interaction, and
all intergenic and repetitive sequences were thrown out, leaving 112 distinct ORFs
identified in the two stage mitotic-specific Y2H screen.
Yeast Lysate Generation
50ml cultures of yeast strains were grown in appropriate media, YPD for TAP-
tagged strains. Cultures were harvested by centrifugation 5min 2000g in 50ml conicals,
and resuspended in 0.5ml PB (50mM Tris pH 8.0, 150mM NaCl) by vortexing. Cells
were transferred to 2ml screw cap tube, spun down for 1min at full speed, the supernatent
was vacuumed off, and the wash repeated. Cells were resuspended completely in 200ul
2X PBT (PB + 1% Triton X-100, 1mM DTT, 2mM EDTA, 1 mM AEBSF, 1 ýig/mL
aprotinin, 1 [pg/mL leupeptin, 10 iM E64, 1 gg/mL pepstatin A, 1.6 Cjg/mL benzamidine,
2 mM Na 3VO 4, 10 mM NaF, 20 nM microcystin LR, 5 nM okadaic acid, 2 PM
canthardin, 0.00073% p-bromotetramisole, 0.4 nM cypermethrin, 100 [M dephostatin,
100 nM bestatin, 100 ng/mL TPCK). -700ul acid washed glass beads were added
(Sigma), and the tube completely filled with PBT buffer. Cells were lysed with a multi-
bead beater Fastprep machine (Biol01) at speed 6.0m/s for 45s for eight cycles with at
least Imin on ice between cycles. The lysate was spun out of the bottom of the tube
through a hole poked in the bottom of the tube with a needle, and centrifuged at top speed
in microfuge for 20min to pellet cell debris. The supernatant was used in experiments.
PBD Pulldown Assay
The PBD pull-down assay was performed in Polo-box binding buffer (50 mM
Tris, 150 mMd NaCI, 2mM EDTA, 1 mM PMSF, 1 mM DTT, 1 % TritonX-100 and
Complete protease inhibitor). Freshly prepared yeast cell lysates (containing 2 mg total
protein in 300gl for each assay) were mixed with 20jl of GSH-beads saturated with 10ug
pure GST-Cdc5PBD or mutant GST-Cdc5PBD H641A/K643M. Reactions were
incubated for two hours at 40C and then washed four times with binding buffer. Bound
proteins were eluted from the beads by boiling in 20ul of 3X protein sample buffer, ran
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on SDS-PAG, transferred to nitrocellulose, and analyzed by western blotting with goat
anti-rabbit IgG antibody to detect the TAP tag or other tag-appropriate antibody.
Phosphopeptide Binding Assay
Cdc5-PBD wild-type and H641A/K643M, along with Plkl-PBD wild-type and
H538A/K540M, were in vitro transcribed and translated in the presence of [35S]-
methionine off of the pcDNA3.1+hisC vector with T7 polymerase using the TNT Quick
T7 IVT kit (Promega). Streptavidin beads (Pierce, 75pmol/PL gel) were incubated with a
ten-fold molar excess of each biotinylated library in 50 mM Tris/HCl (pH7.6), 150 mM
NaC1, 0.5% NP-40, 1 mM EDTA, 2 mM DTT and washed five times with the same
buffer to remove unbound peptide. The bead-immobilized libraries (10pL of gel) were
added to 10 jpL of the in vitro translated [35S]-labeled proteins in 150 IiL binding buffer
(50 mM Tris/HCl (pH7.6), 150 mM NaC1, 0.5% NP-40, 1 mM EDTA, 2 mM DTT, 8
pg/mL pepstatin, 8 tg/mL aprotinin, 8 pg/mL leupeptin, 800 PLM Na3VO4, 25 mM NaF).
After incubation at 40C for 3 hours, the beads were washed three times 200 gpL with
binding buffer prior to SDS-PAGE (12.5%) and autoradiography. The peptide libraries
used were biotin-Z-Met-Ala-X-X-X-X-pThr-Pro-X-X-X-Ala-Lys-Lys-Lys and biotin-Z-
Met-Ala-X-X-X-X-Thr-Pro-X-X-X-Ala-Lys-Lys-Lys with Z indicating aminohexanoic
acid and pThr indicating phospho-threonine.
Bioinformatic Analysis
Candidate Cdc5 substrates were initially selected based on information available
in September 2003 as follows. First, Cdc5-dependent processes were used as keywords
in Gene Ontology (GO) term searches, and the resulting proteins were included in the
screen if they contained a minimal phosphorylation or PBD motif. Second, yeast proteins
in SWIS-PROT were evaluated with Scansite using position-specific scoring matrixes
representing the phosphorylation and binding motifs of the Cdc5 kinase domain and Cdc5
Polo-box domain respectively. The Scansite algorithm assigns final scores (Sf) that
range from 0 to 1 depending upon how closely the query sequence matches the optimal
Cdc5 PBD or kinase motif, when normalized to all proteins in the database [37]. A
Scansite final score of 0 corresponds to a perfect match, while a score of 1 corresponds to
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the complete lack of even a minimal binding or phosphorylation motif. The Cdc5
substrate likelihood score was defined as 1-[0.5 (SfPBD+SfKn)], where SfPBD and SfKi,
were the final Scansite scores for the individual PBD and kinase motifs, respectively.
Candidates were selected based on top scores and by considering the remaining proteins
in turn by score, including those with cell cycle function and localization in the same
compartment as Cdc5 (nucleus or cytoplasm).
Plk1 Kinase Assay
Plkl kinase domain with a T210D activating mutation was expressed in bacteria
and purified to homogeneity. TAP tagged proteins were isolated from cell extracts by
pulldown with IgG sepharose (GE Healthcare). Several micrograms of each protein was
incubated with or without Plkl and 100lM ATP and 1I Ci of 32P-y-ATP in Plkl kinase
buffer (50mM Tris pH 7.5, 150mM NaC1, 10mM MgC12, ImM DTT) for two hours at
30°C. Samples were taken at several timepoints, run on an SDS-PAG, and exposed to a
phosphoimager plate for autoradiography. In this way, Cyk3, Cnm67, and Spc72 were
confirmed to be in vitro substrates of Plkl, and by implication, Cdc5.
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Figure 3.1: Modified Yeast Two Hybrid Strategy Identifies Mitotic-Dependent
Interactions.
(A) Schematic of the two step yeast two hybrid strategy for identification of mitotic
specific polo-box domain interactors.
(B) Growth of the diploid yeast two hybrid strain was tested on plates containing various
concentrations of benomyl. 50[]I of a saturated overnight culture grown in YPD was
plated as serial two-fold dilutions on plates containing the indicated amount of benomyl.
(C) Example of results of the second step of the yeast two hybrid, with dark blue colonies
seen on the plates containing benomyl (top) and weak blue staining similar among all
colonies on replica plates of the same yeast on plates without benomyl (bottom).
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Figure 3.2: Yeast Two Hybrid Results Summary.
(A) Pie chart showing GO categories for all identified Cdc5-PBD interactors listed in
Table 3.1.
(B) Pie chart showing more specific GO categories for those proteins originally identified
as being part of the GO category "Cell Cycle" in Figure 3.2A.
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Figure 3.3: Cdc5 Kinase Domain is Similar to Plkl Kinase Domain
(A) Rooted tree of conservation between Plk 1, Plk3, and Cdc5 kinase domains.
(B) Sequence alignment of the kinase domains of human Plk 1, human Plk3, and Cdc5
with the critical Thr in the phosphorylation loop indicated with a star above it.
A 29% -mkIK3 KD
k1 KD
^A I" KD%
'cU I;.
plk3-kin-new
plkl-kin
ada5 -kin
plk3-kin-new
plkl-kin
cdcS -kin
conseunsues
plk3-kin-new
plkl-kin
cdcS -kin
consensus
plk3-kin-new
plkl-kin
ada5-kin
consmensuem
plk3-kin-new
plkl-kin
CdeS-kin
consensus
plk3 -kin-new
plkl-kln
cdc5-kin
consensus
P---- GPLSPRPP•QAAA PP GPPPPS-------------ALRQPELEKLAALPA ---- ----- a D AGPG----------- APPG-AP - APAAg&PP
LGPL IQLNTRSKLVHT IKGNTADaVGKENHFKQTRLDPNNDRHRQPAQKKK
Ms-----Av------t--kla-aPa-pa-agvpg-------------a- -g- -pag-
--iSALCKI PU I.T.
-- di--li-dPS-$---
p I- I -l- I- ff v FII IIIel Wk
phqREKil-EI-iBral-n-hiV-P---FPD-dnvyivLE1C-rkgLlel-Kruk-LtEP
yTL4
IvRyylaQll
ketTsr% -eag
k#TI3UtaLR-
kettrr~-w?- ey
S--AX 9LP Au&R' IDQZXRW 3 iTIaYmnLE L-I T RNPVFA8 * aR
DKPI8DN IRg  2IXDYVd- F POL STVKBES P-
IP--k-is--ar-Li- -iL--dP-dRPi-eil- -dFt-Gy-P-rPit-cvvP---
170
B
Figure 3.4: Bioinformatic Prediction of Cdc5 Substrates.
(A) Schematic representation of substrate recognition by Cdc5. The substrate is depicted
to contain a Cdc5 phosphorylation motif, (D/E/N)X(S/T)hnd a binding motif,
S(pS/pT)(P/X), which binds the Cdc5 polo boxes (PB1 and PB2). X represents any
amino acid, p represents phosphorylation.
(B) Bioinformatic mining of the yeast proteome for candidate Cdc5 substrates. The
distribution .of assigned Cdc5 substrate likelihood scores is shown for Cdc5 candidate
substrates compared with the proteome, with high scores reflecting likely candidates.
(C) Cdc5 candidate substrates are enriched in low abundance proteins. Normalized
distribution of protein abundance [3] comparing candidate Cdc5 substrates to the entire
proteome. The data set means were statistically different (P=0.0003) by unpaired t-test.
Proteins without abundance values [3] are excluded from the analysis.
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Figure 3.5: Cdc5 Polo-box Domain Binds Phosphopeptides.
(A) Cartoon drawing of Cdc5 domain structure with critical residues indicated.
(B) Sequence alignment of the PBD of Cdc5 and human Plk1 with conserved critical
residues for phosphopeptide binding indicated with a star above them.
(C) Phosphopeptide binding assay of the Cdc5-PBD with a pTP and TP peptide library
with Plkl-PBD as a positive control.
A Cdc5 Domain Structure
Kinase domain Polo-Box Domain
PB1 P2 I]
B cdc5 -pbd
plkl -pbd
I M 3V 1 1 m
T238 W517 H"I K"3
T-Loop Phompho-$Ic'vty
*DXPREQSiURZICN3S14dJBSSDKMSRQRXD T IlaSXBANKLRREYNIIRPF 4p
.......... PgSSDPS WPUVUNKGNPLP2RFPtRIE 3EV
ad-- .. qu vu · f - a 1---- -id -.r - - ---------- P-
dade-phd SLSP3BTZQK EAQIpgi3ABY :zu
plkl-pbd VR--------------------- - -
conowamus ---- GgtktjkykgVVVD -Ln-L ------ - - - - avR-Vlaitmtnvlk..+nmz
c4g 5- phd xIaSICXLTJ'z~vxzag~veed'Krx4IKPI~#R?3I~inUUNY SSTI
plkli-pbd -------------------------- NAEDEACIPIF · CD*SG
consensus lrs~chltlngiv*&*&qykmgqlp ---- P-------VRGtYL---i
cdcS5-pbd
plk 1-phd W SURELYK8?Wi tEWRtlSWT ... WIUFS K"IU3URr
consensus VLIN--T-vl---Dae --- TI--D--K-vv-.hyllB--P--L-r-l-vv-fP--TX---
cdc5-phd 83113T--FGU-SITKDDVR "4IimU4PF lj F I-K lglASDGGXL
plk2-phd *I A Tmu3ALiTIAz.KinruvvuvuriniI;cp LAA
cou..busu L-x---aEL--Kg.*----- £LR-y-R-k- -va LB Gt-Q NSf-PHKa-----
cdc5-phd ýIBPBSH3BTPMPvLK3eIPGTPESEPVPE 4KI zQU4VTD - -
plkl-pbhd KRURqB*LICK CXtLAfSR- LTAR KLMMSSASNRSK&I
cansensu VTTI---- *--TT-L--v--IG ----------n-R---Tli--- L- -k----v-&a
WT
nCL
H641A
K643M
*5 CL,CL F
Cdc6
387-706
Wr0
Plk3 t
345-603
HS38A
K540M
172
C
r-
Figure 3.6: Polo-box Domain Pulldown Confirms Specific Interactors.
Western blot of Cdc5-PBD pulldowns with goat anti-rabbit IgG to visualize the proteinA
region of the TAP tag. Each pulldown was from lysates from a particular TAP-tagged
strain of yeast, as indicated by the gene name above each blot. Pulldowns were
performed with wild-type Cdc5-PBD (left lane each blot) or mutant Cdc5-PBD (middle
lane each blot), and the TAP-tagged protein was also confirmed to be expressed in the
lysate (right lane each blot). Arrows indicate expected size of protein, and arrows with
question mark indicated a suspected breakdown product of the expected protein. The
Cdc5-PBD is also recognized by this antibody and is also marked with an arrow and the
word PBD in each pulldown. All the proteins shown specifically interacted with the
wild-type Cdc5-PBD and not the mutant version. Proteins were sorted by GO categories
as indicated on the left side of each row.
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Figure 3.6 Continued:
Specific Cdc5-PBD Interactors
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Figure 3.6 Continued:
Specific Cdc5-PBD Interactors
Modifying Enzymes
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Figure 3.7: Polo-box Domain Pulldown Identifies Non-specific Interactors.
Same as Figure 3.6 except that the proteins identified in this group do not bind the wild-
type Cdc5-PBD specifically. Instead they bind equally well or better to the mutant Cdc5-
PBD.
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Figure 3.8: Analog-sensitive Cdc5 is Inhibited by CMK
(A) Sequence alignment of kinase domain regions spanning the gatekeeper residue and
the reactive cysteine. The Cdc5 sequence is in bold, and the specificity filters critical for
RSK2 inhibition by CMK [44] are highlighted in gray.
(B) Chemical structure of CMK. CMK (in gray), with features of the kinase active site
depicted, including a cysteine to react with the electrophilic chloromethyl ketone and a
gatekeeper residue that controls access to a hydrophobic binding pocket. A predicted
steric clash between the Cdc5 leucine gatekeeper residue and CMK is illustrated.
(C) Cell viability halo assay of wild type and cdc5-asl yeast. Inhibition of cell growth in
the region surrounding a disc spotted with 1 nmol CMK or scaffold molecule is observed
only upon CMK application to cdc5-as 1 (center), indicating a requirement for both the
gatekeeper mutation and the electrophilic reactivity of CMK.
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Figure 3.9: A Candidate Based In Vivo Screen Identifies Cdc5 Substrates.
(A) Approach to screening for substrates phosphorylated by Cdc5 in vivo.
(B) Result of the screen. The gel shifts of five TAP-tagged candidate substrates are
altered upon Cdc5 inhibition with 10 ýlM CMK (+) as compared with a DMSO control
treatment (-).
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Figure 3.10: Spc72 Binds to the Cdc5 Polo-box Domain
(A) Spc72 is bound by the Cdc5 PBD, and PBD* has reduced Spc72 binding. Anti-TAP
(Spc72) western blot indicates Spc72 present in the input G2/M cell extract (I) or pulled
down (P) with GST-PBD (PBD) or GST-PBD* (PBD*). Total protein staining indicates
the amount of GST-fusion protein in pulldown lanes (P).
(B) Cdc5 preferentially binds mitotic Spc72. Wild type PBD pulldowns from G2/M
phase cell extracts (as in A) or GI phase cell extracts were probed for Spc72.
(C) Mutation of consensus Cdc5 binding residues in Spc72 reduces binding to the PBD.
PBD binding to Spc72 or Spc72(S231A,S232A) as in A. I = 5% input, P = pulldown.
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Figure 3.11: Cyk3, Cnm67, and Spc72 are Plk Substrates In Vitro.
(A) In vitro phosphorylation of Spc72 by Cdc5. Spc72 is phosphorylated (32P) upon
addition of Cdc5 (left panels), and no Spc72 phosphorylation is seen when Cdc5 is added
to a mock pulldown reaction (untagged Spc72, - Spc72-TAP, right panels).
(B) In vitro phosphorylation of immunoprecipitated full length TAP-cyk3 and TAP-
cnm67 proteins. Proteins were incubated with Plkl T210 kinase domain and y32P-ATP
for indicated times.
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Figure 3.12: Cyk3 is Regulated by Cdc5.
(A) The Acyk3 strain was complimented with wild-type cyk3, non-Cdc5-PBD binding
cyk3, or vector alone. The wild-type cyk3 expressing strain overcame the cell clumping
phenotype of the deletion strain whereas the non-Cdc5-PBD binding cyk3 expressing
strain did not.
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Table 3.2: TAP-tagged Strains used in Cdc5-PBD Pulldown
Systematic Common Identified Molecules Molecular PBDSit PBDSite KinaseSite
Name Name By Per Cell ' Weight 2 e S(S/T) S(S/T)P (E/D)X(S/T) Saw in LysatePositive HilNegative Hit
YAL024C LTE1 Bioinformatics 304 163 yes yes yes x x
YAR019C CDC15 Bioinformatics 238 110 yes yes yes x
YBL023C MCM2 Bioinformatics 1690 ±261 99 yes yes yes x x
YBL079W NUP170 Y2H 1560 169 yes no yes x x
YBR002C RER2 Y2H 8970 33 yes no yes x x
YBR060C ORC2 Bioinformatics 1700 ±82.5 71 yes yes yes x
YBR143C SUP45 Y2H 13100 49 yes no yes x
YBR200W BEMI Bioinformatics 6490 62 yes yes yes x
YBR218C PYC2 Y2H 17000 130 yes yes yes x x
YCL014W BUD3 Bioinformatics technical problenm 185 yes yes yes
YCL024W KCC4 Bioinformatics 538 116 yes yes yes x
YCR087C-A LUG1 Y2H 3430 18 yes no yes x x
YCRO88W ABP1 Bioinformatics 606 66 yes yes yes x
YDL017W CDC7 Bioinformatics 1600 ±816 58 yes yes yes x
YDLO21W GPM2 Y21-I 2020 36 yes yes yes x
YDL117W CYK3 Y2H 377 101 yes yes yes x x
YDR072C IPT1 Y2H 606 61 yes yes yes
YDR146C SWI5 Bioinformatics 688 80 yes yes yes
YDR177W UBC1 Y2H 8940 24 yes no yes x x
YDR217C RAD9 Bioinformatics 400 148 yes yes yes x x
YDR330W UBX5 Y21-H 6630 57 yes no yes x
YDR331W GPI8 Y2H1 1560 47 yes no yes x
YDR388W RVS167 Y21H 14600 53 yes no yes x
YDR389W SAC7 Y2H 1420 74 yes yes yes x x
YDR398W UTP5 Y2H 33100 72 yes no yes
YDR513W GRX2 Y2H 31400 16 yes yes yes x x
YEL032W MCM3 Bioinformatics 35100 ±5540 108 yes yes yes x
YEL043W YEL043W Y2H 149 106 yes yes yes
YER018C SPC25 Y21H 3280 25 yes no yes x x
YER020W GPA2 Y2H 4570 50 yes yes yes x x
YER063W THO1 Y2H 6580 24 yes no yes x
YER101C AST2 Y2H 937 48 yes no yes
YER164W CHD1 Y2H 1620 168 yes no yes x
YER183C FAU1 Y2H 468 24 yes no yes x x
YFLO53W DAK2 Y2H low signal 62 yes yes yes
YGL140C YGL140C Y2H 1080 138 yes yes yes
YGL167C PMR1 Y2H 6900 105 yes yes yes x x
YGL216W KIP3 Y2H 736 91 yes yes yes x x
YGL219C MDM34 Y2H 377 52 yes yes yes x
YGL248W POE1 Y2H 1400 42 yes yes yes
YGR003W CUL3 Bioinforrnatics 174 86 yes yes yes
YGR005C TFG2 Y2H 520 ±123 47 yes no yes x
YGRO097W ASK10 Bioinforrnatics low signal 127 yes yes yes
YGR147C NAT2 Y2H 1240 33 yes no yes x x
YGR172C CDC28 Y2H 6670 34 yes no yes x x
YHL007C STE20 Bioinformatics 259 102 yes yes yes x
YHL025W SNF6 Y2H 2900 38 yes no yes x
YHR102W KIC1 Y2H 1040 117 yes yes yes x x
YHR104W GRE3 Y2H 12900 37 yes no yes x
YHR118C ORC6 Bioinformatics 2970 ±143 50 yes yes yes x
YILO31W ULP2 Bioinforriatics 450 117 yes yes yes x
YIL129C TAO3 Y2PH 206 270 yes yes yes x x
YIL140W AXL2 Y2- 396 91 yes no yes x x
YJL095W BCK1 Bioinformatics 112 164 yes yes yes
YKL012W PRP40 Y2H low signal 69 yes no yes
YKL067W YNK1 Y2H 7130 17 yes no yes x x
YKLO91C YKLO91C Y2H 2870 36 yes no yes x
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Table 3.2 Continued: TAP-tagged Strains used in Cdc5-PBD Pulldown
Systematic Common Identified Molecules Molecular PBDSit PBDSite KinaseSite
Name Name By Per Cell Weight e S(S/T) S(S/T)P (E/D)X(Sf/) Saw in LysatePositive HitNegative Hit
YKL185W ASH1 Bioinformatics 1800 66 yes yes yes
YKL213C DOA1 Y2H 6800 80 yes no yes x
YKL214C YRA2 Y2H 1310 24 yes no yes x x
YLR045C STU2 Bioinformatics 1660 101 yes yes yes x
YLR057W YLRO57W Y2H 71.6 97 yes yes yes
YLR129W DIP2 Y2H 9620 106 yes no yes x x
YLR175W CBF5 Bioinformatics 33600 ±2870 55 yes yes yes x x
YLR197W SIK1 Y2H 13500 ±5780 57 yes no yes x
YLR219W MSC3 Y2H 131 81 yes no yes
YLR234W TOP3 Y2H 468 74 yes no yes x
YLR257W YLR257W Y2i- 18600 36 yes yes yes x
YLR265C MSMI Y21-H 3120 67 yes no yes x
YLR265C NEJ1 Y2H 377 39 yes yes yes x x
YLR399C BDF1 Y2H 8100 77 yes yes yes x x
YML034W SRC1 Bioinformatics 2100 95 yes yes yes x
YML057W CMP2 Y2H 7110 69 yes no yes x
YML082W YML082W Y21H 2810 74 yes yes yes x x
YML103C NUPi88 Y2H 11700 189 yes yes yes x x
YMR115W FMP24 Y21H 8970 58 yes no yes x
YMR121C RPL15B Y2HI 721 24 yes no yes x x
YMR263W SAP30 Y2H 704 23 yes no yes x x
YNL004W HRB1 Y2H 1990 49 yes yes yes x x
YNL022C YNL022C Y2H 922 56 yes no yes x x
YNL023C FAP1 Y2H 589 108 yes no yes x
YNL027W CRZ1 Y2H 1160 76 yes yes yes
YNLO82W PMSI Bioinformatics 521 99 yes yes yes
YNL126W SPC98 Bioinformatics 56.9 98 yes yes yes x
YNL191W YNL191W Y2H 7300 40 yes no yes
YNL197C WHI3 Bioinformatics 5730 71 yes yes yes x
YNL225C CNM67 Bioinformatics technical problem 67 yes yes yes x x
YNL242W ATG2 Y2H 876 178 yes yes yes
YNL243W SLA2 Y2H 40600 109 yes yes yes x x
YNR046W TRM112 Y2H 4800 15 yes no yes x x
YNR047W YNR047W Y2H 752 101 yes yes yes
YOR058C ASEI Bioinformatics 556 102 yes yes yes
YORI97W MCAI Y2H 1400 51 yes no no x
YOR231W MKKI Bioinforrnatics 1040 57 yes yes yes
YOR239W ABP140 Y2H 17000 71 yes no yes x x
YOR260W GCDI Y21-1 9530 ±1760 66 yes no yes x x
YOR336W KRE5 Y21H 815 156 yes yes yes x
YOR373W NUD1 Y2h 892 94 yes no yes x x
YPL105C YPL105C Y2H 830 94 yes yes yes x
YPL106C SSE1 Y2H 71700 77 yes yes yes x x
YPL115C BEM3 Bioinformatics 752 125 yes yes yes
YPL119C DBPI Y2H 1480 68 yes yes yes
YPL155C KIP2 Bioinformatics 656 78 yes yes yes x x
YPL179W PPQI Bioinformatics 319 61 yes yes yes
YPL190C NAB3 Y2H 5830 ±541 90 yes yes yes
YPL198W RPL7B Y2H 7080 28 yes no no x x
YPL245W YPL245W Y2H 1130 52 yes no yes
YPR083W MDM36 Y2H 414 65 yes no yes
YPR137W RRP9 Y2H 5130 65 yes no yes x x
YPR167C MET16 Y2H 217 30 yes no yes x x
Totals 81 27 17
Notes:
1: As given in Ghammeiati et al. which is reference #3 in Chapter 3.
2: Molecular Weight is given for endogenous protein without the addition of the TAP tag which adds 21kd.
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Chapter Four
Cytokinesis-Specific Function of RhoGEFs
Controlled by Polo-like Kinases in Yeast and Human
Yeast Portion Shortened From
Satoshi Yoshida, Keiko Kono, Drew M. Lowery, Sara Bartolini,
Michael B. Yaffe, Yoshikazu Ohya, and David Pellman.
Polo-like kinase Cdc5 controls the local activation of Rhol to promote cytokinesis.
Science 313, 2006.
Subsequently several papers on similar topics in mammalian cells were published, data
for which I now reference concurrently with the text on the original yeast work along
with inserting my own work on the mammalian RhoGEF, Ect2, in cytokinesis.
Contributions:
Satoshi Yoshida performed all of the yeast work not explicitly mentioned below and
wrote much lof the manuscript. Keiko performed the Rhol assays shown in Figure 4.7
and elsewhere. Sara generated a huge number of constructs and strains, and performed
many of the genetic analyses with Satoshi. The mammalian Ect2 was done in
collaboration with Mark Burkard in Prasad Jallapelli's laboratory. Mark and Prasad both
made significant intellectual contributions to the project, and Mark performed the
experiments shown in Figure 4.10A. Karl Clauser in Steve Carr's laboratory at the Broad
Institute performed the mass spectrometry based identification of phosphorylation sites
shown in Table 4.3 and 4.5. For the yeast work I designed and performed the PBD
pulldown assay with Satoshi as shown in Figure 4.2, performed all the in vitro kinase
reactions as detailed in Tables 4.1-2, performed sequence analysis of PBD interactors and
suggested appropriate mutations, and provided advice on biochemical methods. For the
mammalian work I performed the experiments, made the figures, and wrote all related
text to Figures 4.3, 4.19, and 4.10B, and Tables 4.3 and 4.5.
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Abstract
The links between the cell cycle machinery and the cytoskeletal proteins
controlling cytokinesis are poorly understood. The small guanine nucleotide triphosphate
(GTP)-binding protein RhoA stimulates type II myosin contractility and formin-
dependent assembly of the cytokinetic actin contractile ring. We found that budding
yeast Polo-like kinase Cdc5 controls the targeting and activation of Rhol (RhoA) at the
division site via Rhol guanine nucleotide exchange factors. This role of Cdc5 (Polo-like
kinase) in regulating Rho 1 is likely to be relevant to cytokinesis and asymmetric cell
division in other organisms. Subsequently several groups demonstrated that in
mammalian cells Plkl controls the targeting and activation of RhoA at the division site
through multiple mechanisms including via the RhoGEF Ect2 [1-3] though the role of
Ect2 in RhoA targeting was already well established [4-6]. We go on to show that Ect2 is
localized to the division site through a phosphorylation dependent interaction between the
Ect2 tandem BRCT domains and the Plkl substrate Cyk4.
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Introduction
Cytokinesis, the physical separation of daughter cells after mitosis, involves the
dynamic reorganization of the cortical cytoskeleton and is precisely regulated both in
time and space [7, 8]. Successful cytokinesis is critical to the maintenance of genome
stability as cytokinesis failure can lead to chromosome aberrations and cancer [9]. The
timing and mechanism of contractile actin ring (CAR) assembly is an important but
poorly understood aspect of the eukaryotic cell cycle.
The Polo-like kinase Cdc5 controls many aspects of cell division, including
cytokinesis [10, 11]. Plkl is involved in cytokinesis in animal cells, but its precise role
has been difficult to address because manipulations that inhibit Polo-like kinase produce
spindle assembly defects, which affect CAR organization [7, 12, 13]. RhoA/1 is an
attractive candidate to be under Polo-like kinase regulation because of its essential role in
CAR assembly and contraction [7, 8, 14, 15]. In yeast, cytokinesis is largely independent
of microtubules [14], making yeast an advantageous system to study the role of Polo-like
kinase. Additionally, the contractile ring is not essential in most budding yeast strains;
another mechanism involving cell wall deposition can substitute for CAR function [16,
17]. This facilitates genetic analysis because null alleles affecting CAR function can be
studied in viable cells. Despite these differences, the core machinery for CAR assembly
is conserved in budding yeast: CAR assembly requires Rho 1, the functional homolog of
RhoA in animal cells, which activates actin filament assembly via formins [14, 18].
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Results andi Discussion
The timing of CAR assembly was characterized by actin staining and by labeling
of the CAR with a fusion between tropomyosin and green fluorescent protein (Tpm2 -
GFP) (Figure 4. 1A). To identify cell cycle regulators required for CAR assembly, we
reexamined CAR assembly in mutants that block mitotic exit [17, 19]. The CAR
assembled in cdcl5-2 or cdcl4-1 strains, mutations that compromise the canonical
mitotic exit network (MEN) (Figure 4. A). By contrast, CAR assembly was impaired in
mutants lacking Cdc5 (Figure 4.1A). The defect in CAR assembly in cells lacking Cdc5
was not a secondary consequence of the anaphase defect in these cells as mutations in
other Cdc5 regulated processes, such as cdcl4 which is a member of the FEAR network
(Figure 4. 1A), did not overcome this defect [20]. To test whether Cdc5 was also required
to maintain 'CAR formation we performed the experiment in Figure 4. 1B. In this
experiment, cells were first arrested in telophase by overexpression of Bfal, an inhibitor
of mitotic exit [21, 22] at 230C. This cell cycle block is after CAR assembly (Figure
4.1 B). After the temperature shift to the restrictive temperature (34.5 °C), the cdc5-2
strain failed to maintain a visible CAR (Figure 4. 1B). In the absence of Cdc5, a residual
fraction of cells were observed that had thin CARs (Figure 4. A). Thus, Cdc5, although
not absolutely essential for CAR assembly, is an important regulator. Similarly Plkl
activity is required for the assembly of many components of the contractile ring in
mammalian cells including anillin and myosinII [1-3] though it is not required for
chromosome separation in anaphase [2, 3]. Plkl activity is required after CDK1
inactivation and independently of Aurora B to promote initiation of cytokinesis [2].
Next we characterized the nature of the CAR assembly defect in cdc5-2 cells at
the restrictive temperature, with the use of the MEN mutant cdcl5-2 as a control. By
contrast, although the formin Bnil and Rhol localized normally to the neck in cdc]5-2-
arrested cells, neither Bnil nor Rhol was detectable at the bud neck in cdc5-2-arrested
cells (Figure: 4.1C). Furthermore, Bnil was often mistargeted to the bud tip in cdc5-2-
arrested cells (Figure 4.1C). Thus, Cdc5 is required for the neck recruitment of Rhol and
Bnil, a key ,downstream factor required for CAR assembly. Plkl activity is similarly
required for the localization of RhoA to the future cleavage furrow site [1-3].
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To identify potential Cdc5 substrates relevant to Rho 1 regulation, we screened all
known budding yeast Rho guanine triphosphate (GTPase) regulators for interaction with
the Polo-box domain (PBD) of Cdc5 [13, 23, 24]. PBD binding partners include the
Rhol guanine nucleotide exchange factors (GEFs) Rom2 and Tusl, the Rhol GTPase
activating protein (GAP) Sac7, and a putative Rho-GAP, Ecm25 (Figure 4.2A and 4.2B).
The PBD also binds Bem3, a GAP for Cdc42, the major small GTPase that controls
polarized morphogenesis in budding yeast. These interactions are highly specific to the
priming phosphorylation of the candidates, because the interaction was lost with a
Polobox pincer mutation, PBD* (Figure 4.2A and 4.2B), that abolishes phosphospecific
recognition of the substrates by PBD [24]. All the candidates had multiple potential
Polo-box binding sequences, binding motifs that are often primed by cyclin-dependent
kinase (CDK)-dependent phosphorylation [23]. Tusl, Bem3, Sac7, and Ecm25 are also
good CDK substrates [25]. The only RhoA regulator known to bind the Plkl-PBD is the
Rom2 and Tusl homologue, Ect2 (Figure 4.3A) [26].
Because of the requirement of Rhol [27] and RhoA [8] for CAR assembly, we
focused our subsequent analysis on the Rho GEFs, Tus , Rom2, and in human cells Ect2.
Genetic analyses demonstrate that null mutants of TUS 1 and ROM2 impair the
CAR/Myosin II pathway. The null mutant of ROM2 also partially impaired the CAR-
independent cytokinesis pathway suggesting ROM2 has multiple cytokinesis roles [20].
Consistent with this, the combination of tuslA with rom2A resulted in a synergistic defect
in CAR assembly while deletion of the third Rhol GEF, Roml, did not have any affect
on CAR assembly [20]. These findings are consistent with the requirement for the fission
yeast Tus1 homolog in cytokinesis [28-30]. The pattern of synthetic lethality observed
with cdc5-2 also provided genetic evidence for a role for Cdc5 in the CAR-dependent
mechanism [20], though CAR-independent roles for Cdc5 were also observed [20]. This
is not surprising given that Cdc5 is required for global activation of Rhol as described
later (Figure 4.7B) and that overexpression of a dominant-negative form of Cdc5
interferes with both the CAR-dependent and CAR-independent pathways for cytokinesis
[11].
We next evaluated the possibility that Tus is a direct Polo-like kinase substrate.
The N terminus of Tus1 (Tus 1-30 ), containing two Polo-box binding motifs (Ser-
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Ser/Thr-Pro), is sufficient for Polo-box binding (Figure 4.4A and 4.4B). The serine
residues immediately preceding the CDK consensus site in the Polo-box binding motifs
of Tusl (Ser7 and Ser92) were mutated to threonine (hereafter referred to as ST
mutations), a well-characterized change that disrupts binding to the PBD [23, 24] but that
should not affect CDK-dependent phosphorylation. Glutathione S-transferase (GST)-
PBD precipitation experiments revealed that neither Tusl-ST1-300 nor full-length Tusl-
ST protein bound to the PBD (Figure 4.2C and 4.4B). Similar ST substitutions were
introduced into the coding sequence for Rom2; the Rom2-ST protein also had a reduced
affinity for the Cdc5 PBD (Figure 4.5). Thus, Tusl and Rom2 interact with Cdc5 by a
mechanism similar to that of other known Polo substrates. Ect2 also binds to the Plkl -
PBD in a phosphorylation dependent manner through phosphorylation of Thr413 in Ect2
by CDK1 (Figure 4.3B) [26].
Biochemical experiments suggested that Tus 1 is a bona fide in vivo Cdc5
substrate. Although we were not able to detect a clear mobility shift of the full-length
Tusl (1307 amino acids), the Tusl Polo-box interacting domain (PID), Tus 11-300, was
phosphorylated in vivo as evidenced by a motility shift that was abolished by
phosphatase treatment in cdcl5-2-arrested cells (Figure 4.4C). Most notably, the slowest
migrating form of Tusl 1-300 (hereafter referred to as hyperphosphorylated) was absent in
cdc5-2-arrested cells (Figure 4.2D). This hyperphosphorylated form could also be
induced in cycling cells by overexpression of Cdc5 (Figure 4.4D). Furthermore, Tusl-
ST1-300 also lost this hyperphosphorylated band (Figure 4.2D). Thus, Tus 1 1-300 is
phosphorylated in late mitosis in a manner that depends on Cdc5. The fact that this
Cdc5-dependent phosphorylation also required physical interaction between Tus 11-300 and
the Polo box strongly suggests that the Cdc5-dependent phosphorylation of Tus 11-300 is
direct. Indeed, mass spectrometry confirmed that the Tus 1-300 was readily
phosphorylated by a human Polo-like kinase, Plkl, in vitro (Table 4.1), identifying at
least 12 phosphorylated residues. Although we were not able to map phosphorylation
sites directly on full-length Tus1 because of its low expression [31], together with our
genetic data these findings strongly suggest that Tusl is a Cdc5 substrate.
We attempted similar experiments to characterize the potential Polo-like kinase
dependent phosphorylation of Rom2. We identified several in vitro Plkl phosphorylation
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sites by mass spectrometry (Table 4.2). However, we were not able to identify a mobility
shift for full-length Rom2, nor were we able to detect a mobility shift for several N-
terminal Rom2 fragments. These fragments were not well expressed in Escherichia coli
and thus may not fold properly. Nevertheless, the similar phenotypes of rom2-ST and
tusl-ST strains (Table 4.4, and Figure 4.6, text below) suggest that in vivo Cdc5 regulates
Rom2 similarly to Tusl. Ect2 is a knownin vitro target of Plkl [26] which we confirmed
(Figure 4.3C), and we were able to map two phosphorylation sites in Ect2 through mass
spectrometry (Table 4.3) at sites T319 and S636. In vivo evidence that Ect2 is a Plkl
substrate is lacking though the expression of a PBD binding site mutant of Plkl does
cause RhoA activation problems [26]. Since these two sites do not conform to any
known Plk consensus phosphorylation motif they could be an in vitro artifact that do not
have an in vivo functional role.
The synthetic lethal interactions observed with tusl-ST and rom2-ST suggested
that these mutations were specifically defective in the CAR-dependent pathway for
cytokinesis but not other Rhol-dependent cellular functions (Table 4.4, and Figure 4.6).
tusl-ST hoflA strains displayed a striking reduction in fitness whereas tusl-ST myolA
strains grew like the myolA single deletion strain (Figure 4.6). This suggests that tusl-ST
has a specific defect in the CAR pathway. Furthermore, unlike tuslA, tusl-ST was viable
when combined with a deletion of MPKI (Table 4.4). Mpkl/Slt2 is a component of the
Rhol-Pkcl-MAP kinase cascade that responds to cell wall defects [32]. Thus, Tusl-ST,
though defective for CAR assembly, is proficient for its role in maintaining cell wall
integrity. Consistent with the hypothesis that the "ST" mutation in ROM2 partially
compromised the CAR pathway, rom2-ST hoflA double mutants also exhibited a
moderate growth defect and rom2-ST did not enhance the growth defect of myolA strains
(Figure 4.6). Furthermore, although Rom2, together with Roml, is essential for cell wall
biosynthesis during bud emergence [33], romlA rom2-ST strains were viable with normal
bud morphology unlike romlA rom2A strains (Table 4.4). Finally, tuslA rom2A strains
are inviable because of a cell wall integrity defect [32] whereas tusl-ST rom2-ST strains,
despite a severe cytokinesis defect, grow even at 370 C (Table 4.4). Thus, the ST mutants
are separation-of-function alleles that are specifically defective in contractile ring
function. Supporting this hypothesis, tusl-ST strains arrested in telophase were defective
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in CAR assembly, and this defect was enhanced in tusl-ST rom2-ST double mutant
strains (Figure 4.7A).
A Tus protein containing several phosphomimetic mutations at putative Cdc5
phosphorylation sites provided further evidence for the importance of Cdc5-dependent
phosphorylation of Tusl for CAR assembly. Phosphomimetic mutations (Ser to Asp or
Thr to Glu) were introduced at Ser or Thr residues within Plkl phosphorylation
consensus sites (Asp/Glu-X-Ser/Thr, where X is any amino acid). This consensus is
optimal for Plkl -dependent phosphorylation of vertebrate Cdc25 [34] and perfectly
matches the in vivo Cdc5 target phosphorylation sites on Mcdl (Sccl) [35]. Three out of
four Plkl phosphorylation consensus sites within Tus 1-300 were phosphorylated by Plkl
in vitro (Table 4.1). A Tusl mutant containing six putative phosphomimetic changes
(Tusl-6DE) partially bypassed the requirement for Cdc5, both for CAR formation and for
Rhol localization to the division site (Figure 4.2E). A control Tus1 mutant where the
putative phosphorylation sites were mutated to Ala failed to restore CAR assembly and
Rhol localization in cdc5-2 cells, demonstrating that only the negatively charged residues
caused a gain-of-function effect at these sites. The magnitude of the gain-of-function
phenotype induced by TUS1-6DE is likely to be an underestimate, because the
introduction of negatively charged residues appears to reduce the already low steady state
expression of Tusl (Figure 4.4E) [31].
Our experiments suggest that Cdc5 controls Rhol through Tusl and Rom2. This
was directly tested by monitoring the amount of active Rhol both globally and locally at
the bud neck. The total amount of active GTP-bound Rhol was detected by a
precipitation assay with the Rhol-binding domain (RBD) of Pkcl (Figure 4.7B). The
amount of active Rho 1 was diminished in cdc5-2-arrested cells in comparison with
cdcl5-2-arrested cells (Figure 4.7B). We also visualized active Rhol by
immunofluorescence using an antibody that specifically detects GTP-bound Rhol [36].
Consistent with the precipitation experiment of active Rhol, activated Rhol was barely
detectable in cdc5-2-arrested cells but was abundant and recruited to the bud neck region
in cdcl5-2-arrested cells (Figure 4.7A). By contrast, tusl-STrom2-ST cells arrested at
the cdc15-2 block had active Rhol at the bud cortex but lacked active Rhol at the bud
neck (Figure 4.7A). Consistent with this observation, the precipitation assay indicated
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that Rhol activity was not diminished in tusl-ST rom2-ST strains and in fact was slightly
elevated (Figure 4.7B). The fact that total Rhol activity was high in tusl-STrom2-ST
strains but low in cdc5-2 strains suggests that Cdc5 also controls global Rhol activity
through another mechanism, perhaps through Rhol GAPs such as Sac7 (Figure 4.2B).
Thus, Cdc5-dependent regulation of Tus1 and Rom2 controls the local activation of Rhol
at the division site but not the global levels of active Rhol in the cell. This is still unclear
in mammalian cells as though clearly Plkl is required for RhoA localization [1-3] the
connection with RhoA activation has not been fully worked out though work is in
progress (see below).
Next, we determined whether Cdc5-dependent phosphorylation is required to
recruit Tus1 and Rom2 to the bud neck. Consistent with its important role in CAR
assembly, Tusl-GFP was recruited to the bud neck just before CAR constriction. The
bud neck localization of Tus was dependent on Cdc5 activity but not on other MEN
components (Figure 4.8A). Furthermore, Tusl-ST-GFP failed to localize to the division
site in cdcl5-2-arrested cells that had high Cdc5 activity (Figure 4.8A). Similarly Ect2
was dependent on Plkl activity for localization to the cell division site [1-3]. Previously
Ect2 localization to the division site had been shown to be required for localization of
active RhoA to the division site [4]. Thus taken together it seems Plkl, like Cdc5, is
responsible for localization of active RhoA, though the direct connection between Cdc5
phosphorylation of Tusl is not yet present in the Plkl and Ect2 system.
We next tested whether the requirement for Cdc5 regulation of Tus could be
bypassed by tethering the ST variant to the bud neck. The coding sequence for Tusl-ST-
GFP was fused to the coding sequence for Mlc2, a nonessential type II myosin light chain
[37], and expressed from the endogenous TUS1 promoter. Indeed, in cdcl5-2-arrested
cells, Tusl-ST-Mlc2-GFP protein localized to the bud neck and activated CAR assembly,
unlike Tusl-ST-GFP (Figure 4.8B). Furthermore, Tusl-Mlc2-GFP could partially restore
CAR assembly in cdc5-2-arrested cells (Figure 4.8B). Thus, a critical function of the
Cdc5-dependent regulation of cytokinesis is to recruit Tus1, and thus Rhol, to the site of
CAR assembly. These results do not exclude the additional possibility that Cdc5 also
affects Tusl GEF activity. However, in mammalian cells it does not seemlikely that
Plkl does not regulate the GEF activity of Ect2 as I have not seen a difference in Ect2
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GEF assays in the presence of Plkl (data not shown). Nor does the GEF activity of Ect2
seem to be critical for RhoA activity during cytokinesis as siRNA depletion of Ect2
results in loss of active RhoA localization but no change in bulk active RhoA levels [38].
Thus, the relative importance of GEF activity versus localization for both RhoA and
Rhol remains unclear.
Our study reveals a molecular pathway by which Cdc5 and Plkl control
contractile ring assembly in budding yeast and mammalian cells. Cdc5/Plkl is required
for the recruitment of Rho GEFs to the division site that in turn is necessary for
recruitment and activation of Rho 1/A. The failure of this mechanism results in the
mistargeting of the formin Bnil from the bud neck to the bud tip in budding yeast This
causes a defect in CAR assembly, because the actin filaments in the contractile ring are
assembled by formins [7, 8, 14]. It is possible that Cdc5 and Plkl have more broad roles
in Rho-type GTPase regulation than the local activation of Rho 1 at the division site.
Cdc5 is required for the global activation of Rho l in late mitosis (unknown for Plkl),
whereas the Cdc5/Plkl regulation of Tus1, Rom2, and Ect2 is required for local Rhol/A
recruitment and activation. Cdc5/Plkl could exert additional control of Rhol/A via Rho
GAPs. It is also possible that Cdc5/Plk1 could exert Polo-box independent regulation of
Rhol/A GEFs. Lastly, given that fission yeast Polo kinase was recently shown to be
required for stress-induced polarized growth [39], it is intriguing that our biochemical
screen identified Bem3, a Cdc42 GAP, as a Polo-box binding partner. Our findings thus
elucidate a mechanism by which Polo-like kinase governs Rhol/A during cytokinesis and
raise the possibility that Polo-like kinase controls other aspects of the cortical
cytoskeleton through other Rho GTPases.
Cdc5 control of the localization of the RhoGEFs Tus and Rom2 (and therefore
localization of active Rhol) is directly dependent on Cdc5-PBD binding and Cdc5
phosphorylation of Tusl and Rom2. In the Plkl and Ect2 case this has not been shown.
Instead Ect2 localization is dependent on the centralspindlin complex and specifically
binds Cyk-4 (also known as MgcRacGAP) [4] in a manner that requires Plkl activity [1,
2]. This interaction has been narrowed down to require the tandem BRCT domains of
Ect2 and the N-terminus of Cyk-4, and occurs in a phosphodependent manner in
anaphase cells but not metaphase cells [4]. Intriguingly I helped identify tandem BRCT
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domains as phospho-dependent binding domains (Appendix One) [40], so Ect2 might
bind to Cyk-4 in a manner analogous to that of Brcal and Bachl (Appendix One) [41]. A
sequence alignment ofBrcal, PTIP, and Ect2 (Figure 4.9A) reveals that they all have
conserved residues at the sites where Brcal directly binds phosphate as revealed by
Brcal crystal structures (Appendix One) [41]. Mutation of these residues in PTIP also
eliminates phosphopeptide binding (Duaa Mohammad - personal communication). Thus
it seems likely that Ect2 binds phosphopeptides in a similar manner. However, when I
performed peptide library binding experiments (for methods see Appendix One) I did not
observe any specific phospho-binding by the Ect2 BRCTs (Figure 4.9B). It is possible
than none of the libraries tested have enough specificity for the Ect2 BRCTs despite the
fact that they all can be bound by both PTIP and Brcal BRCTs (Appendix One and
Figure 4.9B). Another possibility is that the Ect2 BRCT phosphorylation-dependent
binding is weaker than those of PTIP and Brcal, and requires either a full protein for
binding or multiple binding sites to create an avidity effect.
Since the weight of the evidence suggested that the Ect2 BRCTs and Cyk-4 (also
known as MgcRacGAP) interacted in a phosphorylation and Plkl dependent manner [1, 2,
4] we directly investigated whether Plkl could generate binding sites that contributed to
the Ect2/Cyk-4 interaction in vitro. Active full length Plkl kinase was incubated with
either CDB-Cyk4 or the Ect2 E5 fragment (residues 1-421) which encompass the BRCT
domains. The kinase reactions were stopped by adding excess EDTA, various
combinations of proteins were mixed, and complexes were pulled-down using chitin
beads which bind to the CBD tag on Cyk-4. Only when Cyk-4 was pre-incubated with
Plkl did a complex form between Cyk-4 and Ect2 (Figure 4.10A). Pre-incubation of Ect2
with Plkl produced no change in the amount of Ect2 pulled down with Cyk-4.
Interestingly Cyk-4 that had been pre-incubated with Plkl also pulled-down Plk1
suggesting a direct interaction between the two proteins (Figure 4.10A). To further
examine this complex active Plkl kinase domain was used instead of full length Plkl.
Similar results were seen as pre-incubation of Cyk-4 with Plkl kinase domain generated
binding sites for Ect2 on Cyk-4 and for the PBD of Plkl on Cyk-4, though the
background seen without the kinase was higher than in the previous experiment, perhaps
due to using ten-fold less detergent in the wash buffer (Figure 4.10B). In order to map
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the phosphorylation sites on Cyk-4 a larger sample of Cyk-4 was incubated with Plkl
kinase domain and sent for mass spectrometry identification of phospho-peptides. Four
phospho-peptides were identified (S 157, S170, S214, T260) (Table 4.5) which all
perfectly matched the consensus motif for Plkl phosphorylation [34] (Jes Alexander -
personal communication). Also two of them (S170 and T260) when phosphorylated by
Plkl make perfect (S(pS/pT)P) PBD binding sites [23, 24]. Mutation of all the Plkl -
dependent phosphorylation sites in Cyk-4 is ongoing, so that the sites necessary for PBD
and Ect2 binding can be determined by the same pulldown assay. With the mutant
versions of Cyk-4 that can no longer bind Ect2 or the PBD in hand, in vivo experiments
can be done to determine if these mutants can fufill the various roles of Cyk-4. In
particular the localization of Ect2, RhoA, and Plkl to the spindle midzone and cleavage
furrow will be assessed in cells expressing the non-binding mutant versions of Cyk-4
where the endogenous protein has also been knocked down by siRNA.
Thus, In mammalian cells once can construct a model where Plkl targets Cyk-4
after the metaphase to anaphase transition to create a docking site for the Ect2 BRCT
domains, recruiting Ect2 and ultimately RhoA to the cleavage initiation site. The
mechanism whereby this is inhibited until anaphase is unclear, but at a minimum,
consists of inhibitory CDK1 phosphorylation of Ect2 [4]. The finding that Ect2 can bind
the PBD and is a potential substrate of Plkl (Figure 4.3) [26] remains without known
functional consequences though perhaps Plkl targeting of Ect2 also helps to relieve the
inhibition that Ect2 in under in early mitosis [4] or otherwise modify Ect2 to activate its
binding capacity [26, 42]. Overall there is a clear direct role for Cdc5 in targeting Tus 1
and Rom2 to the bud neck to create a zone of active Rhol, but Plkl is just as effective in
an indirect manner in targeting Ect2 to generate a zone of active RhoA at the cleavage
furrow.
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Experimental Procedures
Yeast genetics and molecular biology techniques
Media and genetic techniques were as previously described [43]. All the yeast
strains were isogenic to BY4741 (MA Ta his3 leu2 metl5 ura3 from Open Biosystems).
cdc5-2, cdcl5-2 and cdcl4-1 strains were backcrossed at least four times to BY4741
background from W303-1A and 3 out of 3 independent clones of each mutant showed
indistinguishable terminal phenotypes in telophase arrest and in CAR formation at
34.50 C. Gene deletion or modifications were performed with PCR mediated gene
replacement [44] and correct integrations were confirmed by colony PCR. For a
description of the strains and plasmids, see Tables 4.6 and 4.6. tusl-ST mutant constructs
were created as follows. Briefly, a wild type truncated TUS1 [containing 600 base pairs
(bp) upstream of the ATG translation start site to 900 bp downstream of ATG] fragment
was cloned into a pRS306 vector using EcoRI and PstI. Site-directed mutagenesis was
carried out using QuikChange Site-Directed mutagenesis kit (Stratagene, La Jolla, CA).
Ser7 and Ser92 were mutated to Thr generating Tus -ST mutant. Mutagenesis was
confirmed using restriction digests followed by DNA sequencing. All constructs were
targeted by linearization with BglII to the TUS1 locus in a wild type diploid. The strains
were sporulated and tetrads were dissected to obtain a haploid isolate of the integrant.
Correct integration and introduction of all the mutations were confirmed by colony PCR
and by subsequent DNA sequencing of the genomic locus. tusl-6A and tusl-6DE were
constructed essentially the same as tusl-ST. Mutations were introduced on the pRS304
plasmid containing a wild type truncated TUS1 fragment (containing 600 bp upstream of
the ATG translation start site to 1892 bp downstream of ATG). The indicated Ser/Thr
were mutated to Ala in Tusl-6A or Asp/Glu in Tusl-6DE (Serl81, Serl91, Ser221,
Thr257, Thr392 and Thr408). All constructs were targeted by linearization with SacII to
the TUS1 locus. rom2-st mutant constructs and strains were made analogously.
Functionality of the epitope-tagged constructs
The coding sequence for a linker (Gly-Gly-Ser-Gly-Gly-Ser) was introduced
between the coding sequence for the epitopes and the carboxyl terminus of Tus 1, Rom2
204
and Tpm2. For the tagged constructs, the functionality was examined as follows. TUS1-
myc and TUS1-GFP were crossed to rom2A and tested for the growth at 240C, 300 C,
34°C, and 370 C. We did not observe either a synthetic growth defect or cytokinesis
failure. Rom2-myc and Rom2-GFP also fully supported cell viability at 240 C, 300 C,
34°C, and 370 C in the absence of Tusl or Roml. BNI-3xGFP was introduced to bnrlA
cells by a genetic cross and the BNIJ-3xGFP bnrlA cells grew normally at 240 C, 300 C,
34°C, and 370 C. They also did not exhibit round bud morphology or a cytokinesis defect,
characteristics of bnilA strains. MYO1-GFP, IQG1-GFP, HOFJ-GFP, and SHS1-GFP
didn't cause cytokinesis defects at 240C, 300 C, 34°C, or 370 C. Tpm2-GFP is only
partially functional because tpmlATPM2-GFP cells were viable but grew poorly.
However, TPM2-GFP had no dominant inhibitory effect on cell cycle progression or
cytokinesis and CAR assembly and CAR constriction occurred with identical kinetics in
TPM2 and TPM2-GFP cells. Tusl-Mlc2-GFP is a functional Tus1 protein because
rom2ATUS1-MLC2-GFP strains grew even at 370C whereas rom2AtuslA was lethal.
Localization of Tusl-Mlc2-GFP mimicked Mlc2 and was recruited to the bud neck at the
bud emergence (unlike Tusl- GFP, which localized to the neck just prior to the mitotic
exit) and disappeared after its constriction during cytokinesis. We could not determine
whether Tusl-Mlc2-GFP is fully functional as Mlc2 protein because a mlc2 deletion
strain has no obvious growth defects. The coding sequence for a linker (Gly-Gly-Ser-
Gly-Gly-Ser) was introduced between the carboxyl terminus of Tusl and amino terminus
of Mlc2.
Fluorescence imaging and image analysis
Cells were observed in an automated Zeiss 200M inverted microscope (Carl Zeiss,
Thornwood, NY) as previously described [45]. All image processing was performed
using SlideBook software. To characterize the localization of proteins to the bud neck,
we acquired images at 0.3 gtm intervals in the Z focal plane, enabling visualization of the
relatively small budding yeast bud neck region (usually less than 1 gm in diameter).
Shown are selected Z focal plane slices though the bud neck. Cells were fixed in 3.7 %
formaldehyde for 10 ninutes and washed twice in phosphate-buffered saline solution
before microscopic observation of GFP tagged proteins (or GFP variants). For timelapse
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live cell microscopy 2jtl of the culture [in the synthetic complete (SC) medium
supplemented with adenine] were spotted onto a glass slide and immediately imaged at
room temperature (approximately 24°C). Staining of actin cytoskeleton by Alexa-568
phalloidin was described previously [46]. Immunofluorescence method for Rhol and
HA-Rho 1 was as described [36] with thanks to M. Abe for providing the antibody
specific to Rhol-GTP. For visualizing Bnil-3xGFP in cdc15-2 and in cdc5-2 block, the
cells were treated with 100 jpm latrunculin A for 5 minutes before fixation to enhance the
polarized (e.g. bud tip or bud neck) localization of Bnil since cytoplasmic high
background of Bnil-3xGFP masks the cortical and neck localized signals.
Biochemical methods
Western blotting and phosphatase treatment was performed as described [47].
The cell lysates for the Western blotting were prepared by treating the yeast cells with
120 mM Sodium hydroxide for 15 minutes at 40C. The cell pellets were boiled for 5
minutes with SDS-sample buffer. Mouse monoclonal anti-myc antibody (9E10), mouse
monoclonal anti-HA antibody (12CA5), rabbit polyclonal anti-Mpkl/Slt2 antibody and
mouse monoclonal anti-GFP antibody were obtained from commercial sources. Rabbit
anti- Rhol antibody and anti-active Rhol antibody were described previously [36, 48].
The pull-down assay for active Rholp was performed as follows. Yeast cells
were lysed in a lysis buffer [50 mM Tris-HCI (pH 7.5), 150 mM NaCl, 1 mM EDTA, 12
mM MgClB2B, 1 mM DTT, 1 mM PMSF, 25 jtg/ml TPCK, 25 gpg/ml TLCK, 25 gtg/ml
leupeptin, 25 jtg/ml pepstatin, 25 pg/ml antipain, 25 glg/ml aprotinin, 25 tg/ml
chymostatin, 0.6% CHAPS, 0.12% cholesteryl hemisuccinate], incubated with a bead-
bound GST fusion of an RBD of Pkcl or that of Bnil, washed, and subjected to SDS-
PAGE. Bound Rholp was detected by western blot analysis.
The PBD pull-down assay was performed in Polo-box binding buffer (50 mM
Tris, 150 mM NaC1, 2mM EDTA, 1 mM PMSF, 1 mM DTT, 1 % TritonX-100 and
Complete protease inhibitor). Freshly prepared yeast cell lysates (containing 2 mg total
protein in 300 jtl for each assay) were mixed with 20 tl of the beads saturated with pure
PBD or PBD*. Bound proteins were analyzed by Western blotting with goat anti-Rabbit
IgG antibody to detect the TAP tag [31] or other tag appropriate antibody.
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Plk1 kinase domain with a T210D activating mutation was expressed in bacteria
and purified to homogeneity. Tus 1-300, Rom2 1-400, mouse Ect21-421, mouse Ect2414639
and Cyk-41-288 were all expressed and purified from bacteria. Several micrograms of each
protein was incubated with Plkl and 100lM ATP in Plk1 kinase buffer (50mM Tris pH
7.5, 150mM NaCI, 10mM MgCl 2, 1mM DTT) for two hours at 300C. The entire reaction
was run on a single lane of a SDS-PAG, stained with coomassie blue, and the band
corresponding to the desired protein was cut out. Tus 1-300 and Rom21400 were sent to
the Taplin Biological Mass Spectrometry Facility at Harvard Medical School for
phospho-peptide determination by mass spectrometry (thanks to R. Tomaino and S.
Gygi). The mouse Ect2 fragments and Cyk-4 fragment were sent to our collaborator K.
Clauser in S. Carr's laboratory for phospho-peptide determination by LC/MS/MS after
in-gel trypsin cleavage. Separate kinase reactions were also performed with one tenth the
amount of protein and Plkl kinase domain with 10pCi of 32p-y-ATP added to the mixture.
Samples were taken at several timepoints, ran on an SDS-PAG, and exposed to a
phosphoimager plate for autoradiography. In this way all of the proteins were confirmed
to be in vitro phosphorylated by Plkl.
Ect2 tandem BRCT domain phosphopeptide binding studies were performed as
described in Appendix One. Alignments of tandem BRCT domains were generated using
standard algorithms. Ect2/Cyk4 binding studies were performed as follows. GST-Ect21-
421, CBD-Ect21- 421, and CBD-Cyk41- 288 proteins were expressed and purified from
bacteria. To generate untagged forms the tags were cleaved with TEV (for CBD tags) or
thrombin (for GST tags) on beads freeing the untagged version. Proteins were
phosphorylated with Plkl full length, Plkl kinase domain, Plkl kinase domain kinase
dead, or mock as described above without the radioactive ATP. After phosphorylation
proteins were mixed and pulled-down with chitin beads which bind the CBD tag on Cyk4
for two hours or overnight at 40C in binding buffer (20mM Hepes pH 7.2, 50mM NaC1,
5mM MgC12, 1% Triton, 1mM DTT, ImM PMSF). Beads were washed four times in
binding buffer, boiled in protein sample buffer, and analyzed by SDS-PAGE and western
blotting.
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Figure 4.1: Cdc5 is required for CAR assembly.
(A) CAR assembly is defective in cdc5- but not cdcl5- or cdcl4-arrested cells. Cells
were released from a G block (ca factor) and examined at intervals after release at the
nonpermissive temperature 34.5 0 C for budding index (diamonds), percentage of anaphase
cells by labeling nuclear DNA (squares), and bud neck localization of Tpm2-GFP
(triangles). The c factor was re-added at 60 min to prevent progression into a second cell
cycle. (Bottom) Representative images of cells from the 120-min time point. Scale bar
indicates 5 gtm.
(B) Cdc5 is required to maintain the CAR. Log-phase cultures of cdc5-2 and control cells
were arrested in telophase by overexpression of BFA1 from the GAL] promoter for 3
hours. The telophase-arrested cells were shifted to a restrictive temperature (34.5 0C) to
inactivate cdc5-2 and cdcl5-2, fixed, and the CAR formation was visualized with the use
of Tpm2-GFP.
(C) Cdc5 is required for the subcellular targeting of Bni 1 and Rho 1. Bnil -3xGFP
expressed at an endogenous level was visualized after 2-hour incubation of the cells at
34.5 0 C. Rhol was visualized by immunofluorescence labeling with a rabbit antibody
against Rhol 130 min after release to 34.50 C from a G1 block. Arrows point to the bud
neck signals in cdcl5 cells and the bud tip signals in cdc5 cells.
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Figure 4.2: A screen for Polo-box binding partners suggests that Cdc5 controls
multiple Rho-type GTPase regulators.
All potential Rho GTPase regulators in the yeast genome were screened for physical
interaction with the Cdc5 PBD and a control pincer mutation (PBD*).
(A) In cases where epitope-tagged constructs were not available from the yeast tandem
affinity purification (TAP)-tagged library [31], epitope-tagged constructs were generated.
Tus and Romi were overexpressed from the GAL] promoter for this initial screen. After
precipitation assay, Western blotting was performed to detect the indicated epitope tags
of the bound proteins. + indicates the wild-type GST-PBD; +* indicates the pincer
mutant.
(B) PBD or PBD* precipitation assays with lysates from strains from the yeast TAP-tag
fusion library.
(C) Endogenous-level Tus binds to the PBD. This binding is abolished by the ST
mutation and thus requires the Polo-box binding motif. WT, wild type.
(D) Hyperphosphorylation of Tus 1-300-myc requires Cdc5 and the Polo-box binding
motifs. Shown are Western blots to detect endogenous-level Tusll-300-myc or its ST
derivative in the indicated strains after 2.5 hours at the restrictive temperature of 34.5 0C.
(E) Phosphomimetic mutations at Polo-consensus phosphorylation sites partially bypass
the requirement for Cdc5 for CAR assembly and Rhol recruitment. The indicated strains
were arrested with cx factor and released at the nonpermissive temperature (33.5 0 C) for
140 min. The CAR was visualized with the use of Tpm2-GFP, and Rhol was visualized
by immunofluorescence. More than 400 cells were counted for each sample. The
experiment was repeated three times with near-identical results. By a Student's t test, the
difference in Tpm2-GFP labeling in cells expressing Tusl-6DE versus Tus was
significant (P = 0.011). Error bars indicate SEM. Scale bar, 5 gm; arrows point to the bud
neck signal.
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Figure 4.2 Continued
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Figure 4.3: Ect2 binds the PBD and is a PlkI substrate in vitro
(A) Flag-Ect2 was expressed in U20S cells, and either treated with nocodazole or mock
treated. Lysates were used in Plkl-PBD pulldowns with wild-type or the non-binding
mutant of the Plkl-PBD, and blotted for the presence of Flag-Ect2. Ect2 specifically
came down with the wild-type Plkl-PBD during mitosis.
(B) The indicated Flag-Ect2 constructs were expressed in U20S cells, and
immunoprecipitated with anti-Flag resin. Blotting for endogenous Plki indicates that
Plkl interacts with full length Ect2 and the N-terminus, but not the PBD site mutants.
(C) Ect2 serves an a substrate of Plkl in vitro. The indicated Ect2 fragments were
incubated with Plkl kinase domain and y32 P-ATP for the indicated times and phosphate
incorporation was monitored by autoradiograph.
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Figure 4.4: Characterization of Tusl protein.
(A) Domain structure ofTusl. The Dbl-PH domain is the catalytic domain for nucleotide
exchange. The function of the CNH domain is not known. Tus1 contains two potential
Polo box binding motifs in the N-terminal Polo box interaction domain (PID).
(B) Endogenous level Tusl'1-3 binds to the PBD. This binding is abolished by the "ST"
mutation and thus requires the Polo box binding motif. Shown is a pull down assays as in
Fig. 5.3C.
(C) Tusl 1-30ois a phosphoprotein. Tus 1-300 was immunoprecipitated from cdcl5- arrested
cells. The immunoprecipitate was divided and subjected to the indicated treatments.
(D) Overexpression of Cdc5 induces hyper phosphorylation of Tus l'300-myc.
GAL1-CDC5 or GAL1-cdc5N209A [encoding a kinase dead mutant [49]] were induced
by galactose for 3 hrs.
(E) Expression level of full length Tus I-myc. Shown is a Western blot to detect
endogenous level, Tus -myc or its derivatives from log phase cultures. Mpkl was
detected as a loading control.
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Figure 4.5: Characterization of Rom2-ST.
(A) Domain structure of Rom2. The DbI-PH domain is the catalytic domain for
nucleotide exchange. The function of the DEP and CNH domains are not known. Rom2
contains two potential Polo-box binding motifs in the N-terminal region.
(B) Endogenous level full-length Rom2 binds to the PBD but not the pincer mutation
PBD*. Lanel, 3, 5; pulldown with PBD. Lane 2, 4, 6; pull-down with PBD*. Lane7-9;
total lysates. Rom2-myc extract was applied for lanes 1, 2 and 7. Rom2-ST-13 myc
extract was applied in lanes 3, 4 and 8. Untagged controls are in lanes 5, 6 and 9. This
binding is strongly diminished by the "ST" mutation and thus requires the Polo-box
binding motif.
(C) Localization of Rom2-GFP and Rom2-ST-GFP. The "ST" mutation does not affect
Rom2 localization in small budded cells (percentages indicated in white lower left, n=
200 from a log-phase culture). By contrast, Rom2-ST-GFP was severely compromised
for neck localization in large budded cells.
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Figure 4.6: tusl-ST and rom2-ST are separation-of-function alleles that have
reduced fitness when combined with hoflA but not myolA.
Shown are 5-fold serial dilutions of the indicated strains grown for 3 days at 370C.
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Figure 4.7: Polo regulation of Tusl and Rom2 is critical for CAR assembly and local
Rhol activation.
(A) Polo regulation of Tus and Rom2 is required for CAR assembly and for recruitment
of active Rhol to the bud neck. CAR assembly was assayed with use of Tpm2-GFP.
Active Rhol was detected by immunofluorescence by using an antibody that specifically
recognizes Rhol-GTP but not Rhol-GDP [36]. Error bars indicate SEM; scale bar, 5 gm;
arrows point to the bud neck signals.
(B) The total cellular level of active Rho 1 requires Cdc5- but not Polo-dependent
phosphorylation of Tus 1 and/or Rom2. The precipitation assay was performed with the
use of Pkc 1-RBD.
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Figure 4.8: Cdc5 targets Tusl to the division site.
(A) Tusl-GFP requires Cdc5 and its Polo-box binding motifs to localize to the bud neck.
Tusl-GFP or the ST derivatives were imaged in cdc5-2 or in cdc15-2 2 hours after
incubation at 34.50 C (n > 100), along with the percentages of the large budded cells with
GFP signal at the bud neck. Scale bar, 5 gm.
(B) Tethering Tusl-ST to the bud neck by fusion to Mlc2 corrects the CAR assembly
defect of tusl-ST rom2-ST strains and partially bypasses the requirement for Cdc5 in
CAR assembly. (Left) Numerical summary of the data. The bars indicate the percentage
of cells with detectable contractile rings. Error bars indicate SEM. The dark bars indicate
the percentage of cells with robust contractile rings. (Right) Examples of cells. (Top)
GFP imaging of the indicated fusions. (Bottom) Actin was visualized with alexa568-
phalloidin. Arrows indicate cells with robust CAR labeling.
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Figure 4.9: Ect2 tandem BRCTs do not bind phosphopeptides in vitro
(A) Sequence alignment of the tandem BRCT domains of BRCA 1, PTIP, and Ect2 reveal
conserved phosphobinding residues. Residues that directly contact the phosphate in the
Brcal crystal structure (Chapter two) are marked with red stars.
(B) In vitro transcription/translation reactions 35S-methionine of indicated Ect2 constructs
were incubated with indicated peptide libraries, washed, and visualized by
autoradiography. E3 is Ect2 116-333, E5 is Ect21 -421. All libraries were verified to be
functional through control binding experiments to known phosphobinding domains.
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Figure 4.10: Ect2 binds Cyk4 after Plk1 phosphorylation of Cyk4
(A) Ect2 and CBD-Cyk4 N-terminal fragments were generated in bacteria and pre-treated
with active full length Plkl or mock treated. The treated proteins were then used in a
CBD pulldown to identify what proteins interacted with Cyk4.
(B) The same experiment as A was performed except using active Plk1 kinase domain
instead of full length Plkl. The GST-Ect2 N-terminal fragment was added to the two left
lanes and the GST-Plkl-PBD was added to the right two lanes. Increased binding to the
Cyk-4 N-terminal fragment was seen with both proteins after pre-incubation of the Cyk-4
N-terminal fragment with active Plkl kinase domain.
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Table 4.1 Plkl-dependent phosphorylation sites on Tus11-30 0 in vitro
Peptide Sequences identified
1. 24 3VSEALESVYSDSDYTFNNS*NAR 26 4
2. 243VSEALESVYSDSDYT*FNNSNARP 26 4
3. 243VSEALESVYSDSDYT*FNNS*NAR 264
4. 243VSEALES*VYSDSDYT*FNNSNAR 2 64
5. 135SPNKLS*FIGNSEER 48
6. I04RPPPPPPLLYS*TESIR11 9 or '04RPPPPPPLLYST*ESIR1 9
7. 236NVSGNS*R 242
8. 149HHMEYISNHS*R 1 59
9. '79DSS*KQQAHFSDESDLR' 94 or 179PDS*SKQQAHFSDESDLR 194
10. 183QQAHFSDES*DLR 194
11. 139LS*FIGNSEERP148
12. 201PALPPIPFT*T*T*LLLS*PFDDEDSEFFTKPPPPLSTSRP 235
one site on four possible locations
13. 201ALPPIPFT*T*T*LLLS*PFDDEDSEFFTKPPPPLS*T*S*R 23 5
two sites - one on four possible locations (T,T,T or S)
the other on three possible locations (S,T or S)
Legend to Table 4.1
Phosphorylated residues were determined by microcapillary LC/MS/MS techniques
after trypsin digestion. Shown are peptides that were identified at least twice.
Residues indicated with a star (*) are phosphorylation sites that were definitively
identified. Underlined phosphorylation sites were mutated in the Tusl-6DE or Tusl-6A
mutants.
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Table 4.2 Plkl-dependent phosphorylation sites on Rom2 1 40 0 in vitro
Peptide Sequences identified
1. 289SMS*LNSSTLK 298
2. 76S*GVEAAIDDS*DIPNNEMK 93
3. 2OSQSS*FSTGSASTTPTQAR 221 or 205QS*SFSTGSASTTPTQAR 221
4. '09EVPDTQS*LSSADNTPVSSPKl28
Legend to Table 4.2
Phosphorylation sites were determined by microcapillary LC/MS/MS techniques after
sequential digestion by trypsin and by chymotrypsin. Shown are peptides that were
identified at least twice. Residues indicated with a star (*) are phosphorylated
residues that were definitively identified.
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Table 4.3 Plkl-dependent phosphorylation sites on Ect2 in vitro
Peptide Sequences identified
1. 316AGET*MYLYEK325
2. 327VDGCPANLLS*SHR 639
Legend to Table 4.3
Phosphorylated residues were determined by microcapillary LC/MS/MS techniques
after trypsin digestion. Shown are peptides that were identified at least twice.
Residues indicated with a star (*) are phosphorylation sites that were definitively
identified.
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Table 4.4 Summary of the rom2-ST and tusl-ST genetic analysis
Genotype
Wild type
rom2A
rom2-ST
tuslA rom2-ST
tusl A
tusl-ST
rom2A tusl-ST
rom2A tusl A
tusl-ST rom2-ST
romlA
romlA rom2A
romlA rom2-ST
romlA tuslA
romlA tusl-ST
mpklA
mpklA tusl A
mpklA tusl-ST
YPD (24°C) YPD (370C)
+++4 +++
+++ ++
+++ +++
+++ ++
+++ ++
+++ +++
+1-
+~
YPD+Sorbitol (370C)
+++
++
+++
++
-H- ++f
Legend to Table 4.4
All the mutants were generated by genetic crosses and 3 independent clones were tested
for growth. rom2A tuslA, romlA rom2A, mpklA tuslA, and mpklA tuslST were
germinated on YPD plates containing 1 M sorbitol as an osmotic stabilizer. The growth
was judged after 3 days at the indicated temperature. The number of "+" reflects the
robustness of the growth. "-" indicates no growth.
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SC (370C)
+++
+++
~+
+1*
+++
Table 4.5 Plkl-dependent phosphorylation sites on Cyk-4 in vitro
Peptide Sequences identified
1. 149SGSILSDIS*FDKTDE' 63
2. 164SLDWDSS*LVKl 73
3. 203SIGSAVDQGNES*IVA 217
4. 255LTQPWNSDST*LNSR 264
Legend to Table 4.5
Phosphorylated residues were determined by microcapillary LC/MS/MS techniques
after trypsin digestion. Shown are peptides that were identified at least twice.
Residues indicated with a star (*) are phosphorylation sites that were definitively
identified.
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Table 4.6 List of the yeast strains
Strain Mat Relevant genotype
PY3295 a wild type his3 leu2metl5ura3
PY5237 a cdcl4-1
PY5255 a cdcl4-1 tpm2.:TPM2-GFP-HIS3
PY5220 a cdc15-2
PY5217 a cdcl5-2 tpm2.:.TPM2-GFP-HIS3
PY5206 a cdcl 5-2 shsl::SHS1-GFP-HIS3
PY5207 a cdcl5-2 myol.:.:MYO1-GFP-HIS3
PY5327 a cdcl5-2 iqg::IQGI-GFP-HIS3
PY5328 a cdcl5-2 bnil::.BNI1-3xGFP-LEU2
PY5329 a cdc15-2 tusl.::TUS1-GFP-HIS3
PY5199 a cdcl5-2 tusl::TUSl-13myc-HIS3
PY5261 a cdcl5-2 tusl::TUS'1-300-13myc-HIS3
PY5254 a cdcl5-2 tusl::tusl-ST-URA3
PY5300 a cdcl5-2 tusl.'.'tusl-ST-GFP-HIS3
PY5330 a cdcl5-2 tusl::tusl-ST-13myc-HIS3
PY5331 a cdc15-2 tusl::tusl-ST1-300-13myc-HIS3
PY5332 a cdcl5-2 tusl:.:tusl-ST-URA3 tpm2::TPM2-GFP-HIS3
PY5253 a cdcl5-2 rom2.::rom2ST-LEU2
PY5333 a cdc]5-2 rom2::rom2ST-LEU2 tpm2::TPM2-GFP-HIS3
PY5252 a cdcl5-2 tusl:.'tusl-ST-URA3 rom2.':rom2ST-LEU2
PY5334 a cdcl5-2 tusl::tusl-ST-URA3 rom2::rom2ST-LEU2
tpm2.": TPM2-GFP-HIS3
PY5323 a cdc5::cdc5-2-URA3
PY5335 a cdc5-2::URA3 tpm2::TPM2-GFP-HIS3
PY5292 a cdc5.:.:cdc5-2-URA3 Aswel::KAN
PY5336 a cdc5.:.cdc5-2-URA3 shsl::SHS1-GFP-HIS3
PY5337 a cdc5::cdc5-2-URA3 myol::MYO1-GFP-HIS3
PY5339 a cdc5:.:cdc5-2-URA3 iqgl:.:.IQGI-GFP-HIS3
PY5340 a cdc5.::cdc5-2-URA3 bnil::BNII-3xGFP-LEU2
PY5341 a cdc5.:.:cdc5-2-URA3 tusl.":.TUS1-GFP-HIS3
PY5198 a cdc5::cdc5-2-URA3 tusl::TUSl-13myc-HIS3
PY5260 a cdc5.:.cdc5-2-URA3 tusl..::TUSlj-3 00-13myc-HIS3
PY5343 a cdc5::cdc5-2-URA3 tusl::.TUS1-6A-LEU2
tpm2..::TPM2-GFP-HIS3
PY5318 a cdc5::.cdc5-2-URA3 tusl::TUS1-6DE-LEU2
tpm2. .TPM2-GFP-HIS3
PY5344 a cdc5::.cdc5-2-ura3::HIS3
PY5345 a cdc5:: GAL- 3HA- CD C5-KanR
PY5346 a cdc5.:GAL-3HA-CDC5-KanR tpm2:.:TPM2-GFP-HIS3
PY5347 a cdc5:.:GAL-3HA-CDC5-KanR tpm2: :TPM2-GFP-HIS3
ura3 : : CFP-TUB1-GFP- URA3
PY5256 a tpm2.: TPM2-GFP-HIS3 ura3:.:CFP-TUBI-GFP-URA3
PY5349 a tusA.A::KANR
PY5350 a tusl::TUS1-GFP-HIS3
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PY5197 a tusl::TUS1-13myc-HIS3
PY5259 a tusl::TUS11'-3-13myc-HIS3
PY5351 a tusl::TUS1-300-13myc-HIS3 CDC5::GAL1-CDC5-URA3
PY5352 a tusl::TUS1 -300 -13myc-HIS3 CDC5::GALI-cdc5N209A-URA3
PY5202 a tusl : :tusl-ST-URA3
PY5353 a tusl::tusl-ST-GFP-HIS3
PY5354 a tusl::tusl-ST-13myc-HIS3
PY5355 a tusi::tusl-STI-300-13myc-HIS3
PY5279 a tusl::tusl-6DE-LEU2
PY5356 a tusl ::tusl-6DE-GFP-HIS3
PY5357 a tusl::tusl-6DE-13myc-HIS3
PY5358 a tusl::tusl-6A-LEU2
PY5359 a tusl::tusl-6A-GFP-HIS3
PY5360 a tusl::tusl-6A-13myc-HIS3
PY5156 a myolA::HIS3
PY5158 a hoflA::HIS3
PY5361 a romlA::KanR
PY5031 a rom2A::KanR
PY5362 a mpklA::KanR
PY5363 a romlA::KanR tuslA::KanR
PY5364 a rom2A::KanR tusl A::KanR
PY5365 a rom2A::KanR hoflA::HIS3
PY5366 a rom2A::KanR myolA::HIS3 (complemented with PB2521)
PY5367 a tuslA::KanR hoflA::HIS3 (complemented with PB2520)
PY5368 a tuslA::KanR myolA::HIS3
PY5369 a rom2::rom2-ST-LEU2
PY5370 a tuslA::KanR rom2::rom2-ST-LEU2
PY5371 a romlA::KanR rom2::rom2-ST-LEU2
PY5372 a myolA::KanR rom2:.:rom2-ST-LEU2
PY5373 a hoflA::KanR rom2::rom2-ST-LEU2
PY5374 a rom2A::KanR tusl::tusl-ST-URA3
PY5375 a romlA::KanR tusl::tusl-ST-URA3
PY5376 a myolA::KanR tusl::tusl-ST-URA3
PY5377 a hofld::KanR tusl:.:tusl-ST-URA3
PY5378 a mpklA::KanR tusl::tusl-ST-URA3
PY5379 a mpklA::KanR tuslA::KanR
PY5380 a tusl::tusl-ST-URA3 rom2::rom2-ST-LEU2
PY5201 a myol::MYOI-CFP tusl::TUS1-GFP-HIS3
PY5257 a myol::MYO1-CFP tpm2:.:TPM2-GFP-HIS3
PY5235 a myol::MYO1-CFP rom2::ROM2-3xGFP-HIS3
PY5381 a ura3::CFP-TUB1 tusl::TUS1-GFP-HIS3
PY5256 a ura3::CFP-TUB1 tpm2::TPM2-GFP-HIS3
PY5382 a ura3::CFP-TUB1 rom2::ROM2-3xGFP-LEU2
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Table 4.6 Continued List of the yeast strains
Strain Mat Relevant genotype
PY4315 a trplA::NatR
PY5384 a roml::GAL1-GFP-ROM1-TRP1 trplA::NatR
PY5385 a cdc24::CDC24-13myc-HIS3
PY5386 a bag7::BAG7-13myc-HIS3
PY5387 a bfal::GAL1-HA-BFAl-HIS3 tpm2::TPM2-GFP-HIS3
PY5388 a cdcl5-2 bfal::GAL1-HA-BFAl-HIS3 tpm2::TPM2-GFP-HIS3
PY5389 a cdc5::cdc5-2-URA3 bfal::GAL1-HA-BFAI -HIS3
tpm2::TPM2-GFP-HIS3
TAP tagged strains used for Fig. 4.2B are from the commercially available TAP fusion
library [31] and are not described in this list.
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Table 4.7 List of the plasmids
Name GENE (ORF) Marker Other* Source
PB2520 TUS1-GFP URA3 YCp
PB2521 ROM2-GFP URA3 YCp
PB2202 CDC5 URA3 YCp A. Amon
PB2522 MYO1 URA3 YCp E. Bi
PB2523 HOFI URA3 YEp E. Bi
PB 1993 BNI1-3xGFP LEU2 YIp
PB2525 TUS1 (1-600) LEU2 YIp
PB2526 TUS1 (1-600)-6A LEU2 YIp
PB2527 TUSi (1-600)-6DE LEU2 YIp
PB2476 TUSI (1-300) URA3 YIp
PB2477 TUS1 (1-300)-ST URA3 YIp
PB2478 ROM2 (1-500) LEU2 YIp
PB2528 ROM2 (1-500)-ST LEU2 YIp
PB2529 ROM2-3xGFP LEU2 YIp
c* YCp= Yeast Centromeric Plasmid
YEp= Yeast Episomal Plasmid
YIp== Yeast Integrative Plasmid
Bacterial expression
PB2530 GST-Cdc5PBD Amp+
PB2531 GST-Cdc5PBD* Amp+
PB2532 GST-Rom2 (1-400) Kan+
PB2533 GST-Tusl (1-300) Kan+
PB2534 GST-Tusl (216-450) Kan+
PB2535 GST-RBD (Pkcl) Amp+
Mammalian Work
GST-mEct2 (1-421) Amp+
GST-mEct2 (414-639) Amp+
Plkl kinase domain T210D Kan+
CBD-CYK4 (1-288) Kan+
GST-PlklPBD Amp+
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Chapter Five
Conclusions, Other Observations, and
Future Directions
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PBD binding site timing and accessibility: Temporal distribution of Plk substrates
One of the more confusing aspects of Plkl 's (and orthologs) function is how
various Plk substrates are targeted at different time-points during mitosis. There is a
clear linear order to some mitotic events, yet how different substrates of the same kinase
are targeted at different points is not clear. For Plkl (and orthologs), this could be a
simple consequence of PBD binding site generation by different kinases at different
points during mitosis. Particularly puzzling is why PBD binding sites generated by Plkl
itself are not created until late mitosis. This suggests a shift in Plkl targets from early
mitosis, where Cdkl is active and the PBD binding sites are mostly Cdkl -generated with
other kinases contributing at particular subcellular locales such as the centrosome, to late
mitosis, where Cdkl is inactive and the PBD binding sites are mostly generated by Plkl
itself or other cytokinesis kinases. One explanation of this shift is that Cdkl might block
the ability of Plkl to phosphorylate its self-generated PBD binding sites through
phosphorylation at other sites in the same protein. This has been observed for PRC 1 [1]
and is also likely for MKPL2 [2]. Similarly, in budding yeast, Sccl is targeted by Cdc5
in metaphase, and Bfal is not targeted until anaphase [3], though the PBD binding site-
generating kinases for these proteins are unknown. PBD binding site-generating kinases,
other than Cdkl and Plkl, probably only function on a few select substrates and do not
contribute to this overarching shift in PBD targeting from early to late mitosis.
However, even within early mitosis, certain targets are phosphorylated at different
rates and at different times than other substrates. This is very evident for Cdkl and has
been studied in some detail. To assess whether the current state of the mitotic cell or
some intrinsic factor to the substrates themselves controlled the kinetics, Georgi et al. [4]
looked at the phosphorylation of a number of different Cdkl substrates in cell extracts
that had entered mitosis at various times. They found that no matter how long the extract
had been in mitosis, the substrates were phosphorylated with the same kinetics (which
varied widely between the different substrates tested), indicating that the kinetics of Cdkl
phosphorylation are somehow controlled by the substrates themselves. The same thing
likely occurs for Plkl, suggesting that PBD targeting is not nearly the entire story.
Instead, there must be some differentiation of substrates through another mechanism.
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One interesting theory is that Plkl targets with strong single PBD binding sites might be
early substrates, whereas Plkl targets with multiple weak PBD binding sites might be
later substrates, though this has not been tested. Another theory is that there is a
previously undiscovered regulatory subunit of Plkl that additionally modulates its
targeting to substrates. A regulatory subunit of Plkl could control Plkl's function during
early mitosis but be degraded by the APC at the metaphase to amphase transition
allowing different Plkl behavior during late mitosis. Or a series of regulatory subunits
controlled by other mitotic kinases could modify Plkl behavior at different stages of
mitosis.
Other external factors might also be at work, such as kinases that can
phosphorylate the Ser immediately preceding the Ser that needs to be phosphorylated to
generate a PBD binding site. PBD binding site accessibility, and thus Plkl substrate
status, could be controlled through a kinase/phosphatase pair, as was suggested for
vimentin above. Even the PBD binding site itself might be controlled by a phosphatase
to prevent PBD binding and Plkl phosphorylation too early. Shugoshin binds to PP2A
and brings it to the centromere where PP2A probably acts on Shugoshin and cohesin to
keep them dephosphorylated until the spindle association checkpoint has been satisfied
[5-7]. Plkl and orthologs are responsible for phosphorylation of both Shugoshin and
cohesin to release them from chrormsomes [8-11], but as long as PP2A activity is present,
this does not occur. Whether PP2A dephosphorylates the Plkl-generated
phosphorylation site or the PBD binding site is not clear. Interestingly, Separase function
is required for Shugoshin delocalization in Drosophila [12] and high Separase activity
can prompt Cdc5 to phosphorylate its anaphase targets while the cells are still in
metaphase [3]. Separase cleavage of its targets is not required for this phenomenon so
how Separase controls Plk function is unclear though Separase could control a theoretical
Plk regulatory subunit described earlier. Overall, multiple mechanisms collaborate to
produce a temporal pattern of Plkl substrates through mitosis, with PBD binding site-
accessibility at the core of the regulation.
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Phospho-dependent binding reactions downstream of Plk phosphorylation events
Just as the PBD binds to phosphorylated sites downstream of CDK and other
kinases, there might be domains that bind to sites that have been phosphorylated by Plks.
Plks can generate the epitope for the phospho-specific antibody known as 3F3/2 [13, 14],
suggesting that Plk-generated motifs are accessible to binding interactions. There are
several possible candidates for domains that could bind Plk-generated sites based on
current literature. The first is the Ect2 BRCT domains as described extensively in
Chapter Four. Another promising candidate is 14-3-3 sigma which is the only 14-3-3
protein with a specific mitotic role [15]. Many of the translational machinery proteins
that were found to bind to 14-3-3 sigma [15] also were identified as binding targets of the
Plkl PBD (Chapter Two). Perhaps the PBD and 14-3-3 sigma could compete for the
same binding sites, but the optimal binding motifs for these domains are quite different
and no sites within EIF4B appear to be able to bind both 14-3-3 and the PBD [16-18].
Instead, it seems more likely that the PBD binds these proteins to direct Plkl to
phosphorylate them at another site, which generates 14-3-3 sigma binding sites. The
protein EIF4B was shown to be a critical target of 14-3-3 in mitosis, as overexpression of
EIF4B overcame the 14-3-3 sigma-dependent suppression of translation in mitosis [15].
EIF4B was also identified as a PBD interactor (Table 2.1). Looking at all the possible
14-3-3 sigma binding sites in EIF4B reveals that several of them also match consensus
Plk1 phosphorylation sites, and there is a potential CDK-generated PBD binding site
(Figure 5.1). This leads to the straightforward hypothesis that Cdkl activity in early
mitosis phosphorylates EIF4B, allowing binding by the PBD, which in turn targets Plkl
activity to phosphorylate EIF4B so it can be bound by 14-3-3 sigma. Binding of EIF4B
by 14-3-3 sigma disrupts cap-dependent, and leads to cap-independent, translation, which
is a hallmark or mitotic cells [15]. To demonstrate that Plkl generates the 14-3-3 sigma
binding sites, a 14-3-3 sigma pull-down can be done with bacterial-produced EIF4B that
is pre-incubated with Plkl kimse. Mapping of the relevant sites through mutational
analysis and/or mass spectrometry should easily follow. Then, the relevant mutations can
be tested in vivo for functionality using the add back system described in Wilker et al.
[15]. There should be less mutant EIF4B required (that cannot bind 14-3-3 sigma) to
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overwhelm the 14-3-3 sigma-dependent suppression of mitotic translation than wild-type
EIF4B. Similarly, knockdown of Plki by siRNA using the method of van Vugt et al.
[19] should give the same mitotic translation defect as seen in the 14-3-3 sigma
knockdown cells. The Ect2 tandem BRCTs and 14-3-3 sigma have dramatically different
folds and appear to recognize dramatically different motifs, however, they may both bind
to specific Plkl-dependent phosphorylation sites. As Plkl participates in such a vast
range of mitotic functions ([20, 21], Figure 2.4), other domains that recognize Plkl-
phosphorylated motifs likely exist.
Suspected Polo-like kinase targets
Cdcl4/Net1
Cdcl4 and Net were identified in the bioinformatic screen for Cdc5 substrates,
but were not verified to bind the Cdc5-PBD. Cdcl4 is a phosphatase conserved from
yeast to humans that dephosphorylates CDK sites during late mitosis [22], and Cdcl4 is
held inactive in the nucleolus by Netl until the FEAR (cdcl4 early anaphase release
network) and MEN (mitotic exit network) pathways cause Cdcl4 release [23, 24]. Both
of these pathways require Cdc5 kinase activity though the mechanism of Cdc5 action is
unknown [25, 26].
Netl has been shown to be an in vitro Cdc5 substrate and multiple Cdc5-
dependent phosphorylation sites have been mapped, but mutation of these sites caused
minimal phenotypic consequences [27, 28]. On the other hand, Netl has been shown to
be an vivo CDK substrate, and mutation of three of these sites in the N-terminal 341
amino acids, which are required for Netl to hold Cdcl4 in the nucleolus, eliminates the
ability of Netl to release Cdcl4 [29]. One of these three sites makes a perfect PBD
binding site. Of course, mutation of this residue eliminates both the CDK
phosphorylation and the potential PBD binding. Single mutations have not tested in the
reported literature, but it will be interesting to see whether mutation of this single residue,
T212, has the same phenotypic consequences. Also critical is to test whether mutation of
the -1 Ser (S211) also results in the same phenotypic consequences. This mutant will
presumably be a separation-of- function allele for CDK phosphorylation and PBD binding.
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PBD binding studies of wild-type and mutant Netl, as well as phosphorylation site
mapping experiments by mass spectrometry, will be necessary to confirm this.
If the expected results are obtained, this would lead to a model that the Cdc5-PBD
targets Cdc5 to Netl. But since Cdc5 activity against Netl is not biologically relevant
[27], it is likely that, as has been suggested [28], Cdc5 phosphorylates Cdcl4, which
contains five optimal, and more than ten minimal, Plk consensus phosphorylation motifs
but no consensus motifs for PBD binding. This phosphorylation of Cdcl4 by Cdc5 could
be the driving force behind the separation of Netl and Cdcl4. Thus, Netl and Cdcl4 are
a likely example of the distributive phosphorylation model, where PBD binding to Net
allows Plk phosphorylation of Cdc14. Very recently human Cdcl4A was found to bind
Plkl in vivo and to be a Plkl substrate in vitro [30], confirming the possible connection
between Cdcl4 and Plks.
Ltel
In my Cdc5-PBD pulldown screen from the TAP-tagged yeast collection, I
identified Ltel, a member of the mitotic exit network [26], as a specific PBD interactor
(Chapter Three). This is in agreement with a previous report that full-length Cdc5
interacts with Ltel by both pulldown and co-immunoprecipitation [31]. Ltel is a
member of the MEN pathway described just above. Activity of Ltel is only required at
low temperatures [32], and Ltel is synthetically lethal with Spol2 [33], which is part of
the FEAR network [25], even at normal temperatures. This allows easy assessment of
Ltel function through the use of an Ltel/Spol2 double deletion strain with a covering
ura-marked Spol2 plasmid. Growth of this strain on 5-FOA plates will eliminate the ura-
marked plasmid and cause cell death which can be rescued by expression of a wild-type
Ltel covering plasmid. Alternatively, an Ltel deletion strain can be grown at low
temperature (150 C), causing death which again can be rescued by the presence of a wild-
type Ltel covering plasmid. Overexpression of the central CHD domain region of Ltel
rescues the cold sensitivity [34]. This region contains five optimal CDK phosphorylation
sites of the sequence (S/T)PX(K/R), and mutation of all five of these sites in full-length
Ltel still rescues both the cold sensitivity and spol2 synthetic lethality of a Ltel deletion
strain [35]. This allele of Ltel with five mutations can still function as a CDK target in
238
vitro and in vivo [35], indicating other minimal CDK target sites, (S/T)P, are also
phosphorylated.
Intriguingly, within this region there are three optimal PBD binding sites (S630,
S643, S667) of the form S(S/T)P, of which two are within optimal CDK phosphorylation
sites. My hypothesis is that CDK phosphorylation of these sites targets the Cdc5-PBD to
Ltel causing subsequent phosphorylation of Ltel by Cdc5 to regulate Ltel function.
Thus, mutation of these three sites will eliminate Ltel function in the assays described
earlier. Ideally, wild-type Ltel will be compared to the double mutant in the two optimal
CDK phosphorylation sites and the triple mutant in all three potential PBD binding sites.
Presumably, the double mutant would rescue the low temperature and spol2 synthetic
lethality just as well as the wild-type protein, considering that a mutant of five sites,
including these two, rescued these phenotypes [35]. If the triple mutant fails to rescue, it
will be imperative to show that this mutant does not bind the PBD like the wild-type
protein, and that the triple mutant Ltel is still a substrate for CDK in vitro, to show that
CDK regulation has not been completely lost. Also, the single mutant at S643 should
also be tested, though this will likely rescue similarly to wild-type. Ltel has more than a
dozen potential Cdc5-phosphorylation sites based on the known phosphorylation motif
for Plk's [36, 37], further suggesting Plk regulation of this molecule. A shift to a non-
permissive temperature of a temperature-sensitive Cdc5 allele does not eliminate the gel
shift associated with Ltel phosphorylation in mitosis [31], but this gel shift has been
fairly convincingly demonstrated to be CDK-dependent [35].
Npml
Npml, nucleophosmin, was identified as a specific Plkl PBD interactor in my
PBD-pulldown mass spectrometry screen (Table 2.1). Npml is a mammalian RNA
binding protein involved in preribosomal assembly and transport of ribonucleoproteins
between cellular compartments (ref). In addition, we identified a phosphopeptide
corresponding to phosphorylation of T219 in Npml (Table 2.2). This threonine sits
within the sequence STP which, when phosphorylated, matches the optimal PBD binding
site. As this is the only optimal PBD binding site found within Npml, it is likely to
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directly bind the PBD. To test this, S218A and T219A mutants can be made in Npml
and tested for binding in a PBD pulldown assay.
Npm.l is already known to be regulated by Plkl during mitosis through
phosphorylation of serine four in Npml by Plkl [38]. Mutation of this site to alanine
results in lack of centrosome duplication and failure of chromosome segregation, whereas
mutation of this site to the phosphomimic residue D results in centrosome over-
duplication and cytokinesis defects [38]. If the S218A and T219A mutations do
eliminate PBD binding, then it will be interesting to test whether expression of these
mutants in tissue culture cells mimics the phenotypes seen with expression of the S4A
mutant. (It may be necessary to siRNA-deplete the endogenous Npml to see the
phenotype.) If the S4A and PBD site mutants have the same phenotype, this will confirm
that Npml is regulated through Plkl phosphorylation subsequent to PBD binding. A
double mutant in the PBD binding site with the S4D would be expected to result in the
same phenotype as the S4D mutant alone, because Plkl phosphorylation is downstream
of PBD binding. However, the phenotypes may be different, indicating a separate need
for PBD binding and Plkl -dependent phosphorylation, or the presence of additional
PBD-dependent Plk1 phosphorylation sites. This is unlikely, however, because no other
consensus Plk1 phosphorylation motifs are present on Npml. Npml likely represents a
model protein for demonstrating the processive phosphorylation model.
More: intriguingly, there is growing evidence that Npml is a dynamically-
regulated molecule during the cell cycle that contributes to genomic stability and
ribosome processing along with being a proto-oncogene [39]. The localization of Npml
to nucleoli during interphase is disrupted during mitosis, through phosphorylation by
CDKs, and this phosphorylation blocks the RNA binding function of Npml, that it uses
to bind pre-ribosomal particles [40]. Whether Plkl activity is required for these changes
in Npml activity is unclear, and it could be easily tested using the mutants described
above. The function of Npml at centrosomes is also a bit unclear, but it appears Npml is
involved in physical separation of paired centrioles after CDK phosphorylation.
Interestingly, this function is mediated through Npml activation of Rock2, and in fact
Npml binding to Rock2 enhances the kinase activity of Rock2 [41]. Considering that
Npml [38] and Rock2 (Chapter Two) are both regulated by Plkl, and that both Npml
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[41] and Plk 1 (Chapter Two) activate Rock2, there is likely to be three-way regulation
between all three proteins. The binding of Npml and Rock2 could be Plkl-stimulated, in
addition to being CDK-stimulated [41], which could easily be tested using the mutants of
Npml described above. If this turns out to be true, then Plkl will have three mechanisms
for activating Rock2: direct phosphorylation of Rock2 (Chapter Two), activation of Ect2
(Chapter Four) (which activates furrow-localized Rock2), and activation of Npml (which
activates centrosome -localized Rock2). Loss of Npml in mouse models leads to
aneuploid tumors [39], suggesting spindle and/or cytokinesis failure, consistent with the
phenotypes seen with Plkl and Rock2 gain or loss (Chapter Two). Lastly, Npml has been
found to be a target of the Brcal/Bardl Ubiquitin Ligase at the centrosome [42],
suggesting an additional layer of control that could be tested in the HCC1937 cell line
(Appendix One).
NIPA
A mechanism, whereby Cdkl/cyclinB1 is kept inactive during interphase, is
through ubiquitination and degradation of cyclinB 1 by an SCF complex with NIPA
(nuclear interacting partner of ALK) as the substrate specificity factor [43]. Recently,
NIPA has been identified as a mitotic phosphoprotein [43, 44]. At least two sites in
NIPA, S354 and S359, are phosphorylated during G2, disrupting the association of NIPA
with its SCF complex, and thus preventing NIPA from directing cyclinB I degradation
[44]. Interestingly, the S359 site is within an SSP motif that could be bound by the PBD.
Subsequent to the partial activation of Cdkl/cyclinB I allowed by the disruption of NIPA,
Cdkl/cyclinB1 phosphorylates NIPA on S395, in the context of another SSP motif [44].
All three of these sites have been shown to be in vivo-relevant, through the use of point
mutations, whereas several other mapped Cdkl/cyclinB 1 in vitro phosphorylation sites
on NIPA were shown to be irrelevant in vivo [44]. Plkl did not phosphorylate NIPA in
vitro without prior phosphorylation by Cdkl/cyclinB 1 [44], so there is a strong
possibility that Plkl is involved in the regulation of this molecule, considering the two
PBD binding motifs that are generated. These sites are all fully conserved in mouse
NIPA, though only the sequence context of the S395 site is conserved in Xenopus. This
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would bring yet another layer of Plkl regulation into the story of how Cdkl/cyclinB1
gets activated to promote mitotic entry [21, 45].
MCMs and ORCs
One interesting set of proteins that has not been implicated in any process
overlapping with Plkl are the mini-chromosome maintenance proteins (MCMs) and the
origin recognition complex proteins (ORCs). Six separate MCMs (MCM2-7) are known
to form a complex which is thought to be the replicative helicase in eukaryotic organisms
[46]. They form part of the pre-replicative initiation complex along with several
members of the ORC protein family [47]. After replication initiation, several ORC
proteins are phosphorylated by CDK family members to exclude formation of new pre-
replication initiation complexes until after chromosome segregation is completed during
anaphase [48, 49]. The MCM complex stays with the replication complex until
replication is complete, and then several members of it are regulated through CDK
phosphorylation [48]. The details on the regulation of ORC and MCM proteins differ
between organisms, but in all cases, multiple members are either degraded through
ubiquitin-dependent pathways, excluded from the nucleus, or otherwise prevented from
performing their replication function [49]. Outside S phase several of these proteins have
different functions, including Orc6, which, when disrupted, interferes with chromosome
segregation and cytokinesis [50] and binds septins at the cleavage furrow [51]. Mcm2
[52] and Orc2 [52, 53] are located at the centrosome throughout mitosis, and depletion of
Mcm2 and Orc2 by siRNA causes similar defects to those seen with depletion of Orc6
[52]. Orc2 also recruits Cdkl to chromatin to promote RPA (replication protein A) foci
disassembly to allow mitotic chromosome condensation [54].
Plkl PBD can bind various MCMs and probably the entire MCM2-7 complex
[55], though no function was ascribed to this interaction. We identified Mcm2, Mcm4,
and Mcm6, in the PBD pulldown mass spectrometry screen, as specific PBD interactors
(Chapter Two). All three of these have optimal PBD binding sites, whereas the other
three members of the complex, Mcm3/5/7, do not have any optimal PBD binding sites.
Several PBD binding motifs in MCM2 and MCM4 have been mapped as in vivo
phosphorylation sites ( [56], Table 2.2), leading to a strong possibility that the PBD can
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directly bind these proteins. In a yeast two-hybrid experiment, interaction was seen
between full-length Plkl, Mcm2, and Orc2, but not any of the other MCM or ORC
proteins [52]. The role of PBD binding of these MCMs is unclear, and there are multiple
possibilities. If this interaction normally takes place during mitosis, it might be a
secondary inhibition mechanism to prevent pre-replicative initiation complexes from
forming to early, beyond just phosphorylation by CDKs. Since the nucleus breaks down
during mitosis, perhaps PBD binding and/or phosphorylation by Plkl maintains the
separation of the MCMs from chromatin. Alternatively, Plkl regulation ofMCMs in
mitosis might extend the period of inhibition of MCMs past when CDK activity is lost at
the beginning of anaphase, considering that MCMs are thought to re-associate with
chromatin starting in telophase [48, 49]. Furthermore, Plkl regulation of MCMs could
have relieve the CDK generated inhibition of MCMs, if the PBD interaction takes place
in late nitosis, like the PBD interactions of cytokinesis regulators. The re-association of
pre-replicative complexes with DNA might be monitored in a checkpoint fashion in late
mitosis, since elimination of Mcm2, Orc2, and Orc6 causes cytokinesis failure [50, 52].
The activity of Plkl may be required to satisfy this checkpoint, by being partially
responsible for the re-establishment of pre-replicative complexes. More simply, Plkl
may regulate mitotic-specific functions of Mcm2 and Orc2, rather than having any
impact on the DNA replication activities of these proteins.
Rho-activated Kinases and Myosin Phosphatase Targeting Subunit
In Chapter Two, we demonstrated extensively that Rock2 is under the control of
Plkl. In addition Rockl, citron kinase, and myosin phosphatase targeting subunit
(MYPT) were all identified as specific PBD binders (Table 2.1 and Figure 2.6 F,H). All
four of these proteins are known to be involved in cytokinesis and regulate the
phosphorylation of myosin regulatory light chain, which in turn controls the activation
state of myosin in the acto-myosin ring [57]. The three kinases are all regulated by
binding RhoA. It will be interesting to see if Rockl and citron kinase are also activated
by Plkl, like Rock2 (Figure 2.8F). Rock2 has a single potential CDK-generated PBD
binding site, but I have not been able to demonstrate that this site mediates the interaction
with the PBD, as mutation of this site does not eliminate the Rock2/PBD interaction by
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pull-down. Potentially, the PBD binding site on Rock2 could be generated by Plkl, as is
known for several other proteins involved in cytokinesis ([1, 2], and Chapter Four).
Rockl does not contain any potential CDK-generated PBD binding sites, so again it may
be regulated through Plkl-generation of its own PBD binding site. Citron kinase, on the
other hand, has six potential CDK-generated PBD binding sites, of which we mapped one
as being an in vivo phosphorylation site (Table 2.2). Finally, the phosphatase, MYPT,
also has two potential CDK-generated PBD binding sites. All have lots of potential Plkl
phosphorylation sites, as judged by optimal consensus motifs. These four proteins all
contribute to the same pathway, so it may make sense for Plkl to regulate all of them in
similar fashion, at the sane time, in order to promote the forward progression of
cytokinesis. Considering the large role of Plkl in regulating RhoA networks, as
discussed in Chapter Four, it seems likely that Plkl also helps control these downstream
RhoA targets.
RAM Network Components
Another late mitotic pathway in budding yeast is the RAM (regulation of Ace2
activity and cellular morphogenesis) network. It is similar in structure to the MEN, with
a small G-protein regulating the activity of a kinase cascade, with the ultimate target
being the daughter cell-specific transcription factor, Ace2 [58]. I identified the RAM
network scaffold, Tao3, in my Cdc5-PBD yeast two-hybrid and pulldown assay (Chapter
Three). The upstream RAM network kinase, Kic 1, also came down with the Cdc5-PBD,
though it came down equally well with the mutant version (Chapter Three). Intriguingly,
the laboratory of Eric Weiss at Northwestern has identified Kic 1 to be a Cdc5 substrate
(Eric Weiss - personal communication). Also, the downstream kinase Cbkl, which is a
member of the NDR family of kinases, is an in vitro substrate of Plkl (unpublished
observations). Though Cbkl does not have any consensus binding sites for the PBD, its
obligate binding partner, Mob2, does have a consensus PBD binding site. Further genetic
experiments need to be performed to show that Cdc5 regulates the RAM network and to
identify which components are the targets.
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Other Proteins Identified as PBD Interactors in This Thesis
For the proteins identified as specific Cdc5-PBD interactors (Chapter Three -
Table 3.1 and 3.2), it will be interesting to continue to perform interaction-defective
genetics. For those proteins where identification of the PBD binding site is
straightforward, mutants can be made that lose Cdc5-PBD binding. The genomic copy of
the gene can be easily replaced with this non-binding mutant, or single copy plasmids
containing the wild-type or non-binding mutant version of the gene can be placed in
strains with the genomic copy deleted. Either way, this represents a powerful genetic
system for examining the effects of Cdc5 regulation of many key mitotic processes.
Furthmore, the availability of the cdc5-as 1 allele and the corresponding inhibitor
(Chapter Three) allows for direct assessment of whether these yeast proteins are also
Cdc5 substrates in addition to Cdc5-PBD binders.
For other human proteins with mapped phosphorylation sites that match optimal
PBD binding sites (Table 2.2), it will be interesting to examine whether PBD binding is
indeed mediated through the phosphorylation, and whether mutation of that site to
eliminate PBD binding has any phenotypic consequences. Ideally, mutants of both the
phosphorylation site and the -1 serine will be tested in a PBD pulldown assay and in vivo
assay. This will allow for separation of function between the consequences of
phosphorylation of the residue by CDK, which should be normal in the -1 serine mutant,
and the consequence of loss of PBD binding. Ideally, to test the biological significance
of PBD-binding, the endogenous copy of the gene will be knocked down by siRNA or
other methods, and the wild-type copy of non-binding mutants will be added back in a
form that cannot be targeted by the siRNA. Over- and mis-expression effects will be
difficult to overcome, which is why the yeast system is so much more powerful.
The Function of Plk1 at the Central Spindle
There are a large number of PBD binding partners and Plkl substrates at the
central spindle, as described previously in Chapter Two, and as more fully illuminated by
recent papers. In order to put all these proteins in context, I generated a new protein-
protein interaction map (as previously done in Chapter Two) of the central spindle
245
machinery that connects the central spindle (shown as tubulin in figure) to the
actomyosin ring focused on Plkl and Aurora B (Figure 5.2). Many of the core
components known to be involved in central spindle formation (Mklpl, Mklp2, Cyk4,
and vimentin) are regulated by these two kinases [59-65], though the only direct link
known between these two kinases is the phosphorylation of the Aurora B modulator,
INCENP, by Plkl [66]. The microtubule bundling protein PRC1 recruits the kinesins,
Mklpl, Mklp2, KIF4, and KIF14, to the central spindle where they, in turn, recruit many
of the other central spindle components [59]. As described in Chapters Two and Four,
this core spindle machinery connects to the RhoA-mediated cytokinesis pathways
through the RhoGEF, Ect2, with Plkl as a regulator of both processes. Rho-dependent
kinases control the activation of myosin, through phosphorylation of regulatory myosin
light chain and, in turn, contraction of the actomyosin ring [57]. Plkl also regulates these
kinases (Chapter Two) as well as anillin [67], which plays a role in the construction and
contractility of the actomyosin ring [68]. In addition, not shown are the Plkl -regulated
proteins, NudC, Cepl70, Cep55, Nir2, and TTDN1, which all localize to the central
spindle, and depletion of which causes cytokinesis defects, though none of these proteins
have any known direct connection to the central spindle or RhoA mediated processes [69-
73].
Why are there so many binding partners of the PBD at the central spindle and so
many Plkl substrates? Depletion of almost any of these PBD binding partners prevents
Plkl localization to the central spindle, which suggests that either all the binding events
are somehow co-dependent or, more likely, that depletion of any of these components
causes mitotic defects that prevent proper central spindle assembly. The ability of Plkl
to localize in cells expressing non-PBD binding mutants of these proteins has not been
tested, but could serve to identify an order of importance of these proteins in Plkl
localization. Similarly, after the Plkl -dependent phosphorylation sites on all these
proteins have been mapped, cell lines expressing non-phosphorylatable mutants can be
used to determine the relevance of these sites to cytokinesis function. Perhaps some of
the Plkl-dependent phosphorylation sites are extraneous to the actual functioning of
cytokinesis and only occur due to the proximity of Plkl and the proteins. Still, the
coordinated phosphorylation of so many proteins by one kinase at one time in one
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process suggests that Plkl phosphorylation of all the proteins may be required to get
timely and accurate cytokinesis. Similarly, Aurora B-mediated phosphorylation of many
of the same components creates a system where a large number of potentially-
independent events have to match up, in time and space, in order for the irreversible
process of cytokinesis to occur. In this view, the vast number of Plkl and Aurora B
substrates can simply be seen as an exquisite unidirectional control mechanism.
On the Implications of the Number of Plk Substrates and PBD Binders
The sheer number of known and suspected Plkl targets requires that Plkl does
not bind to its substrates for a long time. PBD binding to a ligand seems like a fairly
strong interaction with a measured Kd of 280nm with an isolated phosphopeptide [18].
This is similar to Kds of 40nm for the Lck SH2 domain with an optimal peptide [74],
510nm for 14-3-3 with its binding peptide from Raf [16], and 330nm for the FHA domain
of Rad53 with an optimal peptide [75]. Whether this number has anything to do with the
Kd of an interaction between the PBD and a full-length protein is unclear. Certainly, the
autoinhibition of the kinase domain and the PBD in the full-length molecule may
contribute to a lower Kd, as seen for peptides in vitro [17]. However, it is thought that
during mitosis, when Plkl is activated by phosphorylation on T210 [76-79], this
autoinhibition is mostly eliminated [80]. This could be more fully tested in vitro by
phosphopeptide binding studies using full length Plkl, with or without pre-treatment with
PKA to phosphorylate the T210 site [81]. Arguing that the PBD does bind tightly in vivo,
in full-length Plkl, is the data that expression of a kinase-dead Plkl, or the isolated PBD,
causes mitotic defects [79, 80, 82]. If the PBD interactly weakly with full length
substrates in vivo due to a fast off rate, the endogenous wild-type Plkl should be able to
drive mitosis even in the presence of kinase-dead Plkl or isolated PBD, though a mitotic
delay might occur. Taking all the evidence together, it seems that the PBD's interaction
strength in vivo must be modified by the activity of the Plk kinase. The obvious
hypothesis is that Plkl phosphorylation of PBD ligands somehow modifies the PBD
interaction, either through disruption or preventing re-binding after dissociation. This
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could happen due to structural rearrangements of PlkI substrates, direct interference with
the PBD binding site by the Plkl -generated phosphorylation, or other mechanisms.
The degree of interference with PBD binding by Plki phosphorylation could, and
probably will, vary widely between Plkl substrates. Proteins with a single PBD site and
a Plk phosphorylation site in close proximity might be nearly completely inhibited from
PBD binding after Plk phosphorylation. On the other hand, for those PBD binders that
have a large number of low affinity PBD binding sites, it seems unlikely that Plk
phosphorylation will greatly dininish PBD binding, unless there are a similarly large
number of Plk-dependent phosphorylation sites. Proteins that have Plkl -generated PBD
binding sites might be on those proteins that Plkl needs to stay attached to for significant
periods of time. These proteins would be the scaffolds in the distributive phosphorylation
model (Figure 1.3). Spacing requirements, at least in two dimensions, for the distance
between a PBD binding site and a Plk phosphorylation site, could also be tested in vitro
using peplides containing a PBD binding site and an optimal Plk phosphorylation site at
various distances away. Kinase assays, to measure the incorporation of phosphate into
the Plk phosphorylation site, and equilibrium binding studies, to measure the binding
affinity of the PBD to its binding site, of these peptides would show the interplay
between Plk phosphorylation and PBD binding. At short distances, Plk will probably not
be able to phosphorylate its target efficiently, and thus the observed PBD binding affinity
will not change much. At long distances, the Plk phosphorylation site will not interfere
with PBD binding despite full phosphorylation. But, presumably, at some intermediate
distance, Plk phosphorylation of its target site will interfere with PBD binding.
Summary and Future Directions
Before this project started a fair bit was known about the role of Plks in mitosis
[21 ], and about the function of the polo-box domain with the identification of it as a
phosphopeptide binding domain [18]. These studies have added a large number of
additional PBD interactors and potential Plkl and Cdc5 substrates to a list that has been
growing rapidly over the past few years (Table 1.1). More specifically we have
demonstrated a mechanistic role for Plkl and Cdc5 in the control of Rho-mediated
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cytokinesis signaling through Plk control of RhoGEFS and Rho-activated kinases.
Additionally we will demonstrate a role for Cdc5 in control of septum deposition and
nuclear migration which have not been previously described. The methods and assays
designed for these projects can be harnessed for a number of other potential uses.
The pulldown mass spectrometry screen described in Chapter Two can be readily
extended to other phosphopeptide binding domains under other cellular conditions.
Utilizing a mutant that no longer binds phosphopeptides provides an optimal negative
control to identify specific interactors. This has already been done for the
phosphobinding protein, 14-3-3 sigma, for cell cycle stage specific interactions by
another member of our laboratory [15]. In addition any protein-protein interaction
domain that has a known mutation that interferes with the protein-protein interaction
surface could be used in this system. For example, the mammalian inhibitor of apoptosis
protein, survivin, is known to interact with the pro-apoptotic protein, Smac, and mutation
of Arg-71 in survivin to alanine blocks this interaction. Performance of the pulldown
mass spectrometry screen with wild-type and mutant surviving should detect Smac as a
specific survivin interactor, and might detect other survivin interactors that bind the same
surface. Perhaps more interestingly, this approach could be used to map differential
interactions among cell types or mutant proteins associated with disease states. For
example, there are a number of known cancer-associated mutations in the tandem BRCT
domain of BRCA1 (Appendix One). A panel of these mutants could be used in a
pulldown mass spectrometry screen from human tumor cell lysates to determine how
these mutations affect the binding pattern of BRCA1. The mutant BRCA1 proteins could
fail to interact with critical BRCA1 ligands, or they could interact with ligands that wild-
type BRCA 1 does not bind, to promote a transformed cellular state.
The context-dependent yeast two hybrid scheme described in Chapter Three has a
multitude of potential uses for both identification of phosphorylation-dependent
interactions along with identification of any activity-dependent interaction. Initially other
phosphopeptide binding domains can be tested under appropriate conditions where they
bind their ligands. For example the budding yeast protein, Rad9, is required for cell cycle
arrest after DNA damage, and contains a tandem BRCT domain that is a phosphopeptide
binding module. The tandem BRCT domain of Rad9 could be used in a context-
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dependent yeast two hybrid screen looking for interactions that occur after exposure of
yeast cells to various agents that activate the DNA damage response network, such as
methyl-methonyl-sulfate (MMS), UV irradiation, hydroxyurea, or gamma irradiation.
Different interactions may be identified with different treatments giving a broad picture
of the range of Rad9 responses to DNA damage. The screening strategy is clearly
extendable to domains that bind post-translational modifications other than
phosphorylations, but even more broadly it could be used to look for any interactions that
occur only under a particular cellular state. For example, in mammalian cells, p53 and
mdm2 interact upon unstressed conditions, but upon a variety of cellular stresses this
interaction is lost. This interaction could be identified by performing the same screen as
above for Rad9, but looking at those hits that bind stronger in the untreated condition
compared to the treated condition.
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Figure 5.1: Potential 14-3-3 Sigma and Plk1 Related Sites in EIF4B
(A) Potential 14-3-3 Sigma Related Sites in EIF4B
MAASAKKKNKKGKTISLTDFLAEDGGTGGGSTYVSKPVSWADETDDLEGDVSTTWHSNDDDVYRAPPIDR
SILPTAPRAAREPNIDRSI YTAFLGNLPYDVTEESI KEFFRGLNISAVRLP NPERLKGFG
YAEFEDLDSLLSALSLNEESLGNRRIRVDVADQAQODKD GRD KTDTDWRARPATDSFDD
YPPR GDKYRD· RYRDGYRDGYRDGPRRDMDRYGGRDRYDDRGSRDYDRGYDSRIGSGRE
3YRRDDDYRGGGDRYEDRYDR DRSDYRRDDRGPPQRPKLNLKPRSTPKEDDSSAS
TSQST IFGGAKPVDTAAREREVEERLQKEQEKLQRQLDEPKLERRPRE~E
GSESSQTGTSTTSSRN•E KSLENETLNKEEDCHSPTSKPPKPDQPLKVMPAPPPKENAWVKRSSN
PPA DTEQQSPTSGGGKVAPAQPSEEGPGRKDENKVDGMNAPKGQTGNSSRGPGDGGNRDHWKESD
RKDGKKDQDSRSAPEPKKPEENPASKFSSASKYAALSVDGEDENEGEDYAD
Red = 14-3-3 binding mode #1 RSX(pS/pT)XP
Pink = 14-3-3 binding mode #2 RXPhiX(pS/pT)XP
(B) Potential Plkl Related Sites in EIF4B
MAASAKKKNKKGKTISLTDFLAEDGGTGGGSTYVSKPVSWADETDDLEGDVSTTWHSNDDDVYRAPP I
*LPTAPRAAREPNIDRSRLPKSPPYTAFLGNLPYDV I KEFFRGLNISAVRLPREPSNPERLKGFG
YAEFEDLDSLLSALSLNcNRRIRVDVADQAQDKDR D1RDRNRDSDKTDTDWRARPATDSFDD
YPPRRGI GDKYRDRYDSDRYRDGYRDGYRDGPRRDMDRYGGRDRYDDRGSRDYDRGYDSRIGSGRRA
FGSGYRRDDDYRGGGDRYEDRYDRR DSSRDDYSRDDYRRDDRGPPQRPKLNLKPRIKEDDSSAS
TSQSTRAASIFGGAKPVDTAAREREVEERLQKEQEKLQRQLDEPKLERRPRERHPSWRSEETQERERSRT
GSESSQTGTSTTSSRNARRRES KEEDCHSPTSKPPKPDQPLKVMPAPPPKENAWVKRSSN
PPARSQSSDTEQQSPTSGGGKVAPAQPSEEGPGRKDENKVDGMNAPKGQTGNSSRGPGDGGNRDHWKESD
RKDGKKDQDSRSAPEPKKPEENPASKFSSASKYAALSVDGEDENEGEDYAD
Green = strong potential Plk1 phosphorylation site (E/D/N)X(S/T)(F/Y/W/V/I/L/M)
Yellow = weak potential Plkl phosphorylation site (E/D/N/Q)X(S/T)
Blue = potential PBD binding site S(S/T)P
(C) Potential 14-3-3 Sigma Binding Sites Generated by Plkl
MAASAKKKNKKGKTISLTDFLAEDGGTGGGSTYVSKPVSWADETDDLEGDVSTTWH S NDDDVYRAP P IDR
SILPTAPRAAREPNIDRSRLPKSPPYTAFLGNLPYDVTEESIKEFFRGLNISAVRLPREPINPERLKGFG
YAEFEDLDSLLSALSLNEESLGNRRIRVDVADQAQDKDRDEGRDRNRDSDKTDTDWRARPATD S FDD
YPPRRGIGDKYRDRYDSDRYRDGYRDGYRDGPRRDMDRYGGRDRYDDRGSRDYDRGYDSRIGSGRRA
FGSGYRRDDDYRGGGDRYEDRYDRRD lSSRDDISRDDYRRDDRGPPQRPKLNLKPRSTPKEDDSSAS
TSQSTRAASIFGGAKPVDTAAREREVEERLQKEQEKLQRQLDEPKLERRPRERHPSWRSEEQERERRT
GSESSQTGTSTTSSRNARRRESEKSLENETLNKEEDCHSPTSKPPKPDQPLKVMPAPPPKENAWVKRSSN
PPARSQSDTEQQSPTSGGGKVAPAQPSEEGPGRKDENKVDGMNAPKGQTGNSSRGPGDGGNRDHWKESD
RKDGKKDQDSRSAPEPKKPEENPASKFSSASKYAALSVDGEDENEGEDYAD
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Figure 5.2: Central Spindle Protein-Protein Interaction Network
Protein-protein interactions that occur during cytokinesis connecting the central spindle
(tubulin) to the actomyosin ring are shown as lines between protein nodes. Proteins are
indicated with their common names rather than official gene names. All interactions
shown are verified in vivo interactions except for those between Plkl and Rockl, Citron,
and MYPT which are suggested in Chapter Two. Colors are consistent with Figure 2.6
with Aurora B and INCENP also in orange like Plk as central kinase regulators.
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Tandem BRCT Domains Function as Phosphopeptide
Binding Modules and Control the DNA Damage
Responsive Functions of BRCA1
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Structure and mechanism of BRCA1 BRCT domain recognition of phosphorylated
BACH1 with implications for cancer. Nat Struct Mol Biol 11, 2004.
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Timmy Ho helped with BRCT domain protein and DNA production. Irma Rangal-
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Abstract
We used a proteomic approach to identify phosphopeptide-binding modules
mediating signal transduction events in the DNA damage response pathway. Using a
library of partially degenerate phosphopeptides biased to resemble the phosphorylation
motif of the phosphatidylinositol 3-kinase-related kinase (PIKK) family members, ataxia-
telangiectasia-mutated (ATM), ataxia-telangiectasia- and RAD3-related (ATR), we
identified tandem BRCA1 carboxy-terminal (BRCT) domains in Pax transactivation
domain-interacting protein (PTIP) and BRCA1 as phosphoserine (pSer)- or
phosphothreonine (pThr)-specific binding modules that recognize a subset of substrates
phosphorylated by the PIKKs in response to y-irradiation (IR). These interactions direct
the localization of the tandem BRCT domains to foci in response to IR. Furthermore, we
report the 1.85A X-ray crystal structure of the Brcal tandem BRCT domains in complex
with a phosphorylated peptide representing the minimal interacting region of the DEAH-
box helicase Bachl. Germline mutations in the tandem BRCT domains of the Brcal
tumor suppressor often result in a significant increase in susceptibility to breast and
ovarian cancers, and we show that a subset of disease-linked mutations appear to act
through specific disruption of phospho-dependent Brcal interactions.
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Introduction
Signal transduction by protein kinases in eukaryotes results in the directed assembly
of multi-protein complexes at specific locations within the cell [1]. This process is
particularly evident following DNA damage, where activation of DNA damage response
kinases results in the formation ofprotein-protein complexes at discrete foci within the
nucleus [2]. In many cases, kinases directly control the formation of these multi protein
complexes by generating specific phosphorylated-motif sequences; modular binding
domains then recognize these short phospho-motifs to mediate protein-protein
interactions [3, 4]. We used a proteomic screening approach [5] to identify novel
modular pSer- or pThr-binding domains involved in the DNA damage response, and
found that BRCT (Brcal C-terminal) domains function downstream of DNA damage
dependent protein kinases.
The original gene found to contain tandem BRCT domains is the breast-cancer
susceptibility gene product, Brcal, which plays important roles in cell cycle control,
transcriptional regulation, chromatin remodeling, and the response to DNA-damage [6-9].
Brcal is a large, modular protein of 1863 amino-acid residues containing an N-terminal
RING domain, a central region rich in SQ/TQ dipeptide pairs, and the tandem BRCT
domains at its C-terminus (Figure Al.1C). Brcal interacts with a large number of protein
partners at different stages of the cell cycle, or following genotoxic stress. For example,
Brcal interacts with the DNA helicase BACH1 during S and G2 in normally cycling cells
[10, 11], whereas Brcal interacts with a subset of ATM/ATR substrates in response to
DNA damage (Figure A1.4B,D). In both S-phase and irradiated/mutagen-treated cells,
Brcal localizes to distinct nuclear foci thought to represent sites of DNA-damage [12, 13]
where Brcal is thought to function, at least in part, as a scaffold for the assembly of
DNA-repair complexes.
Mutations in Brcal occur in 50% of women with inherited breast cancer and up to
90% of women with combined breast and ovarian cancer [14-17]. Most frameshift and
deletion mutants truncate all or part of the BRCT repeats, while more that 70 missense
mutations lie within the BRCT domains themselves
(http://research.nhgri.nih.gov/projects/bic/). BRCT domains occur singly or as multiple
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repeats in a number of proteins in addition to Brcal that are involved in cell-cycle
regulation and DNA-damage responses [18, 19]. Comprised of 80-100 amino acids,
BRCT domains are generally thought to function as protein-protein recognition modules
[19]. The molecular basis underlying Brcal BRCT function, and how cancer-causing
mutations in the BRCT domains act at the structural level, however, remains unresolved,
despite significant structural, biochemical, and mutagenic analysis [ 19-23]. It has been
suggested that mutational effects are manifested through structural destabilization,
however a number of mutations are located on the protein surface, indicating that they
may specifically affect BRCT interactions with other Brcal-associated targets.
We present here the identification of BRCT domain containing proteins as
phosphorylation dependent binding partners of DNA damage responsive proteins
downstream of DNA damage dependent kinases. To determine the structural basis for
phosphopeptide binding and phosphopeptide-motif selection, and investigate alternative
structural mechanisms underlying Brcal BRCT mutations and cancer predisposition, we
solved the high resolution X-ray crystal structure of the Brcal tandem BRCT repeats
bound to a Bachl phosphopeptide. We show that a set of cancer-associated Brcal BRCT
mutations eliminate phosphopeptide binding in vitro and Bachl phosphoprotein binding
in vivo, or alter the phosphopeptide recognition motif for the Brcal tandem BRCT
domains, revealing a molecular and structural basis for mutation-associated loss of Brcal
function.
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Results
Identification of tandem BRCT domains as phosphopeptide binding modules
We used a proteomic screening approach [5] to identify novel modular pSer- or pThr-
binding domains involved in the DNA damage response. In cells exposed to IR, the PIKK
family members phosphorylate transcription factors, DNA repair proteins, protein kinases,
and scaffolds on Ser-Gln and Thr-Gln motifs [24]. We therefore constructed an oriented
peptide library biased to resemble the motif generated by ATM and ATR [25, 26] (Figure
Al.1 legend and nethods). The phosphorylated and non-phosphorylated peptide libraries
were immobilized and screened against approximately 96,000 in vitro translated (IVT)
polypeptides (960 pools each encoding - 100 transcripts) over a 10-week period in a
high-throughput approach. The majority of IVT products either failed to bind to either of
the immobilized peptide libraries or bound slightly better to the non-phosphorylated
control (Figure Al.1A). Several pools, however, contained cDNAs encoding proteins
that bound preferentially to the (pSer or pThr)-Gln library.
Pool EE 11 contained the strongest phosphopeptide-binding clone, EE 11-9, which
encoded the C-terminal 70% of human PTIP (Figure A1.1B). PTIP was originally
identified as a transcriptional control protein although later data suggests that PTIP also
appears to also play a critical role in the DNA damage response pathway [27-29].
Human PTIP contains at least 4 BRCT domains, known protein-protein interaction
modules present in many DNA damage response and cell cycle checkpoint proteins [19].
Unfortunately the PTIP clone used throughout this study and referred to as full length
PTIP is not actually the entire protein. Subsequent to the completion of this work it was
recognized that PTIP is a much longer protein with an extended N-terminus that possibly
contains another two BRCT domains. A series of deletion constructs was generated and
analyzed for the minimal phosphopeptide-specific binding region (Figure A1.1B). A
construct containing only the tandem 3rd and 4 th BRCT domains displayed strong and
specific binding to the (pSer or pThr)-Gln library. Constructs of PTIP lacking both of
these domains failed to bind or lacked phospho-discrimination. Furthermore, neither the
3" or 4 th BRCT domains alone bound to phosphopeptides, suggesting that the PTIP
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tandem C-terminal BRCT pair functions as a single module that is necessary and
sufficient for phospho-specific binding.
BRCT domains are often found in tandem pairs, or multiple copies of tandem pairs,
and the tandem BRCA1 BRCT domains behave as a single stable domain ((BRCT) 2) [20].
To investigate whether (pSer or pThr)-binding is a general feature of (BRCT) 2 domains,
we screened (BRCT)2 domains from a number of other DNA damage response proteins
(Figure A1.2A). Like those in PTIP, the BRCAI-(BRCT) 2domain showed phospho-
specific binding and individual BRCA1 BRCT domains were insufficient for phospho-
specific interactions. Phospho-specific binding by the (BRCT) 2 domains of MDC 1,
53BP1, or the PTIP N-terminal pair was not observed, and only a low amount of
phospho-specific binding for S. cerevisiae RAD9 was detected, suggesting that the
phosphopeptide-binding function is present in only a subset of (BRCT) 2 domains.
We used oriented peptide library screening to determine the optimal phospho-binding
motifs for the C-terminal (BRCT) 2 domains of PTIP and BRCA1 (Figure A1.2B and
Table Al.1) [30]. PTIP- and BRCAl-(BRCT) 2 displayed strongest binding to similar, but
not identical, motifs with extremely strong selection for either aromatic or aliphatic
residues, and aromatic residues only, respectively, in the (pSer or pThr)+3 position when
screened with a (pSer or pThr)-Gln library. Prominent amino acid selection was also
observed in the (pSer or pThr)+2 and +5 positions, with more moderate selection at other
positions. We investigated the relative importance of Gln in the (pSer or pThr)+l position,
since this residue is critical for ATM and ATR phosphorylation, using individual pSer-,
pThr- and (pSer-X-X-Phe)-oriented peptide libraries. This revealed selection for Gin, Ile,
Phe, and Tyr in the degenerate +1 position. Furthermore, the absence of a Gln in the +1
position reduced the selection for aromatic and aliphatic residues in the +3 and +5
positions, suggesting that although Gin in the (pSer or pThr)+l position was not essential,
it is a favored residue.
We defined an optimal (BRCT) 2 domain-binding peptide (BRCTide) as Y-D-I-(pSer
or pThr)-Q-V-F-P-F. Isothermal titration calorimetry showed that the optimal
phosphoserine-containing peptide bound to the C-terminal (BRCT) 2 domain of PTIP with
a dissociation constant of 280 nM, and to the (BRCT) 2 domain of BRCA1 with a
dissociation constant of 540 nM (Table A1.2). Replacement of pThr for pSer reduced the
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affinity of the peptide for the PTIP- and BRCAl-(BRCT) 2 domains by a factor of -7 and
substitution of Ser or Thr for pSer abrogated binding altogether. To further verify motif
selection, binding of the PTIP- and BRCAI-(BRCT) 2 domains to a solid-phase array of
immobilized phosphopeptides was performed in which each amino acid flanking the
pThr-Gln or the pSer core in the optimal BRCTtide was varied (Figure A1.3). The
resulting selectivities were generally consistent with the results obtained using oriented
peptide libraries in solution and confirmed the importance of the (pSer or pThr) +3
position in (BRCT)2 domain binding.
To examine the role of (BRCT) 2 domains in binding to proteins phosphorylated
by ATM and ATR, lysates from U20S cells that had been treated with 10 Gy IR or mock
treated were incubated with GST-(BRCT) 2 fusion proteins. Bound proteins were detected
by immunoblotting with an antibody to the (pSer or pThr)-Gln motif generated by ATM
and ATR (Cell Signaling Technologies) (Figure A1.4). After IR, both PTIP- and
BRCAI-(BRCT) 2 domains interact with different phospho-proteins, despite similar
phospho-peptide recognition motifs. The PTIP-(BRCT) 2 phospho-protein interactions are
inhibited by incubating the (BRCT)2 domains with a (pSer or pThr)-Gln peptide library,
but not with a pThr-Pro library or the non-phosphorylated (Ser or Thr)-Gln library
(Figure A1.4A). Binding of both PTIP- and BRCA1-(BRCT) 2 domains to phospho-
proteins was largely eliminated by treatment of the cells with caffeine to inhibit the
activity of ATM and ATR[31] and by the BRCTide but not by the non-phosphorylated
analogue (Figure A1.4B and A1.4D).
In response to IR, the DNA damage protein 53BP1 undergoes phosphorylation by
ATM and facilitates the ability of ATM to phosphorylate additional cellular substrates
[32-34]. Endogenous 53BP1 from U20S cell lysates bound to the C-terminal PTIP-
(BRCT)2 domain only in lysates from cells treated with IR (Figure A1.4C). Binding was
inhibited by the optimal BRCTtide but not by its non-phosphorylated counterpart.
Binding was also eliminated by incubation of the (BRCT) 2 domain with the (pSer or
pThr)-Gln peptide library, but not by pre-incubation with a pThr-Pro library or the non-
phosphorylated (Ser or Thr)-Gln library, and binding was also eliminated in cells treated
with caffeine before IR, or in lysates treated with X-phosphatase after irradiation.
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Structure of the Brcal BRCT:Bachl Phosphopeptide Complex
BRCAl-(BRCT) 2 domains bound to the interacting phosphopeptide from BACH 1
(residues 986-995) were crystallized and the structure solved at 1.85A resolution by X-
ray diffraction (Figure Al.5A,B). Phases were determined by molecular replacement
using the previously determined structure of the un-liganded BRCAI-(BRCT) 2 domains
(PDB ID 1JNX) as a search model [20], (Table Al.1 and Methods). Difference Fourier
maps revealed well-defined electron density for the phosphopeptide allowing modeling of
eight residues corresponding to Bachl Ser 988 - Lys 995. Each BRCT repeat forms a
compact domain (Figure Al.5A) in which a central, four-stranded beta-sheet is packed
against two helices, al and a3, on one side and a single helix, a2 on the other. The two
domains pack together through interaction between a2 of BRCTI and the al '/3' pair of
BRCT2. A linker region connecting the two BRCT domains contains a 0-hairpin-like
structure OL and a short helical region, aL, that forms part of the interface through
interactions with a2 of BRCT1 and the N-terminal end of a3' from BRCT2. Overall, the
structure of the BRCAI-(BRCT) 2 domains :phosphopeptide complex is similar to that of
the un-liganded domains (rmsd ~ 0.4A for all Ca atoms). However, superposition of the
individual BRCT repeats reveals that phosphopeptide-binding is associated with a slight
relative rotation of each BRCT domain and a translation of BRCT1 helix al towards the
cleft between the domains.
The Bachl phosphopeptide binds in an extended conformation to a groove located
at the highly conserved interface between the N- and C-terminal BRCT domains (Figures
Al.5A and Al.6A), consistent with the requirement of both domains for efficient
phosphopeptide binding [35, 36]. This mode of binding is distinct from thatobserved in
the phospho-independent interaction between p53 and the 53BP-1-(BRCT) 2 domains,
which occurs primarily through the linker region [37, 38]. Our structure clearly shows
that the phospho-dependent interactions that are necessary and sufficient for formation of
the Bachl/Brcal complex occur on the opposite side of the BRCT-BRCT interface from
those involved in the p53:53BP-1 interaction.
BRCAI-(BRCT) 2 domains binding to library-selected peptides in vitro [35, 36], and
to phosphorylated Bach1 in vivo [11] is dominated by the presence of a
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phosphoserine/threonine and a phenylalanine three residues C-terminal to it (Phe +3).
This is now confirmed by our structure which shows that the Bachl pSer 990 phosphate
moiety binds to a basic pocket through three direct hydrogen-bonding interactions
involving the side chains of Ser 1655 and Lys 1702, and the main-chain NH of Gly 1656
(Figure A1.7A). All three of these residues are located in BRCT1 and all are absolutely
conserved in Brcal homologues. Ser 1655 and Gly 1656 are situated within the loop
preceding al1 and are brought into proximity with the phosphate moiety as a result of a
conformational change in the loop that occurs upon phosphopeptide binding. Intriguingly,
a S 1655F mutation has been identified in a single breast cancer patient, although its link
to disease has not been confirmed. In addition to these direct interactions, the phosphate,
and some peptide main-chain atoms are also tethered through a highly organized network
of water molecules, many of which are tetrahedrally hydrogen bonded (Figure A1.7A).
Indirect protein-solvent-phosphate contacts are unusual in phospho-dependent protein-
protein interactions but have been observed previously in structures of phosphopeptide
complexes of the human Plkl Polo-box domain [39, 40].
The Phe +3 peptide side-chain fits into a hydrophobic pocket at the BRCT interface
consisting of the side chains of Phe 1704, Met 1775 and Leu 1839 contributed from both
BRCT domains (Figures A1.7A and A1.8A). This finding rationalizes the strong
selection for aromatic amino acids in the +3 position of the binding motif seen in peptide
library experiments [35, 36], as well as the observation of Yu et al that mutation of Phe
993 to Ala eliminates Brcal:Bachl binding [11 ]. Additional hydrogen-bonds with the
main-chain N and C=O atoms of Phe +3 are supplied by main- and side-chain atoms from
Arg 1699, a site of mutation also associated with cancer predisposition. The
phosphorylated Ser 990 of Bachl is preceded by an Arg residue in the -3 position and
followed by a proline residue in the +1 position, suggesting potential Ser 990
phosphorylation by either basophilic and/or proline-directed kinases. BRCA1-(BRCT)2
domains are also known to interact with pSQ-containing motifs characteristic of PI 3-
kinase-like kinases such as ATM and ATR (Figure A1.4B,D). In the tandem
BRCT:Bachl phosphopeptide co-crystal structure, there are no direct interactions
between the +1 Pro side chain and the BRCT domains. Instead, this residue participates
in only a single water-mediated hydrogen bond involving its carbonyl oxygen (Figure
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A1.7A), consistent with the idea that various types of protein kinases can generate
tandem BRCT phospho-binding motifs. The Lys +5 side chain makes two salt-bridging
interactions with residues in BRCT2 (Figure A1.7A), consistent with the Lys selection
observed in this position by spot blot and peptide library experiments [35, 36].
Cancer-Associated Brcal BRCT Mutations
Residues that form or stabilize the phosphopeptide binding surface, and the
domain-domain interface, are among the most highly conserved portions of the molecule
in Brcal orthologs from humans, primates, rats and mice (Figure A1.6A). Interestingly,
these regions correlate strongly with the location of cancer-associated mutations (Figure
A1.6B). Some cancer-associated mutations may disrupt the global BRCT fold while
others are more likely to specifically interfere with ligand binding [19, 21-23, 37].
Approximately 80 tumor-derived mutations have been identified within the BRCAl-
(BRCT) 2 domains, though only a few of these have been subsequently confirmed to result
in cancer predisposition, including D1692Y, C1697R, R1699W, A1708E, S1715R,
G1738E, P1749R, M1775R, 5382InsC (a frameshift mutation that results in a stop codon
at position 1829), and Y1853X (which truncates the last 11 residues). Most of these
cluster at or near the phosphopeptide-interacting surface (Figure A1.6B). Two of these
mutated residues, Arg 1699 and Met 1775, directly interact with residues in the
phosphopeptide (Figure A1.7A). Two others, Pro 1749 and Gly 1738, are located at the
BRCT1/BRCT2 interface beneath the molecular surface and their effects are likely to be
mediated through alterations in the relative orientation of the tandem BRCT motifs that
our structure suggests is necessary for phospho-dependent interactions with partner
proteins.
To verify the phosphoserine phosphate interactions observed in the X-ray
structure and to investigate the effects of the most common tumor-derived point
mutations, we investigated the binding of a panel of site-directed mutant BRCAl-
(BRCT) 2 domains to the interacting region of Bachl. Binding was determined by
measuring the ability of in vitro transcribed and translated proteins to bind to either
phosphorylated and non-phosphorylated biotinylated peptides (Figure A1.7B). Wild-type
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BRCAI-(BRCT) 2 domains clearly bind to phosphorylated but not non-phosphorylated
peptides, while mutation of the conserved Ser 1655 and Lys 1702, alone or in
combination, completely abolished the interaction. Five bona fide cancer-linked
mutations, P1749R, G1738E, M1775R, Y1853X and 5382InsC all result in complete loss
of phosphopeptide binding. A mutation R1699W is cancer-linked and a second, R1699Q,
has been detected in breast cancer patients but has not yet been directly related to disease-
predisposition. We surmised that the glutamine side-chain might still participate in main-
chain hydrogen bonding to the peptide and this is, indeed, the only BRCA1-(BRCT) 2
domains mutant that retained a small degree of binding in our assays. Somewhat
surprisingly, however, the R1699Q mutant largely loses phospho-specificity, and instead
bound to both phosphorylated and non-phosphorylated peptides.
To investigate the in vivo binding of cancer-predisposing mutant BRCA1-
(BRCT)2 domains to endogenous Bachl, we transfected U20S cells with a vector
encoding the C-terminal 550 amino acids of Brcal containing a myc tag and an SV40
nuclear localization sequence as described by Chen et al [41]. As shown in Figure A1.7C,
interaction between the wild type BRCA1-(BRCT) 2 domains with full-length Bachl was
easily detected. In contrast, no in vivo interaction was observed between Bach 1 and
mutant BRCA -(BRCT) 2 domains that disrupt phosphate-binding or predispose to breast
and ovarian cancer. All of these cancer-associated mutant proteins were expressed at
comparable levels when transfected into mammalian cells [42] (Figure A1.7C).
Subsequently we generated two other BRCA cancer associated mutations
(D1692Y and R1751Q) that did not act the same as the previous mutations in the IVT-
pulldown or Bachl co-immunoprecipitation experiment. Both proteins showed phospho-
specific binding to the pSXXF and pS peptide libraries that were described in Figure
A1.2A (Figure Al.8A), and interacted with Bachl (Figure A1.8B). In all cases the
interactions were weaker than that seen with the wild-type BRCA1-(BRCT) 2 domains,
but significant based on a complete lack of interaction seen with the M1775R and
S1655A/K1702M negative controls. In addition we tested the R1699Q mutant with these
peptide libraries, and saw weak phospho-specific binding to the pS library though as
before this mutant failed to interact with Bachl (Figure A1.8A,B). This data shows that
not every cancer-associated BRCAI-(BRCT) 2 domains has lost its phosphobinding
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activity, and there must be some other reason that these mutations predispose women to
breast and ovarian cancer. One explanation is that these mutations, as well as many of
the previously tested ones, may be intrinsically unstable [20, 21, 43]. However, we
observed equal expression of our wild-type and mutant BRCAI-(BRCT) 2 domains
constructs in both in vitro translation and overexpression in tissue culture cells systems
(Figure A1.8 A,B), in agreement with a previous study [42]. Alternatively these mutants
that retain phosphopeptide binding may disrupt other interaction surfaces on Brcal not
required for phosphopeptide binding [19].
Interpretation of the structural effects of the M1775R mutation is simplified since
the X-ray crystal structure of the M1775R BRCAI-(BRCT) 2 domains mutant has been
determined (PDB ID 1N50) [21], revealing a nearly identical structure as the wild-type
protein with an average rmsd of 0.35 A for all Ca atoms. Superposition of the mutant
structure with that of our Bachl complex shows that the guanidine portion of the
substituent arginine side-chain extrudes into the tandem BRCT cleft, where it occupies
the binding site for the essential Phe +3 of the phosphopeptide (Figure A1.9A, B). In this
case, loss of phosphopeptide-binding in vitro and Bachl binding in vivo appear to be
attributable to the severe steric clash of the Arg 1775 side-chain with an important
determinant of phosphopeptide specificity and affinity. The M1775R mutant protein does,
however, bind weakly to a BACH 1 phosphopeptide in which the +3 Phe is mutated to
Asp or Glu (Figure A1.9C). This is consistent with the introduction of a basic residue at
the pSer +3 binding site (Figure A1.6B) and with the observation that this mutation
creates new anion binding sites in the M1775R crystal structure [21]. Thus, in addition to
disrupting the native Brcal:BACHI interaction, this mutation may also result in the
formation of inappropriate BRCA1-(BRCT) 2 domains interactions.
Phosphopeptide-Binding and Nuclear Foci Formation
The binding of the PTIP-(BRCT) 2 domain to ATM and ATR phosphorylated
proteins could localize PTIP at sites of DNA damage in vivo. To investigate this, we
transfected U20S cells with GFP fusions of full-length PTIP, PTIP lacking the C-
terminal (BRCT) 2 domain, or the C-terminal (BRCT) 2 domain (Figure Al.10). In the
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absence of DNA damage, PTIP was diffusely nuclear with a small amount of cytosolic
staining. Two hours after IR, PTIP re-localized into discrete nuclear foci that co-
localized with (pSer or pThr)-Gln phosphoepitopes, 53BP1 and y-H2AX (Figure
Al.1OA). PTIP from which the C-terminal (BRCT)2 domain was deleted, was not
predominantly detected in the (pSer or pThr)-Gln and 53BP1 foci after IR (Figure
A.10B). However, the fragment containing the C-terminal (BRCT)2 domain, was
nuclear and formed minor amounts of foci in the absence of DNA damage, but re-
localized into prominent nuclear foci that co-localized with 53BP 1 after IR (Figure
A1.1 C). Further supporting the role of ATM and ATR in PTIP localization, caffeine
treatment prior to IR reduced the full-length PTIP foci formation (Figure Al.11).
Subcellular localization and nuclear foci formation by the wild type,
S1655A/K1702M phosphopeptide-binding mutant and the M1775R cancer-associated
mutant BRCAI-(BRCT) 2 domains were studied before and after DNA damage in
unsynchronized U20S cells (Figure A1.12). To maximize visualization of nuclear foci,
the cells were permeabilized with buffers containing 0.5% Triton X-100 prior to fixation
and immunostaining [44]. In un-extracted cells the wild-type BRCT domains and both of
the mutant BRCT proteins showed equivalent diffuse nuclear localization. Extraction of
the un-irradiated cells prior to fixation resulted in near complete loss of BRCT domain
staining in all cases (Figure Al.12A). Under these conditions, less than 5% of the wild-
type and M1775R tandem BRCT-containing cells displayed 5 or more nuclear foci, and
no foci were observed with the S1655A/K1702M double mutant. When the cells were
irradiated with 10 Gy of y-irradiation, and 2 hrs later permeabilized, fixed, and stained,
nearly all of the cells containing the wild-type Brcal tandem BRCT domains
demonstrated sharp punctate nuclear foci that largely co-localized with the staining
pattern of an anti-pSer/pThr-Gln epitope antibody that recognizes ATM- and ATR-
phosphorylated substrates (Figure A1.12B). In contrast, the S1655A/K1702M mutant
protein displayed only faint staining with a very fine granular pattern that completely
failed to co-localize with pSer/pThr-Gln staining. This failure of foci formation and
pSer/pThr-Gln co-localization is strong evidence that the phospho-binding function of the
Brcal tandem BRCT domains is critical for normal subcellular localization following
DNA damage. The M1775R mutant protein that binds weakly to phosphopeptides with a
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different specificity than the wild-type Brcal BRCT domains also formed punctate
nuclear foci, although these were slightly reduced in number and showed less co-
localization with pSer/pThr-Gln staining foci than the wild-type protein. This
localization might result from synergistic weak binding to alternative non-optimal
phosphorylated ligands present in high abundance in nuclear foci following DNA damage,
as has been observed for other phosphopeptide-binding domain interactions [45].
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Discussion
(BRCT) 2 domains are unusual in binding to pSer-containing peptides more
strongly than to pThr-containing peptides since 14-3-3 proteins, WW domains, WD40
domains, FHA domains and Polobox domains either bind pThr-peptides better than pSer-
peptides, or do not bind to pSer-peptides at all [5, 46, 47]. Intriguingly, ATM and ATR
preferentially phosphorylate Ser-Gln over Thr-Gln motifs [25], suggesting functional
convergence between the motifs generated by the PIKKs and the motifs recognized by
BRCT domains. The observed (BRCT) 2 domains selection for aromatic and aliphatic
residues in the (pSer or pThr)+3 positions exceeds their selection for Gln in the +1
position. Thus, only a subset of ATM and ATR phosphorylated substrates are likely to
bind with high affinity, and kinases other than Gln-directed kinases might also generate
potential (BRCT)2 domain-binding motifs.
The specific role of PTIP in the DNA damage response though remains
exceedingly unclear. Few studies have been performed looking at PTIP function, and its
biological role is still mysterious. Initially, PTIP was identified as an interactor of the
Pax2 transcription factor, and found to play a role in transcriptional silencing of Pax2
targets [27, 48]. In fact, PTIP is now thought to be a member of a histone
methyltransferase complex [49] further supporting its role as a transcriptional regulator.
The knockout mouse phenotype of PTIP first indicated that it could be involved in the
DNA damage response, as the mouse was inviable with similar phenotypes to the ATR,
Chkl, and Brcal knockout mice [28]. Trophoblast cells grown from these mice were
more sensitive to IR, and overall, the embryos had few cells in mitosis [28], consistent
with a role for PTIP in the DNA damage response. The fact that an interaction of PTIP
with a known DNA damage response protein, 53BP1, is enhanced by IR, and the
formation of PTIP foci following IR (Figure A1.4) confirms this potential for PTIP
regulation of the DNA damage response. A more recent study has confirmed that PTIP
forms nuclear foci after IR (but not other DNA damaging agents), and that knockdown of
PTIP by siRNA reduced ATM-mediated phosphorylation of p53 at Serl5 [50].
This still leaves many open questions regarding the role for PTIP in cycling and
non-cycling cells. PTIP clearly has multiple functions, perhaps functioning as a
transcriptional regulator during development and in specialized cell populations, and
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functioning in the DNA damage response pathway in cycling cells. The fact that PTIP
only forms foci after IR suggests that PTIP plays a role in the ATM signaling network,
though the mouse knockout data suggests PTIP is part of the ATR/Chkl pathway [2].
One interesting question is whether formation of foci by PTIP is dependent on 53BP1
foci formation. This can easily be answered through the use of a 53BPI siRNA depletion
strategy, which has been successfully used before to order foci formation pathways [34].
Once at foci, what is the role of PTIP? Considering the loss of p53 phosphorylation
following PTIP knockdown, it appears that PTIP functions as a scaffold for DNA
damage-responsive kinase activity, similarly to the other BRCT domain-containing
proteins in the DNA damage response network such as 53BP1, MDC1, and Brcal [2].
Are there other PTIP BRCT domain interactors, as indicated by the multiple bands pulled
down by the PTIP BRCTs after IR (Figure Al.4), or is 53BPI the only in vivo interactor?
Mass spectrometry identification of the bands would at least allow further candidates to
be tested. The availability of mouse Cre-Lox PTIP cells [51] will allow further studies
to look at the role of PTIP in multiple DNA damage-signaling responses in otherwise
wild-type MEFs, without the limitations of incomplete knockdown by siRNA or
redundant pathway upregulation during development. It remains an open question
whether PTIP has a distinct and necessary role in the DNA darmge response, though
evidence is slowly accumulating.
The 1.85A BRCA1-(BRCT) 2 domains:phosphopeptide structure described here is
the highest resolution X-ray structure of any BRCT domain structure solved to date, and
provides an enhanced structural framework within which the molecular basis of breast
and ovarian cancer can be further investigated. The structure reveals why tandem BRCT
repeats, rather than single BRCT domains, are required for binding to pSer- or pThr-
containing phosphopeptides with high affinity and specificity, since motif recognition is
mediated by residues contributed from both domains across the domain-domain interface.
In addition, the structure rationalizes the observation that the BRCAI-(BRCT) 2 domains
do not bind to pTyr-containing sequences (Figure A1.3), since the phosphate recognition
pocket appears too shallow to accept a bulky phenyl ring. Despite the fact that mutations
in Brcal ultimately predispose women to cancer, wild-type Brcal paradoxically
constitutes a target for anti-cancer therapy. Given the importance of Brcal in homologous
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recombination and DNA repair [9, 52-54], disruption of the pSer-binding function would
be expected to result in enhanced sensitivity to chemotherapy and radiation, as has been
observed in Brcal null murine embryonic stem cells [53]. Thus, the structural
delineation of the pSer binding surface provides a new target for rational drug design.
The BRCAl-(BRCT) 2 domains:phosphopeptide structure, in combination with
biochemical and cell biological analysis, shows that some pro-oncogenic mutations in the
Brcal C-terminal domains directly disrupt phosphopeptide binding or perturb the BRCT
interface that forms the phospho-dependent binding surface. Four bona fide cancer-
linked mutations, P1749R, G1738E, 53821nsC, and Y1853X all result in loss of
phosphopeptide binding. A fifth mutation, M1775R, binds weakly to phosphopeptides
with altered motif specificity, and can still form nuclear foci after DNA damage, however
it completely loses the ability to interact with wild-type Bachl. These effects of the
P1749 and M1775 lesions confirm the previous observations that these mutations are
sufficient to abrogate Brcal-Bachl interactions in vivo [10]. Since Bachl mutations
have also been shown to be associated with the development of cancer [55], these
findings suggest that the loss of this critical Brcal M1775R:Bachl interaction may be the
critical event responsible for cancer predisposition [11, 55]. However, the observation
that some (D1692Y, R1751Q) mutants can still bind to Bachl suggests this theory may
not be fully correct. These mutants do bind Bachl more weakly that wild-type Brcal
suggesting that there could be a critical threshold of the Brcal:Bachl interaction required
for the tumor suppressor activity of Brcal in vivo.
It remains unclear how phosphopeptide binding by the BRCA1 (BRCT)2 domain
contributes to propagating signals in the DNA damage response network. In order to
study the role of Brcal BRCT phospho-binding activity, we attempted to generate a
Brcal knockout system, where different mutants of Brcal could be added back for assay.
Unfortunately, depletion of Brcal by siRNA or by a microRNA vector caused massive
cell death, preventing simple interpretations of follow-up experiments. Fortunately, there
is a cell line available from a breast cancer patient, HCC1937, which has one deleted
Brcal allele and one 5832InsC allele, which has a missense mutation that causes
premature termination before the BRCTs. Thus, this cell line can be used for in vivo
assays of (BRCT)2 domain function. The cell line grows very slowly and cannot be
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transfected to an appreciable rate using standard techniques, but it can be infected with
retro- or lenti- viruses. Addition of wild-type Brcal rescues the function of the cell line
in response to DNA damage [42], while certain cancer associated mutations still lose
function [42]. We were able to replicate the rescue using a wild-type Brcal virus, and
found that MAPKAPK2 activation after certain DNA damage signals is dependent on
Brcal (Figure A1.13). Future experiments are planned to characterize whether other
cancer-associated mutations are deficient in various DNA damage-responsive events,
particularly the D1692Y and R1751Q mutants, which retain BACH1 binding function.
Also, the S1655A/K1702M mutant will be tested to see whether phospho-binding activity
is generically required for Brcal function in these processes.
Our experimental evidence and crystal structure-based sequence alignments suggest
that not all tandem BRCT domains can bind to phosphorylated ligands, despite the fact
that several residues involved in the binding are relatively conserved. The only other
definitive phosphorylation-dependent tandem BRCT domain besides PTIP and Brcal was
found in MDC1 by another member of our lab, and it appears that MDC1 binding is
specialized because it requires a free carboxy terminus at the +3 position for binding [56].
A set of tandem BRCT domains of TopBP1 might also bind in a phospho-dependent
manner, as the sixth BRCT domain of TopBP1 was found to bind to E2F1 in a manner
that was enhanced upon phosphorylation of E2F1 by ATM [57], and the tandem BRCT
domains of the yeast homolog of TopBP1 (Rad4) bind to Rad9 in a phosphorylation-
dependent manner [58]. There is a clear suggestion that the tandem BRCT domains of
Ect2 also are phospho-specific binders, but they do not bind in the IVT-pulldown assay
(Chapter Four), perhaps due to lack of an appropriate phosphopeptide library. Other
tandem BRCT domains may function like Ect2, with too low, or like Mdc , with too
specialized, of a binding affinity to be seen in the standard IVT-pulldown assays used in
the screen to identify new phosphobinding domains (Figure Al. A). It appears likely,
however, that a minority of BRCT domains have a phospho-binding function, as there are
many examples of single BRCT domains [59], BRCT domains have been previously
thought to be non-phosphorylation-mediated interaction surfaces [59], and BRCT
domains are conserved in bacteria which presumably do not have any need for
phosphoSer/Thr-dependent binding. Even PTIP itself has four other BRCT domains that
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do not have phosphobinding ability (Duaa Mohammad - personal communication) and no
known function. Non-phosphorylation-dependent binding events are not unprecedented
in a class of phosphorylation-dependent binding domains, as seen in FHA domains [60],
in tandem BRCT domains themselves in 53BP1 [37, 38], and even in Brcal [61].
Perhaps BRCT domains are simply protein interaction surfaces which in some cases have
evolved to be phosphorylation-dependent.
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Experimental Procedures
ATM/ATR phospho-motif screen for phoshoserine/threonine binding domains.
An oriented (pSer/pThr) phosphopeptide library biased toward the
phosphorylation motifs for ATM/ATR kinases, and its non-phosphorylated counterpart
were constructed as follows: biotin-Z-Gly-Z-Gly-Gly-Ala-X-X-X-B-(pS/pT)-Gln-J-X-X-
X-Ala-Lys-Lys-Lys and biotin-Z-Gly-Z-Gly-Gly-Ala-X-X-X-B-(Ser/Thr)-Gln-J-X-X-X-
Ala-Lys-Lys-Lys where pS denotes phosphoserine, pT phosphothreonine, Z indicates
aminohexanoic acid, B represents a biased mixture of the amino acids Ala, Ile, Leu, Met,
Asn, Pro, Ser, Thr, Val and J represents a biased mixture of 25% Glu, 75% X, where X
denotes all amino acids except Arg, Cys, His, Lys. The amino acids Arg, Lys, and His
were intentionally omitted from the degenerate positions in the peptide library to decrease
the likelihood of identifying phosphopeptide-binding domains such as 14-3-3 which
target basophilic motifs generated by kinases such as AKT, PKA, and PKCs.
Streptavidin beads (Pierce, 75pmol/tL gel) were incubated with a ten-fold molar excess
of each biotinylated library in 50 mM Tris/HCl (pH7.6), 150 mM NaCl, 0.5% NP-40, 1
mM EDTA, 2 mM DTT and washed five times with the same buffer to remove unbound
peptide. The bead-immobilized libraries (10pIL of gel) were added to 10 gLL of an in vitro
translated [35S]-labeled protein pool in 150 gtL binding buffer (50 mM Tris/HCl (pH7.6),
150 mM NaC1, 0.5% NP-40, 1 mM EDTA, 2 mM DTT, 8 gtg/mL pepstatin, 8 jtg/mL
aprotinin, 8 pg/mL leupeptin, 800 pM Na3VO4, 25 mM NaF) in a 96 well plate format.
Each pool consisted of -100 radiolabeled proteins produced by the ProteoLink in vitro
expression cloning system (Promega). After incubation at 40C for 3 hours, the beads were
rapidly washed three times 200 pL with binding buffer using a 96 well vacuum manifold
prior to SDS-PAGE (12.5%) and autoradiography. Positively scoring hits were identified
as protein bands that interacted more strongly with the phosphorylated immobilized
library than with the unphosphorylated counterpart. Pools containing positively scoring
clones were progressively subdivided and re-screened for phosphobinding until single
clones were isolated and identified by DNA sequencing. The same procedure was used
on individual plasmids to test the phosphobinding ability of various tandem BRCT
containing proteins and all the BRCA1 mutant.
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Protein Cloning, Expression, and Purification
For deletion mapping of the PTIP and BRCA BRCT phospho-binding region
and for expression of MDC1, Rad9, and 53BP1 (Figures A1.1 and A1.2), fragments were
generated by PCR, cloned into pcDNA3.1 (Invitrogen), and subjected to in vitro
transcription and translation. The original MDC1 and 53BP1 plasmids were gifts from S.
Elledge and K. Iwabuchi respectively. For production of recombinant GST-PTIP BRCT
domains and GST-BRCA1 BRCT domains, residues 550-757 of PTIP and residues 1634-
1863 of BRCA1 were ligated into the EcoRI and Notl sites ofpGEX-4T1 (Pharmacia)
and subsequently transformed into DH50a E. Coli. Protein induction occurred at 370 C for
4 hrs or at 250C for 16 hrs in the presence of 0.2-0.4 mM IPTG. GST-PTIP BRCT
domains and GST-BRCAI BRCT domains were isolated from bacterial lysates using
glutathione agarose, eluted with 40mM glutathione/50mM Tris/HCl (pH 8.1), and
dialyzed into 50mM Tris/HCI (pH 8.1)/300mM NaCl. For ITC experiments, purified
GST-PTIP BRCT domains were dialyzed into cleavage buffer (25mM Tris-HCl, 100mM
NaC1, 2mM CaCI2), and cleaved in solution with thrombin (Sigma). Free GST was
removed by incubation with glutathione agarose and the PTIP BRCT domains were
further purified on a mono-Q column and eluted with a NaCl gradient. The appropriate
fractions were dialyzed into 25mM Tris/HCl (pH 8.1), 100mM NaCl. The GFP-PTIP
constructs FL (residues 1-757), ? BRCT (residues 1-549), or (BRCT) 2 (residues 550-757)
were cloned into the EcoRI and Sall sites of pEGFP-C2 (Clontech). For crystallization
experiments, human Brcal BRCTs (residues 1646-1859) were expressed as glutathione
S-transferase (GST) fusions in pGEX-4T1 (Amersham Pharmacia Biotech) in
Escherichia coli BL21 at 180C. The GST was removed by 48-hour treatment with
thrombin before gel filtration. Synthetic peptides for crystallization were prepared by W.
Mawby, University of Bristol, U.K. A Brcal BRCT clone (residues 1313-1863) in
pcDNA3 containing a N-terminal Myc-tag and a SV40 nuclear localization sequence was
a gift from R. Scully and D. Livingston [41], and was used for the co-
immunoprecipitation and immunofluorescence assays. All mutations were generated
using the Stratagene Quick Change Mutagenesis Kit, and verified by sequencing.
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Peptide library screening
Phosphoserine and phosphothreonine oriented degenerate peptide libraries
consisting of the sequences Gly-Ala-X-X-X-B-(pS/pT)-Gln-J-X-X-X-Ala-Lys-Lys-Lys,
Met-Ala-X-X-X-X-pThr-X-X-X-X-Ala-Lys-Lys-Lys, Met-Ala-X-X-X-X-pSer-X-X-X-
X-X-Ala-Lys-Lys-Lys, and Gly-Ala-X-X-X-X-pSer-X-X-Phe-X-X-Ala-Tyr-Lys-Lys-
Lys, where X denotes all amino acids except Cys. In the (pS/pT)-Gln library pS denotes
phosphoserine, pT phosphothreonine, B represents a biased mixture of the amino acids
Ala, Ile, Leu, Met, Asn, Pro, Ser, Thr, Val and J represents a biased mixture of 25% Glu,
75% X, where X denotes all amino acids except Arg, Cys, His, Lys. Peptides were
synthesized using N-a-FMOC-protected amino acids and standard BOP/HOBt coupling
chemistry. Peptide library screening was performed using 125-250 Al of glutathione
beads containing saturating amounts of GST-PTIP BRCT or GST-BRCA1 BRCT
domains (1-1.5 mg) [30]. Beads were packed in a lmL column and incubated with 0.45
mg of the peptide library mixture for 10 min at room temperature in PBS (150 mM NaC1,
3 mM KC1, 10 mM Na2HPO4, 2 mm KH 2PO 4, pH 7.6). Unbound peptides were removed
from the column by three washes with PBS containing 1.0% NP-40 followed by three
washes with PBS. Bound peptides were eluted with 30% acetic acid for 10 min at room
temperature, lyophilized, resuspended in H20, and sequenced by automated Edman
degradation on a Procise protein microsequencer. Selectivity values for each amino acid
were determined by comparing the relative abundance (mole percentage) of each amino
acid at a particular sequencing cycle in the recovered peptides to that of each amino acid
in the original peptide library mixture at the same position.
Isothermal Titration Calorimetry
Peptides were synthesized by solid phase technique with three C-terminal lysines
to enhance solubility. Peptides were then purified by reverse phase HPLC following
deprotection and confirmed by MALDI-TOF mass spectrometry. Calorimetry
measurements were performed using a VP-ITC microcalorimeter (MicroCal Inc.).
Experiments involved serial 10pL injections of peptide solutions (20giM-150gM) into a
sample cell containing 15pM PTIP BRCT domains (residues 550-757) or 15[tM GST-
BRCA1 BRCT domains (residues 1634-1863) in 25-50mM Tris/HC1 (pH 8.1), 100-
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300mM NaCI. Twenty injections were performed with 240s intervals between injections
and a reference power of 25 itCal/s. Binding isotherms were plotted and analyzed using
Origin Software (MicroCal Inc.)
Peptide Filter Array
An ABIMED peptide arrayer with a computer controlled Gilson diluter and liquid
handling robot was used to synthesize peptides onto an amino-PEG cellulose membrane
using N-a-FMOC-protected amino acids and DIC/HOBT coupling chemistry. The
membranes were blocked in 5% milk/TBS-T (0.1%) for 1hr at room temperature,
incubated with 0.025-0.1 jpM GST-PTIP BRCT domains (residues 550-757) or GST-
BRCA1 BRCT domains (residues 1634-1863) or 0.25 pM GST-Brcal BRCTs M1775R
in 5% milk, 50 mM Tris/HCl (pH 7.6), 150 mM NaCl, 2 mM EDTA, 2mM DTT for 1 hr
at room temperature and washed four times with TBS-T (0.1%). The membranes were
then incubated with anti-GST conjugated HRP (Amersham) in 5% milk/TBS-T (0.1%)
for 1 hr at room temperature, washed five times with TBS-T (0.1%), and subjected to
chemiluminescence using ECL (Perkin-Elmer).
PTIP BRCT domains and BRCA1 BRCT domains binding to cellular substrates
U20S cells were either treated with 10 Gy of ionizing radiation or mock
irradiated and allowed to recover for 30-120 min. Cells were subsequently lysed in 50
mM Tris/HCl (pH7.6), 150 mM NaCl, 1.0% NP-40, 5 mM EDTA, 2 mM DTT, 8 jpg/mL
pepstatin, 8 jpg/mL aprotinin, 8 jpg/mL leupeptin, 2 mM Na3VO4, 10 mM NaF, 1 giM
microcystin. The lysates (0.5-2mg) were incubated with 20 tL glutathione beads
containing 10-20 jpg of GST-PTIP BRCT domains (residues 550-757), GST-BRCA1
BRCT domains (residues 1634-1863) or GST for 120 min at 40C. Beads were washed
three times with lysis buffer. Precipitated proteins were eluted in sample buffer and
detected by blotting with anti-ATM/ATR substrate (pSer/pThr)Gln antibody (Cell
Signaling), polyclonal anti-53BP1 (Oncogene), or monoclonal anti-HA (Covance). For
peptide competition experiments, GST-PTIP BRCT domains or GST-BRCA1 BRCT
domains were immobilized on glutathione beads and preincubated with 350 jiM of
BRCTtide-(7pSer, 7pThr, 7Thr, 7Ser) (Table A1.2), (pSer/pThr)Gln-library,
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(Ser/Thr)Gln-library, or pThrPro-library for 1 hr at 40C and washed three times with lysis
buffer. For the phosphatase experiment the lysate was treated for one hour with lambda
protein phosphatase (Sigma) prior to incubation with glutathione beads containing GST-
PTIP BRCT domains.
Co-immunoprecipitation of Brcal BRCTs and Bachl
U20S cells were grown to 50% confluency in 100cm2 dishes and transfected with
the myc-tagged wild-type or mutant Brcal BRCT constructs (residues 1313-1863) using
FuGene6 transfection reagent (Roche) according to manufacturer's protocol. Cells were
collected 30 hrs following transfection, lysed in lysis buffer (50 mM Tris/HCl (pH7.6),
150 mM NaC1, 1.0% NP-40, 5 mM EDTA, 2 mM DTT, 8 Cpg/mL AEBSF, 8 jPg mL-1
aprotinin, 8 jtg mL-1 leupeptin, 2 mM Na3VO4, 10 mM NaF and the phosphatase
inhibitors microcystin and okadaic acid). Lysates containing equal amounts of protein (3
mg) was incubated with 3 pL of a mouse anti-myc antibody (Cell Signaling) for 2 hr at
4°C and then 10 pL of protein G-sepharose beads (Sigma-Aldrich) were added and
samples incubated for an additional 2 hr at 40C. Beads were washed four times with lysis
buffer, bound proteins eluted in SDS-PAGE sample buffer, analyzed on 6%
polyacrylamide gels, transferred to PVDF membrane, and detected by blotting with rabbit
anti-Bachl antibody (a gift from D. Livingston and R. Drapkin). A portion of the lysates
were also run and blotted with the anti-Bachl antibody and the anti-myc antibody to
further ensure equal protein loading.
Immunofluorescence and Microscopy
U20S cells were seeded onto 18mm 2 coverslips and transfected with GFP-PTIP
constructs [FL (residues 1-757), ? BRCT (residues 1-549), or (BRCT)2 (residues 550-
757)] or myc-Brcal BRCT constructs (residues 1313-1863) using FuGene6 transfection
reagent (Roche) according to manufacturer's protocol. Twenty to thirty hours following
transfection, the cells were either treated with 10 Gy of ionizing radiation or mock
irradiated and allowed to recover for 30-480 minutes. Cells were fixed in 3%
paraformaldehyde/2% sucrose for 15 min at RT and permeabilized with a 0.5% Triton X-
100 solution containing 20 mM Tris-HCI (pH 7.8), 75 mM NaC1, 300 mM sucrose, and 3
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mM MgC12 for 15 min at RT. When necessary, cytosolic proteins were extracted after IR
treatment as described previously[44]. In brief, cells were incubated with extraction
buffer (10mM PIPES pH6.8, 100mM NaC1, 300mM sucrose, 3mM MgC12, lmM EGTA,
0.5% (v/v) Triton X-100) for 5 minutes on ice followed by incubation with extraction
stripping buffer (10mM Tris-Hcl pH 7.4, 10mM NaC1, 3mM MgCl2, 0.5% (v/v) Triton
X-100) for 5 minutes on ice followed by successive washes in ice cold PBS. Slides were
stained with primary antibodies at 4°C overnight, then stained with a Texas Red
conjugated anti-mouse or anti-rabbit secondary antibody for 60 min (Molecular Probes)
at RT. Primary antibodies used were rabbit polyclonal anti-53BP1 (Oncogene), mouse
anti-y-H2AX (Upstate), mouse anti-myc (Cell Signaling), and rabbit anti-(pSer/pThr)Gln
(Cell Signaling). Images were either collected on a Deltavision microscope (Carl Zeiss)
and digitally deconvolved using Softworx graphics processing software (SGI) or captured
using a spinning disk confocal detector mounted on a Nikon TE2000 microscope using
OpenLab software (Improvision).
Crystallization and Structure Determination
Crystals were grown at 180C by microbatch methods. The Bachl phosphopeptide
(SRSTpS 990PTFNK) was mixed with the Brcal BRCTs in a 1.5:1 stoichiometric excess
and concentrated to 0.35mM in a buffer containing 50mM Tris-HC1 (pH 7.5), 0.4M NaC1,
and 3mM DTT. Crystals grew from 50 mM MES (pH 6.5), 0.1 M (NH4)2SO 4, and 13%
PEG 8K (w/v) Crystals belonged to the trigonal space group P3221 (a = b = 65.8 A, c =
93.1 A, a = 3 = 90.00, y = 120.00) with one complex in the asymmetric unit. Data were
collected from flash-cooled crystals at 100K on a Raxis-II detector mounted on a Rigaku
RU200 generator. Diffraction data were integrated and scaled using DENZO and
SCALEPACK [62]. The structure was solved by molecular replacement using the
coordinates 1JNX.brk [20] as a model with AMORE [63]. Subsequent refinement was
carried out using REFMAC5 [63] and manual model building in O [64]. Figures were
constructed using Pymol. The atomic coordinates and structure factors have been
deposited in the Protein Data Bank (Accession code 1T15).
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Figure AI.1: Identification of phosphoSer/Thr-binding domains using an
ATM/ATR-motif library vs. expression library screen.
(A) An oriented (pSer/pThr) phosphopeptide library, biased toward the phosphorylation
motifs of ATM and ATR, was immobilized on Streptavidin beads. The library [pSQ=
biotin-ZGZGGAXXXB(pS/pT)QJXXXAKKK] and its non-phosphorylated counterpart
(SQ) were screened against in vitro translated 35S-Met labeled proteins. (pS/pT) denotes
50% phosphoserine and 50% phosphothreonine, Z indicates aminohexanoic acid, B
represents a biased mixture of the amino acids (A, I, L, M, N, P, S, T, V) and J represents
a biased mixture of (25% E, 75% X), where X denotes all amino acids except (R, C, H,
K) (see methods). In each panel, the first and second lanes show binding of proteins
within the pool to the phosphorylated (pSQ) and non-phosphorylated (SQ) libraries,
respectively. Identification of PTIP, denoted by arrow and asterisk, occurred through
progressive subdivision of the EE 11 pool to a single clone.
(B) Deletion mapping of the phospho-binding domain of PTIP. Truncations of PTIP
assayed for selective binding to the pSQ library (Figure Al.1A). BRCT domain
boundaries were determined from sequence alignments [65].
(C) Domain structure of BRCA1 is indicated in cartoon format.
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Figure A1.1 Continued
ATMIATR-motif library
vs. library screen
Pool AD9 CF4 EE10 EE11 EE12
Peptide
library
Sib selection
of clone EEl 1-9
-%
PTIP
B
Residues Gin Rich
227-757 ckon EE1
1-757
1-549
292-479
392435
5-7517
550456
636-757
BRCT I BRCT 2
ema
BRCT 3
CORM
- -I
)I
m-
a~CSll
S1C913
10%
BRCT 4 Input
em
Url I
em,
UI
emB~
pSO SQ Mw
flM -60
oggV" -87
-.- 63
-21
-28
-23
-13
-14
C
1-1863 W/TO Rich e- ýýe7
A
287
Imm
Figure A1.2: Comparison of the tandem BRCT domains and determination of the
PTIP and BRCA1 BRCT optimal phosphopeptide-binding motifs.
(A) PTIP, BRCA1, BRCA1 M1775R, MDC1, 53BP1 and Rad9 (BRCT)2 domains were
assayed for binding as in Figure lA. The peptide libraries used were pSQ (Figure
Al. 1A), pS= biotin-ZGZGGAXXXXpSXXXXXAKKK, pT=biotin-
ZGZGGAXXXXpTXXXXXAKKK, pSXXF=biotin-
ZGZGGAXXXXpSXXFXXAYKKK, where pS is phosphoserine, pT is
phosphothreonine, Z indicates aminohexanoic acid, X denotes all amino acids except Cys.
Domain boundaries: PTIP as indicated in Fig 1; BRCT1 and 2, aa 1633-1863; BRCT1
alone, aa 1633-1740; BRCT2 alone, 1741-1863; MDC1, aa 1874-2089; 53BP1, aa 1622-
1972; Rad9, 985-1309.
(B) Strong selection by the PTIP- and BRCAl-(BRCT) 2 domains for Phe at the
(pSer/pThr)-Gln +3 position (7.0 or 7.5), respectively (Table Al.1). Bar graphs show the
relative abundance of each amino acid at a given cycle of sequencing compared to its
abundance in the starting peptide library mixture[30]. In these types of assays ratios
greater than 1.8 are considered to indicate significant selection and ratios greater than 2.5
are very significant.
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Figure A1.3: PTIP and BRCA1 BRCT domains binding to a filter array of
phosphopeptides
Binding of GST-PTIP and BRCA1 (BRCT) 2 domains to a filter array of peptide spots,
comprising single point mutants of the optimal BRCT domain phosphopeptide (left
column). Bound GST-(BRCT)2 domains were detected by blotting with HRP-conjugated
anti-GST antibody. The resulting consensus binding motif is indicated in the right
column; X denotes no dominant selection, < denotes residues with aliphatic or aromatic
side chains, and letters enclosed in square brackets are specifically de-selected. The top
row indicates the amino acid that was substituted for the optimal amino acid.
Substitution of pSer for pThr enhanced binding for both PTIP and BRCA1 (BRCT)2
domains, consistent with the ITC results. Substitution of pTyr for pThr eliminated
binding altogether, verifying that (BRCT) 2 domains are pSer/pThr-specific binding
modules. Replacement of pThr with Thr, Ser or Tyr abrogated (BRCT)2 domain binding.
The pTQ oriented blots on the left show strong selection at several positions for both
PTIP and BRCA1 BRCT domains; especially for Phe in the +3 position in agreement
with the oriented peptide library screening data. The pS oriented blots on the right show
that the +3 position is the most important position for peptide selection.
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Figure A1.4: Association of tandem PTIP and BRCA1 BRCT domains with DNA
damage-induced phosphoproteins through their phosphopeptide-binding pockets.
(A) Lysates from U20S cells before or 2 hours after 10 Gy of IR were incubated with
GST-PTIP-(BRCT) 2. Bound proteins were detected by immunoblotting with an antibody
to the (pSer/pThr)-Gln motif generated by ATM and ATR.
(B) Interaction of the PTIP-(BRCT)2 domain with phosphoproteins. U20S cells were
treated with caffeine (5 mM) before IR exposure or the beads were incubated with an
optimal BRCT-binding peptide (7pT) or the non-phosphorylated counterpart (7T).
(C) Tandem BRCT domains of PTIP interact with 53BP1 following DNA damage.
Endogenous 53BP1 from IR treated U20S cells was precipitated with GST-PTIP-
(BRCT) 2 and detected by immunoblotting with an antibody to 53BP1. Interaction of
GST-PTIP-(BRCT) 2 with HA-tagged 53BP1, detected by anti-HA blotting, was analyzed
as in panels A and B.
(D) Lysates from U20S cells 2 hrs following IR were incubated with GST-BRCA1
tandem BRCT domains. DNA damage-induced phosphoproteins were detected by
blotting with the anti-ATM/ATR phosphoepitope motif antibody. The interaction of the
GST-BRCA1 tandem BRCT domains with the phosphoproteins were analyzed as in
panel B.
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Figure A1.5: Structure of the Brcal tandem BRCT domains:Bachl phosphopeptide
complex.
(A) Ribbons representation of the BRCAI-(BRCT)2 domains domains in complex with
the pSer-containing Bachl peptide shown as stick representation in yellow. The Bach 1
phosphopeptide binds at the interface between the two BRCT repeats. The secondary-
structure elements in BRCT2 are labeled 'prime' to differentiate them fromthe
secondary-structure elements in BRCTI. The BRCT inter-domain liker is shown in green.
Areas of 31o-helix are not labeled.
(B) Electron density map (2Fo-F,) covering the Bachl phosphopeptide.
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Figure A1.6: Sites of Brcal tandem BRCT domain cancer-linked mutations and
sequence conservation in relation to the Bachl phosphopeptide binding-site.
(A) Comparison of the front and back views of the molecular surface showing the
clustering of residues (magenta) conserved in human, chimp, mouse, rat, chicken and
Xenopus BRCAI-(BRCT) 2 domains. The Bachl peptide binds in a conserved
phosphopeptide binding-groove.
(B) A molecular surface representation of BRCAI-(BRCT) 2 domains showing how the
cancer-associated mutations S1655F, D1692Y, C1697R, R1699Q, S1715R, M1775R and
Y1853X cluster with respect to the phosphopeptide binding-site. BRCT1 is colored blue,
BRCT2 is colored grey, and the mutations are colored red, except for the S1655 which is
colored green as its cancer predisposition has not been confirmed by pedigree analysis.
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Figure A1.7: Functional effects of tandem BRCT domain mutations.
(A) Schematic representation of protein-peptide contacts between BRCAI -(BRCT)2
domains and the Bachl phosphopeptide. Hydrogen bonds, Van der Waals interactions
and water molecules are denoted by dashed lines, pink crescents, and green circles
respectively.
(B) The wild-type and mutant myc-tagged BRCAI-(BRCT) 2 domains constructs
containing the indicated mutations were transcribed and translated in vitro in the presence
of [35S]-methionine and analyzed for binding to a bead-immobilized optimal tandem
BRCT domain-interacting phosphopeptide, YDIpSQVFPF, or its non-phosphorylated
counterpart. The weak phospho-independent binding of the R1699Q mutant was
observed using 10-fold more sample input than that in the other lanes.
(C) U20S cells were transfected with the wild-type and mutant myc-tagged BRCA1-
(BRCT)2 domains constructs containing the indicated mutations. Protein lysates were
immunoprecipitated with a mouse anti-myc antibody and analyzed for association with
endogenous Bachl.
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Figure A1.8: Some Cancer-Associated Mutations in the Brcal (BRCT)2 Domain
Retain Phospho-binding
(A) The wild-type and mutant myc-tagged BRCAI-(BRCT) 2 domains constructs
containing the indicated mutations were transcribed and translated in vitro in the presence
of [35S]-methionine and analyzed for binding to a bead-immobilized optimal tandem
BRCT domain-interacting phosphopeptide, YDIpSQVFPF, or its non-phosphorylated
counterpart.
(B) U20S cells were transfected with the wild-type and mutant myc-tagged BRCA1-
(BRCT) 2 domains constructs containing the indicated mutations. Protein lysates were
immunoprecipitated with a mouse anti-myc antibody and analyzed for association with
endogenous Bach 1.
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Figure A1.9: The Phe +3 position of the Bachl phosphopeptide is essential for Brcal
tandem BRCT domain binding-specificity.
(A) Residues Phe 1704, Met 1775, and Leu 1704 from Brcal tandem BRCT domains
form a hydrophobic pocket to accommodate the Phe +3 position of the Bach 1
phosphopeptide.
(B) Superposition of the crystal structure of Brcal M1775R (BRCT) 2 domains mutant
[21] with the wild-type:Bachl phosphopeptide complex reveals that this mutation
occludes the Bach Phe +3 position.
(C) Brcal wild type (BRCT) 2 domains and the M1775R mutant binding to a Bachl
phosphopeptide spot array. The M 1775R mutant spot blot was performed using 10 times
the amount of protein and was exposed to film for a significantly longer amount of time
than the wild-type protein.
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Figure A1.10: Full length PTIP forms DNA damage induced foci and co-localizes
with (pSer/pThr)-Gln proteins, 53BP1, and y-H2AX.
(A) U2OS cells were transfected with a full length PTIP-GFP construct (PTIP-FL
residues 1-757).
(B) U2OS cells were transfected with a PTIP deletion construct in which the last two
BRCT domains had been removed (PTIP-? BRCT, residues 1-550)
(C) U2OS cells were transfected with a PTIP construct containing only the last two
BRCT domains ((BRCT) 2, residues 550-757). In A-C, 24 hrs following transfection cells
were either treated with 10 Gy of ionizing radiation or mock irradiated, allowed to
recover for 2 hrs, stained, and analyzed by immunofluorescence microscopy.
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Figure A1.11: Caffeine attenuates recruitment of PTIP to DNA damage foci in
response to ionizing radiation.
U20S cells transfected with full-length PTIP-GFP cDNA were mock treated or pretreated
with 10mM caffeine for 70 minutes before exposure to 10Gy ionizing radiation.
(A) In response to IR, mock-treated U20S cells formed nuclear foci containing PTIP (in
green) and H2AXp (in red); these two proteins co-localize at sites of DNA damage
(merge).
(B) In response to IR, caffeine treated U20S cells formed reduced numbers of nuclear
foci; PTIP was mislocalized and did not form discrete nuclear foci (in green) and there
were reduced numbers of H2AXp (in red) containing foci; pretreatment with caffeine
effectively abolished co-localization of PTIP and H2AXp (merge).
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Figure A1.12: Localization of the Brcal-BRCT Domains to Phosphoproteins.
U2OS cells were transfected with the wild-type, M1775R, or K1702M/S1655A versions
of the myc-tagged BRCAI-(BRCT) 2 domains construct.
(A) Un-irradiated cells were stained using an anti-myc antibody prior to (left panels) or
following (right panels) extraction using Triton X-100-containing buffers.
(B) Two hours after exposure of cells to 10 Gy of ionizing irradiation, extracted cells
were stained using an anti-myc antibody and an anti-pSer/pThr-Gln epitope antibody that
recognizes the phosphorylation motif generated by the DNA damage-response kinases
ATM and ATR.
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Figure A1.13: Brcal controls activation of MAPKAPK2
HCC1937 cells, which do not have any functional Brcal, were complemented with full-
length wild-type Brcal (right three lanes) or vector alone (left three lanes). Cells were
treated with doxorubicin or UV, in order to create a DNA damage response using DMSO
as a control. Lysates were generated and probed for total MAPKAPK2, active
MAPKAPK2, Brcal, and actin as a loading control. Brcal was required to activate
MAPKAPK2 after doxorubicin treatment, but not UV treatment.
DMSO + - - + - -
doxorubicin - + - - + -
UV - - + - - +
anti MK-2
anti pMK-2
anti BRCAI1
anti P-actin
pLNCX2 F.F.BRCA1
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Table A1.1
Phosphoserine and Phosphothreonine Peptide
Motif Selection by PTIP and BRCA1 Tandem BRCT Domains
PTIP
-4 -3 -2 -1 +1 +2 +3 +4 +5
X Y (1.5) G (2.3) L (2.6) pS/pT V F P (1.6) 1(2.9)
D (1.5) 1(2.5) Q (3.8) (70) F (2.7)
E (1.4) M (2.5) 1(2.8) L L (2.4)
V (1.9) V (2.0)(4.3) Y (2.0)
X X E (1.3) 1(1.4) pS F (1.7) V(1.8) X 1(1.9)
M (1.4) 1(1.5) T (1.5) F F (1.7)
V (1.4) Q (1.5) M (1.6)
......... .... ... .3.. .... . ) .............. L(1.4)
G(1.6) Y(1.1) D (1.2) L(1.2) pS Q (1.3) V(2.1) F(2.3) P(1.2) Y(1.3)
E (1.1) 1 (1.2) 1(1.3) 1(1.7) 1(2.3)
M (1.2) P (1.2) V (1.8)
L (1.7)
............... ..............................  ... . ..... ... ................. .............. ................................................................ Y ..................................
X X X 1(2.1) pT Q (1.5) Y (1.4) 1 (1.4) F (1.5) AL (1.8) F (1.4) L (1.3) Y (1.4)
W 1(1.3) V (1.2) P (1.3)(1.3)
BRCA1
-4 -3 -2 -1 +1 +2 +3 +4 +5
X F (1.7) D (1.2) 1(1.4) pS/pT V F V (1.5) FY (1.6) E (1.1) V (1.3) Q P (1.4)
L (1.2) T (2.6) Y G (1.8)M (1.2) 1(2.2) (.2
S (1.7)
X R(1.5) E(1.3) V (1.4) pS F (2.1) T (1.9) X F (1.6)
Y(1.4) D (1.2) 1(1.3) Y (1.6) V(1.7) F M (1.4)
M (1.3) 1 (1.4) Y (1.3)
. ... ... . .................... . .................................................(1 4     .... .. ................ 
X X Y (1.2) X pS Q (1.4) V (1.2) F (2.4) 1 (1.2) X
F .......(1.3) I,(1.2) .Y. 1.) .......
S E (1.5) D(1.9) 1(1.6) pT Q (1.5) D(1.5) F (1.9) D(1.4)
E(1.5) L(1.4) E (1.4) Y (1.3) Y (1.2) P(1.2) AF (1.3) 1 (1.2)
A GST fusion of the PTIP or BRCA1 tandem BRCT domains was screened for binding to four
phosphopeptide libraries, which contained the sequences GAXXXB(pS/pT)QJXXXAKKK,
GAXXXXpSXXFXXAYKKK, MAXXXXpTXXXXAKKK, and MAXXXXSpXXXXXAKKK, where X indicates all
amino acids except Cys. In the library MAXXXB(pS/pT)QJXXXAKKK B indicates A, I, L, M, N, P, S, T, V,
and J represents a biased mixture of 25% E, 75% X, while X indicates all amino acids except Arg, Cys, His,
Lys for all positions in this library. Residues showing strong enrichment are underlined.
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Table A1.2
Peptide Binding Affinities for
Peptide Sequence
the Tandem BRCT Domains
(BRCT) 2  Kd
Domain
BRCTtide-7pS
BRCTtide-7pT
BRCTtide-7S
BRCTtide-7T
BRCTtide-7pS
BRCTtide-7pT
BRCTtide-7S
BRCTtide-7T
GAAYDI-pS-
QVFPFAKKK
GAAYDI-pT-
QVFPFAKKK
GAAYDI- S-
QVFPFAKKK
GAAYDI- T-
QVFPFAKKK
GAAYDI-pS-
QVFPFAKKK
GAAYDI-pT-
QVFPFAKKK
GAAYDI- S-
QVFPFAKKK
GAAYDI- T-
QVFPFAKKK
PTIP
PTIP
PTIP
PTIP
BRCA1
BRCA1
BRCA1
BRCA1
280 nM
2.1 pM
N.D.B.
N.D.B.
540 nm
4.5 pM
N.D.B.
N.D.B.
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Appendix Two
Natural-like Function in Artificial WW Domains
Adapted and Expanded From:
William P. Russ, Drew M. Lowery, Prashant Mishra,
Michael B. Yaffe, and Rama Ranganathan.
Natural-Like Function in Artificial WW Domains. Nature 437, 2005.
Contributions:
Bill Russ designed and performed all experiments not described below and co-wrote the
manuscript. Prashant Mishra helped Russ with WW domain cloning, expression, and
purification. Mike designed the WW domain binding screen. Rama Ranganathan
developed the SCA methodology, provided intellectual support to all portions of the
project, and co-wrote the manuscript. I designed and executed the validation phase of the
WW domain binding screen shown in Figure A2.2 and A2.3 and utilized in A2.4A, A2.5,
and A2.6, wrote the methods section for this experiment, and designed the peptide array
binding experiment shown in Figure A2.7.
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Abstract
Protein sequences evolve through random mutagenesis with selection for optimal
fitness [1]. Cooperative folding into a stable tertiary structure is one aspect of fitness, but
evolutionary selection ultimately operates on function, not on structure. In a previous
paper [2], Ranganathan and colleagues proposed a model for the evolutionary constraint
on a small protein interaction module (the WW domain) through application of the SCA,
a statistical analysis of multiple sequence alignments [3, 4]. Construction of artificial
protein sequences directed only by the SCA showed that the information extracted by this
analysis is sufficient to engineer the WW fold at atomic resolution. Here, we demonstrate
that these artificial WW sequences function like their natural counterparts, showing class-
specific recognition of proline-containing target peptides [5-8]. Consistent with SCA
predictions, a distributed network of residues mediates functional specificity in WW
domains. The ability to recapitulate natural-like function in designed sequences shows
that a relatively small quantity of sequence information is sufficient to specify the global
energetics of amino acid interactions.
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Results and Discussion
The basic premise of the SCA is that in accord with the cooperative nature of
amino acid interactions in determining protein stability and function, the evolutionary
constraint on proteins should be a distributed (rather than intrinsic) property of amino
acid positions. That is, the conservation of amino acids at one site should be the result of
constraints on that site taken independently, and of the constraints arising through
energetic interactions with other positions. For example, consider the SCA for an
alignment of 292 members of the WW domain family (Figure A2.1). This small protein
interaction module adopts a curved three-stranded B-sheet structure with a binding site for
proline-containing peptides formed on the concave surface of the sheet (Figure A2.1A).
The binding surface includes an X-Pro binding site (positions 19 and 30, shown in blue as
CPK representation; Figure A2.1 A) that recognizes the canonical proline in target
peptides, and a specificity site formed by residues in B 2 and the B 2- B 3 loop (positions
21, 23 and 26, shown in yellow as CPK representation; Figure A2. 1A) [9]. WW domains
are classified into four groups based on target peptide sequence motifs: group I, PpxY
[6]; group II, PPLP [7]; group III, PPR [5]; and group IV, pS/pT-P [8], where x stands for
any amino acid. The SCA output for the WW family is a matrix of coupling values
organized such that columns represent positions in the WW alignment, and rows
represent sites where perturbations are introduced to interrogate evolutionary coupling [4]
(Figure A2. 1B). Thus, each pixel shows the coevolution score for one pair of WW sites.
Hierarchical clustering of this matrix reveals a remarkably simple global organization of
conserved evolutionary interactions between amino acids. WW positions fall into two
main clusters, one that shows minimal coupling to other sites, and one that comprises
eight positions (marked in red) related by strong mutual coevolution (Figure A2. 1C).
Is the amino acid composition at sites plus the information in the SCA matrix all
the sequence information required to specify the WW domain? The prior paper provides
the first phase of this experimental test by showing that artificial sequences designed
using only these parameters adopt a stable WW-like tertiary structure [2]. However, a key
further test is the sufficiency of this information for specifying function. If the SCA
matrix captures the fitness constraints on the WW family, then the artificial sequences
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should show class-specific recognition of proline-containing sequences and binding
affinities like those of natural WW domains.
In order to assess the function of our artificial generated sequences we had to
design an oriented peptide library binding assay for measuring WW domain binding
specificity. Four biotinylated degenerate peptide libraries were constructed, each
oriented around one group-specific WW recognition motif (Table A2.1). For example,
the group-I-oriented peptide library was biotin-Z-GMAxxxPPxYxxxAKKK, where Z is
6-aminohexanoic acid and x stands for any amino acid except cysteine (theoretical
degeneracy of 8.9 x 108 sequences). A fifth proline-oriented library was also made as a
control for nonspecific binding (Table A2.1). At first we attemtped to use these peptide
libraries as probes in far western blots. The WW domains were run on SDS-PAG,
transferred to nitrocellulose, probed with the biotinylated peptide libraries, and detected
with avidin-HRP. After confirming similar amounts of proteins were run by coomassie
stain (Figure A2.2A) the WW domains were probed with the five peptide libraries
(Figure A2.2B). Very clear binding was seen with the postive controls for PPxY binding,
Yapl and Yap2, along with fairly robust binding to N35 and the designed WW domains
CP11 and CP43 to the PPxY library (Figure A2.2B). However, very little if any binding
was seen to any of the other peptide libraries suggesting that this assay only works for
tightly binding sequences. Further tweaking of the system through optimization of
washing and biotin binding reagents did not improve the results of the assay, and no
signal was ever seen for the other libraries including the pSP library with a Pinl WW
domain construct.
Failure of the far western approach for screening of WW domain binding motifs
suggested that a more quantitative method was required, so we turned to a 96 well plate
ELISA assay. In this assay the biotinylated peptide libraries were bound to streptavidin
coated 96 well plates, the WW domains were incubated in the plates, and the WW
domains that remained bound after extensive washing detected by GST-HRP since the
WW domains were all produced as GST fusion proteins in bacteria. To quantify the
binding the amount of horse radish peroxidase (HRP) present was determined by
incubation with 3,3',5,5'-tetramethylbenzidine liquid substrate system for five minutes
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(which was found to give the optimal signal to noise ratio). The reaction was stopped by
the addtion of sulfuric acid, and the absorbance measured at 450 nm which is the peak
absorance wavelength for the product after HRP mediated cleavage. Typical results are
shown in Figure A2.3A with a picture of the plate shown in Figure A2.3B. The
background seen with GST against each of the libraries was relatively low, but the
background seen with each individual protein against no peptide or the Pro only peptide
varied widely. However, after subtracting this background specific sinals were seen as
expected for the various WW domains indicated. Both the Yap and Taz WW domains
gave specific PPxY binding as expected. FBP11A very specifically binds the PPLP
library, which is as expected. Pinl has very high background, but the only signal above
background was seen with pSP, which is the expected binding motif. CP11, CP43, and
N39 all bind PPxY as expected, but also have some background with the Pro only library
perhaps due to the existence of a fraction of the PPxY motif in this library. Additionally
CP43 bind pSP and N39 binds PPR. Further optimization of this protocol gave consistent
results and thus it was adopted for use against the full panel of natural and designed WW
domains.
For a group I domain (Nedd4.3, or N39 by the numbering system in the
accompanying paper [2]) the peptide library assay confirms specific interaction with the
PPxY-containing sequences [10] (Figure A2.4A). Interestingly, CC43, an artificial WW
domain created through SCA-based protein design [2], also specifically interacts with the
PPxY peptide library (Figure A2.4B), suggesting that CC43 functions as a group I WW
domain. To confirm these results independently, we carried out phage-display and
fluorescence-based quantitative binding assays for N39 and CC43. Consistent with the
peptide library screens, both N39 and CC43 selectively isolate PPxY-containing
sequences from a random 12-mer phage display library (Figure A2.4C,D). In addition,
both of these domains show similar binding affinities to a model group I peptide (N39,
dissociation constant (Kd) = 11.2 -- 1.2 tM; CC43, Kd = 1.7 ± 0.1 jPM; mean -- s.d.;
Figure A2.4E). Taken together, these data validate the oriented peptide library assay for
classification of WW domain specificity, and demonstrate that one artificial WW domain,
CC43, displays group I-specific binding.
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Figure 6.5 summarizes the results of peptide library screening for 27 randomly
chosen natural and ten natively folded artificial WW domains [2]. The Pinl WW domain
was added to the list of natural domains tested because it is the best-characterized
member of the group IV specificity class [ 11]. The data are shown in clustered matrix
format, with each row showing the binding for one domain to all five oriented peptide
libraries normalized between the minimum (white) and the maximum (black) observed
signal to allow comparison of specificity profiles. Group I WW domains fell into two
distinct subclusters (I and Im (marginal group I)) that significantly differed in the degree
of specificity for the PPxY motif library (Figure A2.6). Group III domains bound to the
PPR-oriented peptide library as expected but also showed binding to the PPxY library
and weak binding to PPLP and proline-alone libraries. The binding to the PPxY library
may simply reflect the fact that this library contains a non-trivial fraction of PPRY
sequences. Nevertheless, the overall profiles show that group III domains display far
more relaxed specificity than group I domains (Figure A2.6). A similar ambiguity in the
binding specificity of group III domains has been reported previously [12]. Finally, a
minor fraction of the total natural sequences tested (2 out of 28) bound to pSP- and
PPLP-oriented libraries, and were scored as group IV and group II, respectively.
Artificial (CC) WW domains are functionally indistinguishable from natural WW
sequences (Figure A2.5). Of the ten artificial domains studied, six displayed group I
specificity (one is Im) and four showed group III specificity, numbers that approximately
reflect the distribution of these sequences in our MSA and in prior samplings of WW
specificity [13, 14]. Quantitative binding isotherms measured for all group I artificial
sequences show a range of binding affinities typical for natural WW domains (Figure
A2.5, rightmost column). To probe further the similarity between natural and designed
WW sequences, we carried out a saturation mutagenesis study of the group I and group
III peptide ligands. In this experiment, every position of the target peptide is replaced
individually to each of the 20 amino acids, and the effect on binding is measured by
detecting protein hybridization to the array of peptide variants [14]. Figure A2.7 shows
these data for two natural WW domains (N39, group I [10], and N31, group III [5, 14]),
and two artificial domains (CC43, group I, and CC20, group III), demonstrating that the
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designed sequences show a pattern of sensitivity to ligand mutagenesis similar to that for
natural sequences. Thus, the amino acid composition at sites plus the information
contained in the SCA matrix encodes the sequence rules for quantitatively specifying
function in the WW domain.
No artificial sequences with group II or group IV specificity were identified.
However, the paucity of group II and group IV sequences in our alignment of natural
WW domains and the relatively small number of artificial domains tested so far probably
account for the lack of these specificity classes. These classes may emerge from larger-
scale design of artificial WW sequences.
Given these results, can we infer which positions constitute the sequence
determinants for WW binding specificity? The eight positions comprising the primary
cluster of coevolving residues in the WW family (Figure A2.1C) are highlighted in
yellow in Figure A2.5. Sequences experimentally found to display group I binding
specificity, whether natural or designed, strictly conserve a specific sequence motif in the
coevolving cluster (3L4p6G8E21I/V 22D/N23H 28T). In contrast, the average sequence
identity in non-cluster positions is barely different for group I sequences in comparison
with all WW sequences: 40.9 ± 2.9% within group I sequences and 35 ± 3.9% overall
(mean ± s.d.). These results strongly suggest that this network of mutually evolving
residues is the major determinant of group I binding specificity. In accord with this
conclusion, marginal group I domains or the weakly specific group III domains display
considerable variation within this cluster. A larger study of designed sequences may help
to distil the minimal sequence profiles of these and other WW groups.
The spatial organization of the network residues provides an unexpectedly
distributed picture of binding specificity in the WW domain. Rather than being restricted
to the ligand-binding surface, the eight network residues are organized into a physically
contiguous network linking the primary specificity determining pocket (positions 21, 23
and 28) with residues on the opposite side (3 and 4) through a few intervening residues (6,
8 and 22) (Figure A2.8). The coevolution of these positions predicts that some residues
act at long range in mediating peptide binding, and the network amino acids act
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cooperatively in determining the binding free energy. Previous mutagenesis studies
already suggest that network residues at or close to the peptide binding surface (8, 21, 23
and 28) mediate binding specificity [15-18], and structural work in the dystrophin WW
domain provides a mechanistic understanding for the contribution of these residues in
group I domains [19]. To test more of the network for contribution to peptide binding,
and to test the prediction of cooperative action, we carried out thermodynamic double
mutant cycle analysis [20, 21] to measure the energetic coupling between mutations at
binding-site position 28 and positions 3, 8 and 23 in the Nedd4.3 WW domain. In the
mutant cycle method, the effect of one mutation on the equilibrium dissociation constant
for peptide binding is measured in two conditions: (1) the wild-type background (Xl =
KdMI/KdWT), and (2) in the background of a second mutation (X2 = KdMI'M 2/KdM2) (Figure
A2.8B). The ratio of these effects gives the coupling parameter ? , a measure of the
degree of interaction between the two mutations. If the two mutations are
thermodynamically independent, the effect of the first mutation is the same in conditions
1 and 2, and ? = 1. If ? ?1, then the two mutations act cooperatively.
Consistent with earlier studies [17, 19], the E8A, H23A and T28A mutations all
affected binding of a PPxY-containing peptide (Figure A2.8C). However, L3A also had a
significant effect (5.15 0.99 fold; mean s.d.), although located on the opposite surface
from the peptide-binding site. In addition, mutant cycle analyses for the T28A mutation
with each of the three other mutations show ? values that significantly differ from unity
(Figure A2.8C; see also Figure A2.9). Specifically, the effects of mutations at 3, 8 and 23
are either diminished (L3A and H23A) or abrogated (E8A) in the background of T28A
(Figure A2.9). Thus T28A is thermodynamically coupled to mutations at 3, 8 and 23.
These results support the model that a distributed and cooperative network of residues
predicted by the SCA contributes to peptide recognition in the WW domain.
It is perhaps surprising that all folded artificial WW domains could be classified
into a known functional group. The SCA emphasizes the deeply conserved couplings
between sequence positions in a protein family while down-weighting or even ignoring
less conserved couplings. These weak couplings typically arise from small clades of more
recently diverged sequences in the MSA, which are expected to contain many positional
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correlations yet to be relaxed through variation. If these recent branchings of the
phylogenetic tree also hold important information about the physical chemistry of
specific binding in extant proteins, we might have expected many folded but functionally
undifferentiated WW domains in SCA-based design. The data here suggest that at least as
defined by in vitro assays, information specifying binding specificity is captured in
positional interactions that are in the deep evolutionary record. Future studies of
functional complementation in vivo will help further to address the completeness of the
SCA-based sequence information in specifying natural-like proteins.
Compared with the current field of protein design, the SCA-based protein design
takes a completely different but complementary approach to understanding the design of
natural proteins. Using atomistic energy functions that approximate the physical forces
between atoms, several groups have now achieved spectacular successes in the re-design
of natural folds [22-24], including WW domains [25], and even in the de novo
construction of artificial folds [26, 27]. These successes demonstrate the accuracy of the
scoring functions used, but important unsolved issues remain. The basic design principle
in atomistic protein design is optimization of a target potential function that produces
sequences with deep thermodynamic minima in the native state and structures with high
thermal stabilities [22, 27]. However, natural proteins are thought to have native states
with shallow energy minima, resulting in marginally stable but dynamic folds that are
often capable of supporting more than one conformation. In a purely statistical and
mechanism-free way, SCA-based protein design produces sequences that show the same
marginal stability of natural proteins and function like natural proteins. It may be
interesting to combine the mechanistic description of energetics from atomistic design
with the sparse and distributed architecture of amino acid interactions in SCA to
understand better the design of evolved proteins. Ultimately having a better
understanding of how folding relates to function in WW domains will allow the design of
more potent or novel action inhibitors which may at a minimum be useful in treatment of
Pinl overexpressing breast cancers [28].
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Experimental Procedures
Statistical coupling analysis
SCA was conducted as previously described [3, 4] on an alignment of 292 WW domain
sequences, updated from the original alignment of 120 sequences in the accompanying
paper using the March 2004 release of the non-redundant database. SCA results are
essentially identical for the two alignments. Sequences were collected using PSI-BLAST
(e-scores <0.001) and aligned using ClustalW [29] followed by manual adjustment. The
alignment is available from our laboratory website (http://www.hhmi.swmed.edu/Labs/rr),
and the code is available upon request.
Oriented peptide library assay
Five biotinylated degenerate peptide libraries were synthesized using N-cL-FMOC
protected amino acids and standard BOP/HOBt coupling chemistry. The libraries were
constructed to present either a proline-only control (biotin-Z-GMAxxxxPxxxxAKKK) or
the four different characteristic WW domain binding motifs: group-I-oriented (biotin-Z-
GMAxxxPPxYxxxAKKK), group-IH-oriented (biotin-Z-GMAxxxPPLPxxxAKKK),
group-III-oriented (biotin-Z-GMAxxxPPRxxxAKKK) and group-IV-oriented (biotin-Z-
GMAxxxxpSPxxxxAKKK), where Z is 6-aminohexanoic acid, pS is phosphoserine, and
x denotes all amino acids except cysteine. In the original assay design these petide
libraries were used as probes for WW domains in a far western blot. WW domains
purified from bacteria were run on SDS-PAG, transferred to nitrocellulose, probed with
the biotinylated peptide libraries, and detected using avidin-HRP (Sigma). To visualize
the signal ECL (Enhanced chemiluminsence - Perkin Elmer) was used and the
nitrocellulose exposed to Biomax film (Kodak). Subsequently a different assay was used
as described below. Peptide libraries were immobilized onto pre-washed streptavidin-
coated 96-well plates (10 jig per well) in phosphate-buffered saline plus 0.5% Tween-20
(PBST) at 4 "C for 1 h. Wells were washed in PBST and incubated with GST-WW
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domains (0.5 jig) for 2 h, washed, and detected by ELISA using a horseradish peroxidase-
conjugated anti-GST antibody (Amersham) at 1:5,000 dilution for 1 h at 4 oC followed
by reaction with 3,3',5,5'-tetramethylbenzidine liquid substrate system (Sigma) for 5 min.
Absorbance was monitored at 450 nm.
Phage display
Phage display was carried out using a commercial random 12-mer library (PhD Phage
Display kit, NEB) per protocols supplied by the manufacturer. Phage isolates were
sequenced after three rounds of amplification and nonspecific elution with glycine-HC1,
pH 2.2.
Binding assays
Tryptophan fluorescence-based peptide binding assays were conducted on a PTI
spectrofluorimeter, monitoring fluorescence emission at 340 nm (excitation at 295 nm).
Group I peptide, EYPPYPPPPYPSG (Tufts Protein Chemistry Facility), was purified
using reverse-phase high-performance liquid chromatography. Binding assays were
conducted at 4 OC in buffer A (100 mM TrisHCL, pH 8.0, 100 mM NaCl) with 1 gLM
WW domain. WW domains were cloned into the pHIS8-3 vector (provided by J. P. Noel),
expressed and purified as described [2]. The assay follows the fraction of protein bound
to peptide by the normalized fluorescence quenching of the Trp residue in the X-Pro
binding pocket. Isothermal titration calorimetry measurements were made using a
MicroCal VP-ITC calorimeter in buffer A at 4 OC, starting with 50-200 ý-M WW domain
in the sample cell and titrating 0.5-3 mM of the group I peptide. Data were fit using
MicroCal Origin software provided by the manufacturer, using a one-site binding model.
The marginal stability of WW domains required correction of apparent dissociation
constants to account for the fraction of folded protein at the assay temperature. Assuming
a two-state folding reaction, the correction applied was K = d.= (1 ,, where Kf is the
equilibrium constant for the folding reaction. For each protein assayed, Kf was calculated
using thermal denaturation studies carried out as in the accompanying paper [2], and
assuming a previously reported value for the change in heat capacity for the unfolding
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reaction[30]. Kf values were: wild type, 38.8; L3A, 1.65; E8A, 15.7; H23A, 22.7; T28A,
32.0; L3A/T28A, 1.25; E8A/T28A, 8.54; H23A/T28A, 21.5.
Protein hybridization assay
Protein hybridization assays were performed as described [14]. Arrays of all single amino
acid substitutions for a group I peptide (GTPPPPYTVG) and a group III peptide
(PPGPPPRGPPP) were synthesized on membranes by the M.I.T. Biopolymers
Laboratory. Membranes were washed in PBS plus 0.1% Tween-20 (PBST), blocked for
2 h at room temperature in PBST plus 5% non-fat dry milk, washed, and incubated at
4 'C overnight with 10-400 gg ml-' of purified GST-WW domains. Membranes were
washed, treated with horseradish peroxidase-conjugated anti-GST antibodies (Sigma) in
PBST plus 5% non-fat dry milk at 4 OC for 2 h, washed again, and bound WW domains
were detected using the ECL kit (Amersham).
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Figure A2.1
(A) The peptide-binding surface of the WW domain contains two structurally defined
pockets: the X-Pro binding site (in blue) and a specificity site (in yellow). Shown is the
Nedd4.3 WW domain (Protein Data Bank 115H) bound to a group I peptide (in green)
[31].
(B) A matrix of coevolution scores between all WW positions (columns) and 12
moderately conserved positions (rows) in an alignment of 292 WW domains. The colour
scale ranges from blue (no coevolution) to red (maximal coevolution). Checked boxes
mark the trivial self-correlation of sites in the SCA method.
(C) Hierarchical clustering shows that a single group of eight positions (marked in red)
share a pattern of strong mutual coevolution.
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Figure A2.2
(A) Coomassie blue stained gel of the indicated WW domains purified from bacteria
indicate approximately equal loading.
(B) WW domains detected by far western with the indicated biotinylated peptide library.
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Figure A2.3
(A) Values of absorbance readings at 405nm of the plate shown in part B that indicate the
amount of binding of the WW domains listed across the top to the biotinylated peptide
libraries listed across the right. Well lanes and columns are also noted for convience.
(B) Scan of 96 well plate after ELISA assay to determine binding between the WW
domains and biotinylated peptide libaries indicated in part A.
A.
Yapl Yapl Yap2 FBP11 FBP30
2 3 4 5 6
.0502 .1617 .0751 .1640 .3112
.0576 .0841 .0562 .2142 .3422
.5418 .5137 .5598 .1914 .4008
.0739 .1205 .0914 .1871 .2289
.1183 .0867 .0479 .5945 .4357
.0758 .1237 .0488 .1595 .3350
Pinl Taz CP11 CP43 N39 GST
7 8 9 10 11 12
.9701 .1599 .2683 .2071 .4618 .0784 None
1.0126 .3861 .5042 .8376 .7066 .1630 P
.8084 .5504 .6719 .8367 .8312 .1807 PPXY
.8468 .2408 .2174 .2093 .7241 .0781 PPR
.8575 .1841 .1618 .2181 .4622 .1150 PPLP
1.4280 .0696 .1400 .4314 .4863 .0383 pSP
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Figure A2.4
(AB) Oriented peptide library screening (see Methods) of binding specificity for N39, a
natural domain with group I (PPxY) specificity (A), or CC43, an artificial WW domain
showing 37% average and 68% top-hit identity to natural WW domains in the MSA (B).
Binding is reported as fold above background in the absence of target peptides.
(C,D) Phage display analysis of binding specificity for N39 and CC43 WW domains;
both domains select PPxY-containing sequences from a random 12-mer peptide library.
(E) Binding isotherms for N39 (Kd = 11.2 ±1.2 pM) and CC43 (Kd = 1.7 -0.1 gM),
assayed by Trp fluorescence quenching using a model group I peptide
(EYPPYPPPPYPSG). Error bars represent standard deviation from at least four
independent assays.
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Figure A2.5
The matrix shows the results of oriented peptide library assays, clustered to reveal the
similarities in binding specificity for different domains. The colour scale ranges from
white (ninimum signal) to black (maximum signal) for each domain. Class assignments
for domains are shown at the right. Dissociation constants for selected group I domains
were either measured by fluorescence binding assay (N39 and all artificial sequences) or
were derived from literature references. Sequences are aligned per the MSA, and
positions corresponding to the cluster of eight coevolving residues (Figure A2.1C) are
highlighted in yellow. SCA-based designed sequences are shown in bold. Measurements
are mean s.d.
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Figure A2.6
(A) Binding specificity assays determined by the oriented peptide library assay for 28
natural WW domains. Binding is measured by ELISA using an HRP-assay, and the data
are reported as fold above background binding in the absence of peptide substrate.
Peptide libraries are as described in the Figure A2.4 legend. Error bars show the standard
deviation of 3-4 independent measurements.
(B) As in A for 10 artificial WW domains designed using the SCA matrix [2].
327
Figure A2.6 Continued
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Figure A2.7
Saturation mutagenesis of the peptide ligands for the two major functional classes of WW
domains identified.
(A) A natural group I (Nedd4.3) WW domain was assayed for binding to an array of
immobilized peptides representing all possible amino acid substitutions to a canonical
group I peptide. The wild-type peptide sequence is given at the left of the blot, and each
row represents the binding to peptides where that position is mutated to every amino acid
as marked.
(B) A natural group III (FE65.1) WW domain assayed as in A using a canonical group III
peptide.
(C) As in (A) with the group I artificial WW domain CC43. The artificial domain shows
the same pattern of sensitivity to mutation of ligand positions as the natural domain.
(D) As in (B) with a group III artificial WW dornnin CC20. The artificial domain shows
the same pattern of sensitivity to mutation of ligand positions as the natural domain.
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Figure A2.8
(A) The cluster of eight coevolving residues (Figure A2. 1 C) mapped on the Nedd4.3
WW domain structure (in red). The cluster forms a connected network that links binding
site residues with the opposite side through a few intervening positions.
(B) The thermodynamic mutant cycle formalism. The fold effect of one mutation (M 1) on
an equilibrium constant is calculated in the wild-type background (XI) or in the
background of the second mutation (X2). The coupling parameter ? is the ratio of these
fold effects (XI/X2); that is, the degree to which the effect of one mutation depends on
the second.
(C) Mutant cycle analysis of selected coevolving positions. Residues are shown in the
same orientation as in A (right), with distances between B-carbons of residues indicated.
Single mutations at all sites affect peptide binding (fold effect relative to wild type in
parentheses), and mutant cycle analysis demonstrates energetic coupling (? > 1) between
position 28 and positions 3, 8 and 23. Measurements are mean "s.d.
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Figure A2.9
Thermodynamic double mutant cycles [20, 21] in the WW domain Nedd4.3 (N39),
measuring the energetic coupling between the T28A mutant and mutants at three other
sites within the network of co-evolving residues (L3A, E8A, and H23A). The
thermodynamic mutant cycle formalism is shown in Figure A2.6B. Briefly, each corner
of the box contains the equilibrium dissociation constant for a group I peptide
(EYPPYPPPPYPSG) and either wild-type, single mutant, or double mutant WW proteins,
measured through isothermal titration calorimetery. Values represent the mean and
standard deviation of at least three measurements, reported in units of pM. •2 is the
coupling pararneter as described in the text.
WT
14.2 ± 1.1
1
L3A
73.1 ± 20.8
WT
14.2 ± 1.1
I
E8A
25.4 ± 2.9
WT
14.2 ± 1.1
I
T23A
219 ± 22.7
Q = 1.8 + 0.62
Q = 1.9± 0.36
0 = 6.3 + 0.89
T28A
44.8 + 2.4
L3A/T28A
127 ± 20.8
T28A
44.8 ± 2.4
E8A/T28A
41.9 ± 5.1
T28A
44.8 + 2.4
T23A/T28A
109 ± 2.4
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Table A2.1: The Peptide Libraries
Orientation Library Name Peptide Library Sequence
proline-only control P biotin-Z-GMAxxxxPxxxxAKKK
group-I-oriented PPxY biotin-Z-GMAxxxPPxYxxxAKKK
group-II-oriented PPR biotin-Z-GMAxxxPPLPxxxAKKK
group-III-oriented PPLP biotin-Z-GMAxxxPPRxxxAKKK
group-IV-oriented pSP biotin-Z-GMAxxxxpSPxxxxAKKK
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